{"b4ee37a4e219327d8735c606e6fd4733be26e694": [["IntroductionCoronavirus disease 2019 (COVID-19) emerged in Wuhan, China, in December 2019.", [["IntroductionCoronavirus disease", "DISEASE", 0, 31], ["COVID-19", "CHEMICAL", 38, 46], ["IntroductionCoronavirus disease", "PROBLEM", 0, 31]]], ["(1) Due to the sustained human-to-human transmission, rapidly, the COVID-19 has spread globally to more than 215 countries affecting over 22 million people with over 777,680 deaths, as of August 16, 2020.", [["human-to-human transmission", "DISEASE", 25, 52], ["deaths", "DISEASE", 174, 180], ["human", "ORGANISM", 25, 30], ["human", "ORGANISM", 34, 39], ["people", "ORGANISM", 149, 155], ["human", "SPECIES", 25, 30], ["human", "SPECIES", 34, 39], ["people", "SPECIES", 149, 155], ["human", "SPECIES", 25, 30], ["human", "SPECIES", 34, 39], ["the COVID", "TEST", 63, 72]]], ["(2) About 80% of COVID-19 cases are asymptomatic or mild, 15% are severe requiring oxygen, and 5% are critical infections requiring ventilation.", [["oxygen", "CHEMICAL", 83, 89], ["infections", "DISEASE", 111, 121], ["oxygen", "CHEMICAL", 83, 89], ["oxygen", "SIMPLE_CHEMICAL", 83, 89], ["COVID", "TEST", 17, 22], ["asymptomatic", "PROBLEM", 36, 48], ["oxygen", "TREATMENT", 83, 89], ["critical infections", "PROBLEM", 102, 121], ["ventilation", "TREATMENT", 132, 143], ["mild", "OBSERVATION_MODIFIER", 52, 56], ["severe", "OBSERVATION_MODIFIER", 66, 72], ["oxygen", "OBSERVATION_MODIFIER", 83, 89], ["infections", "OBSERVATION", 111, 121]]], ["(3) Asymptomatic infection refers to the revealing of nucleic acid of the virus by reverse transcriptase polymerase chain reaction (RT-PCR), in patient not showing typical clinical symptoms.IntroductionOne of the characteristics that has made COVID-19 pandemic difficult to control has been the infectious status of those who are asymptomatic or very mild symptomatic.(3) Asymptomatic COVID-19 infections have the same infectivity (4) and similar viral load as of symptomatic infections.", [["infection", "DISEASE", 17, 26], ["nucleic acid", "CHEMICAL", 54, 66], ["infections", "DISEASE", 394, 404], ["infections", "DISEASE", 476, 486], ["patient", "ORGANISM", 144, 151], ["COVID-19", "ORGANISM", 385, 393], ["reverse transcriptase", "PROTEIN", 83, 104], ["patient", "SPECIES", 144, 151], ["COVID-19", "SPECIES", 385, 393], ["Asymptomatic infection", "PROBLEM", 4, 26], ["nucleic acid of the virus", "PROBLEM", 54, 79], ["reverse transcriptase polymerase chain reaction", "PROBLEM", 83, 130], ["RT-PCR", "TEST", 132, 138], ["typical clinical symptoms", "PROBLEM", 164, 189], ["COVID", "TEST", 243, 248], ["asymptomatic", "PROBLEM", 330, 342], ["very mild symptomatic", "PROBLEM", 346, 367], ["Asymptomatic COVID-19 infections", "PROBLEM", 372, 404], ["similar viral load", "PROBLEM", 439, 457], ["symptomatic infections", "PROBLEM", 464, 486], ["infection", "OBSERVATION", 17, 26], ["infectious", "OBSERVATION_MODIFIER", 295, 305], ["mild", "OBSERVATION_MODIFIER", 351, 355], ["symptomatic", "OBSERVATION", 356, 367], ["viral load", "OBSERVATION", 447, 457], ["symptomatic", "OBSERVATION_MODIFIER", 464, 475], ["infections", "OBSERVATION", 476, 486]]], ["(5, 6) Contracting viral infection without showing clinical symptoms is highly likely to occur in the event of close contact with confirmed cases.", [["viral infection", "DISEASE", 19, 34], ["Contracting viral infection", "PROBLEM", 7, 34], ["clinical symptoms", "PROBLEM", 51, 68], ["viral", "OBSERVATION_MODIFIER", 19, 24], ["infection", "OBSERVATION", 25, 34]]], ["In Boston, 88% of the COVID-19 positive cases were asymptomatic.", [["the COVID", "TEST", 18, 27], ["asymptomatic", "PROBLEM", 51, 63]]], ["(7) In Japan, 30.8% of Japanese citizens evacuated from Wuhan were asymptomatic (8) and 51.7% of COVID-19 cases in the \"Diamond Princess\" were also asymptomatic.", [["COVID", "TEST", 97, 102], ["asymptomatic", "PROBLEM", 148, 160]]], ["(9) The viral RNA can be detected in the respiratory secretions of asymptomatic patients for no less than 3-5 days.(5) Thus, a COVID-19 mild or an asymptomatic case would have the potential of transmitting the virus to other people without any awareness.IntroductionThe United Arab Emirates (UAE) is described as a melting pot of cultures, with around 85% of the population consisting of expatriates.", [["respiratory secretions", "ANATOMY", 41, 63], ["patients", "ORGANISM", 80, 88], ["people", "ORGANISM", 225, 231], ["viral RNA", "RNA", 8, 17], ["patients", "SPECIES", 80, 88], ["people", "SPECIES", 225, 231], ["The viral RNA", "PROBLEM", 4, 17], ["a COVID", "TEST", 125, 132], ["a melting pot of cultures", "PROBLEM", 313, 338], ["viral RNA", "OBSERVATION", 8, 17], ["mild", "OBSERVATION_MODIFIER", 136, 140]]], ["UAE is burdened with a high prevalence of noncommunicable diseases mainly obesity and diabetes mellitus (DM), (10) which may contribute to more susceptibility to the COVID-19.", [["noncommunicable diseases", "DISEASE", 42, 66], ["obesity", "DISEASE", 74, 81], ["diabetes mellitus", "DISEASE", 86, 103], ["DM", "DISEASE", 105, 107], ["COVID-19", "CHEMICAL", 166, 174], ["noncommunicable diseases mainly obesity", "PROBLEM", 42, 81], ["diabetes mellitus (DM)", "PROBLEM", 86, 108], ["the COVID", "TEST", 162, 171], ["burdened", "OBSERVATION_MODIFIER", 7, 15], ["high prevalence", "OBSERVATION_MODIFIER", 23, 38], ["noncommunicable", "OBSERVATION_MODIFIER", 42, 57], ["diseases", "OBSERVATION", 58, 66], ["obesity", "OBSERVATION", 74, 81], ["diabetes mellitus", "OBSERVATION", 86, 103]]], ["By August 07, 2020, there were over 61,845 COVID-19 cases and 354 deaths reported in the UAE,.", [["deaths", "DISEASE", 66, 72]]], ["(2) Mass active tracing and testing contacts of COVID-19 cases along testing random samples from highly populated residential areas have contributed dramatically in identifying more COVID-19 cases.", [["Mass active tracing", "TEST", 4, 23], ["testing", "TEST", 28, 35], ["COVID", "TEST", 48, 53], ["testing random samples", "TEST", 69, 91], ["COVID", "TEST", 182, 187], ["Mass", "OBSERVATION", 4, 8]]], ["Relative to the total population, UAE is one of the top 10 countries in terms of the daily number of the tested populations for the COVID-19.", [["the COVID", "TEST", 128, 137]]], ["(2) In several reported studies, the prevalence of asymptomatic COVID-19 positive cases ranged from 20% to 86% that are defined as individuals with positive viral nucleic acid tests, but without any COVID-19 symptoms.", [["nucleic acid", "CHEMICAL", 163, 175], ["COVID-19", "GENE_OR_GENE_PRODUCT", 64, 72], ["asymptomatic COVID", "TEST", 51, 69], ["positive cases", "TEST", 73, 87], ["positive viral nucleic acid tests", "PROBLEM", 148, 181], ["any COVID-19 symptoms", "PROBLEM", 195, 216]]], ["(9, (11) (12) (13) To better understand the identified COVID-19 cases, we characterized COVID-19 cases, described factors associated with COVID-19 symptomatic state, and quantified the strength of association between symptomatic state and repeated positivity in subsequent three RT-PCR testing rounds during the disease course.Materials and MethodsThis study was approved by the Abu Dhabi Health COVID-19 Research Ethics Committee (IRB DOH/CVDC/2020/1518).", [["COVID", "TEST", 88, 93], ["COVID", "TEST", 138, 143], ["symptomatic state", "PROBLEM", 147, 164], ["symptomatic state", "PROBLEM", 217, 234], ["repeated positivity", "PROBLEM", 239, 258], ["PCR testing", "TEST", 282, 293], ["the disease course", "TREATMENT", 308, 326], ["Methods", "TREATMENT", 341, 348], ["This study", "TEST", 348, 358]]], ["Owing to the retrospective analysis nature of the study, patient's informed consent was waived.", [["patient", "ORGANISM", 57, 64], ["patient", "SPECIES", 57, 64], ["the study", "TEST", 46, 55]]], ["This study followed and reported according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.Data sourceWe reviewed the first cohort of 1,249 COVID-19 RT-PCR confirmed cases passively or actively identified and reported to health authorities in the Abu Dhabi emirates up to April 08 2020.", [["This study", "TEST", 0, 10], ["Observational Studies", "TEST", 81, 102], ["COVID", "TEST", 197, 202], ["RT-PCR", "TEST", 206, 212]]], ["The first COVID-19 PCR confirmed case was reported on February 28 2020.Data sourceInformation on the reported symptoms were recorded.", [["COVID-19 PCR", "DNA", 10, 22], ["The first COVID", "TEST", 0, 15], ["PCR", "TEST", 19, 22], ["the reported symptoms", "PROBLEM", 97, 118]]], ["Self-reported sociodemographics (age, gender, nationality, place of work), chronic comorbidities (e.g. diabetes mellitus (DM), .", [["chronic comorbidities", "DISEASE", 75, 96], ["diabetes mellitus", "DISEASE", 103, 120], ["DM", "DISEASE", 122, 124], ["chronic comorbidities (e.g. diabetes mellitus (DM)", "PROBLEM", 75, 125], ["chronic", "OBSERVATION_MODIFIER", 75, 82], ["comorbidities", "OBSERVATION", 83, 96]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintData sourceThe copyright holder for this this version posted September 25, 2020. . https://doi.org/10.1101/2020.09.23.20200030 doi: medRxiv preprint hypertension, anemia, respiratory diseases), and travel history in the past month, were collected.Specimen collection and viral nucleic acid detectionUpper respiratory tract specimens were collected from nasopharyngeal or oropharyngeal swabs by trained medical staffs.", [["respiratory", "ANATOMY", 379, 390], ["respiratory tract specimens", "ANATOMY", 513, 540], ["nasopharyngeal", "ANATOMY", 561, 575], ["oropharyngeal swabs", "ANATOMY", 579, 598], ["CC", "CHEMICAL", 0, 2], ["hypertension", "DISEASE", 357, 369], ["anemia", "DISEASE", 371, 377], ["respiratory diseases", "DISEASE", 379, 399], ["nucleic acid", "CHEMICAL", 485, 497], ["nasopharyngeal", "CANCER", 561, 575], ["oropharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 579, 598], ["hypertension", "PROBLEM", 357, 369], ["anemia", "PROBLEM", 371, 377], ["respiratory diseases", "PROBLEM", 379, 399], ["Specimen collection", "TEST", 455, 474], ["viral nucleic acid", "TEST", 479, 497], ["respiratory tract specimens", "PROBLEM", 513, 540], ["med", "ANATOMY", 102, 105], ["hypertension", "OBSERVATION", 357, 369], ["anemia", "OBSERVATION", 371, 377], ["respiratory diseases", "OBSERVATION", 379, 399], ["collection", "OBSERVATION", 464, 474], ["viral nucleic acid", "OBSERVATION", 479, 497], ["respiratory tract", "ANATOMY", 513, 530], ["oropharyngeal swabs", "ANATOMY", 579, 598]]], ["Viral genome detection was performed using RT-PCR according to manufacturer instructions (BGI Genomics Co. Ltd).", [["Viral genome detection", "TEST", 0, 22], ["RT-PCR", "TREATMENT", 43, 49]]], ["According to the local health authorities' guidelines for repeating testing positive cases, RT-PCR testing should be repeated every 48-72 hours.", [["repeating testing positive cases", "TEST", 58, 90], ["RT-PCR testing", "TEST", 92, 106]]], ["After the first RT-PCR index test, information up to three subsequent RT-PCR testing rounds was available for our COVID-19 cases.Outcomes of interestThe symptomatic state (presenting symptoms vs not having symptoms) of the COVID-19 confirmed cases.Exposure variablesWe categorized the COVID-19 RT-PCR confirmed cases based on their symptomatic status into asymptomatic or symptomatic (presented with at least one symptom).", [["COVID", "DNA", 285, 290], ["the first RT-PCR index test", "TEST", 6, 33], ["PCR testing rounds", "TEST", 73, 91], ["our COVID", "TEST", 110, 119], ["The symptomatic state (presenting symptoms", "PROBLEM", 149, 191], ["symptoms", "PROBLEM", 206, 214], ["the COVID", "TEST", 219, 228], ["the COVID", "TEST", 281, 290], ["RT-PCR", "TEST", 294, 300], ["symptomatic", "PROBLEM", 372, 383], ["symptomatic", "OBSERVATION_MODIFIER", 153, 164]]], ["This sub-categorization was based on the fact that the risk of exposure to COVID-19 and developing symptoms could be associated to the frequency of being exposed to populations with higher risk of transmitting the viral infection such as travelers from highly infected areas.", [["COVID-19", "CHEMICAL", 75, 83], ["viral infection", "DISEASE", 214, 229], ["COVID", "TEST", 75, 80], ["developing symptoms", "PROBLEM", 88, 107], ["the viral infection", "PROBLEM", 210, 229], ["highly infected areas", "PROBLEM", 253, 274], ["viral", "OBSERVATION_MODIFIER", 214, 219], ["infection", "OBSERVATION", 220, 229], ["highly", "OBSERVATION_MODIFIER", 253, 259], ["infected", "OBSERVATION", 260, 268]]], ["The \"not working\" category included housewives, children, visitors, and unemployed .", [["children", "ORGANISM", 48, 56], ["children", "SPECIES", 48, 56]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintExposure variablesThe copyright holder for this this version posted September 25, 2020. . https://doi.org/10.1101/2020.09.23.20200030 doi: medRxiv preprint people.", [["CC", "CHEMICAL", 0, 2], ["people", "ORGANISM", 364, 370], ["people", "SPECIES", 364, 370], ["Exposure variables", "PROBLEM", 208, 226], ["med", "ANATOMY", 102, 105]]], ["The \"working in public places\" category included people working in shopping markets or malls, delivery services, banks, barbershops, hotels, petrol stations, sales, police and security sector, and taxi or bus drivers.", [["people", "ORGANISM", 49, 55], ["people", "SPECIES", 49, 55]]], ["Healthcare setting category included healthcare staff (physicians, nurses, ambulance drivers, and para-medics), cleaners, and people working in administrative positions (recipients and cashiers).", [["people", "ORGANISM", 126, 132], ["people", "SPECIES", 126, 132]]], ["Aviation and tourism services category included people working in airports, travel agencies, and airport taxi and bus drivers.Exposure variablesThe self-reported existence of chronic comorbidities (none or at least one chronic comorbidity) and travel history in the past month (yes or no) each was dichotomized into two subcategories.Statistical analysisContinuous variables are presented as means with standard deviations (SD) and interquartile range (IQR).", [["people", "ORGANISM", 48, 54], ["people", "SPECIES", 48, 54], ["Exposure variables", "PROBLEM", 126, 144], ["chronic comorbidities", "PROBLEM", 175, 196], ["chronic comorbidity", "PROBLEM", 219, 238], ["Statistical analysisContinuous variables", "PROBLEM", 334, 374], ["chronic", "OBSERVATION_MODIFIER", 175, 182], ["comorbidities", "OBSERVATION", 183, 196]]], ["Categorical variables are presented as frequencies and proportions.", [["Categorical variables", "TEST", 0, 21]]], ["The mean difference in continuous variables between symptomatic and asymptomatic COVID-19 cases was compared using Student t-test.", [["The mean difference in continuous variables between symptomatic", "PROBLEM", 0, 63], ["asymptomatic COVID", "TEST", 68, 86], ["Student t-test", "TEST", 115, 129], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["difference", "OBSERVATION_MODIFIER", 9, 19], ["symptomatic", "OBSERVATION_MODIFIER", 52, 63]]], ["Difference in proportions of the measured categorical variables between symptomatic and asymptomatic cases was assessed using the Chi-square test.Statistical analysisCrude and multivariable binary logistic regression models were used to quantify the strength of association between the sociodemographic factors and the symptomatic state compared to asymptomatic and the repeated positivity of RT-PCR in the subsequent three testing rounds, among symptomatic compared to asymptomatic cases.", [["the measured categorical variables between symptomatic and asymptomatic cases", "PROBLEM", 29, 106], ["the Chi-square test", "TEST", 126, 145], ["Statistical analysisCrude", "TEST", 146, 171], ["multivariable binary logistic regression models", "TREATMENT", 176, 223], ["the symptomatic state", "PROBLEM", 315, 336], ["RT-PCR", "TEST", 393, 399], ["symptomatic", "OBSERVATION_MODIFIER", 72, 83]]], ["To control for any potential confounding effect, all measured exposure variables were included in the multivariable model.", [["any potential confounding effect", "PROBLEM", 15, 47], ["all measured exposure variables", "PROBLEM", 49, 80]]], ["Collinearity between exposure variables was investigated using the condition index .", [["Collinearity between exposure variables", "PROBLEM", 0, 39], ["the condition index", "TEST", 63, 82]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintStatistical analysisThe copyright holder for this this version posted September 25, 2020. . https://doi.org/10.1101/2020.09.23.20200030 doi: medRxiv preprint and the variance inflation factor (VIF).", [["CC", "CHEMICAL", 0, 2], ["variance inflation factor", "PROTEIN", 374, 399], ["VIF", "PROTEIN", 401, 404], ["preprintStatistical analysis", "TEST", 200, 228], ["medRxiv preprint", "TREATMENT", 349, 365], ["the variance inflation factor (VIF)", "TREATMENT", 370, 405], ["med", "ANATOMY", 102, 105]]], ["There was no collinearity.", [["collinearity", "PROBLEM", 13, 25], ["no", "UNCERTAINTY", 10, 12], ["collinearity", "OBSERVATION", 13, 25]]], ["The maximum VIF value was 1.3 while for the condition index it was 9.6.Statistical analysisThe proportions of negative conversion (viral shedding) by the symptomatic status were illustrated using Kaplan-Meier plot and the log-rank test was used to determine the difference between the two groups.Statistical analysisStatistical analyses were performed using the IBM SPSS software (version 26).", [["The maximum VIF value", "TEST", 0, 21], ["the condition index", "TEST", 40, 59], ["Statistical analysis", "TEST", 71, 91], ["Meier plot", "TEST", 203, 213], ["the log-rank test", "TEST", 218, 235], ["Statistical analysisStatistical analyses", "TEST", 296, 336], ["the IBM SPSS software", "TEST", 358, 379], ["maximum", "OBSERVATION_MODIFIER", 4, 11], ["VIF", "OBSERVATION", 12, 15], ["negative conversion", "OBSERVATION", 110, 129]]], ["A p-value <0.05 was considered to indicate statistical significance.Profile of the COVID-19 casesA total of 1,249 RT-PCR confirmed COVID-19 cases were investigated and reported to the health authorities from February 28 to April 08, 2020.", [["COVID", "DNA", 83, 88], ["A p-value", "TEST", 0, 9], ["the COVID", "TEST", 79, 88], ["RT-PCR", "TEST", 114, 120], ["COVID", "TEST", 131, 136]]], ["There was missing data on the symptomatic state and other key characteristics in 458 cases.", [["missing data", "PROBLEM", 10, 22], ["the symptomatic state", "PROBLEM", 26, 47]]], ["These cases were excluded from the analysis.", [["These cases", "TEST", 0, 11], ["the analysis", "TEST", 31, 43]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintProfile of the COVID-19 casesThe copyright holder for this this version posted September 25, 2020. . https://doi.org/10.1101/2020.09.23.20200030 doi: medRxiv preprint * Mean number of symptoms = 1.75 (range 1-6 symptoms)Profile of the COVID-19 casesOf the 447 symptomatic cases, 47.9% presented with only one symptom, 48.5% presented with 2-3 symptoms, and 3.6% presented with four or more symptoms.", [["CC", "CHEMICAL", 0, 2], ["COVID", "DNA", 223, 228], ["the COVID", "TEST", 219, 228], ["symptoms", "TEST", 392, 400], ["symptoms", "PROBLEM", 419, 427], ["the COVID", "TEST", 439, 448], ["symptomatic cases", "TEST", 468, 485], ["2-3 symptoms", "PROBLEM", 547, 559], ["more symptoms", "PROBLEM", 593, 606], ["med", "ANATOMY", 102, 105]]], ["The most frequent symptoms were fever (58.0%) followed by cough (41.0%), sore throat (18.9%), and headache fatigue (12.4%) (Fig 2) .", [["fever", "DISEASE", 32, 37], ["cough", "DISEASE", 58, 63], ["sore throat", "DISEASE", 73, 84], ["headache fatigue", "DISEASE", 98, 114], ["The most frequent symptoms", "PROBLEM", 0, 26], ["fever", "PROBLEM", 32, 37], ["cough", "PROBLEM", 58, 63], ["sore throat", "PROBLEM", 73, 84], ["headache fatigue", "PROBLEM", 98, 114]]], ["The mean age of COVID-19 cases was 35.6 \u00b112.7 years.", [["COVID", "TEST", 16, 21]]], ["Majority of the cases were males (79.2%), 57.6% were Asians, 61.7% were working in public places, 23.6% travelled abroad in the past month, and 13.1% reported having at least one chronic comorbidity, mainly DM (6.0%) and hypertension (5.7%).Profile of the COVID-19 casesOf the 791 COVID-19 cases, 388 (49.1%) were re-tested (second testing round) after an average of 2.7 \u00b11.4 days from the first testing round.", [["DM", "DISEASE", 207, 209], ["hypertension", "DISEASE", 221, 233], ["Asians", "TEST", 53, 59], ["chronic comorbidity", "PROBLEM", 179, 198], ["mainly DM", "PROBLEM", 200, 209], ["hypertension", "PROBLEM", 221, 233], ["the COVID", "TEST", 252, 261], ["COVID", "TEST", 281, 286], ["chronic", "OBSERVATION_MODIFIER", 179, 186], ["comorbidity", "OBSERVATION", 187, 198], ["hypertension", "OBSERVATION", 221, 233]]], ["Of these 388 cases, 230 (59.3%) were re-tested (third testing round) after an average of 2.4 \u00b11.2 days from the second testing round, and of these 230 cases, 70.9% were re-tested (fourth PCR testing) after an average of 3.2 \u00b11.8 .", [["fourth PCR testing", "TEST", 180, 198]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintProfile of the COVID-19 casesThe copyright holder for this this version posted September 25, 2020. . https://doi.org/10.1101/2020.09.23.20200030 doi: medRxiv preprint days from the third testing round (Table 1) .", [["CC", "CHEMICAL", 0, 2], ["COVID", "DNA", 223, 228], ["the COVID", "TEST", 219, 228], ["med", "ANATOMY", 102, 105]]], ["Overall, the mean number of days from the first to the fourth RT-PCR testing round was 8.3 days \u00b12.5 days. .", [["PCR testing", "TEST", 65, 76]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintProfile of the COVID-19 casesThe copyright holder for this this version posted September 25, 2020. .1%, valid percentage a Including children, visitors, students, housewives, and not working people b Out of tested in the previous test IQR: interquartile range between the first and third quantiles.Symptomatic versus asymptomaticThe mean age of symptomatic was significantly higher than that of asymptomatic cases (mean difference = 1.8 years, p=0.049).", [["CC", "CHEMICAL", 0, 2], ["children", "ORGANISM", 341, 349], ["children", "SPECIES", 341, 349], ["people", "SPECIES", 399, 405], ["the COVID", "TEST", 219, 228], ["Symptomatic versus asymptomatic", "PROBLEM", 506, 537], ["symptomatic", "PROBLEM", 553, 564], ["asymptomatic cases", "PROBLEM", 603, 621], ["med", "ANATOMY", 102, 105], ["symptomatic", "OBSERVATION_MODIFIER", 553, 564]]], ["There were more symptomatic (35.1%) aged \u2265 40 years than asymptomatic cases (29.0%).", [["asymptomatic cases", "TEST", 57, 75], ["symptomatic", "OBSERVATION_MODIFIER", 16, 27]]], ["There were significant differences in the frequency distributions of the place of work between the symptomatic and asymptomatic cases (p=0.006).", [["significant", "OBSERVATION_MODIFIER", 11, 22], ["differences", "OBSERVATION_MODIFIER", 23, 34], ["symptomatic", "OBSERVATION_MODIFIER", 99, 110]]], ["More than two-thirds of symptomatic and asymptomatic (64.4% and 65.7%, respectively) cases were working in public places.", [["symptomatic", "PROBLEM", 24, 35], ["asymptomatic", "PROBLEM", 40, 52]]], ["Among the COVID-19 cases working in healthcare settings and aviation or tourism services, there were more symptomatic (19.7%) compared to asymptomatic cases (12.9%).", [["asymptomatic cases", "TEST", 138, 156]]], ["The proportion of symptomatic cases with at least one chronic comorbidity was significantly higher than that of asymptomatic cases (16.7% vs 9.6%, respectively).", [["symptomatic cases", "PROBLEM", 18, 35], ["chronic comorbidity", "PROBLEM", 54, 73], ["asymptomatic cases", "TEST", 112, 130], ["symptomatic", "OBSERVATION_MODIFIER", 18, 29], ["cases", "OBSERVATION", 30, 35], ["chronic", "OBSERVATION_MODIFIER", 54, 61], ["comorbidity", "OBSERVATION", 62, 73]]], ["In each of the three subsequent RT-PCR testing rounds, the proportion of testing positive to COVID-19 was substantially higher among symptomatic compared to asymptomatic cases (Table 1) .Crude and independent factors associated with symptomatic stateThe COVID-19 cases aged 40-59 years had 2.3-fold (95% CI: 1.23-4.34) higher odds to be symptomatic.", [["COVID-19", "DNA", 93, 101], ["testing", "TEST", 73, 80], ["COVID", "TEST", 93, 98], ["The COVID", "TEST", 250, 259], ["CI", "TEST", 304, 306], ["symptomatic", "PROBLEM", 337, 348], ["symptomatic", "OBSERVATION", 337, 348]]], ["This association retained insignificant in the multivariable model.", [["retained", "OBSERVATION_MODIFIER", 17, 25], ["insignificant", "OBSERVATION_MODIFIER", 26, 39], ["multivariable model", "OBSERVATION", 47, 66]]], ["Compared to \"not working\", working in public places (aOR: 1.76, 95% CI: 1.11-2.80), in healthcare setting (aOR: 2.09, 95% CI: 1.01-4.31), or in aviation and tourism services (aOR: 2.24, 95% CI: 1.14-4.40) was associated with a higher likelihood of having a symptomatic state.Crude and independent factors associated with symptomatic stateReporting at least one chronic comorbidity was associated with 1.76-time higher likelihood of having symptomatic state (aOR: 1.76, 95% CI: 1.03-3.01).", [["CI", "TEST", 68, 70], ["CI", "TEST", 122, 124], ["aOR", "TEST", 175, 178], ["CI", "TEST", 190, 192], ["a symptomatic state", "PROBLEM", 255, 274], ["chronic comorbidity", "PROBLEM", 361, 380], ["symptomatic state", "PROBLEM", 439, 456], ["CI", "TEST", 473, 475], ["symptomatic", "OBSERVATION", 257, 268], ["chronic", "OBSERVATION_MODIFIER", 361, 368], ["comorbidity", "OBSERVATION", 369, 380]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintCrude and independent factors associated with symptomatic stateThe copyright holder for this this version posted September 25, 2020.Positivity in subsequent RT-PCR testing roundsSymptomatic status was associated with prolonged duration of viral shedding compared to asymptomatic status (p-value for log-rank test 0.0026) (Fig 3) .Positivity in subsequent RT-PCR testing rounds.", [["CC", "CHEMICAL", 0, 2], ["symptomatic state", "PROBLEM", 254, 271], ["subsequent RT-PCR testing", "TEST", 354, 379], ["Symptomatic status", "PROBLEM", 386, 404], ["viral shedding", "PROBLEM", 447, 461], ["asymptomatic status", "PROBLEM", 474, 493], ["p-value", "TEST", 495, 502], ["log-rank test", "TEST", 507, 520], ["subsequent RT-PCR testing rounds", "TEST", 552, 584], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["In each of the three subsequent RT-PCR testing rounds, symptomatic COVID-19 cases were over two times at higher likelihood of testing positive compared to asymptomatic cases, after adjustment for the potential confounders and difference in the mean day duration between any two subsequent testing rounds (Table 3) .Discussion.", [["symptomatic COVID", "TEST", 55, 72], ["testing positive", "PROBLEM", 126, 142]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review) preprintThe copyright holder for this this version posted September 25, 2020. .4The findings described COVID-19 RT-PCR confirmed cases according to their symptomatic sate and identified sociodemographic characteristics associated with presenting symptoms in COVID-19 patients.", [["CC", "CHEMICAL", 0, 2], ["patients", "ORGANISM", 466, 474], ["COVID-19 RT-PCR", "DNA", 302, 317], ["patients", "SPECIES", 466, 474], ["COVID", "TEST", 302, 307], ["RT-PCR", "TEST", 311, 317], ["presenting symptoms", "PROBLEM", 434, 453], ["med", "ANATOMY", 102, 105]]], ["The study also quantified the strength of association between testing positive in three subsequent RT-PCR testing rounds, after the first test.", [["The study", "TEST", 0, 9], ["testing", "TEST", 62, 69], ["the first test", "TEST", 128, 142]]], ["Elder ages, working, or having at least one chronic comorbidity were independently associated with developing symptoms to COVID-19.", [["COVID-19", "CHEMICAL", 122, 130], ["chronic comorbidity", "PROBLEM", 44, 63], ["developing symptoms", "PROBLEM", 99, 118], ["COVID", "TEST", 122, 127]]], ["Symptomatic COVID-19 cases were independently more likely to test positive to COVID-19 after an average duration of 8.3 days from the first confirmatory testing round.4The finding of 43.5% of the reported COVID-19 cases were asymptomatic is higher than the previously reported asymptomatic proportion in Columbia (12.0%), (14) .", [["Symptomatic COVID", "TEST", 0, 17], ["COVID", "TEST", 78, 83], ["the first confirmatory testing", "TEST", 130, 160], ["COVID", "TEST", 205, 210], ["asymptomatic", "PROBLEM", 225, 237], ["higher", "OBSERVATION_MODIFIER", 241, 247]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review) preprintThe copyright holder for this this version posted September 25, 2020. .5The crude finding of an inverse association between young age and presenting symptoms to COVID-19 is consistent with a previous report.", [["CC", "CHEMICAL", 0, 2], ["presenting symptoms", "PROBLEM", 345, 364], ["COVID", "TEST", 368, 373], ["med", "ANATOMY", 102, 105], ["consistent with", "UNCERTAINTY", 380, 395]]], ["(15) Younger people are more likely to be healthier with no underlying co-morbidities such as diabetes or hypertension.", [["diabetes", "DISEASE", 94, 102], ["hypertension", "DISEASE", 106, 118], ["people", "ORGANISM", 13, 19], ["people", "SPECIES", 13, 19], ["underlying co-morbidities", "PROBLEM", 60, 85], ["diabetes", "PROBLEM", 94, 102], ["hypertension", "PROBLEM", 106, 118], ["more likely", "UNCERTAINTY", 24, 35], ["diabetes", "OBSERVATION", 94, 102], ["hypertension", "OBSERVATION", 106, 118]]], ["However, the disappearance of this significant finding in the multivariate model is due to the confounding effect of the \"working status\".", [["significant", "OBSERVATION_MODIFIER", 35, 46]]], ["Younger populations are more likely to be engaged in incomeproducing activities rather than being retired or unemployed.", [["more likely", "UNCERTAINTY", 24, 35]]], ["In the present study, COVID-19 symptomatic state was associated with working in public places (e.g. petrol stations and shopping malls), healthcare settings, or aviation and tourism sector (e.g. cabin crews and airport taxi drivers).", [["the present study", "TEST", 3, 20], ["COVID", "TEST", 22, 27]]], ["Exposure and repeated exposure to COVID-19 carriers are more likely to occur in working places with more exposure to the public.", [["COVID-19", "CHEMICAL", 34, 42], ["COVID-19", "CHEMICAL", 34, 42], ["COVID-19 carriers", "TREATMENT", 34, 51]]], ["Similarly, working in closed spaces including healthcare settings or in aviation and tourism services potentially increases the risk of exposure and re-exposure to the virus carriers such as confirmed patients and international travelers.", [["patients", "ORGANISM", 201, 209], ["patients", "SPECIES", 201, 209], ["healthcare settings", "TREATMENT", 46, 65], ["the virus carriers", "TREATMENT", 164, 182]]], ["Re-exposure to more COVID-19 carriers or contaminated physical services may have contributed to an increased level of the contracted viral load, which may have expedited the symptomatic state.5COVID-19 positive cases with at least one chronic comorbidity were also positively associated with symptomatic state.", [["COVID-19", "CHEMICAL", 20, 28], ["COVID-19", "GENE_OR_GENE_PRODUCT", 20, 28], ["5COVID-19", "GENE_OR_GENE_PRODUCT", 192, 201], ["an increased level", "PROBLEM", 96, 114], ["the contracted viral load", "PROBLEM", 118, 143], ["the symptomatic state", "PROBLEM", 170, 191], ["5COVID", "TEST", 192, 198], ["chronic comorbidity", "PROBLEM", 235, 254], ["symptomatic state", "PROBLEM", 292, 309], ["increased", "OBSERVATION_MODIFIER", 99, 108], ["viral load", "OBSERVATION", 133, 143], ["symptomatic", "OBSERVATION_MODIFIER", 174, 185], ["19 positive", "OBSERVATION_MODIFIER", 199, 210], ["chronic", "OBSERVATION_MODIFIER", 235, 242], ["comorbidity", "OBSERVATION", 243, 254]]], ["In our COVID-19 population, DM and hypertension were the most frequent two chronic comorbidities.", [["DM", "DISEASE", 28, 30], ["hypertension", "DISEASE", 35, 47], ["DM", "PROBLEM", 28, 30], ["hypertension", "PROBLEM", 35, 47], ["two chronic comorbidities", "PROBLEM", 71, 96], ["hypertension", "OBSERVATION", 35, 47], ["chronic", "OBSERVATION_MODIFIER", 75, 82], ["comorbidities", "OBSERVATION", 83, 96]]], ["This observation is in line with other reports that documented DM and hypertension as the most distinctive comorbidities in COVID-19 patients.", [["DM", "DISEASE", 63, 65], ["hypertension", "DISEASE", 70, 82], ["patients", "ORGANISM", 133, 141], ["patients", "SPECIES", 133, 141], ["DM", "PROBLEM", 63, 65], ["hypertension", "PROBLEM", 70, 82], ["COVID", "TEST", 124, 129], ["DM", "OBSERVATION", 63, 65], ["hypertension", "OBSERVATION", 70, 82]]], ["(16) (17) (18) (19) People with chronic comorbidities are more likely to be older in age and to suffer from immune system impairments.", [["immune system", "ANATOMY", 108, 121], ["immune system impairments", "DISEASE", 108, 133], ["People", "SPECIES", 20, 26], ["chronic comorbidities", "PROBLEM", 32, 53], ["immune system impairments", "PROBLEM", 108, 133], ["chronic", "OBSERVATION_MODIFIER", 32, 39], ["comorbidities", "OBSERVATION", 40, 53]]], ["DM patients suffer from a lack of energy supply to immune cells that subsequently increases the virulence of infectious microorganisms.", [["immune cells", "ANATOMY", 51, 63], ["DM", "DISEASE", 0, 2], ["patients", "ORGANISM", 3, 11], ["immune cells", "CELL", 51, 63], ["immune cells", "CELL_TYPE", 51, 63], ["patients", "SPECIES", 3, 11], ["DM", "PROBLEM", 0, 2], ["immune cells", "PROBLEM", 51, 63], ["infectious microorganisms", "PROBLEM", 109, 134], ["infectious", "OBSERVATION_MODIFIER", 109, 119]]], ["(20) (21) (22) These impairments weaken the immune system response to microorganisms.(23) (24) Hence, individuals with DM are more likely to be infected and are at a higher risk for complications and death from COVID-19 and other pathogens including SARS and MERS, (17, (25) (26) (27) and5.", [["immune system", "ANATOMY", 44, 57], ["DM", "DISEASE", 119, 121], ["death", "DISEASE", 200, 205], ["SARS", "DISEASE", 250, 254], ["individuals", "ORGANISM", 102, 113], ["(25) (26) (27) and5", "SIMPLE_CHEMICAL", 270, 289], ["These impairments", "PROBLEM", 15, 32], ["microorganisms", "PROBLEM", 70, 84], ["DM", "PROBLEM", 119, 121], ["complications", "PROBLEM", 182, 195], ["death", "PROBLEM", 200, 205], ["COVID", "TEST", 211, 216], ["other pathogens", "PROBLEM", 224, 239], ["SARS", "PROBLEM", 250, 254], ["MERS", "TEST", 259, 263], ["more likely to be", "UNCERTAINTY", 126, 143], ["infected", "OBSERVATION", 144, 152]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["In our study, although the symptomatic state was associated with a delay in testing negative in the subsequent testing rounds compared to asymptomatic cases, a substantial proportion of asymptomatic cases were also tested positive.", [["our study", "TEST", 3, 12], ["the symptomatic state", "PROBLEM", 23, 44], ["a delay in testing", "PROBLEM", 65, 83], ["asymptomatic cases", "PROBLEM", 186, 204]]], ["In the second RT-PCR testing round, after an average of 2.7 days post the first test, almost three quarters (73.0%) while over a one-thirdLimitations and Strengths.", [["the second RT-PCR testing", "TEST", 3, 28], ["the first test", "TEST", 70, 84], ["round", "OBSERVATION_MODIFIER", 29, 34]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintLimitations and StrengthsThe copyright holder for this this version posted September 25, 2020. . https://doi.org/10.1101/2020.09.", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["The cross-sectional design of the present study limits the causality pathway.Limitations and StrengthsSecond, the collected information on the measured sociodemographic and medical conditions was based on self-reports.", [["the present study", "TEST", 30, 47]]], ["However, this is less likely to occur as all the data was collected by trained healthcare staff who are familiar with data collection and with the definition of chronic comorbidities.", [["data collection", "TEST", 118, 133], ["chronic comorbidities", "PROBLEM", 161, 182], ["less likely", "UNCERTAINTY", 17, 28], ["chronic", "OBSERVATION_MODIFIER", 161, 168], ["comorbidities", "OBSERVATION", 169, 182]]], ["Third, categorization of the COVID-19 cases into the symptomatic and asymptomatic state without further categorization into a mild, moderate, severe, or critical state.", [["the COVID", "TEST", 25, 34], ["the symptomatic and asymptomatic state", "PROBLEM", 49, 87], ["further categorization", "TEST", 96, 118], ["a mild, moderate, severe, or critical state", "PROBLEM", 124, 167], ["symptomatic", "OBSERVATION_MODIFIER", 53, 64], ["mild", "OBSERVATION_MODIFIER", 126, 130], ["moderate", "OBSERVATION_MODIFIER", 132, 140], ["severe", "OBSERVATION_MODIFIER", 142, 148]]], ["This was because of the lack of other clinical parameters that are necessary for such categorization.", [["such categorization", "TEST", 81, 100]]], ["However, performing further analysis according to the number of symptoms (asymptomatic, one symptom, 2-3 symptoms, and \u2265 4 symptoms) was consistent with current findings apart from the significant reduction in the power of the obtained estimates (data not shown).", [["further analysis", "TEST", 20, 36], ["symptoms", "PROBLEM", 64, 72], ["asymptomatic", "PROBLEM", 74, 86], ["one symptom", "PROBLEM", 88, 99], ["3 symptoms", "PROBLEM", 103, 113], ["\u2265 4 symptoms", "PROBLEM", 119, 131], ["the significant reduction", "PROBLEM", 181, 206], ["consistent with", "UNCERTAINTY", 137, 152], ["significant", "OBSERVATION_MODIFIER", 185, 196], ["reduction", "OBSERVATION_MODIFIER", 197, 206]]], ["Another important limitation that would potentially further limit the generalizability of our findings is the substantial proportion (36.7%) of missing data on the symptomatic state of COVID-19 cases.", [["COVID", "DISEASE", 185, 190], ["missing data", "PROBLEM", 144, 156], ["COVID", "TEST", 185, 190]]], ["Nevertheless, to exclude the potential effect of the missing data, the COVID-19 cases included in this analysis were similar to those with missing data, according to the measured exposure variables except for the number of chronic comorbidities.", [["the COVID", "TEST", 67, 76], ["this analysis", "TEST", 98, 111], ["chronic comorbidities", "PROBLEM", 223, 244], ["chronic", "OBSERVATION_MODIFIER", 223, 230], ["comorbidities", "OBSERVATION", 231, 244]]], ["This difference in the proportion of COVID-19 cases with at least one medical condition could be explained by the observed large proportion of missing data on the self-reported medical conditions of the excluded cases.", [["COVID", "TEST", 37, 42], ["missing data", "PROBLEM", 143, 155], ["large", "OBSERVATION_MODIFIER", 123, 128]]], ["Also, there was no information on the number of pre-symptomatic patients who subsequently developed symptoms during observation.", [["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["symptoms", "PROBLEM", 100, 108]]], ["Finally, all the included studies relied on RT-PCR testing without further investigation using chest computed tomography (CT) imaging.", [["RT-PCR testing", "TEST", 44, 58], ["further investigation", "TEST", 67, 88], ["chest computed tomography", "TEST", 95, 120], ["CT) imaging", "TEST", 122, 133], ["chest", "ANATOMY", 95, 100]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintLimitations and StrengthsThe copyright holder for this this version posted September 25, 2020. .", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["1 8 have been missed due to false negative result, or some cases might have been included due to the false positive testing to 34) Despite these limitations, to the best of our knowledge, this is the first study to characterize COVID-19 positive cases in the UAE according to the symptomatic state and to shed light on the strength of association between sociodemographic characteristics and chronic comorbidities with symptomatic state of the COVID-19 cases.", [["false negative result", "PROBLEM", 28, 49], ["the false positive testing", "PROBLEM", 97, 123], ["the first study", "TEST", 196, 211], ["COVID", "TEST", 228, 233], ["chronic comorbidities", "PROBLEM", 392, 413], ["the COVID", "TEST", 440, 449], ["chronic", "OBSERVATION_MODIFIER", 392, 399]]], ["Furthermore, our study was based on data collected by trained personal using a standardized data collection and RT-PCR testing procedure.", [["our study", "TEST", 13, 22], ["a standardized data collection", "TEST", 77, 107], ["RT-PCR testing procedure", "TREATMENT", 112, 136]]], ["Our study also provided empirical evidence on the positive association between symptomatic state and delay in testing negative compared to asymptomatic COVID-19 cases.ConclusionsA substantial proportion of the COVID-19 cases in the Abu Dhabi emirate identified between February 28 and April 08, 2020 was asymptomatic.", [["Our study", "TEST", 0, 9], ["the positive association between symptomatic state", "PROBLEM", 46, 96], ["delay in testing", "TEST", 101, 117], ["asymptomatic COVID", "TEST", 139, 157], ["the COVID", "TEST", 206, 215], ["asymptomatic", "PROBLEM", 304, 316]]], ["Working in settings with a higher likelihood of exposure and re-exposure to confirmed or potential virus carriers, or suffering from at least one chronic comorbidity, were independently positively associated with the symptomatic state of the COVID-19 cases.", [["potential virus carriers", "PROBLEM", 89, 113], ["chronic comorbidity", "PROBLEM", 146, 165], ["the COVID", "TEST", 238, 247], ["chronic", "OBSERVATION_MODIFIER", 146, 153], ["comorbidity", "OBSERVATION", 154, 165]]], ["The estimated proportion of asymptomatic cases is a vital parameter for future studies while the estimated strength of association between identified exposures and the symptomatic state and between testing positive in further RT-PCR testing rounds is vital for public health prevention and control interventions.", [["future studies", "TEST", 72, 86], ["the symptomatic state", "PROBLEM", 164, 185], ["testing", "TEST", 198, 205], ["further RT", "TEST", 218, 228], ["PCR testing", "TEST", 229, 240], ["public health prevention", "TREATMENT", 261, 285], ["control interventions", "TREATMENT", 290, 311], ["asymptomatic", "OBSERVATION", 28, 40]]], ["Further follow up cohort studies are needed to have more insight about viral clearance and clinical outcomes in COVID-19 symptomatic and asymptomatic cases.Conclusions.", [["Further follow up cohort studies", "TEST", 0, 32], ["viral clearance", "TEST", 71, 86], ["COVID", "TEST", 112, 117], ["symptomatic and asymptomatic cases", "PROBLEM", 121, 155]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintConclusionsThe copyright holder for this this version posted September 25, 2020. . https://doi.org/10.1101/2020.09.23.20200030 doi: medRxiv preprint .", [["CC", "CHEMICAL", 0, 2], ["medRxiv preprint", "TREATMENT", 340, 356], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. .", [["CC", "CHEMICAL", 0, 2], ["med", "ANATOMY", 102, 105]]], ["CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintConclusionsThe copyright holder for this this version posted September 25, 2020. . https://doi.org/10.1101/2020.09.23.20200030 doi: medRxiv preprint", [["CC", "CHEMICAL", 0, 2], ["medRxiv", "TREATMENT", 340, 347], ["med", "ANATOMY", 102, 105]]]], "1b0750ca457cae732c86f2bbddb55306e46a9594": [["The 2019 novel coronavirus disease , caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in Wuhan city and rapidly spread throughout China, causing a wide spectrum of severity and being classified by the WHO as a public health emergency of international concern.", [["coronavirus disease", "DISEASE", 15, 34], ["acute respiratory syndrome coronavirus", "DISEASE", 58, 96], ["coronavirus", "ORGANISM", 15, 26], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 51, 98], ["SARS-CoV-2", "ORGANISM", 100, 110], ["coronavirus", "SPECIES", 15, 26], ["severe acute respiratory syndrome coronavirus", "SPECIES", 51, 96], ["SARS-CoV-2", "SPECIES", 100, 110], ["novel coronavirus disease", "PROBLEM", 9, 34], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 47, 96], ["coronavirus disease", "OBSERVATION", 15, 34], ["severe", "OBSERVATION_MODIFIER", 51, 57], ["acute", "OBSERVATION_MODIFIER", 58, 63], ["respiratory syndrome", "OBSERVATION", 64, 84]]], ["To date, WHO estimates that this pandemic has affected 20 million people and taken the lives of more than 750,000 individuals worldwide, not including the unreported cases; and its reach and severity continue to spread [1] .", [["people", "ORGANISM", 66, 72], ["people", "SPECIES", 66, 72]]]], "PMC7194111": [["IntroductionZika virus (ZIKV), first isolated from a rhesus monkey in the Zika forest of Uganda in 1947 (Dick, G W et al., 1952; Routhu, N Kim et al., 2018), is a mosquito-borne, single-stranded, positive-sense RNA arbovirus, and a member of the Flavivirus family (Tham et al., 2018).", [["IntroductionZika virus", "ORGANISM", 0, 22], ["ZIKV", "GENE_OR_GENE_PRODUCT", 24, 28], ["rhesus monkey", "ORGANISM", 53, 66], ["rhesus monkey", "SPECIES", 53, 66], ["IntroductionZika virus", "SPECIES", 0, 22], ["ZIKV", "SPECIES", 24, 28], ["rhesus monkey", "SPECIES", 53, 66], ["IntroductionZika virus", "PROBLEM", 0, 22]]], ["The ZIKV genome encodes three structural proteins (C, prM/M, and E) and seven nonstructural (NS) proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) (Hamel et al., 2015).", [["C", "GENE_OR_GENE_PRODUCT", 51, 52], ["prM", "GENE_OR_GENE_PRODUCT", 54, 57], ["NS1", "GENE_OR_GENE_PRODUCT", 107, 110], ["NS2A", "GENE_OR_GENE_PRODUCT", 112, 116], ["NS2B", "GENE_OR_GENE_PRODUCT", 118, 122], ["NS3", "GENE_OR_GENE_PRODUCT", 124, 127], ["NS4A", "GENE_OR_GENE_PRODUCT", 129, 133], ["NS4B", "GENE_OR_GENE_PRODUCT", 135, 139], ["ZIKV genome", "DNA", 4, 15], ["structural proteins", "PROTEIN", 30, 49], ["C", "PROTEIN", 51, 52], ["prM", "PROTEIN", 54, 57], ["M", "PROTEIN", 58, 59], ["E", "PROTEIN", 65, 66], ["nonstructural (NS) proteins", "PROTEIN", 78, 105], ["NS1", "PROTEIN", 107, 110], ["NS2A", "PROTEIN", 112, 116], ["NS2B", "PROTEIN", 118, 122], ["NS3", "PROTEIN", 124, 127], ["NS4A", "PROTEIN", 129, 133], ["NS4B", "PROTEIN", 135, 139], ["NS5", "PROTEIN", 145, 148], ["ZIKV", "SPECIES", 4, 8], ["proteins", "TEST", 97, 105], ["NS1", "TEST", 107, 110], ["NS2A", "TEST", 112, 116], ["NS2B", "TEST", 118, 122], ["NS3", "TREATMENT", 124, 127], ["NS4A", "TREATMENT", 129, 133], ["NS4B", "TREATMENT", 135, 139], ["ZIKV genome", "OBSERVATION", 4, 15]]], ["ZIKV infection has been associated with several central nervous system diseases, such as Guillain-Barr\u00e9 syndrome, and meningoencephalitis, which are especially harmful to the immature nervous system, and could cause congenital microcephaly in the offspring of pregnant woman (Perez-Cabezas et al., 2019).", [["central nervous system", "ANATOMY", 48, 70], ["nervous system", "ANATOMY", 184, 198], ["ZIKV infection", "DISEASE", 0, 14], ["central nervous system diseases", "DISEASE", 48, 79], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 89, 112], ["meningoencephalitis", "DISEASE", 118, 137], ["harmful to the immature nervous system", "DISEASE", 160, 198], ["congenital microcephaly", "DISEASE", 216, 239], ["nervous system", "ANATOMICAL_SYSTEM", 56, 70], ["Guillain-Barr\u00e9", "ORGANISM", 89, 103], ["nervous system", "ANATOMICAL_SYSTEM", 184, 198], ["woman", "ORGANISM", 269, 274], ["woman", "SPECIES", 269, 274], ["ZIKV", "SPECIES", 0, 4], ["ZIKV infection", "PROBLEM", 0, 14], ["several central nervous system diseases", "PROBLEM", 40, 79], ["Guillain-Barr\u00e9 syndrome", "PROBLEM", 89, 112], ["meningoencephalitis", "PROBLEM", 118, 137], ["congenital microcephaly", "PROBLEM", 216, 239], ["associated with", "UNCERTAINTY", 24, 39], ["several", "OBSERVATION_MODIFIER", 40, 47], ["central nervous system diseases", "OBSERVATION", 48, 79], ["Barr\u00e9 syndrome", "OBSERVATION", 98, 112], ["meningoencephalitis", "OBSERVATION", 118, 137], ["nervous system", "ANATOMY", 184, 198], ["microcephaly", "OBSERVATION", 227, 239]]], ["Scientists have been working on anti-ZIKV research, and most research on drugs is mainly focused on antibody drugs, small-molecule compounds and peptide drugs.", [["small-molecule compounds", "SIMPLE_CHEMICAL", 116, 140], ["drugs", "TREATMENT", 73, 78], ["antibody drugs", "TREATMENT", 100, 114], ["small-molecule compounds", "TREATMENT", 116, 140], ["peptide drugs", "TREATMENT", 145, 158]]], ["Many vaccine candidates have been identified in clinical research, such as DNA vaccines, mRNA vaccines, inactivated virions and viral vectors (Diamond et al., 2019).", [["DNA", "CELLULAR_COMPONENT", 75, 78], ["Many vaccine candidates", "TREATMENT", 0, 23], ["DNA vaccines", "TREATMENT", 75, 87], ["mRNA vaccines", "TREATMENT", 89, 102]]], ["However, vaccination may cause important issues, such as antibody-dependent enhancement (ADE), and recent FDA approved drug screenings have indicated that many drugs can effectively suppress ZIKV, including candesartan cilexetil (Loe et al., 2019), pinocembrin (Lee et al., 2019), aurintricarboxylic acid (Park et al. 2019), ribavirin and sofosbuvir.", [["ZIKV", "CHEMICAL", 191, 195], ["candesartan cilexetil", "CHEMICAL", 207, 228], ["pinocembrin", "CHEMICAL", 249, 260], ["aurintricarboxylic acid", "CHEMICAL", 281, 304], ["ribavirin", "CHEMICAL", 325, 334], ["sofosbuvir", "CHEMICAL", 339, 349], ["candesartan cilexetil", "CHEMICAL", 207, 228], ["pinocembrin", "CHEMICAL", 249, 260], ["aurintricarboxylic acid", "CHEMICAL", 281, 304], ["ribavirin", "CHEMICAL", 325, 334], ["sofosbuvir", "CHEMICAL", 339, 349], ["ZIKV", "SIMPLE_CHEMICAL", 191, 195], ["candesartan cilexetil", "SIMPLE_CHEMICAL", 207, 228], ["pinocembrin", "SIMPLE_CHEMICAL", 249, 260], ["aurintricarboxylic acid", "SIMPLE_CHEMICAL", 281, 304], ["ribavirin", "SIMPLE_CHEMICAL", 325, 334], ["sofosbuvir", "SIMPLE_CHEMICAL", 339, 349], ["ZIKV", "SPECIES", 191, 195], ["vaccination", "TREATMENT", 9, 20], ["important issues", "PROBLEM", 31, 47], ["antibody-dependent enhancement", "PROBLEM", 57, 87], ["drug screenings", "TEST", 119, 134], ["many drugs", "TREATMENT", 155, 165], ["ZIKV", "PROBLEM", 191, 195], ["candesartan cilexetil", "TREATMENT", 207, 228], ["pinocembrin", "TREATMENT", 249, 260], ["aurintricarboxylic acid", "TREATMENT", 281, 304], ["ribavirin", "TREATMENT", 325, 334], ["sofosbuvir", "TREATMENT", 339, 349], ["dependent enhancement", "OBSERVATION_MODIFIER", 66, 87]]], ["However, how to protect pregnant women safely and effectively poses a substantial challenge for the development of small-molecule drugs.", [["women", "ORGANISM", 33, 38], ["women", "SPECIES", 33, 38], ["a substantial challenge", "TREATMENT", 68, 91], ["small-molecule drugs", "TREATMENT", 115, 135], ["small", "OBSERVATION_MODIFIER", 115, 120]]], ["Although ribavirin can effectively inhibit ZIKV replication (Kim et al., 2018), it is not yet widely available because it could cause haemolytic anaemia when administered orally over a long term (Russmann et al., 2006).", [["ribavirin", "CHEMICAL", 9, 18], ["haemolytic anaemia", "DISEASE", 134, 152], ["ribavirin", "CHEMICAL", 9, 18], ["ribavirin", "SIMPLE_CHEMICAL", 9, 18], ["ZIKV", "CELL", 43, 47], ["ZIKV", "SPECIES", 43, 47], ["ribavirin", "TREATMENT", 9, 18], ["haemolytic anaemia", "PROBLEM", 134, 152], ["ribavirin", "OBSERVATION", 9, 18], ["haemolytic", "OBSERVATION_MODIFIER", 134, 144], ["anaemia", "OBSERVATION", 145, 152]]], ["Research has reported that sofosbuvir can also inhibit ZIKV infection (Reznik and Ashby, 2017), but it is not suitable for use in developing countries because of its cost (Bausch et al., 2010).IntroductionLycorine is a benzyl phenethylamine alkaloid, first isolated from Narcissus pseudonarcissus in 1877, and itsthe structure was elucidated in 1956 (Kornienko and Evidente, 2008).", [["sofosbuvir", "CHEMICAL", 27, 37], ["ZIKV infection", "DISEASE", 55, 69], ["IntroductionLycorine", "CHEMICAL", 193, 213], ["benzyl phenethylamine alkaloid", "CHEMICAL", 219, 249], ["sofosbuvir", "CHEMICAL", 27, 37], ["benzyl phenethylamine alkaloid", "CHEMICAL", 219, 249], ["sofosbuvir", "SIMPLE_CHEMICAL", 27, 37], ["ZIKV", "ORGANISM", 55, 59], ["benzyl phenethylamine alkaloid", "SIMPLE_CHEMICAL", 219, 249], ["Narcissus pseudonarcissus", "ORGANISM", 271, 296], ["Narcissus pseudonarcissus", "SPECIES", 271, 296], ["ZIKV", "SPECIES", 55, 59], ["Narcissus pseudonarcissus", "SPECIES", 271, 296], ["sofosbuvir", "TREATMENT", 27, 37], ["ZIKV infection", "PROBLEM", 55, 69], ["a benzyl phenethylamine alkaloid", "TREATMENT", 217, 249], ["sofosbuvir", "OBSERVATION", 27, 37]]], ["Diverse biological properties have been shown for lycorine, including anticancer (Lamoral-Theys et al., 2010), antiplasmodial (Cedron et al., 2010), antitrypanosomal (Toriizuka et al., 2008), anti-inflammatory (Citoglu et al., 2012), and emetic (Kretzing et al., 2011) properties.", [["anticancer", "ANATOMY", 70, 80], ["lycorine", "CHEMICAL", 50, 58], ["lycorine", "CHEMICAL", 50, 58], ["lycorine", "SIMPLE_CHEMICAL", 50, 58], ["anticancer", "CANCER", 70, 80], ["lycorine", "TREATMENT", 50, 58]]], ["Lycorine has also been reported to demonstrate broad-spectrum inhibitory activities against several viruses, such as poliovirus (Hwang et al., 2008), severe acute respiratory syndrome-associated coronavirus (SARS-CoV) (Li et al., 2005), herpes simplex virus (type 1) (Renard-Nozaki et al., 1989), bunyaviruses, Punta Toro virus, and Rift Valley fever virus (Gabrielsen et al., 1992).IntroductionBased on our experiments, lycorine may exert potent and effective antiviral activity against ZIKV replication by restraining RdRp activity.", [["Lycorine", "CHEMICAL", 0, 8], ["acute respiratory syndrome-associated coronavirus (SARS-CoV)", "DISEASE", 157, 217], ["herpes simplex virus", "DISEASE", 237, 257], ["Rift Valley fever", "DISEASE", 333, 350], ["lycorine", "CHEMICAL", 421, 429], ["Lycorine", "CHEMICAL", 0, 8], ["lycorine", "CHEMICAL", 421, 429], ["Lycorine", "SIMPLE_CHEMICAL", 0, 8], ["severe acute respiratory syndrome-associated coronavirus", "ORGANISM", 150, 206], ["SARS-CoV", "ORGANISM", 208, 216], ["herpes simplex virus", "ORGANISM", 237, 257], ["type 1", "ORGANISM", 259, 265], ["Punta Toro virus", "ORGANISM", 311, 327], ["Rift Valley fever virus", "ORGANISM", 333, 356], ["lycorine", "SIMPLE_CHEMICAL", 421, 429], ["ZIKV", "ORGANISM", 488, 492], ["RdRp", "GENE_OR_GENE_PRODUCT", 520, 524], ["RdRp", "PROTEIN", 520, 524], ["associated coronavirus", "SPECIES", 184, 206], ["herpes simplex virus", "SPECIES", 237, 257], ["Punta Toro virus", "SPECIES", 311, 327], ["Rift Valley fever virus", "SPECIES", 333, 356], ["severe acute respiratory syndrome-associated coronavirus", "SPECIES", 150, 206], ["SARS-CoV", "SPECIES", 208, 216], ["herpes simplex virus", "SPECIES", 237, 257], ["Punta Toro virus", "SPECIES", 311, 327], ["Rift Valley fever virus", "SPECIES", 333, 356], ["ZIKV", "SPECIES", 488, 492], ["Lycorine", "TREATMENT", 0, 8], ["several viruses", "PROBLEM", 92, 107], ["poliovirus", "PROBLEM", 117, 127], ["severe acute respiratory syndrome", "PROBLEM", 150, 183], ["associated coronavirus (SARS-CoV)", "PROBLEM", 184, 217], ["Li et al.", "TEST", 219, 228], ["herpes simplex virus", "PROBLEM", 237, 257], ["Renard", "TEST", 268, 274], ["bunyaviruses", "PROBLEM", 297, 309], ["Punta Toro virus", "PROBLEM", 311, 327], ["Rift Valley fever virus", "PROBLEM", 333, 356], ["lycorine", "TREATMENT", 421, 429], ["ZIKV replication", "TREATMENT", 488, 504], ["viruses", "OBSERVATION", 100, 107], ["severe", "OBSERVATION_MODIFIER", 150, 156], ["acute", "OBSERVATION_MODIFIER", 157, 162], ["respiratory syndrome", "OBSERVATION", 163, 183], ["coronavirus", "OBSERVATION", 195, 206]]], ["In addition, lycorine inhibits hepatitis C virus (HCV) replication by inhibiting the expression of hsc70 in host cells (Chen et al., 2015).", [["cells", "ANATOMY", 113, 118], ["lycorine", "CHEMICAL", 13, 21], ["hepatitis C", "DISEASE", 31, 42], ["lycorine", "CHEMICAL", 13, 21], ["lycorine", "SIMPLE_CHEMICAL", 13, 21], ["hepatitis C virus", "ORGANISM", 31, 48], ["HCV", "ORGANISM", 50, 53], ["hsc70", "GENE_OR_GENE_PRODUCT", 99, 104], ["host cells", "CELL", 108, 118], ["hsc70", "PROTEIN", 99, 104], ["host cells", "CELL_TYPE", 108, 118], ["hepatitis C virus", "SPECIES", 31, 48], ["hepatitis C virus", "SPECIES", 31, 48], ["HCV", "SPECIES", 50, 53], ["lycorine", "TREATMENT", 13, 21], ["hepatitis C virus", "PROBLEM", 31, 48], ["HCV) replication", "TREATMENT", 50, 66], ["lycorine", "OBSERVATION", 13, 21]]], ["Enterovirus 71 (EV71) is suppressed by treatment with lycorine, which interferes with viral polyproteins during elongation (Liu et al., 2011).", [["lycorine", "CHEMICAL", 54, 62], ["lycorine", "CHEMICAL", 54, 62], ["Enterovirus 71", "ORGANISM", 0, 14], ["EV71", "ORGANISM", 16, 20], ["lycorine", "SIMPLE_CHEMICAL", 54, 62], ["EV71", "SPECIES", 16, 20], ["Enterovirus", "TEST", 0, 11], ["lycorine", "TREATMENT", 54, 62], ["viral polyproteins", "PROBLEM", 86, 104], ["viral polyproteins", "OBSERVATION", 86, 104]]], ["Furthermore, lycorine inhibits the translocation of the ribonucleoprotein complex from the nucleus in the early stages of influenza virus H5N1 single-cycle and multicycle replication (He et al., 2013).", [["nucleus", "ANATOMY", 91, 98], ["lycorine", "CHEMICAL", 13, 21], ["lycorine", "CHEMICAL", 13, 21], ["lycorine", "SIMPLE_CHEMICAL", 13, 21], ["nucleus", "CELLULAR_COMPONENT", 91, 98], ["influenza virus", "ORGANISM", 122, 137], ["H5N1", "ORGANISM", 138, 142], ["ribonucleoprotein complex", "PROTEIN", 56, 81], ["influenza virus H5N1", "SPECIES", 122, 142], ["influenza virus H5N1", "SPECIES", 122, 142], ["lycorine", "TREATMENT", 13, 21], ["the ribonucleoprotein complex", "PROBLEM", 52, 81], ["influenza virus H5N1", "TREATMENT", 122, 142], ["multicycle replication", "TREATMENT", 160, 182], ["lycorine", "OBSERVATION", 13, 21], ["ribonucleoprotein complex", "OBSERVATION", 56, 81], ["nucleus", "ANATOMY", 91, 98], ["early stages", "OBSERVATION_MODIFIER", 106, 118], ["influenza virus", "OBSERVATION", 122, 137]]], ["In the present study, we assessed the anti-ZIKV activity of lycorine in vitro and in vivo.", [["lycorine", "CHEMICAL", 60, 68], ["lycorine", "CHEMICAL", 60, 68], ["lycorine", "SIMPLE_CHEMICAL", 60, 68], ["lycorine", "TREATMENT", 60, 68]]], ["This comprehensive assessment provided new candidate inhibitors to effectively treat ZIKV infections.Cells, viruses, and compounds ::: Materials and methodsVero (African green monkey kidney), Huh7 (hepatocellular carcinoma cells) and A549 (human alveolar basal epithelial adenocarcinoma) cells were grown and maintained in Dulbecco's modified Eagle\u2019s medium (DMEM, Thermo Fisher Scientific, Waltham, USA) at 37 \u00b0C in 5% CO2.", [["Cells", "ANATOMY", 101, 106], ["kidney", "ANATOMY", 183, 189], ["Huh7 (hepatocellular carcinoma cells", "ANATOMY", 192, 228], ["A549", "ANATOMY", 234, 238], ["alveolar basal epithelial adenocarcinoma) cells", "ANATOMY", 246, 293], ["ZIKV infections", "DISEASE", 85, 100], ["hepatocellular carcinoma", "DISEASE", 198, 222], ["CO2", "CHEMICAL", 420, 423], ["CO2", "CHEMICAL", 420, 423], ["ZIKV", "ORGANISM", 85, 89], ["Cells", "CELL", 101, 106], ["green monkey kidney", "ORGANISM", 170, 189], ["Huh7", "CELL", 192, 196], ["hepatocellular carcinoma cells", "CELL", 198, 228], ["A549", "CELL", 234, 238], ["human", "ORGANISM", 240, 245], ["alveolar basal epithelial adenocarcinoma) cells", "CELL", 246, 293], ["CO2", "SIMPLE_CHEMICAL", 420, 423], ["Huh7", "CELL_LINE", 192, 196], ["hepatocellular carcinoma cells", "CELL_TYPE", 198, 228], ["A549 (human alveolar basal epithelial adenocarcinoma) cells", "CELL_LINE", 234, 293], ["green monkey", "SPECIES", 170, 182], ["human", "SPECIES", 240, 245], ["ZIKV", "SPECIES", 85, 89], ["African green monkey", "SPECIES", 162, 182], ["human", "SPECIES", 240, 245], ["This comprehensive assessment", "TEST", 0, 29], ["new candidate inhibitors", "TREATMENT", 39, 63], ["ZIKV infections", "PROBLEM", 85, 100], ["Huh7 (hepatocellular carcinoma cells", "PROBLEM", 192, 228], ["A549 (human alveolar basal epithelial adenocarcinoma) cells", "PROBLEM", 234, 293], ["kidney", "ANATOMY", 183, 189], ["Huh7", "ANATOMY", 192, 196], ["hepatocellular", "ANATOMY", 198, 212], ["carcinoma cells", "OBSERVATION", 213, 228], ["alveolar", "ANATOMY_MODIFIER", 246, 254], ["basal", "ANATOMY_MODIFIER", 255, 260], ["epithelial adenocarcinoma", "OBSERVATION", 261, 286]]], ["Drugs were dissolved in 100% dimethylsulfoxide (DMSO, Amresco, Washington, USA) and subsequently diluted in culture medium before each assay.", [["dimethylsulfoxide", "CHEMICAL", 29, 46], ["DMSO", "CHEMICAL", 48, 52], ["dimethylsulfoxide", "CHEMICAL", 29, 46], ["DMSO", "CHEMICAL", 48, 52], ["dimethylsulfoxide", "SIMPLE_CHEMICAL", 29, 46], ["DMSO", "SIMPLE_CHEMICAL", 48, 52], ["Drugs", "TREATMENT", 0, 5], ["DMSO", "TREATMENT", 48, 52]]], ["Lycorine (purity > 98%) was purchased from Baoji Chen Guang Biotechnology Company.", [["Lycorine", "CHEMICAL", 0, 8], ["Lycorine", "CHEMICAL", 0, 8], ["Lycorine", "SIMPLE_CHEMICAL", 0, 8], ["Lycorine (purity", "TREATMENT", 0, 16]]], ["Asian ZIKV (ZIKV KU963796) was a gift from the Guangdong Provincial Center for Disease Control and Prevention.", [["ZIKV", "SPECIES", 6, 10], ["ZIKV", "SPECIES", 12, 16], ["Disease Control", "TREATMENT", 79, 94]]], ["All cell experiments were performed under the Biologicalsafety level-2Safety Level-2 (BSL-2) Laboratory.Cytotoxicity measurement ::: Materials and methodsCells were grown at 6 \u00d7 103 cells/well in 96-well culture plates and treated with different concentrations of drug.", [["cell", "ANATOMY", 4, 8], ["Cells", "ANATOMY", 154, 159], ["cells", "ANATOMY", 182, 187], ["cell", "CELL", 4, 8], ["Cells", "CELL", 154, 159], ["cells", "CELL", 182, 187], ["All cell experiments", "TEST", 0, 20], ["the Biologicalsafety level", "TEST", 42, 68], ["2Safety Level", "TEST", 69, 82], ["Cytotoxicity measurement", "TEST", 104, 128], ["Cells", "TEST", 154, 159], ["cells", "TEST", 182, 187], ["culture plates", "TEST", 204, 218], ["drug", "TREATMENT", 264, 268], ["cell experiments", "OBSERVATION", 4, 20]]], ["The control group was treated with an equal volume of DMSO.", [["DMSO", "CHEMICAL", 54, 58], ["DMSO", "CHEMICAL", 54, 58], ["DMSO", "SIMPLE_CHEMICAL", 54, 58], ["an equal volume of DMSO", "TREATMENT", 35, 58]]], ["After 48 h, 10% CCK8 reagent was added to each well, the plate was incubated for 1 h and absorbance values were determined at 450 nm.", [["CCK8", "CHEMICAL", 16, 20], ["CCK8", "CHEMICAL", 16, 20], ["CCK8 reagent", "SIMPLE_CHEMICAL", 16, 28], ["CCK8 reagent", "TEST", 16, 28], ["absorbance values", "TEST", 89, 106]]], ["CC50 was calculated as the compound concentration required to reduce cell viability by 50%.Anti-ZIKV assay ::: Materials and methodsCells were seeded at 2 \u00d7 105 cells/well in 12-well culture plates, and different concentrations of lycorine were added to each well for 2 h.", [["cell", "ANATOMY", 69, 73], ["Cells", "ANATOMY", 132, 137], ["cells", "ANATOMY", 161, 166], ["lycorine", "CHEMICAL", 231, 239], ["lycorine", "CHEMICAL", 231, 239], ["CC50", "SIMPLE_CHEMICAL", 0, 4], ["cell", "CELL", 69, 73], ["Cells", "CELL", 132, 137], ["cells", "CELL", 161, 166], ["lycorine", "SIMPLE_CHEMICAL", 231, 239], ["Anti-ZIKV", "SPECIES", 91, 100], ["CC50", "TEST", 0, 4], ["the compound concentration", "PROBLEM", 23, 49], ["cell viability", "TEST", 69, 83], ["Cells", "TEST", 132, 137], ["culture plates", "TEST", 183, 197], ["lycorine", "TREATMENT", 231, 239], ["cell viability", "OBSERVATION", 69, 83]]], ["Then, each well was infected with ZIKV at a multiplicity of infection (MOI) of 0.1 for 2 h and incubated until 48 h post infection (hpi).", [["ZIKV", "CHEMICAL", 34, 38], ["infection", "DISEASE", 60, 69], ["infection", "DISEASE", 121, 130], ["ZIKV", "ORGANISM", 34, 38], ["ZIKV", "SPECIES", 34, 38], ["ZIKV", "PROBLEM", 34, 38], ["infection", "PROBLEM", 60, 69], ["infection", "PROBLEM", 121, 130], ["infected", "OBSERVATION", 20, 28], ["infection", "OBSERVATION", 60, 69], ["infection", "OBSERVATION", 121, 130]]], ["Cells were used to quantitate the vRNA load using qRT-PCR.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["Cells", "TEST", 0, 5], ["the vRNA load", "TEST", 30, 43], ["qRT", "TEST", 50, 53]]], ["EC50 was calculated as the compound concentration required to reduce viral yields by 50%.Immunofluorescence assay ::: Materials and methodsVero cells were infected with ZIKV at an MOI = 0.1 and treated with lycorine or DMSO.", [["Vero cells", "ANATOMY", 139, 149], ["lycorine", "CHEMICAL", 207, 215], ["DMSO", "CHEMICAL", 219, 223], ["lycorine", "CHEMICAL", 207, 215], ["DMSO", "CHEMICAL", 219, 223], ["Vero cells", "CELL", 139, 149], ["lycorine", "SIMPLE_CHEMICAL", 207, 215], ["DMSO", "SIMPLE_CHEMICAL", 219, 223], ["Vero cells", "CELL_LINE", 139, 149], ["ZIKV", "SPECIES", 169, 173], ["EC50", "TEST", 0, 4], ["the compound concentration", "PROBLEM", 23, 49], ["viral yields", "TREATMENT", 69, 81], ["Immunofluorescence assay", "TEST", 89, 113], ["Vero cells", "PROBLEM", 139, 149], ["ZIKV", "PROBLEM", 169, 173], ["lycorine", "TREATMENT", 207, 215], ["DMSO", "TREATMENT", 219, 223], ["infected", "OBSERVATION_MODIFIER", 155, 163]]], ["At 48 hpi, the cells were subsequently fixed with 4% paraformaldehyde (Biosharp, Shanghai, China) for 15 min.", [["cells", "ANATOMY", 15, 20], ["paraformaldehyde", "CHEMICAL", 53, 69], ["cells", "CELL", 15, 20], ["paraformaldehyde", "SIMPLE_CHEMICAL", 53, 69], ["4% paraformaldehyde (Biosharp", "TREATMENT", 50, 79]]], ["After fixation, the cells were permeabilized with wash buffer (PBS+0.1% BSA) containing 0.2% Triton X-100 (Amresco, Washington, USA) for 5 min.", [["cells", "ANATOMY", 20, 25], ["Triton X-100", "CHEMICAL", 93, 105], ["cells", "CELL", 20, 25], ["BSA", "SIMPLE_CHEMICAL", 72, 75], ["Triton X-100", "SIMPLE_CHEMICAL", 93, 105], ["fixation", "TREATMENT", 6, 14], ["the cells", "TREATMENT", 16, 25], ["wash buffer", "TREATMENT", 50, 61], ["PBS", "TEST", 63, 66], ["fixation", "OBSERVATION", 6, 14]]], ["Then, the cells were blocked with 5% BSA (Beyotime, Jiangsu, China) for 30 min, and the blocking solution was aspirated.", [["cells", "ANATOMY", 10, 15], ["cells", "CELL", 10, 15], ["BSA", "SIMPLE_CHEMICAL", 37, 40], ["5% BSA", "TREATMENT", 34, 40], ["the blocking solution", "TREATMENT", 84, 105]]], ["The cells were then incubated with the mouse anti-pan flavivirus envelope protein mAb 4G2 (Millipore, Massachusetts, USA) at 4 \u00b0C overnight, washed, and incubated with fluorescen-conjugated secondary antibodies at room temperature for 30 min.", [["cells", "ANATOMY", 4, 9], ["fluorescen", "CHEMICAL", 168, 178], ["fluorescen", "CHEMICAL", 168, 178], ["cells", "CELL", 4, 9], ["mouse", "ORGANISM", 39, 44], ["fluorescen", "SIMPLE_CHEMICAL", 168, 178], ["mouse anti-pan flavivirus envelope protein mAb 4G2", "PROTEIN", 39, 89], ["fluorescen-conjugated secondary antibodies", "PROTEIN", 168, 210], ["mouse", "SPECIES", 39, 44], ["mouse", "SPECIES", 39, 44], ["the mouse anti-pan flavivirus envelope protein mAb", "TREATMENT", 35, 85], ["fluorescen", "TREATMENT", 168, 178]]], ["Cell nuclei were stained using 4\u2019,6\u2019-diamidino-2-phenylindole (DAPI, Abbkine, Beijing, China) for 5 min in the dark and imaged by confocal microscopy (Leica, Wetzlar, Germany).Plaque forming assay ::: Materials and methodsVero cells incubated overnight (2 \u00d7 105 cells/well) in a 12-well plate were infected with supernatant for 2 h at 37 \u00b0C. After incubation, the inoculum was removed, and the cells were immediately replenished with plaque medium supplemented with 1% methylcellulose (Sigma, Saint Louis, USA).", [["Cell nuclei", "ANATOMY", 0, 11], ["Plaque", "ANATOMY", 176, 182], ["Vero cells", "ANATOMY", 222, 232], ["cells", "ANATOMY", 262, 267], ["supernatant", "ANATOMY", 312, 323], ["cells", "ANATOMY", 394, 399], ["plaque", "ANATOMY", 434, 440], ["4\u2019,6\u2019-diamidino-2-phenylindole", "CHEMICAL", 31, 61], ["methylcellulose", "CHEMICAL", 469, 484], ["4\u2019,6\u2019-diamidino-2-phenylindole", "CHEMICAL", 31, 61], ["DAPI", "CHEMICAL", 63, 67], ["Abbkine", "CHEMICAL", 69, 76], ["methylcellulose", "CHEMICAL", 469, 484], ["Cell nuclei", "CELL", 0, 11], ["4\u2019,6\u2019-diamidino-2-phenylindole", "SIMPLE_CHEMICAL", 31, 61], ["DAPI", "SIMPLE_CHEMICAL", 63, 67], ["Abbkine", "SIMPLE_CHEMICAL", 69, 76], ["Vero cells", "CELL", 222, 232], ["cells", "CELL", 262, 267], ["cells", "CELL", 394, 399], ["methylcellulose", "SIMPLE_CHEMICAL", 469, 484], ["Vero cells", "CELL_LINE", 222, 232], ["Cell nuclei", "TEST", 0, 11], ["diamidino", "TREATMENT", 37, 46], ["DAPI", "TREATMENT", 63, 67], ["Abbkine", "TREATMENT", 69, 76], ["confocal microscopy", "TEST", 130, 149], ["methodsVero cells", "PROBLEM", 215, 232], ["a 12-well plate", "TREATMENT", 277, 292], ["the inoculum", "TREATMENT", 360, 372], ["plaque medium", "TREATMENT", 434, 447], ["infected", "OBSERVATION", 298, 306]]], ["Infected cells were incubated for 7 days.", [["cells", "ANATOMY", 9, 14], ["cells", "CELL", 9, 14], ["Infected cells", "PROBLEM", 0, 14]]], ["After incubation, the plaque medium was removed, and the cells were fixed and stained with 4% formaldehyde and 0.5% crystal violet.Time-of-addition assay ::: Materials and methodsVero cells were seeded in a 12-well plate overnight, and then infected with ZIKV at an MOI = 0.1.", [["plaque", "ANATOMY", 22, 28], ["cells", "ANATOMY", 57, 62], ["Vero cells", "ANATOMY", 179, 189], ["formaldehyde", "CHEMICAL", 94, 106], ["formaldehyde", "CHEMICAL", 94, 106], ["cells", "CELL", 57, 62], ["formaldehyde", "SIMPLE_CHEMICAL", 94, 106], ["crystal violet", "SIMPLE_CHEMICAL", 116, 130], ["Vero cells", "CELL", 179, 189], ["Vero cells", "CELL_LINE", 179, 189], ["ZIKV", "SPECIES", 255, 259], ["the plaque medium", "TREATMENT", 18, 35], ["4% formaldehyde", "TREATMENT", 91, 106], ["0.5% crystal violet", "TREATMENT", 111, 130], ["methodsVero cells", "TREATMENT", 172, 189], ["ZIKV", "PROBLEM", 255, 259], ["plaque", "OBSERVATION", 22, 28], ["Vero cells", "OBSERVATION", 179, 189]]], ["Lycorine was added to the well 2 h prior to virus infection or at 0, 1, 2, 4, 6, and 10 hpi, and incubated for up to 48 hpi.", [["Lycorine", "CHEMICAL", 0, 8], ["infection", "DISEASE", 50, 59], ["Lycorine", "CHEMICAL", 0, 8], ["Lycorine", "SIMPLE_CHEMICAL", 0, 8], ["Lycorine", "TREATMENT", 0, 8], ["virus infection", "PROBLEM", 44, 59]]], ["Cells were used to quantitate the vRNA load using qRT-PCR.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["Cells", "TEST", 0, 5], ["the vRNA load", "TEST", 30, 43], ["qRT", "TEST", 50, 53]]], ["Supernatants were collected for the plaque forming assay.Time-of-removal assay ::: Materials and methodsTime-of-removal assay was performed as previously described (Taguwa et al., 2019).", [["Supernatants", "ANATOMY", 0, 12], ["plaque", "ANATOMY", 36, 42], ["Supernatants", "CELL", 0, 12], ["the plaque forming assay", "PROBLEM", 32, 56], ["removal assay", "TEST", 112, 125], ["plaque", "OBSERVATION", 36, 42]]], ["Vero cells were infected with ZIKV and either lycorine or DMSO was added at 6 hpi.", [["Vero cells", "ANATOMY", 0, 10], ["ZIKV", "CHEMICAL", 30, 34], ["lycorine", "CHEMICAL", 46, 54], ["DMSO", "CHEMICAL", 58, 62], ["lycorine", "CHEMICAL", 46, 54], ["DMSO", "CHEMICAL", 58, 62], ["Vero cells", "CELL", 0, 10], ["lycorine", "SIMPLE_CHEMICAL", 46, 54], ["DMSO", "SIMPLE_CHEMICAL", 58, 62], ["Vero cells", "CELL_LINE", 0, 10], ["ZIKV", "SPECIES", 30, 34], ["Vero cells", "PROBLEM", 0, 10], ["ZIKV", "TREATMENT", 30, 34], ["lycorine", "TREATMENT", 46, 54], ["DMSO", "TREATMENT", 58, 62], ["infected", "OBSERVATION", 16, 24]]], ["The level of vRNA synthesis in the presence or absence of drugs was then monitored for up to 24 hpi.", [["vRNA", "CELLULAR_COMPONENT", 13, 17], ["vRNA synthesis", "PROBLEM", 13, 27], ["drugs", "TREATMENT", 58, 63], ["vRNA synthesis", "OBSERVATION", 13, 27]]], ["Next, the drugs were added at 24 hpi, and the kinetics of ZIKV replication were monitored for an additional 12 h.", [["ZIKV", "SIMPLE_CHEMICAL", 58, 62], ["ZIKV", "SPECIES", 58, 62], ["the drugs", "TREATMENT", 6, 15], ["ZIKV replication", "TREATMENT", 58, 74]]], ["Cells were used to quantitate the vRNA load using qRT-PCR.Detection of ZIKV strand specific RNA by qRT-PCR ::: Materials and methodsPositive- and negative-strand RNA quantification was conducted as previously described with minor modifications(Li et al., 2016).", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["ZIKV strand specific RNA", "RNA", 71, 95], ["ZIKV", "SPECIES", 71, 75], ["Cells", "TEST", 0, 5], ["the vRNA load", "TEST", 30, 43], ["qRT", "TEST", 50, 53], ["ZIKV strand specific RNA", "PROBLEM", 71, 95], ["Materials", "TEST", 111, 120], ["methodsPositive", "TEST", 125, 140], ["strand RNA quantification", "TEST", 155, 180]]], ["Lycorine (1 \u03bcM) and DMSO were added to the culture medium at 24 hpi, and Vero cell was collected at 0, 4, 12, and 24 h for qRT-PCR.", [["Vero cell", "ANATOMY", 73, 82], ["Lycorine", "CHEMICAL", 0, 8], ["DMSO", "CHEMICAL", 20, 24], ["Lycorine", "CHEMICAL", 0, 8], ["DMSO", "CHEMICAL", 20, 24], ["Lycorine", "SIMPLE_CHEMICAL", 0, 8], ["DMSO", "SIMPLE_CHEMICAL", 20, 24], ["Vero cell", "CELL", 73, 82], ["Vero cell", "CELL_LINE", 73, 82], ["Vero", "SPECIES", 73, 77], ["Lycorine", "TREATMENT", 0, 8], ["DMSO", "TREATMENT", 20, 24], ["the culture medium", "TEST", 39, 57], ["Vero cell", "TEST", 73, 82], ["qRT", "TEST", 123, 126], ["PCR", "TEST", 127, 130]]], ["The sequences \u201cGGAGGATTCCGGATTGTCAAT\u201d and \u201cTGCCGTGAATCTCAAAAAGGC\u201d were used to obtain cDNA from the negative- (-RNA) and positive-strand (+RNA) RNA, respectively, and qRT-PCR was then performed with primers for strand-specific RNA detection.Cellular thermal shift assay (CETSA) ::: Materials and methodsCETSA was conducted as previously described with minor modifications (Yang et al., 2018).", [["cDNA", "DNA", 86, 90], ["negative- (-RNA) and positive-strand (+RNA) RNA", "RNA", 100, 147], ["The sequences", "TEST", 0, 13], ["GGAGGATTCCGGATTGTCAAT", "TEST", 15, 36], ["cDNA", "TEST", 86, 90], ["positive-strand (+RNA) RNA", "PROBLEM", 121, 147], ["qRT-PCR", "TEST", 167, 174], ["primers", "TEST", 199, 206], ["strand-specific RNA detection", "TEST", 211, 240], ["Cellular thermal shift assay", "TEST", 241, 269], ["methodsCETSA", "TREATMENT", 296, 308]]], ["Briefly, Vero cells were harvested and rinsed with PBS, and then resuspended in detergent-free buffer (25 mM HEPES, pH 7.0, 20 mM MgCl2, 2 mM DTT) supplemented with protease inhibitors and phosphatase inhibitor cocktail.", [["Vero cells", "ANATOMY", 9, 19], ["HEPES", "CHEMICAL", 109, 114], ["MgCl2", "CHEMICAL", 130, 135], ["DTT", "CHEMICAL", 142, 145], ["Vero cells", "CELL", 9, 19], ["Vero cells", "CELL_LINE", 9, 19], ["phosphatase", "PROTEIN", 189, 200], ["Vero cells", "PROBLEM", 9, 19], ["PBS", "TREATMENT", 51, 54], ["HEPES", "TEST", 109, 114], ["pH", "TEST", 116, 118], ["20 mM MgCl2", "TREATMENT", 124, 135], ["2 mM DTT", "TREATMENT", 137, 145], ["protease inhibitors", "TREATMENT", 165, 184], ["phosphatase inhibitor cocktail", "TREATMENT", 189, 219], ["Vero cells", "OBSERVATION", 9, 19]]], ["The cell suspensions were lysed via ultrasound, and subjected to centrifugation at 20,000\u00d7g for 20 min at 4 \u00b0C to separate the soluble fraction from the cell debris.", [["cell", "ANATOMY", 4, 8], ["cell", "ANATOMY", 153, 157], ["cell suspensions", "CELL", 4, 20], ["cell", "CELL", 153, 157], ["The cell suspensions", "TREATMENT", 0, 20], ["ultrasound", "TEST", 36, 46], ["centrifugation", "TREATMENT", 65, 79], ["the cell debris", "PROBLEM", 149, 164], ["cell suspensions", "OBSERVATION", 4, 20], ["cell debris", "OBSERVATION", 153, 164]]], ["For the CETSA melting curve experiments, the cell lysates were diluted in detergent-free buffer and divided into two aliquots, before being treated with or without 20 \u03bcM lycorine.", [["cell lysates", "ANATOMY", 45, 57], ["lycorine", "CHEMICAL", 170, 178], ["lycorine", "CHEMICAL", 170, 178], ["cell lysates", "ORGANISM_SUBSTANCE", 45, 57], ["lycorine", "SIMPLE_CHEMICAL", 170, 178], ["the CETSA melting curve experiments", "TREATMENT", 4, 39], ["the cell lysates", "TREATMENT", 41, 57], ["detergent-free buffer", "TREATMENT", 74, 95], ["20 \u03bcM lycorine", "TREATMENT", 164, 178]]], ["After 30 min of treatment at room temperature, each sample was divided into 12 small aliquots at 50 \u03bcL/tube, heated individually at different temperatures for 3 min, and immediately cooled for 3 min at room temperature.", [["sample", "ANATOMY", 52, 58], ["tube", "TISSUE", 103, 107], ["treatment", "TREATMENT", 16, 25], ["tube", "TREATMENT", 103, 107], ["tube", "OBSERVATION", 103, 107]]], ["The heated cell extracts were centrifuged at 20,000\u00d7g for 20 min at 4 \u00b0C to separate the soluble fractions from the precipitates.", [["cell extracts", "ANATOMY", 11, 24], ["cell extracts", "ORGANISM_SUBSTANCE", 11, 24], ["The heated cell extracts", "TREATMENT", 0, 24]]], ["After centrifugation, the supernatant was analysed by Westernwestern blotting with an anti-NS5 antibody.", [["supernatant", "ANATOMY", 26, 37], ["anti-NS5 antibody", "GENE_OR_GENE_PRODUCT", 86, 103], ["anti-NS5 antibody", "PROTEIN", 86, 103], ["centrifugation", "TREATMENT", 6, 20], ["the supernatant", "TREATMENT", 22, 37], ["an anti-NS5 antibody", "TREATMENT", 83, 103]]], ["The relative chemiluminescence intensities of each sample at different temperatures were used to generate the temperature dependent melting curve.", [["different temperatures", "TEST", 61, 83], ["the temperature dependent melting curve", "TREATMENT", 106, 145], ["chemiluminescence", "OBSERVATION_MODIFIER", 13, 30], ["intensities", "OBSERVATION_MODIFIER", 31, 42]]], ["The apparent aggregation temperature (Tagg) value was calculated by nonlinear regression.In vitro RNA polymerase assays ::: Materials and methods", [["The apparent aggregation temperature", "TEST", 0, 36], ["aggregation", "OBSERVATION_MODIFIER", 13, 24], ["temperature", "OBSERVATION_MODIFIER", 25, 36]]]], "PMC7111864": [["IntroductionAkabane virus (AKAV) is transmitted by arthropod vectors such as Culicoides oxystoma (Kurogi et al., 1987) and it is the etiological agent that causes Akabane disease.", [["AKAV", "CHEMICAL", 27, 31], ["Culicoides oxystoma", "DISEASE", 77, 96], ["Akabane disease", "DISEASE", 163, 178], ["IntroductionAkabane virus", "ORGANISM", 0, 25], ["AKAV", "GENE_OR_GENE_PRODUCT", 27, 31], ["Culicoides oxystoma", "ORGANISM", 77, 96], ["Culicoides oxystoma", "SPECIES", 77, 96], ["IntroductionAkabane virus", "SPECIES", 0, 25], ["AKAV", "SPECIES", 27, 31], ["Culicoides oxystoma", "SPECIES", 77, 96], ["IntroductionAkabane virus (AKAV)", "PROBLEM", 0, 32], ["Akabane disease", "PROBLEM", 163, 178], ["Akabane disease", "OBSERVATION", 163, 178]]], ["AKAV causes abortions, stillbirths, and congenital disorders in cows, goats, and sheep (Kurogi et al., 1987).", [["AKAV", "CHEMICAL", 0, 4], ["abortions", "DISEASE", 12, 21], ["stillbirths", "DISEASE", 23, 34], ["congenital disorders", "DISEASE", 40, 60], ["sheep", "ORGANISM", 81, 86], ["cows", "SPECIES", 64, 68], ["goats", "SPECIES", 70, 75], ["sheep", "SPECIES", 81, 86], ["AKAV", "SPECIES", 0, 4], ["goats", "SPECIES", 70, 75], ["sheep", "SPECIES", 81, 86], ["abortions", "PROBLEM", 12, 21], ["stillbirths", "PROBLEM", 23, 34], ["congenital disorders", "PROBLEM", 40, 60], ["abortions", "OBSERVATION", 12, 21]]], ["AKAV has been detected in Japan, Korea, China, Israel, Australia, Turkey, Sudan, and Kenya (Kurogi et al., 1975, Lee et al., 2002, Jun et al., 2012, Stram et al., 2004, Della-Porta et al., 1976, Taylor and Mellor, 1994, Elhassan et al., 2014, Davies and Jessett, 1985).", [["AKAV", "CHEMICAL", 0, 4], ["AKAV", "GENE_OR_GENE_PRODUCT", 0, 4], ["AKAV", "PROTEIN", 0, 4], ["AKAV", "SPECIES", 0, 4], ["AKAV", "PROBLEM", 0, 4], ["Porta", "ANATOMY", 175, 180]]], ["AKAV belongs to the Simbu serogroup of the genus Orthobunyavirus in the family Bunyaviridae.", [["AKAV", "CHEMICAL", 0, 4], ["Bunyaviridae", "DISEASE", 79, 91], ["AKAV", "GENE_OR_GENE_PRODUCT", 0, 4], ["AKAV", "PROTEIN", 0, 4], ["genus Orthobunyavirus", "OBSERVATION", 43, 64]]], ["In addition to AKAV, the Simbu serogroup includes Aino virus, Peaton virus, and Shamonda virus.", [["AKAV", "GENE_OR_GENE_PRODUCT", 15, 19], ["Simbu serogroup", "ORGANISM", 25, 40], ["Aino virus", "ORGANISM", 50, 60], ["Peaton virus", "ORGANISM", 62, 74], ["Shamonda virus", "ORGANISM", 80, 94], ["AKAV", "PROTEIN", 15, 19], ["Aino virus", "SPECIES", 50, 60], ["Peaton virus", "SPECIES", 62, 74], ["Shamonda virus", "SPECIES", 80, 94], ["Aino virus", "SPECIES", 50, 60], ["Peaton virus", "SPECIES", 62, 74], ["Shamonda virus", "SPECIES", 80, 94], ["AKAV", "PROBLEM", 15, 19], ["the Simbu serogroup", "PROBLEM", 21, 40], ["Aino virus", "PROBLEM", 50, 60], ["Peaton virus", "PROBLEM", 62, 74], ["Shamonda virus", "PROBLEM", 80, 94]]], ["Recently, a novel Orthobunyavirus called Schmallenberg virus emerged in Europe, which is associated with reduced milk production and diarrhea in adult cattle, as well as congenital malformations in cows and sheep (Garigliany et al., 2012, van den Brom et al., 2012).", [["milk", "ANATOMY", 113, 117], ["Orthobunyavirus", "CHEMICAL", 18, 33], ["Schmallenberg virus", "DISEASE", 41, 60], ["diarrhea", "DISEASE", 133, 141], ["congenital malformations", "DISEASE", 170, 194], ["Schmallenberg virus", "ORGANISM", 41, 60], ["milk", "ORGANISM_SUBSTANCE", 113, 117], ["cattle", "ORGANISM", 151, 157], ["cows", "ORGANISM", 198, 202], ["sheep", "ORGANISM", 207, 212], ["Schmallenberg virus", "SPECIES", 41, 60], ["cattle", "SPECIES", 151, 157], ["cows", "SPECIES", 198, 202], ["sheep", "SPECIES", 207, 212], ["Schmallenberg virus", "SPECIES", 41, 60], ["cattle", "SPECIES", 151, 157], ["sheep", "SPECIES", 207, 212], ["Schmallenberg virus", "PROBLEM", 41, 60], ["reduced milk production", "PROBLEM", 105, 128], ["diarrhea", "PROBLEM", 133, 141], ["congenital malformations in cows", "PROBLEM", 170, 202], ["congenital", "OBSERVATION_MODIFIER", 170, 180], ["malformations", "OBSERVATION", 181, 194]]], ["The AKAV genome comprises three segments of negative sense single-stranded RNA: large (L), medium (M), and small (S).", [["AKAV", "GENE_OR_GENE_PRODUCT", 4, 8], ["AKAV genome", "DNA", 4, 15], ["negative sense single-stranded RNA", "RNA", 44, 78], ["large", "OBSERVATION_MODIFIER", 80, 85], ["small", "OBSERVATION_MODIFIER", 107, 112]]], ["The L segment encodes an RNA-dependent RNA polymerase, the M segment encodes the precursor of glycoproteins (Gn and Gc) and a nonstructural protein (NSm), and the S segment encodes the nucleocapsid protein (N) and a nonstructural protein (NSs).", [["Gn", "GENE_OR_GENE_PRODUCT", 109, 111], ["Gc", "GENE_OR_GENE_PRODUCT", 116, 118], ["NSm", "GENE_OR_GENE_PRODUCT", 149, 152], ["nucleocapsid protein (N)", "GENE_OR_GENE_PRODUCT", 185, 209], ["NSs", "GENE_OR_GENE_PRODUCT", 239, 242], ["L segment", "DNA", 4, 13], ["RNA-dependent RNA polymerase", "PROTEIN", 25, 53], ["M segment", "PROTEIN", 59, 68], ["glycoproteins", "PROTEIN", 94, 107], ["Gn", "PROTEIN", 109, 111], ["Gc", "PROTEIN", 116, 118], ["nonstructural protein", "PROTEIN", 126, 147], ["NSm", "PROTEIN", 149, 152], ["S segment", "PROTEIN", 163, 172], ["nucleocapsid protein", "PROTEIN", 185, 205], ["N", "PROTEIN", 207, 208], ["nonstructural protein", "PROTEIN", 216, 237], ["NSs", "PROTEIN", 239, 242], ["an RNA-dependent RNA polymerase", "PROBLEM", 22, 53], ["glycoproteins", "TEST", 94, 107], ["a nonstructural protein (NSm", "PROBLEM", 124, 152], ["the nucleocapsid protein", "TEST", 181, 205], ["a nonstructural protein (NSs", "TREATMENT", 214, 242], ["L", "ANATOMY_MODIFIER", 4, 5], ["segment", "ANATOMY_MODIFIER", 6, 13], ["RNA", "OBSERVATION", 25, 28], ["dependent", "OBSERVATION_MODIFIER", 29, 38], ["RNA polymerase", "OBSERVATION", 39, 53], ["nucleocapsid protein", "OBSERVATION", 185, 205]]], ["The nonstructural proteins are assumed to interact with the vector/host immune system, thereby contributing to viral pathogenesis (Eifan et al., 2013, Bridgen et al., 2001).IntroductionMitogen-activated protein kinase (MAPK) cascades are intracellular signal transduction pathways that respond to various extracellular stimuli, which are involved in the regulation of a wide variety of cellular process, including growth, proliferation, survival, and apoptosis (Strniskov\u00e1 et al., 2002).", [["intracellular", "ANATOMY", 238, 251], ["extracellular", "ANATOMY", 305, 318], ["cellular", "ANATOMY", 386, 394], ["Mitogen-activated protein kinase", "GENE_OR_GENE_PRODUCT", 185, 217], ["MAPK", "GENE_OR_GENE_PRODUCT", 219, 223], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 238, 251], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 305, 318], ["cellular", "CELL", 386, 394], ["nonstructural proteins", "PROTEIN", 4, 26], ["Mitogen-activated protein kinase", "PROTEIN", 185, 217], ["MAPK", "PROTEIN", 219, 223], ["The nonstructural proteins", "PROBLEM", 0, 26], ["viral pathogenesis", "PROBLEM", 111, 129], ["IntroductionMitogen-activated protein kinase (MAPK) cascades", "TREATMENT", 173, 233], ["intracellular signal transduction pathways", "PROBLEM", 238, 280], ["various extracellular stimuli", "TEST", 297, 326], ["apoptosis", "PROBLEM", 451, 460], ["nonstructural proteins", "OBSERVATION", 4, 26], ["viral", "OBSERVATION_MODIFIER", 111, 116], ["extracellular stimuli", "OBSERVATION", 305, 326], ["cellular process", "OBSERVATION", 386, 402], ["growth", "OBSERVATION_MODIFIER", 414, 420]]], ["The three major MAPK cascades are the extracellular signal-regulated protein kinase cascade, the c-Jun N-terminal kinase (JNK) cascade, and the p38 MAPK cascade.", [["N", "CHEMICAL", 103, 104], ["MAPK", "GENE_OR_GENE_PRODUCT", 16, 20], ["extracellular signal-regulated protein kinase", "GENE_OR_GENE_PRODUCT", 38, 83], ["c-Jun N-terminal kinase", "GENE_OR_GENE_PRODUCT", 97, 120], ["JNK", "GENE_OR_GENE_PRODUCT", 122, 125], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 144, 152], ["MAPK", "PROTEIN", 16, 20], ["extracellular signal-regulated protein kinase", "PROTEIN", 38, 83], ["Jun N-terminal kinase", "PROTEIN", 99, 120], ["JNK", "PROTEIN", 122, 125], ["p38 MAPK", "PROTEIN", 144, 152], ["the extracellular signal", "TEST", 34, 58], ["the p38 MAPK cascade", "TREATMENT", 140, 160], ["MAPK cascades", "OBSERVATION", 16, 29]]], ["JNK is a regulator of the transcription factor c-Jun and a mediator of intra or extracellular stresses such as heat shock, osmotic shock, cytokines, and UV, which is also known as the stress-activated protein kinase (SAPK) cascade (Robinson and Cobb, 1997).", [["extracellular", "ANATOMY", 80, 93], ["shock", "DISEASE", 116, 121], ["shock", "DISEASE", 131, 136], ["JNK", "GENE_OR_GENE_PRODUCT", 0, 3], ["c-Jun", "GENE_OR_GENE_PRODUCT", 47, 52], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 80, 93], ["heat shock, osmotic shock", "GENE_OR_GENE_PRODUCT", 111, 136], ["stress-activated protein kinase", "GENE_OR_GENE_PRODUCT", 184, 215], ["SAPK", "GENE_OR_GENE_PRODUCT", 217, 221], ["JNK", "PROTEIN", 0, 3], ["transcription factor", "PROTEIN", 26, 46], ["Jun", "PROTEIN", 49, 52], ["cytokines", "PROTEIN", 138, 147], ["stress-activated protein kinase", "PROTEIN", 184, 215], ["SAPK", "PROTEIN", 217, 221], ["intra or extracellular stresses", "PROBLEM", 71, 102], ["heat shock", "PROBLEM", 111, 121], ["osmotic shock", "PROBLEM", 123, 136], ["cytokines", "PROBLEM", 138, 147], ["UV", "PROBLEM", 153, 155], ["the stress-activated protein kinase (SAPK) cascade", "PROBLEM", 180, 230], ["shock", "OBSERVATION", 116, 121], ["osmotic shock", "OBSERVATION", 123, 136]]], ["The p38 MAPK cascade is another SAPK signaling pathway; however, there is considerable cross-talk as well as shared components with the JNK cascade (Plotnikov et al., 2011).", [["p38 MAPK", "GENE_OR_GENE_PRODUCT", 4, 12], ["SAPK", "GENE_OR_GENE_PRODUCT", 32, 36], ["JNK", "GENE_OR_GENE_PRODUCT", 136, 139], ["p38 MAPK", "PROTEIN", 4, 12], ["SAPK", "PROTEIN", 32, 36], ["JNK", "PROTEIN", 136, 139], ["The p38 MAPK cascade", "TEST", 0, 20], ["another SAPK signaling pathway", "PROBLEM", 24, 54], ["considerable cross-talk", "PROBLEM", 74, 97], ["considerable", "OBSERVATION_MODIFIER", 74, 86], ["JNK", "ANATOMY", 136, 139]]], ["The activated JNK translocates to the nucleus where it phosphorylates and transactivates c-Jun, and the phosphorylated c-Jun then leads to the formation of activator protein 1 (AP-1).", [["nucleus", "ANATOMY", 38, 45], ["JNK", "GENE_OR_GENE_PRODUCT", 14, 17], ["nucleus", "CELLULAR_COMPONENT", 38, 45], ["c-Jun", "GENE_OR_GENE_PRODUCT", 89, 94], ["c-Jun", "GENE_OR_GENE_PRODUCT", 119, 124], ["activator protein 1", "GENE_OR_GENE_PRODUCT", 156, 175], ["AP-1", "GENE_OR_GENE_PRODUCT", 177, 181], ["JNK", "PROTEIN", 14, 17], ["c-Jun", "PROTEIN", 89, 94], ["phosphorylated c-Jun", "PROTEIN", 104, 124], ["activator protein 1", "PROTEIN", 156, 175], ["AP-1", "PROTEIN", 177, 181], ["the phosphorylated c-Jun", "PROBLEM", 100, 124], ["activator protein", "TEST", 156, 173], ["nucleus", "ANATOMY", 38, 45]]], ["The formation of AP-1 is related to the transcription of a wide variety of proteins, including proapoptotic factors (Dhanasekaran and Reddy, 2008). p38 MAPK is responsible for the phosphorylation and activation of MAP kinase-activated protein kinase 2, heat shock protein 27 (HSP27), activating transcription factor 1, and cAMP response element-binding protein (Dorion and Landry, 2002, Cowan, 2003).IntroductionIn general, activation of the JNK cascade and p38 MAPK cascade induces apoptosis.", [["cAMP", "CHEMICAL", 323, 327], ["cAMP", "CHEMICAL", 323, 327], ["AP-1", "GENE_OR_GENE_PRODUCT", 17, 21], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 148, 156], ["MAP kinase-activated protein kinase 2", "GENE_OR_GENE_PRODUCT", 214, 251], ["heat shock protein 27", "GENE_OR_GENE_PRODUCT", 253, 274], ["HSP27", "GENE_OR_GENE_PRODUCT", 276, 281], ["activating transcription factor 1", "GENE_OR_GENE_PRODUCT", 284, 317], ["cAMP response element-binding protein", "GENE_OR_GENE_PRODUCT", 323, 360], ["JNK", "GENE_OR_GENE_PRODUCT", 442, 445], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 458, 466], ["AP", "PROTEIN", 17, 19], ["proapoptotic factors", "PROTEIN", 95, 115], ["p38 MAPK", "PROTEIN", 148, 156], ["MAP kinase-activated protein kinase 2", "PROTEIN", 214, 251], ["heat shock protein 27", "PROTEIN", 253, 274], ["HSP27", "PROTEIN", 276, 281], ["activating transcription factor 1", "PROTEIN", 284, 317], ["cAMP response element-binding protein", "PROTEIN", 323, 360], ["JNK", "PROTEIN", 442, 445], ["p38 MAPK", "PROTEIN", 458, 466], ["p38 MAPK", "TEST", 148, 156], ["the phosphorylation", "TEST", 176, 195], ["MAP kinase", "TEST", 214, 224], ["activated protein kinase", "TEST", 225, 249], ["heat shock protein", "TEST", 253, 271], ["HSP27", "TEST", 276, 281], ["activating transcription factor", "TEST", 284, 315], ["cAMP response element", "TEST", 323, 344], ["the JNK cascade", "TREATMENT", 438, 453], ["p38 MAPK cascade", "TREATMENT", 458, 474], ["apoptosis", "PROBLEM", 483, 492]]], ["These two activated cascades mediate intracellular signaling and lead to caspase-3 activation, which is indispensable for apoptotic chromatin condensation and DNA fragmentation.", [["intracellular", "ANATOMY", 37, 50], ["chromatin", "ANATOMY", 132, 141], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 37, 50], ["caspase-3", "GENE_OR_GENE_PRODUCT", 73, 82], ["chromatin", "CELLULAR_COMPONENT", 132, 141], ["DNA", "CELLULAR_COMPONENT", 159, 162], ["caspase-3", "PROTEIN", 73, 82], ["caspase-3 activation", "TREATMENT", 73, 93], ["apoptotic chromatin condensation", "PROBLEM", 122, 154], ["DNA fragmentation", "PROBLEM", 159, 176], ["intracellular signaling", "OBSERVATION", 37, 60], ["indispensable for", "UNCERTAINTY", 104, 121], ["apoptotic chromatin condensation", "OBSERVATION", 122, 154], ["DNA fragmentation", "OBSERVATION", 159, 176]]], ["Caspase-3 is synthesized as an inactive proenzyme, which is activated via cleavage at specific Asp residues to yield the active enzyme that contains large (p20) and small (p10) subunits (Cohen, 1997, Cho and Choi, 2002).", [["Asp", "CHEMICAL", 95, 98], ["Caspase-3", "GENE_OR_GENE_PRODUCT", 0, 9], ["large (p20)", "GENE_OR_GENE_PRODUCT", 149, 160], ["Caspase-3", "PROTEIN", 0, 9], ["proenzyme", "PROTEIN", 40, 49], ["active enzyme", "PROTEIN", 121, 134], ["p20", "PROTEIN", 156, 159], ["p10", "PROTEIN", 172, 175], ["Caspase", "TREATMENT", 0, 7], ["an inactive proenzyme", "TREATMENT", 28, 49], ["the active enzyme", "TEST", 117, 134], ["large", "OBSERVATION_MODIFIER", 149, 154], ["small", "OBSERVATION_MODIFIER", 165, 170]]], ["JNK activation is the mediator of apoptosis induction by some viruses such as infectious bursal disease virus, porcine reproductive and respiratory syndrome virus, and equine influenza virus (Wei et al., 2011, Yin et al., 2012, Lin et al., 2001).", [["infectious bursal disease", "DISEASE", 78, 103], ["porcine reproductive and respiratory syndrome virus", "DISEASE", 111, 162], ["equine influenza virus", "DISEASE", 168, 190], ["JNK", "GENE_OR_GENE_PRODUCT", 0, 3], ["infectious bursal disease virus", "ORGANISM", 78, 109], ["porcine reproductive and respiratory syndrome virus", "ORGANISM", 111, 162], ["equine influenza virus", "ORGANISM", 168, 190], ["JNK", "PROTEIN", 0, 3], ["infectious bursal disease virus", "SPECIES", 78, 109], ["porcine", "SPECIES", 111, 118], ["equine influenza virus", "SPECIES", 168, 190], ["infectious bursal disease virus", "SPECIES", 78, 109], ["respiratory syndrome virus", "SPECIES", 136, 162], ["equine influenza virus", "SPECIES", 168, 190], ["JNK activation", "PROBLEM", 0, 14], ["apoptosis induction", "TREATMENT", 34, 53], ["some viruses", "PROBLEM", 57, 69], ["infectious bursal disease virus", "PROBLEM", 78, 109], ["porcine reproductive", "PROBLEM", 111, 131], ["respiratory syndrome virus", "PROBLEM", 136, 162], ["equine influenza virus", "PROBLEM", 168, 190], ["apoptosis", "OBSERVATION", 34, 43], ["viruses", "OBSERVATION", 62, 69], ["infectious", "OBSERVATION_MODIFIER", 78, 88], ["respiratory syndrome", "OBSERVATION", 136, 156]]], ["Furthermore, some viruses such as herpes simplex virus type 1 and rotavirus can manipulate the JNK signaling pathway to regulate viral replication (McLean and Bachenheimer, 1999, Holloway and Coulson, 2006).", [["herpes simplex virus", "DISEASE", 34, 54], ["herpes simplex virus type 1", "ORGANISM", 34, 61], ["rotavirus", "ORGANISM", 66, 75], ["JNK", "GENE_OR_GENE_PRODUCT", 95, 98], ["JNK", "PROTEIN", 95, 98], ["herpes simplex virus type 1", "SPECIES", 34, 61], ["herpes simplex virus type 1", "SPECIES", 34, 61], ["rotavirus", "SPECIES", 66, 75], ["some viruses", "PROBLEM", 13, 25], ["herpes simplex virus type 1", "PROBLEM", 34, 61], ["rotavirus", "PROBLEM", 66, 75], ["viruses", "OBSERVATION", 18, 25]]], ["The p38 MAPK signaling pathway is activated to induce apoptosis by bluetongue virus, soft-shelled turtle iridovirus, and other viruses as well as to control viral replication by viruses such as coxsackievirus B3 and varicella-zoster virus (Mortola and Larsen, 2010, Huang et al., 2011, Si et al., 2005, Rahaus et al., 2004).", [["varicella-zoster", "DISEASE", 216, 232], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 4, 12], ["bluetongue virus", "ORGANISM", 67, 83], ["turtle", "ORGANISM", 98, 104], ["iridovirus", "ORGANISM", 105, 115], ["coxsackievirus B3", "ORGANISM", 194, 211], ["varicella-zoster virus", "ORGANISM", 216, 238], ["p38", "PROTEIN", 4, 7], ["MAPK", "PROTEIN", 8, 12], ["bluetongue virus", "SPECIES", 67, 83], ["coxsackievirus B3", "SPECIES", 194, 211], ["varicella-zoster virus", "SPECIES", 216, 238], ["bluetongue virus", "SPECIES", 67, 83], ["coxsackievirus B3", "SPECIES", 194, 211], ["varicella-zoster virus", "SPECIES", 216, 238], ["The p38 MAPK signaling pathway", "TEST", 0, 30], ["apoptosis", "PROBLEM", 54, 63], ["bluetongue virus", "PROBLEM", 67, 83], ["soft-shelled turtle iridovirus", "PROBLEM", 85, 115], ["other viruses", "PROBLEM", 121, 134], ["viral replication", "PROBLEM", 157, 174], ["viruses", "PROBLEM", 178, 185], ["coxsackievirus B3", "PROBLEM", 194, 211], ["varicella", "PROBLEM", 216, 225], ["zoster virus", "PROBLEM", 226, 238], ["bluetongue virus", "OBSERVATION", 67, 83], ["turtle iridovirus", "OBSERVATION", 98, 115], ["viruses", "OBSERVATION", 127, 134], ["viral replication", "OBSERVATION", 157, 174], ["zoster virus", "OBSERVATION", 226, 238]]], ["In case of severe acute respiratory syndrome-coronavirus, p38 MAPK induces cell death in Vero E6 cells and JNK is related to persistent infection (Mizutani et al., 2004, Mizutani et al., 2005).", [["cell", "ANATOMY", 75, 79], ["Vero E6 cells", "ANATOMY", 89, 102], ["acute respiratory syndrome-coronavirus", "DISEASE", 18, 56], ["infection", "DISEASE", 136, 145], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 58, 66], ["cell", "CELL", 75, 79], ["Vero E6 cells", "CELL", 89, 102], ["JNK", "GENE_OR_GENE_PRODUCT", 107, 110], ["p38 MAPK", "PROTEIN", 58, 66], ["Vero E6 cells", "CELL_LINE", 89, 102], ["JNK", "PROTEIN", 107, 110], ["severe acute respiratory syndrome-coronavirus", "SPECIES", 11, 56], ["Vero E6", "SPECIES", 89, 96], ["severe acute respiratory syndrome", "PROBLEM", 11, 44], ["coronavirus", "PROBLEM", 45, 56], ["p38 MAPK", "TEST", 58, 66], ["cell death", "PROBLEM", 75, 85], ["Vero E6 cells", "PROBLEM", 89, 102], ["JNK", "PROBLEM", 107, 110], ["persistent infection", "PROBLEM", 125, 145], ["severe", "OBSERVATION_MODIFIER", 11, 17], ["acute", "OBSERVATION_MODIFIER", 18, 23], ["respiratory syndrome", "OBSERVATION", 24, 44], ["cell death", "OBSERVATION", 75, 85], ["E6 cells", "OBSERVATION", 94, 102], ["related to", "UNCERTAINTY", 114, 124], ["persistent", "OBSERVATION_MODIFIER", 125, 135], ["infection", "OBSERVATION", 136, 145]]], ["Viruses in the Simbu serogroup replicate and induce apoptosis in cultured cells (Lim et al., 2005, Barry et al., 2014, Varela et al., 2013).IntroductionAKAV infects cultured neuronal cells and astroglia cells and causes degenerative death (Kitani et al., 2000).", [["cells", "ANATOMY", 74, 79], ["neuronal cells", "ANATOMY", 174, 188], ["astroglia cells", "ANATOMY", 193, 208], ["AKAV", "CHEMICAL", 152, 156], ["death", "DISEASE", 233, 238], ["Simbu serogroup", "ORGANISM", 15, 30], ["cells", "CELL", 74, 79], ["AKAV", "GENE_OR_GENE_PRODUCT", 152, 156], ["neuronal cells", "CELL", 174, 188], ["astroglia cells", "CELL", 193, 208], ["cultured cells", "CELL_LINE", 65, 79], ["AKAV", "PROTEIN", 152, 156], ["cultured neuronal cells", "CELL_LINE", 165, 188], ["astroglia cells", "CELL_TYPE", 193, 208], ["Viruses", "PROBLEM", 0, 7], ["IntroductionAKAV infects cultured neuronal cells", "PROBLEM", 140, 188], ["astroglia cells", "PROBLEM", 193, 208], ["degenerative death", "PROBLEM", 220, 238], ["apoptosis", "OBSERVATION_MODIFIER", 52, 61], ["neuronal cells", "OBSERVATION", 174, 188], ["astroglia cells", "OBSERVATION", 193, 208], ["degenerative", "OBSERVATION_MODIFIER", 220, 232]]], ["AKAV induces cytopathic effects (CPE) and apoptosis via the activation of caspase-3 in Vero E6 cells (Lim et al., 2005).", [["Vero E6 cells", "ANATOMY", 87, 100], ["AKAV", "CHEMICAL", 0, 4], ["AKAV", "SIMPLE_CHEMICAL", 0, 4], ["caspase-3", "GENE_OR_GENE_PRODUCT", 74, 83], ["Vero E6 cells", "CELL", 87, 100], ["AKAV", "PROTEIN", 0, 4], ["caspase-3", "PROTEIN", 74, 83], ["Vero E6 cells", "CELL_LINE", 87, 100], ["AKAV", "PROBLEM", 0, 4], ["cytopathic effects", "PROBLEM", 13, 31], ["CPE", "PROBLEM", 33, 36], ["apoptosis", "PROBLEM", 42, 51], ["caspase", "TEST", 74, 81], ["cytopathic", "OBSERVATION_MODIFIER", 13, 23]]], ["However, there have been no detailed studies of the signaling pathways involved in AKAV-induced apoptosis.", [["AKAV", "CHEMICAL", 83, 87], ["AKAV", "GENE_OR_GENE_PRODUCT", 83, 87], ["AKAV", "PROTEIN", 83, 87], ["detailed studies", "TEST", 28, 44], ["AKAV", "PROBLEM", 83, 87], ["induced apoptosis", "PROBLEM", 88, 105], ["apoptosis", "OBSERVATION", 96, 105]]], ["Thus, the aim of the present study was to determine whether the JNK and p38 MAPK signaling pathways play crucial roles in AKAV-induced apoptosis.Cell line and virus ::: Materials and methodsVero E6 cells, a subclone of the African green monkey kidney epithelial cell line, were maintained in minimum essential medium (MEM, Gibco) containing 5% fetal calf serum (Gibco), 100 U/ml penicillin, and 100 \u03bcg/ml streptomycin and incubated at 37 \u00b0C with 5% CO2.", [["Cell line", "ANATOMY", 145, 154], ["Vero E6 cells", "ANATOMY", 190, 203], ["subclone", "ANATOMY", 207, 215], ["kidney epithelial cell line", "ANATOMY", 244, 271], ["fetal calf serum", "ANATOMY", 344, 360], ["AKAV", "CHEMICAL", 122, 126], ["penicillin", "CHEMICAL", 379, 389], ["streptomycin", "CHEMICAL", 405, 417], ["CO2", "CHEMICAL", 449, 452], ["penicillin", "CHEMICAL", 379, 389], ["streptomycin", "CHEMICAL", 405, 417], ["CO2", "CHEMICAL", 449, 452], ["JNK", "GENE_OR_GENE_PRODUCT", 64, 67], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 72, 80], ["AKAV", "GENE_OR_GENE_PRODUCT", 122, 126], ["Cell line", "CELL", 145, 154], ["Vero E6 cells", "CELL", 190, 203], ["monkey", "ORGANISM", 237, 243], ["kidney epithelial cell line", "CELL", 244, 271], ["fetal calf", "ORGANISM_SUBSTANCE", 344, 354], ["serum", "ORGANISM_SUBSTANCE", 355, 360], ["Gibco", "ORGANISM_SUBSTANCE", 362, 367], ["penicillin", "SIMPLE_CHEMICAL", 379, 389], ["streptomycin", "SIMPLE_CHEMICAL", 405, 417], ["CO2", "SIMPLE_CHEMICAL", 449, 452], ["JNK", "PROTEIN", 64, 67], ["p38 MAPK", "PROTEIN", 72, 80], ["AKAV", "PROTEIN", 122, 126], ["Vero E6 cells", "CELL_LINE", 190, 203], ["African green monkey kidney epithelial cell line", "CELL_LINE", 223, 271], ["green monkey kidney", "SPECIES", 231, 250], ["calf", "SPECIES", 350, 354], ["Vero E6", "SPECIES", 190, 197], ["African green monkey", "SPECIES", 223, 243], ["the present study", "TEST", 17, 34], ["the JNK", "TEST", 60, 67], ["AKAV", "PROBLEM", 122, 126], ["induced apoptosis", "PROBLEM", 127, 144], ["methodsVero E6 cells", "TREATMENT", 183, 203], ["epithelial cell line", "TREATMENT", 251, 271], ["penicillin", "TREATMENT", 379, 389], ["streptomycin", "TREATMENT", 405, 417], ["5% CO2", "TREATMENT", 446, 452], ["apoptosis", "OBSERVATION", 135, 144], ["virus", "OBSERVATION", 159, 164], ["E6 cells", "OBSERVATION", 195, 203], ["kidney", "ANATOMY", 244, 250], ["epithelial cell line", "OBSERVATION", 251, 271], ["medium", "OBSERVATION_MODIFIER", 310, 316], ["calf", "ANATOMY", 350, 354]]], ["For the infection experiments, the cells were prepared in 6-well or 24-well tissue culture plates.Cell line and virus ::: Materials and methodsAKAV strain JaGAR39, a prototype of AKAV, was used in this study.", [["cells", "ANATOMY", 35, 40], ["Cell line", "ANATOMY", 98, 107], ["infection", "DISEASE", 8, 17], ["JaGAR39", "CHEMICAL", 155, 162], ["cells", "CELL", 35, 40], ["Cell line", "CELL", 98, 107], ["AKAV", "GENE_OR_GENE_PRODUCT", 179, 183], ["the infection experiments", "PROBLEM", 4, 29], ["AKAV strain JaGAR39", "PROBLEM", 143, 162], ["a prototype of AKAV", "TREATMENT", 164, 183], ["this study", "TEST", 197, 207], ["infection", "OBSERVATION", 8, 17], ["virus", "OBSERVATION", 112, 117]]], ["Cell monolayers were washed once with MEM and then infected with AKAV at a multiplicity of infection (MOI) of 0.5 for 1 h at 37 \u00b0C. Incubation with MEM served as the mock-infected control.", [["Cell monolayers", "ANATOMY", 0, 15], ["MEM", "CHEMICAL", 38, 41], ["AKAV", "CHEMICAL", 65, 69], ["infection", "DISEASE", 91, 100], ["MEM", "CHEMICAL", 148, 151], ["Cell monolayers", "CELL", 0, 15], ["MEM", "ORGANISM_SUBSTANCE", 148, 151], ["AKAV", "SPECIES", 65, 69], ["Cell monolayers", "TEST", 0, 15], ["AKAV", "TREATMENT", 65, 69], ["infection", "PROBLEM", 91, 100], ["infected control", "TREATMENT", 171, 187], ["infection", "OBSERVATION", 91, 100], ["infected", "OBSERVATION", 171, 179]]], ["After adsorption, the cells were incubated in serum-free medium.Antibodies and reagents ::: Materials and methodsAntibodies specific for phospho-JNK1/2 (Thr183/Tyr185) (1:2000, #9251), JNK1/2 (1:2000, #9252), phospho-p38 MAPK (Thr180/Tyr182) (1:2000, #9211), p38 MAPK (1:2000, #9212), phospho-c-Jun (Ser63) (1:1000, #9261), phospho-HSP27 (Ser82) (1:1000, #2401), cleaved caspase-3 (Asp175) (1:1000, #9661), GAPDH (1:4000, #2118), and anti-rabbit IgG HRP-linked secondary antibody (1:10,000 for detection of phospho-c-Jun, phospho-HSP27, and cleaved caspase-3 and 1:20,000 for detection of the others, #7074) were purchased from Cell Signaling Technology (Danvers, USA).Antibodies and reagents ::: Materials and methodsThe JNK inhibitor SP600125 and the p38 MAPK inhibitor SB203580 were purchased from Wako (Osaka, Japan).", [["cells", "ANATOMY", 22, 27], ["serum", "ANATOMY", 46, 51], ["Cell", "ANATOMY", 628, 632], ["SP600125", "CHEMICAL", 736, 744], ["SB203580", "CHEMICAL", 772, 780], ["Tyr185", "CHEMICAL", 160, 166], ["phospho", "CHEMICAL", 209, 216], ["phospho", "CHEMICAL", 324, 331], ["Asp", "CHEMICAL", 382, 385], ["phospho", "CHEMICAL", 507, 514], ["phospho", "CHEMICAL", 522, 529], ["SP600125", "CHEMICAL", 736, 744], ["SB203580", "CHEMICAL", 772, 780], ["cells", "CELL", 22, 27], ["serum", "ORGANISM_SUBSTANCE", 46, 51], ["phospho-JNK1/2", "GENE_OR_GENE_PRODUCT", 137, 151], ["Thr183", "GENE_OR_GENE_PRODUCT", 153, 159], ["JNK1/2", "GENE_OR_GENE_PRODUCT", 185, 191], ["phospho-p38 MAPK", "GENE_OR_GENE_PRODUCT", 209, 225], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 259, 267], ["phospho-c-Jun", "GENE_OR_GENE_PRODUCT", 285, 298], ["phospho-HSP27", "GENE_OR_GENE_PRODUCT", 324, 337], ["caspase-3", "GENE_OR_GENE_PRODUCT", 371, 380], ["Asp175", "GENE_OR_GENE_PRODUCT", 382, 388], ["GAPDH", "GENE_OR_GENE_PRODUCT", 407, 412], ["anti-rabbit IgG HRP", "GENE_OR_GENE_PRODUCT", 434, 453], ["phospho-c-Jun", "GENE_OR_GENE_PRODUCT", 507, 520], ["phospho-HSP27", "GENE_OR_GENE_PRODUCT", 522, 535], ["caspase-3", "GENE_OR_GENE_PRODUCT", 549, 558], ["Cell", "CELL", 628, 632], ["JNK", "GENE_OR_GENE_PRODUCT", 722, 725], ["SP600125", "SIMPLE_CHEMICAL", 736, 744], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 753, 761], ["SB203580", "SIMPLE_CHEMICAL", 772, 780], ["Wako", "ORGANISM_SUBSTANCE", 801, 805], ["phospho-JNK1/2", "PROTEIN", 137, 151], ["Thr183", "PROTEIN", 153, 159], ["Tyr185", "PROTEIN", 160, 166], ["JNK1/2", "PROTEIN", 185, 191], ["phospho", "PROTEIN", 209, 216], ["p38 MAPK", "PROTEIN", 217, 225], ["Thr180", "PROTEIN", 227, 233], ["Tyr182", "PROTEIN", 234, 240], ["p38 MAPK", "PROTEIN", 259, 267], ["Jun", "PROTEIN", 295, 298], ["Ser63", "PROTEIN", 300, 305], ["phospho", "PROTEIN", 324, 331], ["HSP27", "PROTEIN", 332, 337], ["Ser82", "PROTEIN", 339, 344], ["cleaved caspase-3", "PROTEIN", 363, 380], ["Asp175", "PROTEIN", 382, 388], ["GAPDH", "PROTEIN", 407, 412], ["1:4000, #2118", "PROTEIN", 414, 427], ["anti-rabbit IgG HRP", "PROTEIN", 434, 453], ["secondary antibody", "PROTEIN", 461, 479], ["phospho", "PROTEIN", 507, 514], ["Jun", "PROTEIN", 517, 520], ["phospho", "PROTEIN", 522, 529], ["HSP27", "PROTEIN", 530, 535], ["cleaved caspase", "PROTEIN", 541, 556], ["JNK", "PROTEIN", 722, 725], ["p38 MAPK", "PROTEIN", 753, 761], ["anti-rabbit", "SPECIES", 434, 445], ["anti-rabbit", "SPECIES", 434, 445], ["the cells", "PROBLEM", 18, 27], ["methodsAntibodies", "TEST", 106, 123], ["phospho-", "TEST", 137, 145], ["JNK1/2", "TEST", 145, 151], ["JNK1/2", "TEST", 185, 191], ["phospho", "TEST", 209, 216], ["MAPK", "TEST", 221, 225], ["Thr180", "TEST", 227, 233], ["p38 MAPK", "TEST", 259, 267], ["phospho-c", "TEST", 285, 294], ["Jun", "TEST", 295, 298], ["phospho", "TEST", 324, 331], ["HSP27", "TEST", 332, 337], ["cleaved caspase", "TEST", 363, 378], ["Asp", "TEST", 382, 385], ["GAPDH", "TEST", 407, 412], ["anti-rabbit IgG HRP", "TEST", 434, 453], ["secondary antibody", "TEST", 461, 479], ["phospho-c", "TEST", 507, 516], ["Jun", "TEST", 517, 520], ["phospho", "TEST", 522, 529], ["HSP27", "TEST", 530, 535], ["caspase", "TEST", 549, 556], ["The JNK inhibitor SP600125", "TEST", 718, 744], ["the p38 MAPK inhibitor SB203580", "TEST", 749, 780]]], ["We prepared 10 mM stocks of each inhibitor in dimethyl sulfoxide (DMSO).", [["dimethyl sulfoxide", "CHEMICAL", 46, 64], ["DMSO", "CHEMICAL", 66, 70], ["dimethyl sulfoxide", "CHEMICAL", 46, 64], ["DMSO", "CHEMICAL", 66, 70], ["dimethyl sulfoxide", "SIMPLE_CHEMICAL", 46, 64], ["DMSO", "SIMPLE_CHEMICAL", 66, 70], ["each inhibitor", "TREATMENT", 28, 42], ["dimethyl sulfoxide (DMSO", "TREATMENT", 46, 70]]], ["In the inhibition experiments, Vero E6 cells were infected with AKAV at an MOI of 0.5 for 1 h and then incubated in serum-free medium containing 20 \u03bcM of each inhibitor.", [["Vero E6 cells", "ANATOMY", 31, 44], ["serum", "ANATOMY", 116, 121], ["AKAV", "CHEMICAL", 64, 68], ["Vero E6 cells", "CELL", 31, 44], ["serum", "ORGANISM_SUBSTANCE", 116, 121], ["Vero E6 cells", "CELL_LINE", 31, 44], ["Vero E6", "SPECIES", 31, 38], ["Vero E6 cells", "PROBLEM", 31, 44], ["AKAV", "TREATMENT", 64, 68], ["serum", "TEST", 116, 121], ["each inhibitor", "TREATMENT", 154, 168]]], ["Medium containing DMSO was used as the mock treatment control.Western blotting ::: Materials and methodsAfter viral infection at an MOI of 0.5 or mock infection, the cells were lysed by adding 1 \u00d7 sodium dodecyl sulfate sample buffer and boiled at 100 \u00b0C for 5 min.", [["cells", "ANATOMY", 166, 171], ["DMSO", "CHEMICAL", 18, 22], ["viral infection", "DISEASE", 110, 125], ["infection", "DISEASE", 151, 160], ["sodium dodecyl sulfate", "CHEMICAL", 197, 219], ["DMSO", "CHEMICAL", 18, 22], ["sodium dodecyl sulfate", "CHEMICAL", 197, 219], ["DMSO", "SIMPLE_CHEMICAL", 18, 22], ["cells", "CELL", 166, 171], ["sodium dodecyl sulfate", "SIMPLE_CHEMICAL", 197, 219], ["Medium containing DMSO", "TREATMENT", 0, 22], ["the mock treatment control", "TREATMENT", 35, 61], ["viral infection", "PROBLEM", 110, 125], ["mock infection", "PROBLEM", 146, 160], ["1 \u00d7 sodium dodecyl sulfate sample buffer", "TREATMENT", 193, 233], ["viral", "OBSERVATION_MODIFIER", 110, 115], ["infection", "OBSERVATION", 116, 125], ["infection", "OBSERVATION", 151, 160]]], ["Whole-cell extracts were electrophoresed on 12.5% polyacrylamide gels and transferred onto PVDF membranes (Bio-Rad).", [["Whole-cell extracts", "ANATOMY", 0, 19], ["PVDF membranes", "ANATOMY", 91, 105], ["polyacrylamide", "CHEMICAL", 50, 64], ["PVDF", "CHEMICAL", 91, 95], ["cell extracts", "ORGANISM_SUBSTANCE", 6, 19], ["membranes", "CELLULAR_COMPONENT", 96, 105], ["Bio-Rad", "GENE_OR_GENE_PRODUCT", 107, 114], ["Whole-cell extracts", "TREATMENT", 0, 19], ["12.5% polyacrylamide gels", "TREATMENT", 44, 69]]], ["The membranes were blocked at room temperature with Starting Block T20 (TBS) Blocking Buffer (Thermo) for 1 h and then incubated overnight with specific primary antibodies at 4 \u00b0C. After three washes with PBST buffer, the membranes were incubated with secondary antibodies at room temperature for 1 h.", [["membranes", "ANATOMY", 4, 13], ["membranes", "ANATOMY", 222, 231], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["membranes", "CELLULAR_COMPONENT", 222, 231], ["primary antibodies", "PROTEIN", 153, 171], ["secondary antibodies", "PROTEIN", 252, 272], ["Starting Block T20 (TBS) Blocking Buffer (Thermo)", "TREATMENT", 52, 101], ["PBST buffer", "TREATMENT", 205, 216], ["secondary antibodies", "PROBLEM", 252, 272]]], ["Immunoreactive bands were detected using an enhanced chemiluminescence procedure with LAS-3000 (Fujifilm).Induction of apoptosis in Vero E6 cells by AKAV infection ::: ResultsThe cell death was observed at 48 h postinfection (hpi) in Vero E6 cells (Fig. 1A).", [["Vero E6 cells", "ANATOMY", 132, 145], ["cell", "ANATOMY", 179, 183], ["Vero E6 cells", "ANATOMY", 234, 247], ["infection", "DISEASE", 154, 163], ["death", "DISEASE", 184, 189], ["LAS-3000", "CHEMICAL", 86, 94], ["Vero E6 cells", "CELL", 132, 145], ["AKAV", "ORGANISM", 149, 153], ["cell", "CELL", 179, 183], ["Vero E6 cells", "CELL", 234, 247], ["Fig. 1A", "CELL", 249, 256], ["Vero E6 cells", "CELL_LINE", 132, 145], ["Vero E6 cells", "CELL_LINE", 234, 247], ["Vero E6", "SPECIES", 132, 139], ["Vero E6", "SPECIES", 234, 241], ["Immunoreactive bands", "PROBLEM", 0, 20], ["an enhanced chemiluminescence procedure", "TREATMENT", 41, 80], ["LAS", "TEST", 86, 89], ["apoptosis", "PROBLEM", 119, 128], ["AKAV infection", "PROBLEM", 149, 163], ["The cell death", "PROBLEM", 175, 189], ["apoptosis", "OBSERVATION", 119, 128], ["infection", "OBSERVATION", 154, 163], ["cell death", "OBSERVATION", 179, 189]]], ["To determine whether AKAV infection activated caspase-3 in Vero E6 cells, Western blot analysis of the cleaved caspase-3 was performed.", [["Vero E6 cells", "ANATOMY", 59, 72], ["infection", "DISEASE", 26, 35], ["AKAV", "GENE_OR_GENE_PRODUCT", 21, 25], ["caspase-3", "GENE_OR_GENE_PRODUCT", 46, 55], ["Vero E6 cells", "CELL", 59, 72], ["caspase-3", "GENE_OR_GENE_PRODUCT", 111, 120], ["caspase-3", "PROTEIN", 46, 55], ["Vero E6 cells", "CELL_LINE", 59, 72], ["cleaved caspase-3", "PROTEIN", 103, 120], ["AKAV", "SPECIES", 21, 25], ["Vero E6", "SPECIES", 59, 66], ["AKAV infection activated caspase", "PROBLEM", 21, 53], ["Vero E6 cells", "TREATMENT", 59, 72], ["blot analysis", "TEST", 82, 95], ["the cleaved caspase", "TEST", 99, 118], ["infection", "OBSERVATION", 26, 35]]], ["As shown in Fig. 1B, cleaved caspase-3 was detected in AKAV-infected Vero E6 cells at 36 and 48 hpi, thereby indicating that AKAV infection induced apoptosis in Vero E6 cells.Phosphorylation of JNK and p38 MAPK in AKAV-infected cells ::: ResultsJNK and p38 MAPK are activated via phosphorylation at Thr183/Tyr185 and Thr180/Tyr182, respectively (Plotnikov et al., 2011).", [["Vero E6 cells", "ANATOMY", 69, 82], ["Vero E6 cells", "ANATOMY", 161, 174], ["cells", "ANATOMY", 228, 233], ["AKAV", "CHEMICAL", 125, 129], ["infection", "DISEASE", 130, 139], ["Tyr182", "CHEMICAL", 324, 330], ["1B", "GENE_OR_GENE_PRODUCT", 17, 19], ["caspase-3", "GENE_OR_GENE_PRODUCT", 29, 38], ["AKAV", "GENE_OR_GENE_PRODUCT", 55, 59], ["Vero E6 cells", "CELL", 69, 82], ["AKAV", "GENE_OR_GENE_PRODUCT", 125, 129], ["Vero E6 cells", "CELL", 161, 174], ["JNK", "GENE_OR_GENE_PRODUCT", 194, 197], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 202, 210], ["AKAV", "GENE_OR_GENE_PRODUCT", 214, 218], ["cells", "CELL", 228, 233], ["ResultsJNK", "GENE_OR_GENE_PRODUCT", 238, 248], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 253, 261], ["Thr183", "GENE_OR_GENE_PRODUCT", 299, 305], ["Tyr185", "GENE_OR_GENE_PRODUCT", 306, 312], ["Thr180", "GENE_OR_GENE_PRODUCT", 317, 323], ["Tyr182", "GENE_OR_GENE_PRODUCT", 324, 330], ["cleaved caspase-3", "PROTEIN", 21, 38], ["AKAV-infected Vero E6 cells", "CELL_LINE", 55, 82], ["Vero E6 cells", "CELL_LINE", 161, 174], ["JNK", "PROTEIN", 194, 197], ["p38 MAPK", "PROTEIN", 202, 210], ["AKAV-infected cells", "CELL_LINE", 214, 233], ["ResultsJNK", "PROTEIN", 238, 248], ["p38 MAPK", "PROTEIN", 253, 261], ["Vero E6", "SPECIES", 69, 76], ["AKAV", "SPECIES", 125, 129], ["Vero E6", "SPECIES", 161, 168], ["cleaved caspase", "TEST", 21, 36], ["infected Vero E6 cells", "PROBLEM", 60, 82], ["AKAV infection", "PROBLEM", 125, 139], ["apoptosis in Vero E6 cells", "PROBLEM", 148, 174], ["Phosphorylation", "TEST", 175, 190], ["JNK", "TEST", 194, 197], ["p38 MAPK", "TEST", 202, 210], ["AKAV", "TEST", 214, 218], ["infected cells", "PROBLEM", 219, 233], ["ResultsJNK", "TEST", 238, 248], ["p38 MAPK", "TEST", 253, 261], ["phosphorylation", "TEST", 280, 295], ["Fig", "OBSERVATION", 12, 15], ["infected", "OBSERVATION_MODIFIER", 60, 68], ["Vero E6 cells", "OBSERVATION", 69, 82], ["infection", "OBSERVATION", 130, 139], ["Vero E6 cells", "OBSERVATION", 161, 174], ["infected cells", "OBSERVATION", 219, 233]]], ["As shown in Fig. 2, phosphorylated JNK and p38 MAPK were detected at 24 hpi and their levels increased gradually.", [["JNK", "GENE_OR_GENE_PRODUCT", 35, 38], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 43, 51], ["phosphorylated JNK", "PROTEIN", 20, 38], ["p38 MAPK", "PROTEIN", 43, 51], ["phosphorylated JNK", "TEST", 20, 38], ["p38 MAPK", "TEST", 43, 51], ["their levels", "TEST", 80, 92]]], ["In contrast, the protein levels of total JNK and p38 MAPK did not differ at each time point.Phosphorylation of c-Jun and HSP27 by AKAV infection ::: ResultsActivated JNK phosphorylates c-Jun, which regulates a range of cellular processes, including apoptosis and cell proliferation (Dunn et al., 2002).", [["cellular", "ANATOMY", 219, 227], ["cell", "ANATOMY", 263, 267], ["infection", "DISEASE", 135, 144], ["JNK", "GENE_OR_GENE_PRODUCT", 41, 44], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 49, 57], ["c-Jun", "GENE_OR_GENE_PRODUCT", 111, 116], ["HSP27", "GENE_OR_GENE_PRODUCT", 121, 126], ["AKAV", "GENE_OR_GENE_PRODUCT", 130, 134], ["JNK", "GENE_OR_GENE_PRODUCT", 166, 169], ["c-Jun", "GENE_OR_GENE_PRODUCT", 185, 190], ["cellular", "CELL", 219, 227], ["cell", "CELL", 263, 267], ["JNK", "PROTEIN", 41, 44], ["p38 MAPK", "PROTEIN", 49, 57], ["Jun", "PROTEIN", 113, 116], ["HSP27", "PROTEIN", 121, 126], ["JNK", "PROTEIN", 166, 169], ["Jun", "PROTEIN", 187, 190], ["the protein levels", "TEST", 13, 31], ["total JNK", "TEST", 35, 44], ["p38 MAPK", "TEST", 49, 57], ["Phosphorylation", "TEST", 92, 107], ["JNK phosphorylates c-Jun", "PROBLEM", 166, 190], ["apoptosis", "PROBLEM", 249, 258], ["cell proliferation", "PROBLEM", 263, 281], ["infection", "OBSERVATION", 135, 144], ["cellular processes", "OBSERVATION", 219, 237], ["cell proliferation", "OBSERVATION", 263, 281]]], ["HSP27 interacts with key components of the apoptotic signaling pathway, especially during caspase activation, and it is phosphorylated as a result of the activation of p38 MAPK (Concannon et al., 2003).", [["HSP27", "GENE_OR_GENE_PRODUCT", 0, 5], ["caspase", "GENE_OR_GENE_PRODUCT", 90, 97], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 168, 176], ["HSP27", "PROTEIN", 0, 5], ["caspase", "PROTEIN", 90, 97], ["p38 MAPK", "PROTEIN", 168, 176]]], ["Western blot analyses were performed to confirm that JNK and p38 MAPK, which were phosphorylated as a result of AKAV infection, actually phosphorylated c-Jun and HSP27, respectively.", [["infection", "DISEASE", 117, 126], ["JNK", "GENE_OR_GENE_PRODUCT", 53, 56], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 61, 69], ["AKAV", "GENE_OR_GENE_PRODUCT", 112, 116], ["c-Jun", "GENE_OR_GENE_PRODUCT", 152, 157], ["HSP27", "GENE_OR_GENE_PRODUCT", 162, 167], ["JNK", "PROTEIN", 53, 56], ["p38 MAPK", "PROTEIN", 61, 69], ["Jun", "PROTEIN", 154, 157], ["HSP27", "PROTEIN", 162, 167], ["Western blot analyses", "TEST", 0, 21], ["JNK", "TEST", 53, 56], ["p38 MAPK", "TEST", 61, 69], ["AKAV infection", "PROBLEM", 112, 126], ["HSP27", "TEST", 162, 167], ["infection", "OBSERVATION", 117, 126]]], ["As shown in Fig. 3, c-Jun and HSP27 were phosphorylated in AKAV-infected cells where the kinetics agreed with those observed in JNK and p38 MAPK, respectively.", [["cells", "ANATOMY", 73, 78], ["c-Jun", "GENE_OR_GENE_PRODUCT", 20, 25], ["HSP27", "GENE_OR_GENE_PRODUCT", 30, 35], ["AKAV", "GENE_OR_GENE_PRODUCT", 59, 63], ["cells", "CELL", 73, 78], ["JNK", "GENE_OR_GENE_PRODUCT", 128, 131], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 136, 144], ["Jun", "PROTEIN", 22, 25], ["HSP27", "PROTEIN", 30, 35], ["AKAV-infected cells", "CELL_LINE", 59, 78], ["JNK", "PROTEIN", 128, 131], ["p38 MAPK", "PROTEIN", 136, 144], ["c-Jun and HSP27", "TEST", 20, 35], ["AKAV", "TEST", 59, 63], ["infected cells", "PROBLEM", 64, 78], ["JNK", "TEST", 128, 131], ["p38 MAPK", "TEST", 136, 144], ["Fig", "OBSERVATION", 12, 15], ["infected cells", "OBSERVATION", 64, 78]]], ["These results suggest that the JNK and p38 MAPK signaling pathways were activated in response to AKAV infection.Inhibition of AKAV-induced apoptosis by a JNK inhibitor ::: ResultsTo confirm that the JNK and p38 MAPK signaling pathways need to be activated for AKAV-induced apoptosis, we determined the effects of JNK and p38 MAPK inhibition on apoptosis induction by AKAV infection using a JNK inhibitor (SP600125) and a p38 MAPK inhibitor (SB203580).", [["infection", "DISEASE", 102, 111], ["AKAV", "CHEMICAL", 126, 130], ["AKAV", "CHEMICAL", 260, 264], ["infection", "DISEASE", 372, 381], ["SP600125", "CHEMICAL", 405, 413], ["SB203580", "CHEMICAL", 441, 449], ["SP600125", "CHEMICAL", 405, 413], ["SB203580", "CHEMICAL", 441, 449], ["JNK", "GENE_OR_GENE_PRODUCT", 31, 34], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 39, 47], ["AKAV", "GENE_OR_GENE_PRODUCT", 97, 101], ["AKAV", "GENE_OR_GENE_PRODUCT", 126, 130], ["JNK", "GENE_OR_GENE_PRODUCT", 154, 157], ["JNK", "GENE_OR_GENE_PRODUCT", 199, 202], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 207, 215], ["AKAV", "GENE_OR_GENE_PRODUCT", 260, 264], ["JNK", "GENE_OR_GENE_PRODUCT", 313, 316], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 321, 329], ["AKAV", "SIMPLE_CHEMICAL", 367, 371], ["JNK", "GENE_OR_GENE_PRODUCT", 390, 393], ["SP600125", "SIMPLE_CHEMICAL", 405, 413], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 421, 429], ["SB203580", "SIMPLE_CHEMICAL", 441, 449], ["JNK", "PROTEIN", 31, 34], ["p38 MAPK", "PROTEIN", 39, 47], ["AKAV", "PROTEIN", 126, 130], ["JNK", "PROTEIN", 154, 157], ["JNK", "PROTEIN", 199, 202], ["MAPK", "PROTEIN", 211, 215], ["AKAV", "PROTEIN", 260, 264], ["JNK", "PROTEIN", 313, 316], ["p38 MAPK", "PROTEIN", 321, 329], ["JNK", "PROTEIN", 390, 393], ["p38 MAPK", "PROTEIN", 421, 429], ["AKAV", "SPECIES", 97, 101], ["AKAV", "SPECIES", 367, 371], ["the JNK", "TEST", 27, 34], ["p38 MAPK signaling pathways", "TEST", 39, 66], ["AKAV infection", "PROBLEM", 97, 111], ["AKAV", "TREATMENT", 126, 130], ["the JNK", "TEST", 195, 202], ["p38 MAPK signaling pathways", "TEST", 207, 234], ["AKAV", "PROBLEM", 260, 264], ["apoptosis", "PROBLEM", 273, 282], ["JNK", "TEST", 313, 316], ["p38 MAPK inhibition", "TREATMENT", 321, 340], ["apoptosis induction", "TREATMENT", 344, 363], ["AKAV infection", "PROBLEM", 367, 381], ["a JNK inhibitor", "TREATMENT", 388, 403], ["a p38 MAPK inhibitor", "TREATMENT", 419, 439], ["infection", "OBSERVATION", 102, 111], ["infection", "OBSERVATION", 372, 381]]], ["Vero E6 cells were treated with 20 \u03bcM of the inhibitors in serum-free medium for 48 h, and the cell viability was then assayed using Cell Counting Kit-8 (Doujin Chemical).", [["Vero E6 cells", "ANATOMY", 0, 13], ["serum", "ANATOMY", 59, 64], ["cell", "ANATOMY", 95, 99], ["Cell", "ANATOMY", 133, 137], ["Vero E6 cells", "CELL", 0, 13], ["serum", "ORGANISM_SUBSTANCE", 59, 64], ["cell", "CELL", 95, 99], ["Cell", "CELL", 133, 137], ["Kit-8", "GENE_OR_GENE_PRODUCT", 147, 152], ["Vero E6 cells", "CELL_LINE", 0, 13], ["Vero E6", "SPECIES", 0, 7], ["Vero E6 cells", "TREATMENT", 0, 13], ["the inhibitors", "TREATMENT", 41, 55], ["serum-free medium", "TREATMENT", 59, 76], ["the cell viability", "TEST", 91, 109], ["Cell Counting Kit", "TEST", 133, 150], ["E6 cells", "OBSERVATION", 5, 13]]], ["The viabilities of the cells treated with SP600125 or SB203580 were > 90% and approximately 100%, respectively, compared with those of untreated cells.", [["cells", "ANATOMY", 23, 28], ["cells", "ANATOMY", 145, 150], ["SP600125", "CHEMICAL", 42, 50], ["SB203580", "CHEMICAL", 54, 62], ["SP600125", "CHEMICAL", 42, 50], ["SB203580", "CHEMICAL", 54, 62], ["cells", "CELL", 23, 28], ["SP600125", "SIMPLE_CHEMICAL", 42, 50], ["SB203580", "SIMPLE_CHEMICAL", 54, 62], ["cells", "CELL", 145, 150], ["untreated cells", "CELL_TYPE", 135, 150], ["SB203580", "TEST", 54, 62]]], ["There was very little effect on cell viability in Vero E6 cells treated with both SP600125 and SB203580 at 20 \u03bcM.Inhibition of AKAV-induced apoptosis by a JNK inhibitor ::: ResultsAs shown in Fig. 4A, the Western blot analysis with anti-phospho-c-Jun antibody did not detect phosphorylated c-Jun in AKAV-infected Vero E6 cells treated with the JNK inhibitor, i.e., SP600125, at 36 hpi compared with the untreated cells.", [["cell", "ANATOMY", 32, 36], ["Vero E6 cells", "ANATOMY", 50, 63], ["Vero E6 cells", "ANATOMY", 313, 326], ["cells", "ANATOMY", 413, 418], ["SP600125", "CHEMICAL", 82, 90], ["SB203580", "CHEMICAL", 95, 103], ["AKAV", "CHEMICAL", 127, 131], ["SP600125", "CHEMICAL", 365, 373], ["SP600125", "CHEMICAL", 82, 90], ["SB203580", "CHEMICAL", 95, 103], ["SP600125", "CHEMICAL", 365, 373], ["cell", "CELL", 32, 36], ["Vero E6 cells", "CELL", 50, 63], ["SP600125", "SIMPLE_CHEMICAL", 82, 90], ["SB203580", "SIMPLE_CHEMICAL", 95, 103], ["AKAV", "GENE_OR_GENE_PRODUCT", 127, 131], ["JNK", "GENE_OR_GENE_PRODUCT", 155, 158], ["anti-phospho-c-Jun", "GENE_OR_GENE_PRODUCT", 232, 250], ["c-Jun", "GENE_OR_GENE_PRODUCT", 290, 295], ["AKAV", "GENE_OR_GENE_PRODUCT", 299, 303], ["Vero E6 cells", "CELL", 313, 326], ["JNK", "GENE_OR_GENE_PRODUCT", 344, 347], ["SP600125", "SIMPLE_CHEMICAL", 365, 373], ["cells", "CELL", 413, 418], ["Vero E6 cells", "CELL_LINE", 50, 63], ["AKAV", "PROTEIN", 127, 131], ["JNK", "PROTEIN", 155, 158], ["anti-phospho-c-Jun antibody", "PROTEIN", 232, 259], ["phosphorylated c-Jun", "PROTEIN", 275, 295], ["AKAV-infected Vero E6 cells", "CELL_LINE", 299, 326], ["JNK", "PROTEIN", 344, 347], ["Vero E6", "SPECIES", 50, 57], ["Vero E6", "SPECIES", 313, 320], ["cell viability", "PROBLEM", 32, 46], ["Vero E6 cells", "TREATMENT", 50, 63], ["AKAV", "TREATMENT", 127, 131], ["the Western blot analysis", "TEST", 201, 226], ["anti-phospho-c", "TEST", 232, 246], ["Jun antibody", "TEST", 247, 259], ["phosphorylated c-Jun in AKAV", "PROBLEM", 275, 303], ["infected Vero E6 cells", "PROBLEM", 304, 326], ["the JNK inhibitor", "TREATMENT", 340, 357], ["very", "OBSERVATION_MODIFIER", 10, 14], ["little", "OBSERVATION_MODIFIER", 15, 21], ["effect", "OBSERVATION_MODIFIER", 22, 28], ["cell viability", "OBSERVATION", 32, 46], ["E6 cells", "OBSERVATION", 55, 63], ["Vero E6 cells", "OBSERVATION", 313, 326]]], ["The p38 MAPK inhibitor, i.e., SB203580, was also sufficient to block the phosphorylation of HSP27 (Fig. 4A).", [["SB203580", "CHEMICAL", 30, 38], ["SB203580", "CHEMICAL", 30, 38], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 4, 12], ["SB203580", "SIMPLE_CHEMICAL", 30, 38], ["HSP27", "GENE_OR_GENE_PRODUCT", 92, 97], ["Fig. 4A", "GENE_OR_GENE_PRODUCT", 99, 106], ["p38 MAPK", "PROTEIN", 4, 12], ["HSP27", "PROTEIN", 92, 97], ["Fig. 4A", "PROTEIN", 99, 106], ["The p38 MAPK inhibitor", "TEST", 0, 22], ["SB203580", "TEST", 30, 38]]], ["These results indicate that the JNK and p38 MAPK signaling pathways were inhibited by each inhibitor at 20 \u03bcM.Inhibition of AKAV-induced apoptosis by a JNK inhibitor ::: ResultsNext, we investigated whether the JNK and p38 MAPK inhibitors reduced the production of CPE induced by AKAV infection.", [["AKAV", "CHEMICAL", 124, 128], ["CPE", "CHEMICAL", 265, 268], ["AKAV", "CHEMICAL", 280, 284], ["infection", "DISEASE", 285, 294], ["JNK", "GENE_OR_GENE_PRODUCT", 32, 35], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 40, 48], ["AKAV", "GENE_OR_GENE_PRODUCT", 124, 128], ["JNK", "GENE_OR_GENE_PRODUCT", 152, 155], ["JNK", "GENE_OR_GENE_PRODUCT", 211, 214], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 219, 227], ["AKAV", "GENE_OR_GENE_PRODUCT", 280, 284], ["JNK", "PROTEIN", 32, 35], ["p38 MAPK", "PROTEIN", 40, 48], ["AKAV", "PROTEIN", 124, 128], ["JNK", "PROTEIN", 152, 155], ["JNK", "PROTEIN", 211, 214], ["p38 MAPK", "PROTEIN", 219, 227], ["AKAV", "SPECIES", 280, 284], ["the JNK", "TEST", 28, 35], ["p38 MAPK signaling pathways", "TEST", 40, 67], ["AKAV", "TREATMENT", 124, 128], ["the JNK", "TEST", 207, 214], ["p38 MAPK inhibitors", "TREATMENT", 219, 238], ["CPE", "PROBLEM", 265, 268], ["AKAV infection", "PROBLEM", 280, 294], ["infection", "OBSERVATION", 285, 294]]], ["CPE inhibition was clearly observed at 48 hpi in AKAV-infected cells treated with SP600125 compared with that of untreated cells.", [["cells", "ANATOMY", 63, 68], ["cells", "ANATOMY", 123, 128], ["SP600125", "CHEMICAL", 82, 90], ["SP600125", "CHEMICAL", 82, 90], ["AKAV", "SIMPLE_CHEMICAL", 49, 53], ["cells", "CELL", 63, 68], ["SP600125", "SIMPLE_CHEMICAL", 82, 90], ["cells", "CELL", 123, 128], ["AKAV-infected cells", "CELL_LINE", 49, 68], ["untreated cells", "CELL_TYPE", 113, 128], ["CPE inhibition", "PROBLEM", 0, 14], ["infected cells", "PROBLEM", 54, 68], ["SP600125", "TREATMENT", 82, 90], ["untreated cells", "PROBLEM", 113, 128], ["infected cells", "OBSERVATION", 54, 68], ["untreated cells", "OBSERVATION", 113, 128]]], ["However, SB203580 treatment did not inhibit CPE production at 48 hpi compared with that of untreated cells (Fig. 4B).", [["cells", "ANATOMY", 101, 106], ["SB203580", "CHEMICAL", 9, 17], ["CPE", "CHEMICAL", 44, 47], ["SB203580", "CHEMICAL", 9, 17], ["SB203580", "SIMPLE_CHEMICAL", 9, 17], ["CPE", "SIMPLE_CHEMICAL", 44, 47], ["cells", "CELL", 101, 106], ["untreated cells", "CELL_TYPE", 91, 106], ["SB203580 treatment", "TREATMENT", 9, 27], ["CPE production", "PROBLEM", 44, 58], ["untreated cells", "PROBLEM", 91, 106]]], ["We then examined whether the inhibition of JNK and p38 MAPK suppressed AKAV-mediated apoptosis based on Western blot analysis of the cleavage of caspase-3.", [["JNK", "GENE_OR_GENE_PRODUCT", 43, 46], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 51, 59], ["AKAV", "GENE_OR_GENE_PRODUCT", 71, 75], ["caspase-3", "GENE_OR_GENE_PRODUCT", 145, 154], ["JNK", "PROTEIN", 43, 46], ["p38 MAPK", "PROTEIN", 51, 59], ["AKAV", "PROTEIN", 71, 75], ["caspase-3", "PROTEIN", 145, 154], ["JNK", "TEST", 43, 46], ["p38 MAPK", "TEST", 51, 59], ["mediated apoptosis", "PROBLEM", 76, 94], ["Western blot analysis", "TEST", 104, 125], ["the cleavage of caspase", "TREATMENT", 129, 152]]], ["As shown in Fig. 4C, the inhibition of the JNK signaling pathway by the addition of SP600125 led to marked inhibition of caspase-3 compared with that of untreated cells.", [["cells", "ANATOMY", 163, 168], ["SP600125", "CHEMICAL", 84, 92], ["SP600125", "CHEMICAL", 84, 92], ["JNK", "GENE_OR_GENE_PRODUCT", 43, 46], ["SP600125", "SIMPLE_CHEMICAL", 84, 92], ["caspase-3", "GENE_OR_GENE_PRODUCT", 121, 130], ["cells", "CELL", 163, 168], ["JNK", "PROTEIN", 43, 46], ["caspase-3", "PROTEIN", 121, 130], ["untreated cells", "CELL_TYPE", 153, 168], ["caspase", "TEST", 121, 128], ["untreated cells", "OBSERVATION", 153, 168]]], ["In contrast, the amount of cleaved caspase-3 did not differ between control cells and those treated with SB203580 (Fig. 4C).", [["cells", "ANATOMY", 76, 81], ["SB203580", "CHEMICAL", 105, 113], ["SB203580", "CHEMICAL", 105, 113], ["caspase-3", "GENE_OR_GENE_PRODUCT", 35, 44], ["cells", "CELL", 76, 81], ["SB203580", "SIMPLE_CHEMICAL", 105, 113], ["cleaved caspase-3", "PROTEIN", 27, 44], ["control cells", "CELL_TYPE", 68, 81], ["cleaved caspase", "PROBLEM", 27, 42], ["amount", "OBSERVATION_MODIFIER", 17, 23]]], ["The copy numbers of AKAV RNA in the AKAV-infected cells treated with the two inhibitors were almost the same as those in untreated AKAV-infected cells according to real-time PCR at 48 hpi (data not shown).", [["cells", "ANATOMY", 50, 55], ["cells", "ANATOMY", 145, 150], ["AKAV", "GENE_OR_GENE_PRODUCT", 20, 24], ["AKAV", "GENE_OR_GENE_PRODUCT", 36, 40], ["cells", "CELL", 50, 55], ["cells", "CELL", 145, 150], ["AKAV RNA", "RNA", 20, 28], ["AKAV-infected cells", "CELL_LINE", 36, 55], ["AKAV-infected cells", "CELL_LINE", 131, 150], ["AKAV", "SPECIES", 131, 135], ["AKAV RNA", "PROBLEM", 20, 28], ["infected cells", "PROBLEM", 41, 55], ["the two inhibitors", "TREATMENT", 69, 87], ["infected cells", "PROBLEM", 136, 150], ["time PCR", "TEST", 169, 177], ["infected cells", "OBSERVATION", 41, 55], ["infected cells", "OBSERVATION", 136, 150]]], ["These results suggest the involvement of the JNK signaling pathway in AKAV-induced apoptosis but not the p38 MAPK signaling pathway.DiscussionSignaling pathways involved in apoptosis induction by AKAV are unclear.", [["AKAV", "CHEMICAL", 70, 74], ["JNK", "GENE_OR_GENE_PRODUCT", 45, 48], ["AKAV", "GENE_OR_GENE_PRODUCT", 70, 74], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 105, 113], ["AKAV", "GENE_OR_GENE_PRODUCT", 196, 200], ["JNK", "PROTEIN", 45, 48], ["AKAV", "PROTEIN", 70, 74], ["p38", "PROTEIN", 105, 108], ["MAPK", "PROTEIN", 109, 113], ["AKAV", "PROTEIN", 196, 200], ["the JNK signaling pathway", "PROBLEM", 41, 66], ["AKAV", "PROBLEM", 70, 74], ["induced apoptosis", "PROBLEM", 75, 92], ["apoptosis induction", "TREATMENT", 173, 192]]], ["A better understanding of these signaling pathways is needed to further elucidate the molecular virology of AKAV.", [["AKAV", "GENE_OR_GENE_PRODUCT", 108, 112], ["AKAV", "PROTEIN", 108, 112]]], ["In the present study, we demonstrated that AKAV, a member of the Simbu serogroup, activated the JNK and p38 MAPK signaling pathways, where the activation of the JNK signaling pathway was shown to be a crucial mediator of AKAV-induced apoptosis.DiscussionMAPK cascades are activated by various viral infections (Mizutani et al., 2004, Yamane et al., 2009, Bendfeldt et al., 2007).", [["AKAV", "CHEMICAL", 43, 47], ["AKAV", "CHEMICAL", 221, 225], ["viral infections", "DISEASE", 293, 309], ["AKAV", "GENE_OR_GENE_PRODUCT", 43, 47], ["Simbu", "GENE_OR_GENE_PRODUCT", 65, 70], ["JNK", "GENE_OR_GENE_PRODUCT", 96, 99], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 104, 112], ["JNK", "GENE_OR_GENE_PRODUCT", 161, 164], ["AKAV", "GENE_OR_GENE_PRODUCT", 221, 225], ["AKAV", "PROTEIN", 43, 47], ["Simbu serogroup", "PROTEIN", 65, 80], ["JNK", "PROTEIN", 96, 99], ["MAPK", "PROTEIN", 108, 112], ["JNK", "PROTEIN", 161, 164], ["AKAV", "PROTEIN", 221, 225], ["the JNK", "TEST", 92, 99], ["p38 MAPK signaling pathways", "TEST", 104, 131], ["the JNK signaling pathway", "TEST", 157, 182], ["AKAV", "PROBLEM", 221, 225], ["induced apoptosis", "PROBLEM", 226, 243], ["various viral infections", "PROBLEM", 285, 309], ["apoptosis", "OBSERVATION", 234, 243]]], ["In this study, we investigated whether AKAV infection induced JNK and p38 MAPK activation and found that both signaling pathways were activated persistently by AKAV infection.", [["infection", "DISEASE", 44, 53], ["infection", "DISEASE", 165, 174], ["AKAV", "GENE_OR_GENE_PRODUCT", 39, 43], ["JNK", "GENE_OR_GENE_PRODUCT", 62, 65], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 70, 78], ["AKAV", "GENE_OR_GENE_PRODUCT", 160, 164], ["JNK", "PROTEIN", 62, 65], ["p38 MAPK", "PROTEIN", 70, 78], ["AKAV", "SPECIES", 39, 43], ["AKAV", "SPECIES", 160, 164], ["this study", "TEST", 3, 13], ["AKAV infection", "PROBLEM", 39, 53], ["JNK", "PROBLEM", 62, 65], ["p38 MAPK activation", "TEST", 70, 89], ["AKAV infection", "PROBLEM", 160, 174], ["infection", "OBSERVATION", 44, 53], ["infection", "OBSERVATION", 165, 174]]], ["In MAPK cascades, activation of the JNK cascade and the p38 MAPK cascade tend to promote apoptosis, and several studies have demonstrated that virus-mediated activation of these two cascades leads to apoptosis (Franklin and McCubrey, 2000, Wang et al., 2014, Wei et al., 2009).", [["MAPK", "GENE_OR_GENE_PRODUCT", 3, 7], ["JNK", "GENE_OR_GENE_PRODUCT", 36, 39], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 56, 64], ["MAPK", "PROTEIN", 3, 7], ["JNK", "PROTEIN", 36, 39], ["p38 MAPK", "PROTEIN", 56, 64], ["the JNK cascade", "TREATMENT", 32, 47], ["the p38 MAPK cascade", "TEST", 52, 72], ["apoptosis", "PROBLEM", 89, 98], ["several studies", "TEST", 104, 119], ["virus", "PROBLEM", 143, 148], ["MAPK cascades", "OBSERVATION", 3, 16], ["apoptosis", "OBSERVATION", 89, 98], ["virus", "OBSERVATION", 143, 148]]], ["Our data clearly showed that JNK inhibition by treatment with each specific inhibitor resulted in marked suppression of AKAV-induced apoptosis, whereas inhibition of p38 MAPK did not.", [["AKAV", "CHEMICAL", 120, 124], ["JNK", "GENE_OR_GENE_PRODUCT", 29, 32], ["AKAV", "GENE_OR_GENE_PRODUCT", 120, 124], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 166, 174], ["JNK", "PROTEIN", 29, 32], ["AKAV", "PROTEIN", 120, 124], ["p38 MAPK", "PROTEIN", 166, 174], ["Our data", "TEST", 0, 8], ["JNK inhibition", "PROBLEM", 29, 43], ["treatment", "TREATMENT", 47, 56], ["each specific inhibitor", "TREATMENT", 62, 85], ["AKAV", "PROBLEM", 120, 124], ["induced apoptosis", "PROBLEM", 125, 142], ["p38 MAPK", "TEST", 166, 174], ["marked", "OBSERVATION_MODIFIER", 98, 104], ["suppression", "OBSERVATION_MODIFIER", 105, 116]]], ["Thus, the JNK cascade plays a crucial role in apoptosis caused by AKAV.", [["JNK", "GENE_OR_GENE_PRODUCT", 10, 13], ["AKAV", "GENE_OR_GENE_PRODUCT", 66, 70], ["JNK", "PROTEIN", 10, 13], ["AKAV", "PROTEIN", 66, 70], ["the JNK cascade", "PROBLEM", 6, 21]]], ["Oropouche virus is a member of the Simbu serogroup and a cause of acute febrile illness in humans.", [["febrile illness", "DISEASE", 72, 87], ["Oropouche virus", "ORGANISM", 0, 15], ["humans", "ORGANISM", 91, 97], ["humans", "SPECIES", 91, 97], ["Oropouche virus", "SPECIES", 0, 15], ["humans", "SPECIES", 91, 97], ["Oropouche virus", "PROBLEM", 0, 15], ["acute febrile illness in humans", "PROBLEM", 66, 97], ["virus", "OBSERVATION", 10, 15], ["acute", "OBSERVATION_MODIFIER", 66, 71], ["febrile", "OBSERVATION_MODIFIER", 72, 79], ["illness", "OBSERVATION", 80, 87]]], ["Mitochondrial release of cytochrome C and activation of caspase-9 and -3 are detected during viral infection, and Oropouche virus infection causes apoptosis via an intracellular pathway that involves mitochondria (Acrani et al., 2010).", [["Mitochondrial", "ANATOMY", 0, 13], ["intracellular", "ANATOMY", 164, 177], ["mitochondria", "ANATOMY", 200, 212], ["viral infection", "DISEASE", 93, 108], ["infection", "DISEASE", 130, 139], ["Mitochondrial", "CELLULAR_COMPONENT", 0, 13], ["cytochrome C", "GENE_OR_GENE_PRODUCT", 25, 37], ["caspase-9", "GENE_OR_GENE_PRODUCT", 56, 65], ["-3", "GENE_OR_GENE_PRODUCT", 70, 72], ["Oropouche virus", "ORGANISM", 114, 129], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 164, 177], ["mitochondria", "CELLULAR_COMPONENT", 200, 212], ["cytochrome C", "PROTEIN", 25, 37], ["caspase-9 and -3", "PROTEIN", 56, 72], ["Oropouche virus", "SPECIES", 114, 129], ["cytochrome C", "TREATMENT", 25, 37], ["caspase", "TEST", 56, 63], ["viral infection", "PROBLEM", 93, 108], ["Oropouche virus infection", "PROBLEM", 114, 139], ["apoptosis", "PROBLEM", 147, 156], ["an intracellular pathway", "TREATMENT", 161, 185], ["viral infection", "OBSERVATION", 93, 108]]], ["JNK promotes the translocation of the Bcl-2 family pro-apoptotic protein, Bax, into mitochondria via the phosphorylation of 14-3-3 proteins that cause dissociation of Bax, where this translocation is essential for mediating the apoptotic release of cytochrome C (Tsuruta et al., 2004, Papadakis et al., 2006).", [["mitochondria", "ANATOMY", 84, 96], ["JNK", "GENE_OR_GENE_PRODUCT", 0, 3], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 38, 43], ["Bax", "GENE_OR_GENE_PRODUCT", 74, 77], ["mitochondria", "CELLULAR_COMPONENT", 84, 96], ["14-3-3", "GENE_OR_GENE_PRODUCT", 124, 130], ["Bax", "GENE_OR_GENE_PRODUCT", 167, 170], ["cytochrome C", "GENE_OR_GENE_PRODUCT", 249, 261], ["JNK", "PROTEIN", 0, 3], ["Bcl-2 family pro-apoptotic protein", "PROTEIN", 38, 72], ["Bax", "PROTEIN", 74, 77], ["14-3-3 proteins", "PROTEIN", 124, 139], ["Bax", "PROTEIN", 167, 170], ["cytochrome C", "PROTEIN", 249, 261], ["the Bcl", "TEST", 34, 41], ["Bax", "TREATMENT", 74, 77], ["the phosphorylation", "TEST", 101, 120], ["dissociation of Bax", "PROBLEM", 151, 170]]], ["Thus, we suggest that AKAV-induced JNK activation exerts a pro-apoptotic effect via the mitochondrial pathway, thereby regulating Bax translocation into the mitochondria, cytochrome C release, and caspase activation.DiscussionIn conclusion, our results indicate that AKAV infection induces the phosphorylation of JNK and p38 MAPK as well as their downstream substrates, c-Jun and HSP27 in cultured cells.", [["mitochondrial", "ANATOMY", 88, 101], ["mitochondria", "ANATOMY", 157, 169], ["cells", "ANATOMY", 398, 403], ["AKAV", "CHEMICAL", 22, 26], ["AKAV", "CHEMICAL", 267, 271], ["infection", "DISEASE", 272, 281], ["AKAV", "GENE_OR_GENE_PRODUCT", 22, 26], ["JNK", "GENE_OR_GENE_PRODUCT", 35, 38], ["mitochondrial", "CELLULAR_COMPONENT", 88, 101], ["Bax", "GENE_OR_GENE_PRODUCT", 130, 133], ["mitochondria", "CELLULAR_COMPONENT", 157, 169], ["cytochrome C", "GENE_OR_GENE_PRODUCT", 171, 183], ["caspase", "GENE_OR_GENE_PRODUCT", 197, 204], ["AKAV", "GENE_OR_GENE_PRODUCT", 267, 271], ["JNK", "GENE_OR_GENE_PRODUCT", 313, 316], ["p38 MAPK", "GENE_OR_GENE_PRODUCT", 321, 329], ["c-Jun", "GENE_OR_GENE_PRODUCT", 370, 375], ["HSP27", "GENE_OR_GENE_PRODUCT", 380, 385], ["cells", "CELL", 398, 403], ["AKAV", "PROTEIN", 22, 26], ["JNK", "PROTEIN", 35, 38], ["Bax", "PROTEIN", 130, 133], ["cytochrome C", "PROTEIN", 171, 183], ["caspase", "PROTEIN", 197, 204], ["JNK", "PROTEIN", 313, 316], ["p38 MAPK", "PROTEIN", 321, 329], ["Jun", "PROTEIN", 372, 375], ["HSP27", "PROTEIN", 380, 385], ["cultured cells", "CELL_LINE", 389, 403], ["AKAV", "SPECIES", 267, 271], ["AKAV-induced JNK activation", "TREATMENT", 22, 49], ["the mitochondrial pathway", "TREATMENT", 84, 109], ["the mitochondria", "TREATMENT", 153, 169], ["cytochrome C release", "TREATMENT", 171, 191], ["caspase activation", "TREATMENT", 197, 215], ["AKAV infection", "PROBLEM", 267, 281], ["JNK", "TEST", 313, 316], ["p38 MAPK", "TEST", 321, 329], ["their downstream substrates", "TEST", 341, 368], ["HSP27 in cultured cells", "TEST", 380, 403], ["infection", "OBSERVATION", 272, 281]]], ["In particular, JNK activation plays a crucial role in AKAV-induced apoptosis.", [["AKAV", "CHEMICAL", 54, 58], ["JNK", "GENE_OR_GENE_PRODUCT", 15, 18], ["AKAV", "GENE_OR_GENE_PRODUCT", 54, 58], ["JNK", "PROTEIN", 15, 18], ["AKAV", "PROTEIN", 54, 58], ["AKAV", "PROBLEM", 54, 58], ["apoptosis", "PROBLEM", 67, 76], ["apoptosis", "OBSERVATION", 67, 76]]], ["AKAV causes abortions, stillbirths, and congenital disorders in animals.", [["AKAV", "CHEMICAL", 0, 4], ["abortions", "DISEASE", 12, 21], ["stillbirths", "DISEASE", 23, 34], ["congenital disorders", "DISEASE", 40, 60], ["AKAV", "SPECIES", 0, 4], ["abortions", "PROBLEM", 12, 21], ["stillbirths", "PROBLEM", 23, 34], ["congenital disorders in animals", "PROBLEM", 40, 71], ["abortions", "OBSERVATION", 12, 21], ["congenital", "OBSERVATION_MODIFIER", 40, 50], ["disorders", "OBSERVATION", 51, 60]]], ["This study is useful to understand the pathogenicity of AKAV.", [["AKAV", "GENE_OR_GENE_PRODUCT", 56, 60], ["AKAV", "PROTEIN", 56, 60], ["This study", "TEST", 0, 10], ["the pathogenicity of AKAV", "PROBLEM", 35, 60]]]], "PMC7176465": [["According to disease control experts, a pandemic\u2014an infection that spreads widely and affects a significant proportion of the population\u2014is inevitable [1].", [["pandemic\u2014an infection", "DISEASE", 40, 61], ["a pandemic\u2014an infection", "PROBLEM", 38, 61], ["infection", "OBSERVATION", 52, 61], ["significant", "OBSERVATION_MODIFIER", 96, 107]]], ["Although a pandemic event has not struck the modern society, historical accounts have clearly manifested its plausibility and the dire consequences it can bring to the general population.", [["a pandemic event", "PROBLEM", 9, 25]]], ["With the rise of new infections such as the severe acute respiratory syndrome, avian flu, swine flu, as well as the threat of bioterrorism, experts from the General Accounting Office believe it is imminent [2].IntroductionA dynamic extension to interdependence modeling is needed to describe the temporal nature of sector recoveries pursuant to a disaster, such as in the case of a pandemic scenario.", [["infections", "DISEASE", 21, 31], ["acute respiratory syndrome", "DISEASE", 51, 77], ["avian flu", "DISEASE", 79, 88], ["swine flu", "DISEASE", 90, 99], ["avian flu", "SPECIES", 79, 88], ["swine flu", "SPECIES", 90, 99], ["swine flu", "SPECIES", 90, 99], ["new infections", "PROBLEM", 17, 31], ["the severe acute respiratory syndrome", "PROBLEM", 40, 77], ["avian flu", "PROBLEM", 79, 88], ["new", "OBSERVATION_MODIFIER", 17, 20], ["infections", "OBSERVATION", 21, 31], ["severe", "OBSERVATION_MODIFIER", 44, 50], ["acute", "OBSERVATION_MODIFIER", 51, 56], ["respiratory syndrome", "OBSERVATION", 57, 77]]], ["Given the initial inoperabilities caused by a disaster, the dynamic extension gives the trajectory of recovery based on the interdependence and resilience characteristics of the industry sectors.IntroductionWith the looming fear of a pandemic occurring in our present world, it is imperative to develop models for assessing its consequences and for evaluating the efficacy of available mitigation strategies.", [["available mitigation strategies", "TREATMENT", 376, 407]]], ["A pandemic encompasses different consequence categories and can cross multiple geographic jurisdictions.", [["A pandemic encompasses different consequence categories", "PROBLEM", 0, 55]]], ["In an attempt to address the complexities inherent in a pandemic (and in any disasters), this paper develops a dynamic and probabilistic model to account for workforce productivity degradations and resulting workforce-induced economic losses.", [["workforce productivity degradations", "PROBLEM", 158, 193], ["economic losses", "PROBLEM", 226, 241], ["economic losses", "OBSERVATION", 226, 241]]], ["It is worth noting that the traditional use of I-O analysis for estimating the effects of economic shifts (e.g., changes in consumption) has been extended to other applications such as disaster risk management, environmental impact analysis, and energy consumption, among others.", [["economic shifts", "PROBLEM", 90, 105], ["disaster risk management", "TREATMENT", 185, 209]]], ["Various studies for estimating losses pursuant to disasters have employed traditional I-O analysis and extended approaches such as computable general equilibrium (CGE) models.", [["Various studies", "TEST", 0, 15]]], ["Rose and Liao [9] conducted a case study of water-supply disruption scenarios in Portland; they used CGE to account for resilience factors (e.g., substitution and conservation) that business sectors typically consider in order to minimize potential losses.", [["resilience factors", "PROBLEM", 120, 138], ["substitution and conservation", "TREATMENT", 146, 175], ["potential losses", "PROBLEM", 239, 255]]], ["Rose [10] describes that CGE is an extension rather than a replacement of the traditional I-O model.", [["CGE", "CHEMICAL", 25, 28], ["an extension", "PROBLEM", 32, 44], ["a replacement", "TREATMENT", 57, 70]]], ["Other disaster-related applications of I-O and CGE models include [11]\u2013[13].Input\u2013Output Modeling ::: Supporting ModelsThe formulation of the basic Leontief I-O model is shown in (1).", [["I-O", "SIMPLE_CHEMICAL", 39, 42], ["[11]\u2013[13]", "SIMPLE_CHEMICAL", 66, 75]]], ["Through matrix manipulations, the IIM introduces the concept of inoperability into the traditional I-O model which augments typical economic loss analysis.", [["matrix", "ANATOMY", 8, 14], ["matrix manipulations", "TREATMENT", 8, 28], ["typical economic loss analysis", "PROBLEM", 124, 154], ["economic loss", "OBSERVATION", 132, 145]]], ["The IIM was later expanded by Santos and Haimes [15] to quantify the economic losses triggered by terrorism and other disruptive events to economic systems (or industry sectors).", [["the economic losses", "PROBLEM", 65, 84], ["terrorism", "PROBLEM", 98, 107], ["other disruptive events to economic systems", "PROBLEM", 112, 155]]], ["The analysis of economic impacts associated with such events is made possible through the economic I-O data published by the Bureau of Economic Analysis [16].", [["economic impacts", "PROBLEM", 16, 32], ["such events", "PROBLEM", 49, 60], ["Economic Analysis", "TEST", 135, 152]]], ["The formulation of the IIM is as follows:\\begin{document}}{}\\end{document}Iim ::: Supporting ModelsIn essence, the terms in the formulation in (2) are derived from the Leontief formulation in (1) and are interpreted as follows: \\begin{document}}{}\\end{document} is a perturbation vector expressed in terms of normalized degraded final demand (i.e., \u201cas-planned\u201d final demand minus actual final demand, divided by the as-planned production level), \\begin{document}}{}\\end{document} is the interdependence matrix which indicates the degree of coupling of the industry sectors, and \\begin{document}}{}\\end{document} is the inoperability vector expressed in terms of normalized economic losses.Diim ::: Supporting ModelsThe DIIM is an extension of the IIM that provides supplementary risk metrics for assessing the consequences of disasters [17].", [["a perturbation vector", "PROBLEM", 265, 286], ["the inoperability vector", "TREATMENT", 616, 640], ["normalized economic losses", "PROBLEM", 663, 689], ["normalized", "OBSERVATION_MODIFIER", 663, 673], ["economic losses", "OBSERVATION", 674, 689]]], ["Given the initial inoperabilities caused by the disaster, recovery analysis gives the trajectory of recovery based on the interdependence and resilience characteristics of the sectors.", [["recovery analysis", "TEST", 58, 75]]], ["In addition to the inoperability and economic loss metrics, the recovery period and resilience metrics generated from the dynamic analysis can provide insights in describing the recovery process for the affected sectors.", [["the inoperability and economic loss metrics", "PROBLEM", 15, 58], ["resilience metrics", "PROBLEM", 84, 102], ["the dynamic analysis", "TEST", 118, 138]]], ["The model formulation, from Lian and Haimes [3], is as follows:\\begin{document}}{}\\end{document}Diim ::: Supporting ModelsThe term \\begin{document}}{}\\end{document} is a sector resilience coefficient matrix that represents the rates with which sectors recover to their nominal levels of availability following a disruption.", [["The model formulation", "TREATMENT", 0, 21], ["a sector resilience coefficient matrix", "TREATMENT", 168, 206], ["a disruption", "PROBLEM", 310, 322]]], ["The model dictates that the inoperability level at the following time step \\begin{document}}{}\\end{document} is equal to the inoperability at the previous stage \\begin{document}}{}\\end{document} plus the effects of the resilience of the sector.", [["the inoperability level", "PROBLEM", 24, 47]]], ["As seen in the aforementioned equation, \\begin{document}}{}\\end{document} is multiplied with the indirect inoperability resulting from other sectors \\begin{document}}{}\\end{document} plus a productivity disruption factor \\begin{document}}{}\\end{document} minus the current level of inoperability \\begin{document}}{}\\end{document}.Diim ::: Supporting ModelsWhile the aforementioned model provides a foundation for measuring the impact of a pandemic, there are certain idiosyncracies associated with such a disaster that are not accounted for in the current formulation.", [["productivity disruption factor", "PROTEIN", 190, 220], ["a productivity disruption factor", "PROBLEM", 188, 220]]], ["In our DIIM extension, we will explicitly incorporate the analysis and parameterization of disruptions to different workforce sectors.Probabilistic and Dynamic ExtensionsThe previous implementation of the DIIM was typically done in a Microsoft Excel workbook.", [["DIIM", "DNA", 205, 209], ["the analysis", "TEST", 54, 66], ["disruptions", "PROBLEM", 91, 102], ["Dynamic Extensions", "OBSERVATION", 152, 170]]], ["However, with the modifications to the formulation presented in this paper, the Excel workbook is no longer sufficient.", [["no longer", "UNCERTAINTY", 98, 107]]], ["This is a result of the need for multidimensional data structures as well as the need for running simulations of these data structures.", [["multidimensional data structures", "TEST", 33, 65]]], ["To better account for this, a MatLab graphical user interface (GUI) was developed to run the simulations and output the results for analysis.", [["analysis", "TEST", 132, 140]]], ["This represents a central repository of relevant data pertaining to regional economic and survey data.", [["survey data", "TEST", 90, 101]]], ["Examples of economic data include local area personal income, gross domestic product (GDP), and I-O accounts.", [["economic data", "TEST", 12, 25]]], ["This module also contains survey data on local businesses and other pertinent sector-specific data.2)Scenario Generation Module.", [["Scenario Generation Module", "PROBLEM", 101, 127], ["Generation Module", "OBSERVATION", 110, 127]]], ["Sample questions that can be asked (via a pull-down menu in the GUI) are the duration of the scenario and the pandemic attack rates to be simulated.", [["the pandemic attack rates", "PROBLEM", 106, 131]]], ["The user can also specify types of graphs to display with the visualization module.3)Computation Module.", [["the visualization module", "TEST", 58, 82]]], ["This is the computing engine of the program containing the codes for the DIIM application.", [["the DIIM application", "TREATMENT", 69, 89]]], ["This shows the results of the simulation based on the GUI-specified inputs.", [["the simulation", "TEST", 26, 40]]], ["The user has the option to choose from various types of displays such as minimum, expected value, and extreme-event consequences (economic loss and inoperability).Virginia Pandemic Case StudyThis section discusses the usage of regional economic data, as well as pandemic data and model results from the Centers for Disease Control and Prevention (CDC) to determine the impact of a pandemic on the economy of the state of Virginia.", [["economic loss and inoperability", "PROBLEM", 130, 161], ["regional economic data", "TEST", 227, 249], ["pandemic data", "TEST", 262, 275], ["Disease Control", "TREATMENT", 315, 330], ["a pandemic", "PROBLEM", 379, 389]]], ["Results of the model and implications on risk-management decisions are presented and discussed.Virginia Pandemic Case StudyThis case study focuses on a four-week pandemic scenario in Virginia, as shown in Fig. 1.", [["This case study", "TEST", 123, 138]]], ["It explores simulated attack rates, as defined by CDC's FluWorkLoss: 15%, 25%, and 35% [18], [19].", [["simulated attack rates", "PROBLEM", 12, 34]]], ["Nevertheless, comparisons of consequences for other attack rates and durations will be summarized at the end of this section.", [["other attack rates", "PROBLEM", 46, 64], ["this section", "TREATMENT", 112, 124]]], ["The different attack rates will be compared in terms of their overall impact, highest impacted sectors, and general behavior.Virginia Pandemic Case StudyIn subsequent discussions, we will use four different statistical measures for both inoperability and economic loss estimates, namely: 1) minimum; 2) mean; 3) conditional upper tail expectation \\begin{document}}{}\\end{document}; and 4) maximum.", [["}{}\\end{document}", "CHEMICAL", 363, 380], ["The different attack rates", "TREATMENT", 0, 26], ["four different statistical measures", "TREATMENT", 192, 227], ["conditional upper tail expectation", "PROBLEM", 312, 346], ["upper tail", "ANATOMY", 324, 334]]], ["The conditional upper tail expectation will be determined as the average of the highest 10% of the simulated values for inoperability and economic loss.Virginia Pandemic Case StudyAnother interesting behavior is the relatively steep recovery beginning at day 28.", [["inoperability", "DISEASE", 120, 133], ["upper tail", "ORGANISM_SUBDIVISION", 16, 26], ["inoperability", "PROBLEM", 120, 133], ["economic loss", "PROBLEM", 138, 151], ["upper", "ANATOMY_MODIFIER", 16, 21], ["tail", "ANATOMY", 22, 26], ["economic loss", "OBSERVATION", 138, 151]]], ["This is seen more clearly in Fig. 3, a plot of the inoperability of the top ten most inoperable sectors.", [["more clearly", "OBSERVATION_MODIFIER", 13, 25], ["Fig", "OBSERVATION", 29, 32]]], ["Thus, at that point, the model begins to recover as though every person returned to work.", [["person", "SPECIES", 65, 71]]]], "PMC6145877": [["IntroductionA novel duck reovirus (NDRV) disease, called \u201cspleen necrosis disease,\u201d \u201cnew liver disease in Muscovy ducks\u201d or \u201cduck hemorrhagic-necrotic hepatitis,\u201d was recently found among several duckling species, including shelducks, Pekins, wild mallards and Muscovy in China1.", [["spleen", "ANATOMY", 58, 64], ["liver", "ANATOMY", 89, 94], ["duck reovirus (NDRV) disease", "DISEASE", 20, 48], ["spleen necrosis", "DISEASE", 58, 73], ["disease", "DISEASE", 74, 81], ["liver disease", "DISEASE", 89, 102], ["hemorrhagic-necrotic hepatitis", "DISEASE", 130, 160], ["duck reovirus", "ORGANISM", 20, 33], ["NDRV", "ORGANISM", 35, 39], ["spleen", "ORGAN", 58, 64], ["liver", "ORGAN", 89, 94], ["Muscovy ducks", "ORGANISM", 106, 119], ["\u201cduck", "ORGANISM", 124, 129], ["mallards", "ORGANISM", 248, 256], ["duck reovirus", "SPECIES", 20, 33], ["ducks", "SPECIES", 114, 119], ["duck", "SPECIES", 125, 129], ["mallards", "SPECIES", 248, 256], ["duck reovirus", "SPECIES", 20, 33], ["NDRV", "SPECIES", 35, 39], ["Muscovy ducks", "SPECIES", 106, 119], ["IntroductionA novel duck reovirus (NDRV) disease", "PROBLEM", 0, 48], ["spleen necrosis disease", "PROBLEM", 58, 81], ["new liver disease", "PROBLEM", 85, 102], ["\u201cduck hemorrhagic-necrotic hepatitis", "PROBLEM", 124, 160], ["several duckling species", "PROBLEM", 188, 212], ["duck reovirus", "OBSERVATION", 20, 33], ["spleen", "ANATOMY", 58, 64], ["necrosis", "OBSERVATION", 65, 73], ["new", "OBSERVATION_MODIFIER", 85, 88], ["liver", "ANATOMY", 89, 94], ["disease", "OBSERVATION", 95, 102], ["Muscovy", "ANATOMY", 106, 113], ["duck", "OBSERVATION_MODIFIER", 125, 129], ["hemorrhagic", "OBSERVATION_MODIFIER", 130, 141], ["necrotic", "OBSERVATION_MODIFIER", 142, 150], ["hepatitis", "OBSERVATION", 151, 160], ["Muscovy", "ANATOMY", 261, 268]]], ["Similarly, avian reovirus (ARV) infection was recorded in Muscovy ducks (Cairina moschata) in south western Poland during the summer 20122.", [["avian reovirus (ARV) infection", "DISEASE", 11, 41], ["avian reovirus", "ORGANISM", 11, 25], ["ARV", "ORGANISM", 27, 30], ["Muscovy ducks", "ORGANISM", 58, 71], ["Cairina moschata", "ORGANISM", 73, 89], ["avian reovirus", "SPECIES", 11, 25], ["Muscovy ducks", "SPECIES", 58, 71], ["Cairina moschata", "SPECIES", 73, 89], ["Muscovy ducks", "SPECIES", 58, 71], ["Cairina moschata", "SPECIES", 73, 89], ["avian reovirus (ARV) infection", "PROBLEM", 11, 41], ["reovirus", "OBSERVATION", 17, 25], ["infection", "OBSERVATION", 32, 41]]], ["NDRV is a member of the genus Orthoreovirus in the family Reoviridae3.IntroductionThe disease can be distinguished from Muscovy duck reovirus (MDRV) infections by clinical presentation of hemorrhagic and necrotic lesions in the liver and spleen and 5\u201350% mortality rates.", [["necrotic lesions", "ANATOMY", 204, 220], ["liver", "ANATOMY", 228, 233], ["spleen", "ANATOMY", 238, 244], ["NDRV", "CHEMICAL", 0, 4], ["Muscovy duck reovirus (MDRV) infections", "DISEASE", 120, 159], ["hemorrhagic", "DISEASE", 188, 199], ["necrotic", "DISEASE", 204, 212], ["NDRV", "GENE_OR_GENE_PRODUCT", 0, 4], ["Orthoreovirus", "GENE_OR_GENE_PRODUCT", 30, 43], ["Reoviridae3", "GENE_OR_GENE_PRODUCT", 58, 69], ["Muscovy duck reovirus", "ORGANISM", 120, 141], ["MDRV", "ORGANISM", 143, 147], ["necrotic lesions", "PATHOLOGICAL_FORMATION", 204, 220], ["liver", "ORGAN", 228, 233], ["spleen", "ORGAN", 238, 244], ["NDRV", "PROTEIN", 0, 4], ["Reoviridae3", "PROTEIN", 58, 69], ["Muscovy duck reovirus", "SPECIES", 120, 141], ["Muscovy duck reovirus", "SPECIES", 120, 141], ["MDRV", "SPECIES", 143, 147], ["The disease", "PROBLEM", 82, 93], ["Muscovy duck reovirus (MDRV) infections", "PROBLEM", 120, 159], ["hemorrhagic and necrotic lesions in the liver and spleen", "PROBLEM", 188, 244], ["disease", "OBSERVATION", 86, 93], ["hemorrhagic", "OBSERVATION_MODIFIER", 188, 199], ["necrotic", "OBSERVATION_MODIFIER", 204, 212], ["lesions", "OBSERVATION", 213, 220], ["liver", "ANATOMY", 228, 233], ["spleen", "ANATOMY", 238, 244]]], ["Furthermore, the existing commercial vaccines against ARVs or MDRVs fail to prevent NDRV infection and transmission.", [["infection", "DISEASE", 89, 98], ["MDRVs", "SIMPLE_CHEMICAL", 62, 67], ["NDRV", "CANCER", 84, 88], ["NDRV", "SPECIES", 84, 88], ["commercial vaccines", "TREATMENT", 26, 45], ["ARVs", "TREATMENT", 54, 58], ["MDRVs", "TREATMENT", 62, 67], ["NDRV infection", "PROBLEM", 84, 98], ["infection", "OBSERVATION", 89, 98]]], ["A reverse transcription loop mediated isothermal amplification (RT-LAMP) provides a rapid and precise detection assay for viral pathogens with high sensitivity and specificity4.", [["A reverse transcription loop mediated isothermal amplification", "TREATMENT", 0, 62], ["RT-LAMP", "TREATMENT", 64, 71], ["a rapid and precise detection assay", "TEST", 82, 117], ["viral pathogens", "PROBLEM", 122, 137], ["high sensitivity and specificity4", "PROBLEM", 143, 176]]], ["This technique is profitable and convenient, only requires a constant temperature water bath and averts some deficiencies, including high necessity for equipment, tremendous cost, lengthened examination period and low sensitivity5.", [["a constant temperature water bath", "TREATMENT", 59, 92], ["some deficiencies", "PROBLEM", 104, 121], ["lengthened examination", "TEST", 180, 202], ["low sensitivity5", "PROBLEM", 214, 230], ["low sensitivity5", "OBSERVATION_MODIFIER", 214, 230]]], ["In comparison with the equipment required for traditional polymerase chain reaction (PCR) and quantitative polymerase chain reaction (qPCR) assays, RT-LAMP is easy to conduct in resource-limited laboratory settings in underdeveloped countries6.", [["traditional polymerase chain reaction", "PROBLEM", 46, 83], ["PCR", "TEST", 85, 88], ["quantitative polymerase chain reaction", "PROBLEM", 94, 132], ["assays", "TEST", 140, 146]]], ["RT-LAMP has been widely exploited in clinical diagnosis of various viral pathogens including porcine epidemic diarrhea virus (PEDV), transmissible gastroenteritis virus (TGEV), classic swine fever virus (CSFV), H10N8 subtype of influenza A virus, porcine deltacoronavirus (PDCoV), Zika virus (ZIKV), chikungunya virus (CHIKV), Rift Valley fever virus (RVFV), St. Louis encephalitis virus (SLEV), yellow fever virus (YFV), dengue virus serotypes 1\u20134, Japanese encephalitis virus (DENV1\u20134) and West Nile virus (WNV)7\u201310.", [["porcine epidemic diarrhea virus", "DISEASE", 93, 124], ["transmissible gastroenteritis virus", "DISEASE", 133, 168], ["TGEV", "DISEASE", 170, 174], ["swine fever", "DISEASE", 185, 196], ["influenza A", "DISEASE", 228, 239], ["porcine deltacoronavirus (PDCoV), Zika virus (ZIKV), chikungunya virus (CHIKV)", "DISEASE", 247, 325], ["Rift Valley fever virus (RVFV), St. Louis encephalitis", "DISEASE", 327, 381], ["yellow fever", "DISEASE", 396, 408], ["dengue", "DISEASE", 422, 428], ["Japanese encephalitis", "DISEASE", 450, 471], ["porcine epidemic diarrhea virus", "ORGANISM", 93, 124], ["transmissible gastroenteritis virus", "ORGANISM", 133, 168], ["TGEV", "ORGANISM", 170, 174], ["classic swine fever virus", "ORGANISM", 177, 202], ["CSFV", "ORGANISM", 204, 208], ["H10N8 subtype", "ORGANISM", 211, 224], ["influenza A virus", "ORGANISM", 228, 245], ["porcine deltacoronavirus (PDCoV", "ORGANISM", 247, 278], ["Zika virus", "ORGANISM", 281, 291], ["ZIKV", "GENE_OR_GENE_PRODUCT", 293, 297], ["chikungunya virus", "ORGANISM", 300, 317], ["CHIKV", "ORGANISM", 319, 324], ["Rift Valley fever virus", "ORGANISM", 327, 350], ["RVFV", "ORGANISM", 352, 356], ["St. Louis encephalitis virus", "ORGANISM", 359, 387], ["SLEV", "ORGANISM", 389, 393], ["yellow fever virus", "ORGANISM", 396, 414], ["YFV", "ORGANISM", 416, 419], ["dengue virus serotypes 1\u20134", "ORGANISM", 422, 448], ["Japanese encephalitis virus", "ORGANISM", 450, 477], ["DENV1\u20134", "ORGANISM", 479, 486], ["West Nile virus", "ORGANISM", 492, 507], ["WNV", "ORGANISM", 509, 512], ["porcine epidemic diarrhea virus", "SPECIES", 93, 124], ["transmissible gastroenteritis virus", "SPECIES", 133, 168], ["TGEV", "SPECIES", 170, 174], ["swine fever virus", "SPECIES", 185, 202], ["CSFV", "SPECIES", 204, 208], ["influenza A virus", "SPECIES", 228, 245], ["porcine", "SPECIES", 247, 254], ["Zika virus", "SPECIES", 281, 291], ["chikungunya virus", "SPECIES", 300, 317], ["Rift Valley fever virus", "SPECIES", 327, 350], ["RVFV", "SPECIES", 352, 356], ["St. Louis encephalitis virus", "SPECIES", 359, 387], ["yellow fever virus", "SPECIES", 396, 414], ["dengue virus serotypes", "SPECIES", 422, 444], ["Japanese encephalitis virus", "SPECIES", 450, 477], ["West Nile virus", "SPECIES", 492, 507], ["porcine epidemic diarrhea virus", "SPECIES", 93, 124], ["PEDV", "SPECIES", 126, 130], ["transmissible gastroenteritis virus", "SPECIES", 133, 168], ["TGEV", "SPECIES", 170, 174], ["classic swine fever virus", "SPECIES", 177, 202], ["CSFV", "SPECIES", 204, 208], ["influenza A virus", "SPECIES", 228, 245], ["porcine deltacoronavirus", "SPECIES", 247, 271], ["PDCoV", "SPECIES", 273, 278], ["Zika virus", "SPECIES", 281, 291], ["ZIKV", "SPECIES", 293, 297], ["chikungunya virus", "SPECIES", 300, 317], ["CHIKV", "SPECIES", 319, 324], ["Rift Valley fever virus", "SPECIES", 327, 350], ["RVFV", "SPECIES", 352, 356], ["St. Louis encephalitis virus", "SPECIES", 359, 387], ["SLEV", "SPECIES", 389, 393], ["yellow fever virus", "SPECIES", 396, 414], ["YFV", "SPECIES", 416, 419], ["dengue virus", "SPECIES", 422, 434], ["Japanese encephalitis virus", "SPECIES", 450, 477], ["DENV1\u20134", "SPECIES", 479, 486], ["West Nile virus", "SPECIES", 492, 507], ["WNV", "SPECIES", 509, 512], ["various viral pathogens", "PROBLEM", 59, 82], ["porcine epidemic diarrhea virus", "PROBLEM", 93, 124], ["PEDV", "PROBLEM", 126, 130], ["transmissible gastroenteritis virus (TGEV", "PROBLEM", 133, 174], ["classic swine fever virus", "PROBLEM", 177, 202], ["CSFV", "PROBLEM", 204, 208], ["influenza A virus", "PROBLEM", 228, 245], ["porcine deltacoronavirus (PDCoV)", "PROBLEM", 247, 279], ["Zika virus (ZIKV)", "PROBLEM", 281, 298], ["chikungunya virus (CHIKV)", "PROBLEM", 300, 325], ["Rift Valley fever virus", "PROBLEM", 327, 350], ["St. Louis encephalitis virus (SLEV)", "PROBLEM", 359, 394], ["yellow fever virus (YFV)", "PROBLEM", 396, 420], ["dengue virus serotypes", "PROBLEM", 422, 444], ["Japanese encephalitis virus", "PROBLEM", 450, 477], ["viral pathogens", "OBSERVATION", 67, 82], ["gastroenteritis virus", "OBSERVATION", 147, 168], ["influenza", "OBSERVATION", 228, 237]]], ["The ARV structural and molecular compositions are generally similar to those of mammalian reovirus (MRV).", [["mammalian reovirus", "ORGANISM", 80, 98], ["mammalian reovirus", "TREATMENT", 80, 98], ["ARV", "OBSERVATION_MODIFIER", 4, 7], ["structural", "OBSERVATION_MODIFIER", 8, 18], ["molecular compositions", "OBSERVATION", 23, 45], ["mammalian reovirus", "OBSERVATION", 80, 98]]], ["However, some of the ARV biological properties differ from mammalian reovirus, which have been shown elsewhere11,12.", [["mammalian reovirus", "ORGANISM", 59, 77], ["mammalian reovirus", "PROBLEM", 59, 77], ["mammalian reovirus", "OBSERVATION", 59, 77]]], ["The S3 segment encoding the \u03c3B protein of duck and MRVs is structurally similar to ARV \u03c3B gene13.", [["S3", "GENE_OR_GENE_PRODUCT", 4, 6], ["\u03c3B", "GENE_OR_GENE_PRODUCT", 28, 30], ["duck", "ORGANISM", 42, 46], ["MRVs", "GENE_OR_GENE_PRODUCT", 51, 55], ["\u03c3B gene13", "GENE_OR_GENE_PRODUCT", 87, 96], ["S3 segment", "DNA", 4, 14], ["\u03c3B protein", "PROTEIN", 28, 38], ["MRVs", "PROTEIN", 51, 55], ["ARV \u03c3B gene13", "DNA", 83, 96], ["S3", "ANATOMY_MODIFIER", 4, 6], ["segment", "ANATOMY_MODIFIER", 7, 14]]], ["Reverse transcription PCR (RT-PCR) on both sigma C (\u03c3C) and sigma B (\u03c3B)-encoding genes followed by restriction fragment length polymorphism (RFLP) analyses were employed to characterize Tunisian ARV isolates14.", [["sigma C", "GENE_OR_GENE_PRODUCT", 43, 50], ["\u03c3C", "GENE_OR_GENE_PRODUCT", 52, 54], ["sigma B", "GENE_OR_GENE_PRODUCT", 60, 67], ["\u03c3B", "GENE_OR_GENE_PRODUCT", 69, 71], ["sigma C", "DNA", 43, 50], ["sigma B (\u03c3B", "DNA", 60, 71], ["restriction fragment length polymorphism", "DNA", 100, 140], ["RFLP", "DNA", 142, 146], ["Reverse transcription PCR", "TEST", 0, 25], ["RT-PCR", "TEST", 27, 33], ["both sigma C", "TEST", 38, 50], ["sigma B", "TEST", 60, 67], ["encoding genes", "PROBLEM", 73, 87], ["restriction fragment length polymorphism (RFLP) analyses", "PROBLEM", 100, 156]]], ["Furthermore, the highly variable sequences of the S3 and M3 have been reported to differentiate between novel duck reovirus (NDR), MDRV and avian reovirus15.", [["S3", "GENE_OR_GENE_PRODUCT", 50, 52], ["M3", "GENE_OR_GENE_PRODUCT", 57, 59], ["duck reovirus", "ORGANISM", 110, 123], ["NDR", "GENE_OR_GENE_PRODUCT", 125, 128], ["avian reovirus15", "ORGANISM", 140, 156], ["S3", "PROTEIN", 50, 52], ["M3", "PROTEIN", 57, 59], ["duck reovirus", "SPECIES", 110, 123], ["avian", "SPECIES", 140, 145], ["duck reovirus", "SPECIES", 110, 123], ["MDRV", "SPECIES", 131, 135], ["novel duck reovirus", "PROBLEM", 104, 123], ["MDRV", "TREATMENT", 131, 135], ["avian reovirus15", "TREATMENT", 140, 156], ["duck reovirus", "OBSERVATION", 110, 123]]], ["Thus, a simple, rapid and sensitive diagnostic technique for detection of NDRV is required.", [["NDRV", "CANCER", 74, 78], ["NDRV", "PROTEIN", 74, 78], ["NDRV", "SPECIES", 74, 78], ["NDRV", "PROBLEM", 74, 78]]], ["The potential application of RT-LAMP assay using the S3 gene of NDRV-NPO3 strain for specific diagnosis of NDRV infection with limited sensitivity and without its utilization in the detection of NDRV in naturally- and experimentally-infected ducks have been reported16.", [["infection", "DISEASE", 112, 121], ["NDRV", "CHEMICAL", 195, 199], ["S3", "GENE_OR_GENE_PRODUCT", 53, 55], ["NDRV-NPO3", "GENE_OR_GENE_PRODUCT", 64, 73], ["NDRV", "ORGANISM", 107, 111], ["NDRV", "GENE_OR_GENE_PRODUCT", 195, 199], ["ducks", "ORGANISM", 242, 247], ["S3 gene", "DNA", 53, 60], ["NDRV", "DNA", 64, 68], ["ducks", "SPECIES", 242, 247], ["NDRV", "SPECIES", 107, 111], ["NDRV", "SPECIES", 195, 199], ["RT-LAMP assay", "TEST", 29, 42], ["NDRV", "PROBLEM", 64, 68], ["NPO3 strain", "PROBLEM", 69, 80], ["NDRV infection", "PROBLEM", 107, 121], ["the detection", "TEST", 178, 191], ["NDRV", "PROBLEM", 195, 199], ["infected ducks", "PROBLEM", 233, 247], ["infection", "OBSERVATION", 112, 121], ["infected", "OBSERVATION", 233, 241]]], ["In this study, we developed and evaluated a RT-LAMP assay targeting the gene encoding the \u03c3B major outer-capsid protein to detect NDRV in naturally suspected NDRV-infected ducks and experimentally infected ducklings with NDRV.Ethics statement ::: Materials and MethodsThis study was approved by the Animal Ethics Committee of the College of life science and engineering, Foshan University, Guangdong, China.", [["\u03c3B", "GENE_OR_GENE_PRODUCT", 90, 92], ["NDRV", "GENE_OR_GENE_PRODUCT", 130, 134], ["ducks", "ORGANISM", 172, 177], ["ducklings", "ORGANISM", 206, 215], ["\u03c3B major outer-capsid protein", "PROTEIN", 90, 119], ["NDRV", "PROTEIN", 130, 134], ["ducks", "SPECIES", 172, 177], ["ducklings", "SPECIES", 206, 215], ["NDRV", "SPECIES", 158, 162], ["ducks", "SPECIES", 172, 177], ["ducklings", "SPECIES", 206, 215], ["NDRV", "SPECIES", 221, 225], ["this study", "TEST", 3, 13], ["a RT-LAMP assay", "TEST", 42, 57], ["NDRV", "PROBLEM", 130, 134], ["infected ducks", "PROBLEM", 163, 177], ["experimentally infected ducklings", "PROBLEM", 182, 215], ["NDRV", "TREATMENT", 221, 225], ["Methods", "TREATMENT", 261, 268], ["This study", "TEST", 268, 278], ["infected ducks", "OBSERVATION", 163, 177], ["infected", "OBSERVATION", 197, 205]]], ["The College did not issue a number or ID to this animal study, because the studied ducks are not an endangered or protected species.", [["ducks", "ORGANISM", 83, 88], ["ducks", "SPECIES", 83, 88], ["this animal study", "TEST", 44, 61], ["endangered", "OBSERVATION", 100, 110]]], ["Specimen collection was carried out based upon the protocol issued by the Animal Ethics Committee of the College of life science and engineering.", [["Specimen collection", "TEST", 0, 19], ["collection", "OBSERVATION", 9, 19]]], ["Furthermore, all methods were performed in accordance with the relevant guidelines and regulations.Virus isolates for specificity evaluation ::: Materials and MethodsNovel duck reovirus disease SH12 (NDRV- SH12) (preserved in the laboratory of Preventive Veterinary Medicine), was isolated from the infected ducks in Guandong province, China, Muscovy Duck Reovirus (MDRV-S12), Avian Reovirus (ARV-S1133), Duck Disease Virus (DPV), Duck Hepatitis Virus (DHAV), Duck Newcastle Disease Virus (NDV), H9 subtype avian influenza virus (AIV), H5 subtype AIV and duck Tanzuru virus (DTMUV) were stocked at \u221280 \u00b0C in our laboratory at College of life science and engineering, Foshan University, China.", [["reovirus disease", "DISEASE", 177, 193], ["Avian Reovirus", "DISEASE", 377, 391], ["Duck Disease Virus", "DISEASE", 405, 423], ["Duck Hepatitis Virus", "DISEASE", 431, 451], ["Newcastle Disease Virus", "DISEASE", 465, 488], ["avian influenza virus", "DISEASE", 507, 528], ["Virus", "ORGANISM", 99, 104], ["duck reovirus", "ORGANISM", 172, 185], ["NDRV- SH12", "ORGANISM", 200, 210], ["ducks", "ORGANISM", 308, 313], ["Muscovy Duck Reovirus", "ORGANISM", 343, 364], ["MDRV-S12", "ORGANISM", 366, 374], ["Avian Reovirus", "ORGANISM", 377, 391], ["ARV-S1133", "ORGANISM", 393, 402], ["Duck Disease Virus", "ORGANISM", 405, 423], ["DPV", "ORGANISM", 425, 428], ["Duck Hepatitis Virus", "ORGANISM", 431, 451], ["DHAV", "ORGANISM", 453, 457], ["Duck Newcastle Disease Virus (NDV), H9 subtype avian influenza virus", "ORGANISM", 460, 528], ["AIV", "ORGANISM", 530, 533], ["H5 subtype AIV", "ORGANISM", 536, 550], ["duck Tanzuru virus", "ORGANISM", 555, 573], ["DTMUV", "ORGANISM", 575, 580], ["duck reovirus", "SPECIES", 172, 185], ["ducks", "SPECIES", 308, 313], ["Avian", "SPECIES", 377, 382], ["Duck Hepatitis Virus", "SPECIES", 431, 451], ["NDV", "SPECIES", 490, 493], ["avian influenza virus", "SPECIES", 507, 528], ["AIV", "SPECIES", 547, 550], ["duck Tanzuru virus", "SPECIES", 555, 573], ["duck reovirus disease SH12 (NDRV- SH12)", "SPECIES", 172, 211], ["Muscovy Duck Reovirus (MDRV-S12", "SPECIES", 343, 374], ["Avian Reovirus (ARV-S1133", "SPECIES", 377, 402], ["Duck Disease Virus", "SPECIES", 405, 423], ["DPV", "SPECIES", 425, 428], ["Duck Hepatitis Virus", "SPECIES", 431, 451], ["DHAV", "SPECIES", 453, 457], ["Duck Newcastle Disease Virus", "SPECIES", 460, 488], ["NDV", "SPECIES", 490, 493], ["H9 subtype avian influenza virus", "SPECIES", 496, 528], ["AIV", "SPECIES", 530, 533], ["duck Tanzuru virus", "SPECIES", 555, 573], ["DTMUV", "SPECIES", 575, 580], ["all methods", "TEST", 13, 24], ["Virus isolates", "TEST", 99, 113], ["specificity evaluation", "TEST", 118, 140], ["MethodsNovel duck reovirus disease SH12", "PROBLEM", 159, 198], ["NDRV", "TEST", 200, 204], ["China, Muscovy Duck Reovirus", "TEST", 336, 364], ["MDRV", "TEST", 366, 370], ["Avian Reovirus", "PROBLEM", 377, 391], ["ARV", "TEST", 393, 396], ["Duck Disease Virus (DPV)", "PROBLEM", 405, 429], ["Duck Hepatitis Virus (DHAV)", "PROBLEM", 431, 458], ["Duck Newcastle Disease Virus (NDV)", "PROBLEM", 460, 494], ["H9 subtype avian influenza virus", "PROBLEM", 496, 528], ["H5 subtype AIV", "TREATMENT", 536, 550], ["duck Tanzuru virus", "TREATMENT", 555, 573], ["duck reovirus disease", "OBSERVATION", 172, 193], ["infected ducks", "OBSERVATION", 299, 313], ["Muscovy Duck", "ANATOMY", 343, 355], ["Duck", "ANATOMY", 405, 409], ["Duck", "ANATOMY", 431, 435], ["Hepatitis Virus", "OBSERVATION", 436, 451], ["influenza virus", "OBSERVATION", 513, 528]]], ["A total of 15 ducks were collected from the Guangdong region suspected to be infected with NDRV.", [["ducks", "ORGANISM", 14, 19], ["ducks", "SPECIES", 14, 19], ["NDRV", "SPECIES", 91, 95], ["A total of 15 ducks", "TREATMENT", 0, 19], ["NDRV", "TREATMENT", 91, 95], ["total", "OBSERVATION_MODIFIER", 2, 7], ["suspected to be", "UNCERTAINTY", 61, 76], ["infected", "OBSERVATION", 77, 85]]], ["The specimens were sent to the College of life science and engineering, Foshan University, China and examined upon arrival.Experimental infection of ducklings ::: Materials and MethodsTen 1-day-old Muscovy ducklings were randomly divided into 2 groups (5 birds per group).", [["specimens", "ANATOMY", 4, 13], ["infection", "DISEASE", 136, 145], ["ducklings", "ORGANISM", 149, 158], ["Muscovy", "ORGANISM", 198, 205], ["ducklings", "ORGANISM", 206, 215], ["birds", "ORGANISM", 255, 260], ["ducklings", "SPECIES", 149, 158], ["ducklings", "SPECIES", 206, 215], ["Muscovy ducklings", "SPECIES", 198, 215], ["The specimens", "TEST", 0, 13], ["Experimental infection of ducklings", "PROBLEM", 123, 158], ["old Muscovy ducklings", "TREATMENT", 194, 215], ["infection", "OBSERVATION", 136, 145]]], ["Group 1 ducklings were intraperitoneally injected with 0.2 mL (104.00ELD50) of the NDRV allantoic fluid and ducklings in group 2 were intraperitoneally injected with physiological saline and served as the control group.", [["allantoic fluid", "ANATOMY", 88, 103], ["ducklings", "ORGANISM", 8, 17], ["allantoic fluid", "ORGANISM_SUBSTANCE", 88, 103], ["ducklings", "ORGANISM", 108, 117], ["saline", "SIMPLE_CHEMICAL", 180, 186], ["ducklings", "SPECIES", 8, 17], ["ducklings", "SPECIES", 108, 117], ["NDRV", "SPECIES", 83, 87], ["the NDRV allantoic fluid", "TREATMENT", 79, 103], ["ducklings in group 2", "TREATMENT", 108, 128], ["physiological saline", "TREATMENT", 166, 186], ["fluid", "OBSERVATION", 98, 103]]], ["All ducklings were observed hourly for 72 h post-infection (hpi).RNA extraction ::: Materials and MethodsTotal RNA was extracted employing an EasyPure Viral DNA/RNA kit (Transgen, Beijing, China) according to the manufacturer\u2019s protocol and was stored immediately at \u221280 \u00b0C until use.Reverse transcriptase PCR (RT-PCR) ::: Materials and MethodsRT-PCR was performed employing a PrimeScript One Step RT-PCR Kit (TaKaRa, Japan).", [["infection", "DISEASE", 49, 58], ["ducklings", "ORGANISM", 4, 13], ["MethodsTotal RNA", "RNA", 98, 114], ["ducklings", "SPECIES", 4, 13], ["All ducklings", "PROBLEM", 0, 13], ["infection", "PROBLEM", 49, 58], ["MethodsTotal RNA", "TREATMENT", 98, 114], ["an EasyPure Viral DNA", "TREATMENT", 139, 160], ["Reverse transcriptase PCR", "TEST", 284, 309], ["PCR", "TEST", 347, 350], ["infection", "OBSERVATION", 49, 58]]], ["Primers S-F (5\u2032-GCTTTTTGAGTCCTCAGCGTG-3\u2032) and S-R (5\u2032-GATGAATAGGCGAGTCCCGC-3\u2032) were used to amplify the corresponding S3 segment encoding sigma B gene.", [["S-R", "GENE_OR_GENE_PRODUCT", 46, 49], ["sigma B", "GENE_OR_GENE_PRODUCT", 138, 145], ["S", "DNA", 46, 47], ["S3 segment", "DNA", 118, 128], ["sigma B gene", "DNA", 138, 150], ["Primers S", "TEST", 0, 9], ["5\u2032-GCTTTTTGAGTCCTCAGCGTG", "TEST", 13, 37], ["S", "TEST", 46, 47], ["GATGAATAGGCGAGTCCCGC", "TEST", 54, 74], ["S3", "ANATOMY_MODIFIER", 118, 120], ["segment", "ANATOMY_MODIFIER", 121, 128]]], ["For RT-PCR, 2.5 \u00b5L of extracted viral RNA was mixed with a reaction mixture containing 1 \u00b5L primer (10 pmol), 1 \u00b5L Prime Script One Step Enzyme mix, 8 \u00b5L RNase-free H2O and 12.5 \u00b5L 2 \u00d7 One Step Buffer.", [["H2O", "CHEMICAL", 165, 168], ["H2O", "CHEMICAL", 165, 168], ["viral RNA", "RNA", 32, 41], ["RNase", "PROTEIN", 154, 159], ["RT-PCR", "TEST", 4, 10], ["extracted viral RNA", "TREATMENT", 22, 41], ["a reaction mixture", "TREATMENT", 57, 75], ["1 \u00b5L primer", "TREATMENT", 87, 98], ["RNase-free H2O", "TREATMENT", 154, 168], ["viral RNA", "OBSERVATION", 32, 41]]], ["Reverse transcription was performed at 50 \u00b0C for 30 min.", [["Reverse transcription", "TREATMENT", 0, 21]]], ["The cycling conditions for the PCR were 94 \u00b0C for 2 min, followed by 32 cycles of denaturation (94 \u00b0C for 10 s), annealing (58 \u00b0C for 30 s) and extension (72 \u00b0C for 1 min), followed by a final extension at 72 \u00b0C for 7 min.Cloning and sequencing ::: Materials and MethodsThe amplified PCR products were subjected to agarose gel electrophoresis, excised from the gel and purified using an Agarose Gel DNA Purification Kit (TaKaRa, Japan).", [["agarose", "SIMPLE_CHEMICAL", 315, 322], ["the PCR", "TEST", 27, 34], ["denaturation", "TEST", 82, 94], ["annealing", "TEST", 113, 122], ["extension", "TEST", 144, 153], ["Methods", "TREATMENT", 263, 270], ["The amplified PCR products", "TREATMENT", 270, 296], ["agarose gel electrophoresis", "TREATMENT", 315, 342], ["the gel", "TREATMENT", 357, 364], ["an Agarose Gel DNA Purification", "TREATMENT", 384, 415]]], ["The PCR products were cloned into the pMD19-T vector according to the manufacturer\u2019s instructions (TaKaRa, Japan).", [["PCR products", "DNA", 4, 16], ["pMD19-T vector", "DNA", 38, 52], ["The PCR products", "TREATMENT", 0, 16]]], ["After the recombinant plasmid was transformed into DH5\u03b1 competent cells, the plasmid DNA purified using the E.Z.N.A.\u00ae Plasmid Mini Kit I (Omega Bio-Tek, USA) and quantified by spectrophotometric analysis.", [["plasmid", "ANATOMY", 22, 29], ["cells", "ANATOMY", 66, 71], ["plasmid", "ANATOMY", 77, 84], ["DH5\u03b1", "CELL", 51, 55], ["cells", "CELL", 66, 71], ["DNA", "CELLULAR_COMPONENT", 85, 88], ["recombinant plasmid", "DNA", 10, 29], ["DH5\u03b1 competent cells", "CELL_LINE", 51, 71], ["plasmid DNA", "DNA", 77, 88], ["the recombinant plasmid", "TREATMENT", 6, 29], ["the plasmid DNA", "TREATMENT", 73, 88], ["Omega Bio", "TEST", 138, 147], ["spectrophotometric analysis", "TEST", 176, 203]]], ["Three clones were sent to Shanghai Sangon Bioengineering Ltd. to be sequenced using the aforementioned primer pair and the sequence was analyzed.Design of primers for LAMP ::: Materials and MethodsBased on the gene encoding the \u03c3B major outer-capsid protein (GenBank accession number JQ866923.1; 1104 bp) of NDRV (DRB-QY strain), a set of six primers consisted of two outer primers (F3 and B3), two inner primers (FIP and BIP) and two loop primer (Loop primer Fc and Loop primer B) was generated employing the Primer Explorer V4 software (http://primerexplorer.jp/e/).", [["clones", "ANATOMY", 6, 12], ["clones", "CELL", 6, 12], ["\u03c3B", "GENE_OR_GENE_PRODUCT", 228, 230], ["primer pair", "DNA", 103, 114], ["\u03c3B major outer-capsid protein", "PROTEIN", 228, 257], ["NDRV", "PROTEIN", 308, 312], ["DRB", "PROTEIN", 314, 317], ["F3", "DNA", 383, 385], ["B3", "PROTEIN", 390, 392], ["inner primers", "DNA", 399, 412], ["BIP", "PROTEIN", 422, 425], ["Loop primer Fc", "DNA", 448, 462], ["Loop primer B", "DNA", 467, 480], ["Primer Explorer V4 software", "DNA", 510, 537], ["bp", "TEST", 301, 303], ["NDRV", "TEST", 308, 312], ["DRB-QY strain", "TREATMENT", 314, 327], ["a set of six primers", "TREATMENT", 330, 350], ["two outer primers", "TREATMENT", 364, 381], ["two inner primers", "TREATMENT", 395, 412], ["FIP and BIP)", "TREATMENT", 414, 426], ["two loop primer (Loop primer Fc and Loop primer B", "TREATMENT", 431, 480], ["loop primer", "OBSERVATION", 435, 446]]], ["The forward inner primer (FIP) composed of the complementary sequence of F1c and F2.", [["forward inner primer", "DNA", 4, 24], ["F1c", "DNA", 73, 76], ["F2", "DNA", 81, 83], ["The forward inner primer (FIP", "TREATMENT", 0, 29]]], ["The backward inner primer (BIP) consisted of B1c and the complementary sequence of B2c (B2).", [["B2c", "GENE_OR_GENE_PRODUCT", 83, 86], ["backward inner primer", "DNA", 4, 25], ["BIP", "DNA", 27, 30], ["B1c", "DNA", 45, 48], ["B2", "DNA", 88, 90], ["The backward inner primer", "TREATMENT", 0, 25], ["B1c", "TEST", 45, 48]]], ["The outer primers consisted of the forward outer primer F3 and the backward outer primer B3 (the complementary sequence of B3c).", [["B3c", "GENE_OR_GENE_PRODUCT", 123, 126], ["forward outer primer F3", "DNA", 35, 58], ["backward outer primer B3", "DNA", 67, 91], ["B3c", "DNA", 123, 126], ["The outer primers", "TREATMENT", 0, 17], ["the forward outer primer F3", "TREATMENT", 31, 58]]], ["In addition, there are two loop primers (Loop primer Fc and Loop primer B) to accelerate the amplification reaction as previously described17.", [["Loop primer Fc", "DNA", 41, 55], ["Loop primer B", "PROTEIN", 60, 73], ["two loop primers", "TREATMENT", 23, 39], ["Loop primer Fc", "TREATMENT", 41, 55], ["Loop primer B", "TREATMENT", 60, 73], ["the amplification reaction", "PROBLEM", 89, 115], ["two", "OBSERVATION_MODIFIER", 23, 26], ["loop primers", "OBSERVATION", 27, 39], ["amplification reaction", "OBSERVATION", 93, 115]]], ["The positions of the LAMP primers used in this study are shown in Fig. 1 and Table 1.", [["LAMP primers", "DNA", 21, 33], ["the LAMP primers", "TREATMENT", 17, 33], ["this study", "TEST", 42, 52]]], ["Primers were synthesized by Shanghai Sangon Bioengineering Ltd, China.RT-LAMP assay optimization ::: Materials and MethodsThe RT-LAMP reaction was carried out in a final volume of 25 \u03bcL.", [["LAMP reaction", "TEST", 129, 142], ["a final volume", "TEST", 162, 176]]], ["To optimize the RT-LAMP assay, the parameters, including the amplification temperature (59\u201366 \u00b0C) and the amplification time (10\u201360 min) were determined.", [["the RT-LAMP assay", "TEST", 12, 29], ["the amplification temperature", "TEST", 57, 86]]], ["The parameters of the reaction mixtures, such as the ratio of inner and outer primers (2:1\u201312:1), the ratio of loop and outer primers (0:0.2\u20136:1) and the ratio of calcein and manganese ion (1:8\u20131:128) was described independently.", [["inner", "ANATOMY", 62, 67], ["calcein", "CHEMICAL", 163, 170], ["manganese", "CHEMICAL", 175, 184], ["calcein", "CHEMICAL", 163, 170], ["manganese", "CHEMICAL", 175, 184], ["inner", "TISSUE", 62, 67], ["calcein", "SIMPLE_CHEMICAL", 163, 170], ["manganese ion", "SIMPLE_CHEMICAL", 175, 188], ["the reaction mixtures", "TEST", 18, 39], ["outer primers", "TEST", 120, 133], ["inner", "ANATOMY_MODIFIER", 62, 67], ["outer", "ANATOMY_MODIFIER", 72, 77], ["primers", "ANATOMY_MODIFIER", 78, 85], ["loop", "OBSERVATION_MODIFIER", 111, 115], ["outer", "OBSERVATION_MODIFIER", 120, 125], ["primers", "OBSERVATION_MODIFIER", 126, 133]]], ["In addition, the concentrations of betaine (0\u20131.5 mM; Sigma, USA), dNTPs (0.2\u20130.7 mM; Promega, USA), MgSO4 (0\u20136 mM; Sigma, USA), AMV reverse transcriptase (0.06\u20130.16 U/\u00b5L; Takara, Japan), Bst DNA polymerase (0.8\u20130.48 U/\u00b5L; New England Biolabs, USA) and 10 \u00d7 ThermoPol buffer (0\u20134 \u00b5L) were sequentially optimized.Detection of RT-LAMP products ::: Materials and MethodsThe RT-LAMP reactions for NDRV were carried out at 65 \u00b0C for 50 min, followed by denaturation for 5 min at 85 \u00b0C to cease the reaction.", [["betaine", "CHEMICAL", 35, 42], ["dNTPs", "CHEMICAL", 67, 72], ["MgSO4", "CHEMICAL", 101, 106], ["betaine", "CHEMICAL", 35, 42], ["dNTPs", "CHEMICAL", 67, 72], ["MgSO4", "CHEMICAL", 101, 106], ["betaine", "SIMPLE_CHEMICAL", 35, 42], ["dNTPs", "SIMPLE_CHEMICAL", 67, 72], ["MgSO4", "SIMPLE_CHEMICAL", 101, 106], ["DNA", "CELLULAR_COMPONENT", 192, 195], ["NDRV", "SIMPLE_CHEMICAL", 393, 397], ["AMV reverse transcriptase", "PROTEIN", 129, 154], ["betaine", "TEST", 35, 42], ["dNTPs", "TEST", 67, 72], ["MgSO4", "TEST", 101, 106], ["AMV", "TEST", 129, 132], ["transcriptase", "TEST", 141, 154], ["U", "TEST", 166, 167], ["Takara", "TEST", 172, 178], ["Bst DNA polymerase", "TEST", 188, 206], ["U", "TEST", 217, 218], ["ThermoPol buffer", "TREATMENT", 258, 274], ["The RT-LAMP reactions", "TREATMENT", 367, 388], ["NDRV", "TREATMENT", 393, 397], ["the reaction", "PROBLEM", 489, 501]]], ["The RT-LAMP-amplified products were visualized on 2% agarose gel stained with GoldViewTM under UV transillumination.", [["GoldViewTM", "CHEMICAL", 78, 88], ["agarose", "SIMPLE_CHEMICAL", 53, 60], ["GoldViewTM", "SIMPLE_CHEMICAL", 78, 88], ["RT-LAMP-amplified products", "DNA", 4, 30], ["The RT-LAMP-amplified products", "TREATMENT", 0, 30], ["2% agarose gel", "TREATMENT", 50, 64], ["GoldViewTM under UV transillumination", "TREATMENT", 78, 115], ["UV transillumination", "OBSERVATION", 95, 115]]], ["The calcein visualization RT-LAMP assay can be inspected under UV light, which emitted strong green fluorescence.", [["calcein", "CHEMICAL", 4, 11], ["calcein", "CHEMICAL", 4, 11], ["calcein", "SIMPLE_CHEMICAL", 4, 11], ["The calcein visualization", "TEST", 0, 25], ["LAMP assay", "TEST", 29, 39]]], ["To determine the sequence specificity, the cleavage site of RT-LAMP amplified fragment was analyzed by SeqBuilder software and the single Hpa II restriction site was screened.", [["fragment", "CELLULAR_COMPONENT", 78, 86], ["Hpa II", "GENE_OR_GENE_PRODUCT", 138, 144], ["RT-LAMP amplified fragment", "DNA", 60, 86], ["Hpa II restriction site", "DNA", 138, 161], ["the sequence specificity", "TEST", 13, 37], ["the cleavage site", "PROBLEM", 39, 56], ["RT-LAMP amplified fragment", "TREATMENT", 60, 86], ["the single Hpa II restriction site", "TREATMENT", 127, 161], ["RT", "ANATOMY", 60, 62], ["fragment", "OBSERVATION_MODIFIER", 78, 86]]], ["Two microliters of RT-LAMP amplified products were digested with restriction enzyme HhaI (New England Biolabs, USA) at 37 \u00b0C for 2 h according to the manufacturer\u2019s protocol and the restriction enzyme digestion products were analyzed on 2% agarose gel electrophoresis.", [["HhaI", "GENE_OR_GENE_PRODUCT", 84, 88], ["agarose", "SIMPLE_CHEMICAL", 240, 247], ["restriction enzyme HhaI", "PROTEIN", 65, 88], ["restriction enzyme", "PROTEIN", 182, 200], ["RT-LAMP amplified products", "TREATMENT", 19, 45], ["the manufacturer\u2019s protocol", "TREATMENT", 146, 173], ["the restriction enzyme digestion products", "TREATMENT", 178, 219], ["2% agarose gel electrophoresis", "TREATMENT", 237, 267]]], ["Each reaction was repeated at least three times.Specificity of RT- LAMP identification ::: Materials and MethodsTo determine the specificity of RT-LAMP assay, RT-LAMP was conducted with the different nucleic acid templates extracted from Muscovy duck reovirus (MDRV-S12), avian reovirus (ARV-S1133), duck plague virus (DPV-YF15), duck hepatitis virus (DHAV-3), duck Newcastle disease virus (NDV-SS14), H9 subtype avian influenza virus (NH/2013), H5 subtype avian influenza virus (GM/2014) and duck virus (DTMUV-GD13) under the aforementioned conditions.", [["nucleic acid", "CHEMICAL", 200, 212], ["duck plague", "DISEASE", 300, 311], ["duck hepatitis virus", "DISEASE", 330, 350], ["Newcastle disease", "DISEASE", 366, 383], ["avian influenza virus", "DISEASE", 413, 434], ["avian influenza virus", "DISEASE", 457, 478], ["GM", "CHEMICAL", 480, 482], ["Muscovy duck reovirus", "ORGANISM", 238, 259], ["MDRV-S12", "ORGANISM", 261, 269], ["avian reovirus", "ORGANISM", 272, 286], ["ARV-S1133", "ORGANISM", 288, 297], ["duck plague virus", "ORGANISM", 300, 317], ["DPV-YF15", "ORGANISM", 319, 327], ["duck hepatitis virus", "ORGANISM", 330, 350], ["DHAV-3", "ORGANISM", 352, 358], ["duck Newcastle disease virus", "ORGANISM", 361, 389], ["NDV-SS14", "ORGANISM", 391, 399], ["H9 subtype avian influenza virus", "ORGANISM", 402, 434], ["NH/2013", "ORGANISM", 436, 443], ["H5 subtype avian influenza virus", "ORGANISM", 446, 478], ["GM/2014", "ORGANISM", 480, 487], ["duck virus", "ORGANISM", 493, 503], ["DTMUV-GD13", "ORGANISM", 505, 515], ["Muscovy duck reovirus", "SPECIES", 238, 259], ["avian reovirus", "SPECIES", 272, 286], ["duck plague virus", "SPECIES", 300, 317], ["duck hepatitis virus", "SPECIES", 330, 350], ["duck Newcastle disease virus", "SPECIES", 361, 389], ["NDV", "SPECIES", 391, 394], ["avian influenza virus", "SPECIES", 413, 434], ["avian influenza virus", "SPECIES", 457, 478], ["duck virus", "SPECIES", 493, 503], ["Muscovy duck reovirus", "SPECIES", 238, 259], ["MDRV", "SPECIES", 261, 265], ["avian reovirus (ARV-S1133", "SPECIES", 272, 297], ["duck plague virus", "SPECIES", 300, 317], ["DPV-YF15", "SPECIES", 319, 327], ["duck hepatitis virus", "SPECIES", 330, 350], ["DHAV", "SPECIES", 352, 356], ["duck Newcastle disease virus", "SPECIES", 361, 389], ["NDV-SS14", "SPECIES", 391, 399], ["H9 subtype avian influenza virus (NH/2013)", "SPECIES", 402, 444], ["H5 subtype avian influenza virus (GM/2014)", "SPECIES", 446, 488], ["duck virus", "SPECIES", 493, 503], ["Each reaction", "PROBLEM", 0, 13], ["RT-LAMP assay", "TEST", 144, 157], ["RT-LAMP", "TREATMENT", 159, 166], ["the different nucleic acid templates", "PROBLEM", 186, 222], ["Muscovy duck reovirus", "PROBLEM", 238, 259], ["MDRV", "TEST", 261, 265], ["avian reovirus", "PROBLEM", 272, 286], ["ARV", "TEST", 288, 291], ["duck plague virus", "PROBLEM", 300, 317], ["DPV", "TEST", 319, 322], ["duck hepatitis virus", "PROBLEM", 330, 350], ["DHAV", "TEST", 352, 356], ["duck Newcastle disease virus", "PROBLEM", 361, 389], ["NDV", "TEST", 391, 394], ["H9 subtype avian influenza virus", "PROBLEM", 402, 434], ["H5 subtype avian influenza virus", "PROBLEM", 446, 478], ["duck virus", "PROBLEM", 493, 503], ["Muscovy duck", "ANATOMY", 238, 250], ["duck", "ANATOMY", 330, 334], ["hepatitis virus", "OBSERVATION", 335, 350]]], ["Each virus was investigated at least three times.Sensitivity of detection amongst RT-LAMP visualized by calcein, conventional RT-LAMP and RT-LAMP visualized by SYBR Green I ::: Materials and MethodsDetection sensitivities between RT-LAMP visualized by calcein, RT-LAMP analyzed by agarose gel and RT-LAMP visualized by SYBR Green I were compared using 10-fold serial dilutions of the virus-positive total RNA extracts (NDRV) and recombinant plasmid.", [["extracts", "ANATOMY", 409, 417], ["plasmid", "ANATOMY", 441, 448], ["calcein", "CHEMICAL", 104, 111], ["calcein", "CHEMICAL", 252, 259], ["calcein", "CHEMICAL", 104, 111], ["calcein", "CHEMICAL", 252, 259], ["calcein", "SIMPLE_CHEMICAL", 104, 111], ["calcein", "SIMPLE_CHEMICAL", 252, 259], ["agarose", "SIMPLE_CHEMICAL", 281, 288], ["SYBR Green I", "GENE_OR_GENE_PRODUCT", 319, 331], ["extracts", "ORGANISM_SUBSTANCE", 409, 417], ["SYBR Green I", "PROTEIN", 319, 331], ["recombinant plasmid", "DNA", 429, 448], ["Each virus", "PROBLEM", 0, 10], ["detection", "TEST", 64, 73], ["calcein", "TEST", 104, 111], ["MethodsDetection sensitivities", "TEST", 191, 221], ["RT", "TEST", 230, 232], ["LAMP", "TEST", 233, 237], ["calcein", "TEST", 252, 259], ["RT-LAMP", "TREATMENT", 261, 268], ["agarose gel", "TREATMENT", 281, 292], ["the virus", "TREATMENT", 380, 389], ["positive total RNA extracts", "TREATMENT", 390, 417], ["recombinant plasmid", "TREATMENT", 429, 448], ["virus", "OBSERVATION", 5, 10]]], ["Detection limits were determined by the lowest input nucleic acid concentration at which a positive result was apparent.Optimization of RT-LAMP assay for NDRV detection ::: ResultsAll of the possible variables were investigated to enhance the amplification efficiency.", [["nucleic acid", "CHEMICAL", 53, 65], ["NDRV", "SPECIES", 154, 158], ["RT-LAMP assay", "TEST", 136, 149], ["the amplification efficiency", "PROBLEM", 239, 267]]], ["Three replications were carried out for each trial.", [["Three replications", "TREATMENT", 0, 18]]], ["RT-LAMP was performed under different reaction temperatures from 59 \u00b0C to 65 \u00b0C. The results showed that RT-LAMP at 65 \u00b0C produced very clear and bright bands.", [["RT-LAMP", "TEST", 105, 112], ["bright bands", "PROBLEM", 146, 158], ["very", "OBSERVATION_MODIFIER", 131, 135], ["clear", "OBSERVATION", 136, 141], ["bright bands", "OBSERVATION", 146, 158]]], ["Therefore, 65 \u00b0C was selected as the optimal temperature of NDRV RT-LAMP reaction.", [["LAMP reaction", "PROBLEM", 68, 81]]], ["The ratio of calcein and manganese ion (1:8\u20131:128) was analyzed and the color was obvious at the ratio of 1:12.", [["calcein", "CHEMICAL", 13, 20], ["manganese", "CHEMICAL", 25, 34], ["calcein", "CHEMICAL", 13, 20], ["manganese", "CHEMICAL", 25, 34], ["calcein", "SIMPLE_CHEMICAL", 13, 20], ["manganese ion", "SIMPLE_CHEMICAL", 25, 38], ["the color", "TEST", 68, 77]]], ["Consequently, the ratio of 1:12 was selected as the optimal ratio to use in proceeding experiments.", [["the ratio", "TEST", 14, 23]]], ["The effect of Mg2+ ion concentration was analyzed.", [["Mg2", "CHEMICAL", 14, 17], ["Mg2+", "CHEMICAL", 14, 18], ["Mg2+ ion", "SIMPLE_CHEMICAL", 14, 22], ["Mg2", "PROTEIN", 14, 17], ["Mg2+ ion concentration", "TREATMENT", 14, 36]]], ["Magnesium sulfate (Mg2+) was added at a concentrations ranging from 0 to 6 mM reaction mixtures containing positive sample.", [["Magnesium sulfate", "CHEMICAL", 0, 17], ["Mg2", "CHEMICAL", 19, 22], ["Magnesium sulfate", "CHEMICAL", 0, 17], ["Mg2+)", "CHEMICAL", 19, 24], ["Magnesium sulfate", "SIMPLE_CHEMICAL", 0, 17], ["Mg2+", "SIMPLE_CHEMICAL", 19, 23], ["Magnesium sulfate (Mg2+)", "TREATMENT", 0, 24]]], ["Upon gel analysis, bands were obvious at 3 mM Mg2+.", [["Mg2", "CHEMICAL", 46, 49], ["Mg2+", "CHEMICAL", 46, 50], ["Mg2+", "SIMPLE_CHEMICAL", 46, 50], ["gel analysis", "TEST", 5, 17], ["bands", "TEST", 19, 24]]], ["When the concentration was greater than 3.0 mM (lane 4~7), the reaction efficiency decreased but tended to be stable.", [["the reaction efficiency", "PROBLEM", 59, 82], ["reaction efficiency", "OBSERVATION", 63, 82], ["decreased", "OBSERVATION_MODIFIER", 83, 92], ["stable", "OBSERVATION_MODIFIER", 110, 116]]], ["Therefore, 3.0 mM was chosen as the best reaction concentration for NDRV RT-LAMP.", [["NDRV RT-LAMP", "TREATMENT", 68, 80]]], ["Moderately various yields were detected with the different amounts of betaine employed and a concentration of 0.5 mM was found to be proper for a more distinct pattern.", [["betaine", "CHEMICAL", 70, 77], ["betaine", "CHEMICAL", 70, 77], ["betaine", "SIMPLE_CHEMICAL", 70, 77], ["Moderately various yields", "PROBLEM", 0, 25], ["various", "OBSERVATION_MODIFIER", 11, 18], ["yields", "OBSERVATION", 19, 25], ["betaine employed", "OBSERVATION", 70, 86], ["more distinct", "OBSERVATION_MODIFIER", 146, 159]]], ["The size of the ladder increased as the concentration of dNTPs increased and a concentration greater 0.3 mM was found to be sufficient.", [["dNTPs", "CHEMICAL", 57, 62], ["dNTPs", "CHEMICAL", 57, 62], ["dNTPs", "SIMPLE_CHEMICAL", 57, 62], ["the ladder", "PROBLEM", 12, 22], ["the concentration of dNTPs", "TREATMENT", 36, 62], ["a concentration", "TEST", 77, 92], ["size", "OBSERVATION_MODIFIER", 4, 8], ["ladder", "OBSERVATION_MODIFIER", 16, 22], ["increased", "OBSERVATION_MODIFIER", 23, 32], ["dNTPs", "OBSERVATION_MODIFIER", 57, 62], ["increased", "OBSERVATION_MODIFIER", 63, 72]]], ["AMV reverse transcriptase concentration of 0.14 U/\u00b5L was found to be appropriate for the amplification efficiency of NDRV RT-LAMP reaction.", [["AMV", "ORGANISM", 0, 3], ["AMV reverse transcriptase", "PROTEIN", 0, 25], ["AMV", "SPECIES", 0, 3], ["AMV reverse transcriptase concentration", "TREATMENT", 0, 39], ["NDRV", "PROBLEM", 117, 121], ["LAMP reaction", "PROBLEM", 125, 138]]], ["The reaction efficiency decreased as the concentration of the AMV enzyme concentration increased.", [["AMV", "ORGANISM", 62, 65], ["AMV enzyme", "PROTEIN", 62, 72], ["The reaction efficiency", "PROBLEM", 0, 23], ["the AMV enzyme concentration", "TEST", 58, 86], ["reaction efficiency", "OBSERVATION", 4, 23], ["decreased", "OBSERVATION_MODIFIER", 24, 33], ["concentration", "OBSERVATION_MODIFIER", 73, 86], ["increased", "OBSERVATION_MODIFIER", 87, 96]]], ["However, a more intense band was observed with 2.5 \u00b5L of 10 \u00d7 Buffer, a 10:1 ratio of inner vs. outer primers (FIP + BIP 2 M, F3 + B3 0.2 \u00b5M) and a ratio of 4:1 ring and outer primers (LoopF + LoopB 0.8 M, F3 + B3 0.2 \u00b5M) and 0.32 U/L of Bst DNA polymerase (Figs S1; 2\u20133).Optimization of RT-LAMP assay for NDRV detection ::: ResultsTaken together, the optimized parameters of the RT-LAMP reaction system were as follows: 3 mM MgSO4, 0.5 mM betaine, 0.3 mM dNTPs, 0.14 U/\u03bcL AMV reverse transcriptase, 0.32 U/\u03bcL Bst DNA polymerase large fragment, 2.5 \u03bcL10 \u00d7 ThermoPol buffer, the ratio of inner (2.0 \u03bcM; FIP and BIP) and outer (0.2 \u03bcM; F3 and B3) primers and the ratio of loop (0.8 \u03bcM; Loop primer Fc and Loop primer B) and outer primers (0.2 \u03bcM; F3 and B3) with an incubation condition at 65 \u00b0C for 50 min in a water bath.", [["MgSO4", "CHEMICAL", 426, 431], ["betaine", "CHEMICAL", 440, 447], ["dNTPs", "CHEMICAL", 456, 461], ["MgSO4", "CHEMICAL", 426, 431], ["betaine", "CHEMICAL", 440, 447], ["dNTPs", "CHEMICAL", 456, 461], ["MgSO4", "SIMPLE_CHEMICAL", 426, 431], ["betaine", "SIMPLE_CHEMICAL", 440, 447], ["DNA", "CELLULAR_COMPONENT", 514, 517], ["LoopF", "PROTEIN", 185, 190], ["F3", "PROTEIN", 206, 208], ["Bst DNA polymerase", "PROTEIN", 238, 256], ["Figs S1; 2\u20133", "PROTEIN", 258, 270], ["AMV reverse transcriptase", "PROTEIN", 473, 498], ["B3", "PROTEIN", 641, 643], ["Loop primer Fc", "PROTEIN", 684, 698], ["Loop primer B", "PROTEIN", 703, 716], ["NDRV", "SPECIES", 306, 310], ["outer primers", "TEST", 96, 109], ["FIP", "TEST", 111, 114], ["B3", "TEST", 131, 133], ["a ratio", "TEST", 146, 153], ["outer primers", "TEST", 170, 183], ["LoopF", "TEST", 185, 190], ["LoopB", "TEST", 193, 198], ["F3", "TEST", 206, 208], ["B3", "TEST", 211, 213], ["U/L", "TEST", 231, 234], ["Bst DNA polymerase", "TEST", 238, 256], ["RT-LAMP assay", "TEST", 288, 301], ["LAMP reaction system", "TEST", 383, 403], ["MgSO4", "TEST", 426, 431], ["betaine", "TEST", 440, 447], ["dNTPs", "TEST", 456, 461], ["U", "TEST", 468, 469], ["AMV", "TEST", 473, 476], ["transcriptase", "TEST", 485, 498], ["U", "TEST", 505, 506], ["/\u03bcL Bst DNA polymerase large fragment", "PROBLEM", 506, 543], ["Pol buffer", "TREATMENT", 562, 572], ["inner", "TEST", 587, 592], ["outer", "TEST", 619, 624], ["\u03bcM; F3 and B3) primers", "TREATMENT", 630, 652], ["the ratio of loop", "TREATMENT", 657, 674], ["Loop primer Fc", "TREATMENT", 684, 698], ["Loop primer B", "TREATMENT", 703, 716], ["outer primers", "TEST", 722, 735], ["an incubation condition", "TREATMENT", 761, 784], ["a water bath", "TREATMENT", 808, 820], ["large", "OBSERVATION_MODIFIER", 529, 534], ["fragment", "OBSERVATION", 535, 543], ["loop", "OBSERVATION_MODIFIER", 670, 674]]], ["The RT-LAMP-amplified products were resolved on 2.0% agarose gel and checked by visual investigation employing calcein under UV or the production of insoluble manganese/ magnesium phosphate and by electrophoresis on GoldViewTM nucleic acid stained agarose gels under UV light.", [["calcein", "CHEMICAL", 111, 118], ["UV", "CHEMICAL", 125, 127], ["manganese", "CHEMICAL", 159, 168], ["magnesium phosphate", "CHEMICAL", 170, 189], ["nucleic acid", "CHEMICAL", 227, 239], ["calcein", "CHEMICAL", 111, 118], ["manganese", "CHEMICAL", 159, 168], ["magnesium phosphate", "CHEMICAL", 170, 189], ["agarose", "SIMPLE_CHEMICAL", 53, 60], ["calcein", "SIMPLE_CHEMICAL", 111, 118], ["manganese", "SIMPLE_CHEMICAL", 159, 168], ["magnesium phosphate", "SIMPLE_CHEMICAL", 170, 189], ["GoldViewTM nucleic acid", "SIMPLE_CHEMICAL", 216, 239], ["agarose", "SIMPLE_CHEMICAL", 248, 255], ["RT-LAMP-amplified products", "DNA", 4, 30], ["The RT-LAMP-amplified products", "TREATMENT", 0, 30], ["2.0% agarose gel", "TREATMENT", 48, 64], ["visual investigation", "TEST", 80, 100], ["calcein under UV", "TREATMENT", 111, 127], ["insoluble manganese", "TREATMENT", 149, 168], ["magnesium phosphate", "TREATMENT", 170, 189], ["electrophoresis", "TEST", 197, 212], ["nucleic acid", "TEST", 227, 239], ["UV light", "OBSERVATION_MODIFIER", 267, 275]]], ["Moreover, the RT-LAMP products were also visually detected by adding SYBR Green I dye.Analysis of RT-LAMP digestion products ::: ResultsElectrophoresis of the RT-LAMP products showed that all the positive LAMP reactions produced characteristic ladder-like pattern bands on agarose gel.", [["SYBR Green I dye", "GENE_OR_GENE_PRODUCT", 69, 85], ["agarose", "SIMPLE_CHEMICAL", 273, 280], ["RT-LAMP products", "PROTEIN", 14, 30], ["the RT-LAMP products", "TREATMENT", 10, 30], ["Electrophoresis", "TEST", 136, 151], ["the RT", "TEST", 155, 161], ["LAMP products", "TEST", 162, 175], ["the positive LAMP reactions", "PROBLEM", 192, 219], ["characteristic ladder", "PROBLEM", 229, 250], ["agarose gel", "TREATMENT", 273, 284]]], ["HhaI restriction enzyme digestion and electrophoresis gave a strong band at approximately 100 bp corresponding to the predicted sizes (a mixture of 127 bp and 114 bp) (Fig. 4).Specificity of RT-LAMP identification ::: ResultsAs illustrated in Fig. 5, only when the recombinant plasmid and RNA from NDRV were present.", [["plasmid", "ANATOMY", 277, 284], ["HhaI", "GENE_OR_GENE_PRODUCT", 0, 4], ["NDRV", "GENE_OR_GENE_PRODUCT", 298, 302], ["recombinant plasmid", "DNA", 265, 284], ["HhaI restriction enzyme digestion", "PROBLEM", 0, 33], ["electrophoresis", "TEST", 38, 53], ["a strong band", "TREATMENT", 59, 72], ["bp", "TEST", 94, 96], ["bp", "TEST", 152, 154], ["bp", "TEST", 163, 165], ["the recombinant plasmid", "TREATMENT", 261, 284], ["sizes", "OBSERVATION_MODIFIER", 128, 133]]], ["The RT-LAMP reaction was positive and the RT-LAMP-amplified products were detected, showing a typical ladder-like pattern on gel electrophoresis, which indicated that stem-loop DNA with inverted repeats was generated, whereas RT-LAMP reaction was negative for double distilled water (negative control; NC) and the other viruses tested, indicating that the LAMP reaction was highly specific to NDRV.RT-LAMP sensitivity comparison ::: ResultsThe sensitivity of RT-LAMP assay visualized by calcein was first judged by the dilution of RNA input and recombinant plasmid into 2 ng, 200 pg, 20 pg, 2 pg, 200 fg, 20 fg and 2 fg, respectively and the result of this assay was compared with those of RT-LAMP visualized by SYBR Green I and RT-PCR analyzed by agarose gel (Fig. S2A\u2013F).", [["plasmid", "ANATOMY", 557, 564], ["calcein", "CHEMICAL", 487, 494], ["calcein", "CHEMICAL", 487, 494], ["DNA", "CELLULAR_COMPONENT", 177, 180], ["calcein", "SIMPLE_CHEMICAL", 487, 494], ["SYBR Green I", "GENE_OR_GENE_PRODUCT", 712, 724], ["agarose", "SIMPLE_CHEMICAL", 748, 755], ["S2A\u2013F", "GENE_OR_GENE_PRODUCT", 766, 771], ["RT-LAMP-amplified products", "DNA", 42, 68], ["stem-loop DNA", "DNA", 167, 180], ["inverted repeats", "DNA", 186, 202], ["NDRV", "PROTEIN", 393, 397], ["recombinant plasmid", "DNA", 545, 564], ["S2A\u2013F", "PROTEIN", 766, 771], ["The RT-LAMP reaction", "TEST", 0, 20], ["the RT-LAMP", "TEST", 38, 49], ["a typical ladder", "PROBLEM", 92, 108], ["gel electrophoresis", "TEST", 125, 144], ["stem-loop DNA", "PROBLEM", 167, 180], ["inverted repeats", "PROBLEM", 186, 202], ["LAMP reaction", "TEST", 229, 242], ["double distilled water", "TREATMENT", 260, 282], ["NC", "TREATMENT", 302, 304], ["the other viruses", "PROBLEM", 310, 327], ["the LAMP reaction", "PROBLEM", 352, 369], ["RT-LAMP assay", "TEST", 459, 472], ["calcein", "TREATMENT", 487, 494], ["RNA input", "TREATMENT", 531, 540], ["recombinant plasmid", "TREATMENT", 545, 564], ["this assay", "TEST", 652, 662], ["RT", "TEST", 690, 692], ["PCR", "TEST", 732, 735], ["stem", "ANATOMY", 167, 171]]], ["The comparison study revealed that the detection limit of RT-LAMP visualized by calcein was 200 fg.", [["calcein", "CHEMICAL", 80, 87], ["calcein", "CHEMICAL", 80, 87], ["calcein", "SIMPLE_CHEMICAL", 80, 87], ["The comparison study", "TEST", 0, 20], ["calcein", "TREATMENT", 80, 87]]], ["This result is in accord with that of RT-LAMP visualized by SYBR Green I and RT-LAMP analyzed by agarose gel, but it is more sensitive than of conventional RT-PCR (20 pg detection limit).RT-LAMP assay evaluation with field samples (suspected NDRV infection) from Guangdong province ::: ResultsA total of 15 clinical samples were used with their tissue mixed together for each individual duck and 12 clinical sample organs (including heart, liver, spleen, lung, thymus and bursa) were used separately from two NDRV-infected ducks in this study.", [["samples", "ANATOMY", 223, 230], ["samples", "ANATOMY", 316, 323], ["tissue", "ANATOMY", 345, 351], ["sample organs", "ANATOMY", 408, 421], ["heart", "ANATOMY", 433, 438], ["liver", "ANATOMY", 440, 445], ["spleen", "ANATOMY", 447, 453], ["lung", "ANATOMY", 455, 459], ["thymus", "ANATOMY", 461, 467], ["bursa", "ANATOMY", 472, 477], ["NDRV infection", "DISEASE", 242, 256], ["SYBR Green I", "GENE_OR_GENE_PRODUCT", 60, 72], ["agarose", "SIMPLE_CHEMICAL", 97, 104], ["samples", "CANCER", 316, 323], ["tissue", "TISSUE", 345, 351], ["duck", "ORGANISM", 387, 391], ["organs", "ORGAN", 415, 421], ["heart", "ORGAN", 433, 438], ["liver", "ORGAN", 440, 445], ["spleen", "ORGAN", 447, 453], ["lung", "ORGAN", 455, 459], ["thymus", "ORGAN", 461, 467], ["bursa", "ORGAN", 472, 477], ["ducks", "ORGANISM", 523, 528], ["duck", "SPECIES", 387, 391], ["ducks", "SPECIES", 523, 528], ["duck", "SPECIES", 387, 391], ["RT-LAMP", "TREATMENT", 77, 84], ["agarose gel", "TREATMENT", 97, 108], ["conventional RT-PCR", "TREATMENT", 143, 162], ["LAMP assay evaluation", "TEST", 190, 211], ["field samples", "TEST", 217, 230], ["NDRV infection", "PROBLEM", 242, 256], ["clinical samples", "TEST", 307, 323], ["each individual duck", "TEST", 371, 391], ["this study", "TEST", 532, 542], ["heart", "ANATOMY", 433, 438], ["liver", "ANATOMY", 440, 445], ["spleen", "ANATOMY", 447, 453], ["lung", "ANATOMY", 455, 459], ["thymus", "ANATOMY", 461, 467], ["bursa", "ANATOMY", 472, 477], ["infected ducks", "OBSERVATION", 514, 528]]], ["The detailed results of detection (specimen by specimen) are listed in Tables 2 and 3.", [["specimen", "ANATOMY", 35, 43], ["specimen", "ANATOMY", 47, 55]]], ["The comparative evaluation of RT-LAMP and conventional RT-PCR revealed that RT-LAMP and RT-PCR were consistent when the commonly affected organs were mixed together (Table 2).", [["organs", "ANATOMY", 138, 144], ["organs", "ORGAN", 138, 144], ["The comparative evaluation", "TEST", 0, 26], ["RT-LAMP", "TEST", 30, 37], ["conventional RT-PCR", "TEST", 42, 61], ["RT-LAMP", "TEST", 76, 83], ["RT-PCR", "TEST", 88, 94], ["the commonly affected organs", "PROBLEM", 116, 144]]], ["The viral RNAs of NDRV were detected in 20% (3/15) of the 15 duck studied.", [["NDRV", "GENE_OR_GENE_PRODUCT", 18, 22], ["duck", "ORGANISM", 61, 65], ["viral RNAs", "RNA", 4, 14], ["NDRV", "PROTEIN", 18, 22], ["duck", "SPECIES", 61, 65], ["NDRV", "SPECIES", 18, 22], ["The viral RNAs of NDRV", "PROBLEM", 0, 22], ["viral RNAs", "OBSERVATION", 4, 14]]], ["However, the positive rates of conventional RT-PCR and RT-LAMP for separately affected organs NDRV with were 83% (10/12) and 92% (11/12), respectively as indicated in Table 3.RT-LAMP assay evaluation with experimentally infected ducklings ::: ResultsA total of ten 1-day-old ducklings were randomly allocated into two groups (five ducklings each).", [["organs", "ANATOMY", 87, 93], ["organs", "ORGAN", 87, 93], ["ducklings", "ORGANISM", 229, 238], ["ducklings", "ORGANISM", 275, 284], ["ducklings", "ORGANISM", 331, 340], ["ducklings", "SPECIES", 229, 238], ["ducklings", "SPECIES", 275, 284], ["ducklings", "SPECIES", 331, 340], ["conventional RT-PCR", "TREATMENT", 31, 50], ["RT-LAMP", "TREATMENT", 55, 62], ["LAMP assay evaluation", "TEST", 178, 199], ["experimentally infected ducklings", "PROBLEM", 205, 238], ["old ducklings", "PROBLEM", 271, 284], ["positive", "OBSERVATION_MODIFIER", 13, 21], ["rates", "OBSERVATION_MODIFIER", 22, 27]]], ["Group 1 animals were received intraperitoneal inoculation of NDRV allantoic fluid (Table 4).", [["intraperitoneal", "ANATOMY", 30, 45], ["animals", "ORGANISM", 8, 15], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 30, 45], ["NDRV", "SPECIES", 61, 65], ["intraperitoneal inoculation", "TREATMENT", 30, 57], ["NDRV allantoic fluid", "TREATMENT", 61, 81], ["intraperitoneal", "ANATOMY", 30, 45]]], ["Ducklings from group 2 were intraperitoneally inoculated with physiological saline and served as the control group.", [["saline", "SIMPLE_CHEMICAL", 76, 82], ["physiological saline", "TREATMENT", 62, 82]]], ["All ducklings in the infected group died with 72 hours post-infection (hpi).", [["infection", "DISEASE", 60, 69], ["ducklings", "ORGANISM", 4, 13], ["ducklings", "SPECIES", 4, 13], ["infection", "PROBLEM", 60, 69], ["infected", "OBSERVATION_MODIFIER", 21, 29], ["infection", "OBSERVATION", 60, 69]]], ["The gross anatomical lesions of the ducklings showed an enlarged liver (hepatomegaly) and pleural exudates with yellow discoloration 48 hpi and hepatomegaly with brittle texture, plaque bleeding and necrosis, red darken splenomegaly, patchy hemorrhagic necrosis, bursal necrosis, renal bleeding, enlarged heart and inflated intestine 72 hpi (Fig. 6).RT-LAMP assay evaluation with experimentally infected ducklings ::: ResultsTwenty eight samples were collected at 24, 48 and 72 h, respectively from different affected organs, including heart, liver, spleen, lung and brain as well as anal swab (sticky stool) and serum were collected.", [["gross anatomical lesions", "ANATOMY", 4, 28], ["liver", "ANATOMY", 65, 70], ["hepatomegaly", "ANATOMY", 72, 84], ["pleural exudates", "ANATOMY", 90, 106], ["plaque", "ANATOMY", 179, 185], ["bursal", "ANATOMY", 263, 269], ["renal", "ANATOMY", 280, 285], ["heart", "ANATOMY", 305, 310], ["intestine", "ANATOMY", 324, 333], ["samples", "ANATOMY", 438, 445], ["organs", "ANATOMY", 518, 524], ["heart", "ANATOMY", 536, 541], ["liver", "ANATOMY", 543, 548], ["spleen", "ANATOMY", 550, 556], ["lung", "ANATOMY", 558, 562], ["brain", "ANATOMY", 567, 572], ["anal swab", "ANATOMY", 584, 593], ["stool", "ANATOMY", 602, 607], ["serum", "ANATOMY", 613, 618], ["hepatomegaly", "DISEASE", 72, 84], ["hepatomegaly", "DISEASE", 144, 156], ["plaque bleeding", "DISEASE", 179, 194], ["necrosis", "DISEASE", 199, 207], ["splenomegaly", "DISEASE", 220, 232], ["hemorrhagic necrosis", "DISEASE", 241, 261], ["bursal necrosis", "DISEASE", 263, 278], ["renal bleeding", "DISEASE", 280, 294], ["gross anatomical lesions", "PATHOLOGICAL_FORMATION", 4, 28], ["ducklings", "ORGANISM", 36, 45], ["liver", "ORGAN", 65, 70], ["pleural exudates", "ORGANISM_SUBSTANCE", 90, 106], ["plaque", "PATHOLOGICAL_FORMATION", 179, 185], ["renal", "ORGAN", 280, 285], ["heart", "ORGAN", 305, 310], ["intestine", "ORGAN", 324, 333], ["ducklings", "ORGANISM", 404, 413], ["organs", "ORGAN", 518, 524], ["heart", "ORGAN", 536, 541], ["liver", "ORGAN", 543, 548], ["spleen", "ORGAN", 550, 556], ["lung", "ORGAN", 558, 562], ["brain", "ORGAN", 567, 572], ["anal swab", "ORGANISM_SUBSTANCE", 584, 593], ["stool", "ORGANISM_SUBSTANCE", 602, 607], ["serum", "ORGANISM_SUBSTANCE", 613, 618], ["ducklings", "SPECIES", 36, 45], ["ducklings", "SPECIES", 404, 413], ["The gross anatomical lesions of the ducklings", "PROBLEM", 0, 45], ["an enlarged liver (hepatomegaly)", "PROBLEM", 53, 85], ["pleural exudates", "PROBLEM", 90, 106], ["yellow discoloration", "PROBLEM", 112, 132], ["hepatomegaly", "PROBLEM", 144, 156], ["brittle texture", "PROBLEM", 162, 177], ["plaque bleeding", "PROBLEM", 179, 194], ["necrosis", "PROBLEM", 199, 207], ["red darken splenomegaly", "PROBLEM", 209, 232], ["patchy hemorrhagic necrosis", "PROBLEM", 234, 261], ["bursal necrosis", "PROBLEM", 263, 278], ["renal bleeding", "PROBLEM", 280, 294], ["enlarged heart and inflated intestine", "PROBLEM", 296, 333], ["LAMP assay evaluation", "TEST", 353, 374], ["ResultsTwenty eight samples", "TEST", 418, 445], ["heart, liver, spleen, lung and brain", "PROBLEM", 536, 572], ["anal swab (sticky stool", "TEST", 584, 607], ["serum", "TEST", 613, 618], ["gross", "OBSERVATION_MODIFIER", 4, 9], ["anatomical", "OBSERVATION_MODIFIER", 10, 20], ["lesions", "OBSERVATION", 21, 28], ["enlarged", "OBSERVATION", 56, 64], ["liver", "ANATOMY", 65, 70], ["hepatomegaly", "OBSERVATION", 72, 84], ["pleural", "ANATOMY", 90, 97], ["exudates", "OBSERVATION", 98, 106], ["yellow", "OBSERVATION_MODIFIER", 112, 118], ["discoloration", "OBSERVATION_MODIFIER", 119, 132], ["hepatomegaly", "OBSERVATION", 144, 156], ["brittle texture", "OBSERVATION_MODIFIER", 162, 177], ["plaque", "OBSERVATION_MODIFIER", 179, 185], ["bleeding", "OBSERVATION", 186, 194], ["necrosis", "OBSERVATION", 199, 207], ["red", "OBSERVATION_MODIFIER", 209, 212], ["darken", "OBSERVATION_MODIFIER", 213, 219], ["splenomegaly", "OBSERVATION", 220, 232], ["patchy", "OBSERVATION_MODIFIER", 234, 240], ["hemorrhagic", "OBSERVATION_MODIFIER", 241, 252], ["necrosis", "OBSERVATION", 253, 261], ["bursal", "ANATOMY", 263, 269], ["necrosis", "OBSERVATION", 270, 278], ["renal", "ANATOMY", 280, 285], ["bleeding", "OBSERVATION", 286, 294], ["enlarged", "OBSERVATION", 296, 304], ["heart", "ANATOMY", 305, 310], ["inflated", "ANATOMY_MODIFIER", 315, 323], ["intestine", "ANATOMY", 324, 333], ["heart", "ANATOMY", 536, 541], ["liver", "ANATOMY", 543, 548], ["spleen", "ANATOMY", 550, 556], ["lung", "ANATOMY", 558, 562], ["brain", "ANATOMY", 567, 572], ["anal", "ANATOMY", 584, 588]]], ["Among the 21 NDRV LAMP-positive specimens, 18 were positive RT-PCR (Table 4).", [["specimens", "ANATOMY", 32, 41], ["the 21 NDRV LAMP", "TEST", 6, 22]]], ["The RT-LAMP rapid detection assay was 10.7% (3/28) higher than that of the traditional RT-PCR method.", [["The RT-LAMP rapid detection assay", "TEST", 0, 33]]], ["Thus, the conventional RT-PCR method had low sensitivity and is inappropriate for use in diagnosis of NDRV.DiscussionNDRV was isolated and identified from various duck species, for example, Muscovy, Mule, Peking and Sheldrake ducks18.", [["NDRV", "DISEASE", 102, 106], ["NDRV", "CANCER", 102, 106], ["duck", "ORGANISM", 163, 167], ["ducks", "SPECIES", 226, 231], ["NDRV", "SPECIES", 102, 106], ["Sheldrake ducks", "SPECIES", 216, 231], ["the conventional RT-PCR method", "TEST", 6, 36], ["low sensitivity", "PROBLEM", 41, 56], ["NDRV", "PROBLEM", 102, 106], ["various duck species", "PROBLEM", 155, 175]]], ["The infected ducks revealed the fundamental clinical symptoms with hemorrhage and necrosis in the liver results in high mortality rates in ducks.", [["liver", "ANATOMY", 98, 103], ["hemorrhage", "DISEASE", 67, 77], ["necrosis", "DISEASE", 82, 90], ["ducks", "ORGANISM", 13, 18], ["liver", "ORGAN", 98, 103], ["ducks", "ORGANISM", 139, 144], ["ducks", "SPECIES", 13, 18], ["ducks", "SPECIES", 139, 144], ["The infected ducks", "PROBLEM", 0, 18], ["the fundamental clinical symptoms", "PROBLEM", 28, 61], ["hemorrhage", "PROBLEM", 67, 77], ["necrosis in the liver", "PROBLEM", 82, 103], ["high mortality rates in ducks", "PROBLEM", 115, 144], ["infected", "OBSERVATION", 4, 12], ["hemorrhage", "OBSERVATION", 67, 77], ["necrosis", "OBSERVATION", 82, 90], ["liver", "ANATOMY", 98, 103], ["high", "OBSERVATION_MODIFIER", 115, 119], ["mortality", "OBSERVATION_MODIFIER", 120, 129]]], ["In China, NDRV causes tremendous economic losses to the duck industry and most of the affected ducks, particularly ducklings died within 72 hpi.", [["NDRV", "CHEMICAL", 10, 14], ["duck", "ORGANISM", 56, 60], ["ducks", "ORGANISM", 95, 100], ["ducklings", "ORGANISM", 115, 124], ["duck", "SPECIES", 56, 60], ["ducks", "SPECIES", 95, 100], ["ducklings", "SPECIES", 115, 124], ["tremendous economic losses", "PROBLEM", 22, 48], ["tremendous", "OBSERVATION_MODIFIER", 22, 32], ["economic losses", "OBSERVATION", 33, 48]]], ["Therefore, it is crucially required to develop an easy, rapid, highly sensitive and specific diagnostic method for NDRV detection.", [["NDRV", "SPECIES", 115, 119], ["NDRV detection", "TEST", 115, 129]]], ["In this study, we employed RT-LAMP to identify NDVR as a serious pathogen for duck industry in Guangdong province, China.", [["NDVR", "CHEMICAL", 47, 51], ["NDVR", "GENE_OR_GENE_PRODUCT", 47, 51], ["duck", "ORGANISM", 78, 82], ["this study", "TEST", 3, 13], ["a serious pathogen", "PROBLEM", 55, 73]]], ["Specificity of the RT-LAMP primers was investigated exploiting Muscovy Duck Reovirus (MDRV), Avian Reovirus (ARV), Duck Disease Virus (DPV), Duck Hepatitis Virus (DHAV), Duck Newcastle Disease Virus (NDV), H9 subtype avian influenza virus (AIV), H5 subtype AIV and duck Tanzuru virus (DTMUV).", [["Duck Disease Virus", "DISEASE", 115, 133], ["Duck Hepatitis Virus", "DISEASE", 141, 161], ["Newcastle Disease Virus", "DISEASE", 175, 198], ["avian influenza", "DISEASE", 217, 232], ["Muscovy Duck Reovirus", "ORGANISM", 63, 84], ["MDRV", "ORGANISM", 86, 90], ["Avian Reovirus", "ORGANISM", 93, 107], ["Duck Disease Virus", "ORGANISM", 115, 133], ["DPV", "ORGANISM", 135, 138], ["Duck Hepatitis Virus", "ORGANISM", 141, 161], ["DHAV", "ORGANISM", 163, 167], ["Duck Newcastle Disease Virus (NDV), H9 subtype avian influenza virus", "ORGANISM", 170, 238], ["AIV", "ORGANISM", 240, 243], ["H5 subtype AIV", "ORGANISM", 246, 260], ["duck Tanzuru virus", "ORGANISM", 265, 283], ["DTMUV", "CANCER", 285, 290], ["RT-LAMP primers", "DNA", 19, 34], ["Avian", "SPECIES", 93, 98], ["Duck Hepatitis Virus", "SPECIES", 141, 161], ["NDV", "SPECIES", 200, 203], ["avian influenza virus", "SPECIES", 217, 238], ["duck Tanzuru virus", "SPECIES", 265, 283], ["Muscovy Duck Reovirus", "SPECIES", 63, 84], ["MDRV", "SPECIES", 86, 90], ["Duck Disease Virus", "SPECIES", 115, 133], ["DPV", "SPECIES", 135, 138], ["Duck Hepatitis Virus", "SPECIES", 141, 161], ["DHAV", "SPECIES", 163, 167], ["Duck Newcastle Disease Virus", "SPECIES", 170, 198], ["NDV", "SPECIES", 200, 203], ["H9 subtype avian influenza virus", "SPECIES", 206, 238], ["AIV", "SPECIES", 240, 243], ["H5 subtype AIV", "SPECIES", 246, 260], ["duck Tanzuru virus", "SPECIES", 265, 283], ["DTMUV", "SPECIES", 285, 290], ["the RT-LAMP primers", "TEST", 15, 34], ["Muscovy Duck Reovirus (MDRV)", "PROBLEM", 63, 91], ["Avian Reovirus (ARV)", "PROBLEM", 93, 113], ["Duck Disease Virus (DPV)", "PROBLEM", 115, 139], ["Duck Hepatitis Virus (DHAV)", "PROBLEM", 141, 168], ["Duck Newcastle Disease Virus (NDV)", "PROBLEM", 170, 204], ["H9 subtype avian influenza virus", "PROBLEM", 206, 238], ["H5 subtype AIV", "TREATMENT", 246, 260], ["duck Tanzuru virus", "TREATMENT", 265, 283], ["Duck", "ANATOMY", 115, 119], ["Duck", "ANATOMY", 141, 145], ["Hepatitis Virus", "OBSERVATION", 146, 161], ["influenza virus", "OBSERVATION", 223, 238]]], ["The utilization of the six specific primers that recognize distinct regions on the gene encoding the \u03c3B major outer-capsid protein of NDRV assured high specificity of the template nucleic acid amplification.", [["nucleic acid", "CHEMICAL", 180, 192], ["\u03c3B", "GENE_OR_GENE_PRODUCT", 101, 103], ["NDRV", "GENE_OR_GENE_PRODUCT", 134, 138], ["\u03c3B major outer-capsid protein", "PROTEIN", 101, 130], ["NDRV", "PROTEIN", 134, 138], ["the six specific primers", "TREATMENT", 19, 43], ["the template nucleic acid amplification", "TREATMENT", 167, 206], ["capsid protein", "OBSERVATION", 116, 130]]], ["Our data showed that there was no cross-reaction between NDVR and other examined viruses.", [["Our data", "TEST", 0, 8], ["cross-reaction between NDVR", "PROBLEM", 34, 61], ["no", "UNCERTAINTY", 31, 33], ["viruses", "OBSERVATION", 81, 88]]], ["The RT-LAMP specificity detection of NDRV was in accord with other studies about specificity of RT-LAMP reaction in viral detection7\u201310,19.", [["NDRV", "CANCER", 37, 41], ["NDRV", "DNA", 37, 41], ["The RT", "TEST", 0, 6], ["other studies", "TEST", 61, 74], ["RT-LAMP reaction", "PROBLEM", 96, 112]]], ["The RT-LAMP assay in the detection of NDRV displayed sufficient sensitivity in addition to its higher specificity.DiscussionWhen the nucleic acid and plasmid quantities were checked by the RT-LAMP visualized by calcein assay, the detection limit was found to be 200 fg RNA, which was similar to that of RT-LAMP analyzed by agarose gel and RT-LAMP visualized by SYBR Green I. However, the detection limit of the conventional PCR (20 pg RNA).", [["nucleic acid", "CHEMICAL", 133, 145], ["calcein", "CHEMICAL", 211, 218], ["calcein", "CHEMICAL", 211, 218], ["NDRV", "CANCER", 38, 42], ["calcein", "SIMPLE_CHEMICAL", 211, 218], ["agarose", "SIMPLE_CHEMICAL", 323, 330], ["NDRV", "PROTEIN", 38, 42], ["200 fg RNA", "RNA", 262, 272], ["NDRV", "SPECIES", 38, 42], ["The RT-LAMP assay", "TEST", 0, 17], ["the nucleic acid and plasmid quantities", "TEST", 129, 168], ["calcein assay", "TEST", 211, 224], ["the detection limit", "TEST", 226, 245], ["RT", "TEST", 303, 305], ["agarose gel", "TREATMENT", 323, 334], ["RT-LAMP", "TEST", 339, 346], ["the conventional PCR", "TEST", 407, 427]]], ["Interestingly, the current assay is more sensitive than the previously reported one16.", [["the current assay", "TEST", 15, 32]]], ["Furthermore, the sensitivity of RT- LAMP in NDRV-infected ducklings (known) and field samples of ducks (suspected NDVR infection) was found to be higher than that of conventional PCR assay.", [["samples", "ANATOMY", 86, 93], ["NDVR infection", "DISEASE", 114, 128], ["NDRV", "ORGANISM", 44, 48], ["ducklings", "ORGANISM", 58, 67], ["ducks", "ORGANISM", 97, 102], ["ducklings", "SPECIES", 58, 67], ["ducks", "SPECIES", 97, 102], ["ducks", "SPECIES", 97, 102], ["RT- LAMP in NDRV", "TEST", 32, 48], ["infected ducklings", "PROBLEM", 49, 67], ["field samples", "TEST", 80, 93], ["ducks", "PROBLEM", 97, 102], ["NDVR infection", "PROBLEM", 114, 128], ["conventional PCR assay", "TEST", 166, 188], ["infected", "OBSERVATION", 49, 57], ["infection", "OBSERVATION", 119, 128]]], ["Although the current study is based on a small number of experimental animals, RT-LAMP is a simple and powerful amplification method for the rapid diagnosis and early detection of experimentally NDVR- infected ducklings within 48 hpi.DiscussionThe greater sensitivity is due to the high amplification efficiency of the RT- LAMP assay.", [["NDVR", "CHEMICAL", 195, 199], ["ducklings", "ORGANISM", 210, 219], ["ducklings", "SPECIES", 210, 219], ["the current study", "TEST", 9, 26], ["the rapid diagnosis", "TEST", 137, 156], ["experimentally NDVR", "PROBLEM", 180, 199], ["infected ducklings", "PROBLEM", 201, 219], ["the high amplification efficiency", "PROBLEM", 278, 311], ["the RT- LAMP assay", "TEST", 315, 333], ["small", "OBSERVATION_MODIFIER", 41, 46]]], ["Moreover, there is no time loss for thermal alteration under isothermal conditions in RT-LAMP.", [["time loss", "PROBLEM", 22, 31], ["thermal alteration under isothermal conditions", "PROBLEM", 36, 82], ["no", "UNCERTAINTY", 19, 21]]], ["Others have reported that the enzymes used in LAMP are more resistant to inhibitory components in clinical samples25\u201329.", [["the enzymes", "TEST", 26, 37], ["clinical samples", "TEST", 98, 114]]], ["Furthermore, it has been reported that PCR assay is more prone to PCR inhibitors in samples, which interfere with the amplification and sensitivity of PCR in comparison with LAMP assay30,31.", [["samples", "ANATOMY", 84, 91], ["samples", "CANCER", 84, 91], ["PCR assay", "TEST", 39, 48], ["PCR inhibitors", "TEST", 66, 80], ["the amplification", "TEST", 114, 131], ["PCR", "TEST", 151, 154], ["LAMP assay", "TEST", 174, 184]]], ["We compared the performance of both calcein and SYBR Green I and our results indicated that both assays could be utilized to differentiate between positive and negative samples in visible or UV light.DiscussionThe RT-LAMP-amplified products were detected by visual inspection employing calcein and SYBR Green I dyes, as well as by electrophoresis on agarose gels.", [["samples", "ANATOMY", 169, 176], ["calcein", "CHEMICAL", 36, 43], ["calcein", "CHEMICAL", 286, 293], ["calcein", "CHEMICAL", 36, 43], ["calcein", "CHEMICAL", 286, 293], ["calcein", "SIMPLE_CHEMICAL", 36, 43], ["SYBR Green I", "GENE_OR_GENE_PRODUCT", 48, 60], ["calcein", "SIMPLE_CHEMICAL", 286, 293], ["SYBR Green I", "GENE_OR_GENE_PRODUCT", 298, 310], ["agarose", "SIMPLE_CHEMICAL", 350, 357], ["RT-LAMP-amplified products", "DNA", 214, 240], ["both assays", "TEST", 92, 103], ["The RT-LAMP-amplified products", "TREATMENT", 210, 240], ["visual inspection", "TEST", 258, 275], ["calcein", "TREATMENT", 286, 293], ["SYBR Green I dyes", "PROBLEM", 298, 315], ["agarose gels", "TREATMENT", 350, 362]]], ["As a result of the high amplification efficiency of LAMP31,32 and binding affinity of SYBR Green I to DNA33, the sensitivity of LAMP detection using calcein (the fluorescent emissions from calcein and the production of insoluble manganese/magnesium phosphate)34 and SYBR Green I was very high.", [["calcein", "CHEMICAL", 149, 156], ["calcein", "CHEMICAL", 189, 196], ["manganese", "CHEMICAL", 229, 238], ["magnesium phosphate", "CHEMICAL", 239, 258], ["calcein", "CHEMICAL", 149, 156], ["calcein", "CHEMICAL", 189, 196], ["manganese", "CHEMICAL", 229, 238], ["magnesium phosphate", "CHEMICAL", 239, 258], ["LAMP31,32", "SIMPLE_CHEMICAL", 52, 61], ["SYBR Green I", "GENE_OR_GENE_PRODUCT", 86, 98], ["DNA33", "GENE_OR_GENE_PRODUCT", 102, 107], ["calcein", "SIMPLE_CHEMICAL", 149, 156], ["calcein", "SIMPLE_CHEMICAL", 189, 196], ["manganese", "SIMPLE_CHEMICAL", 229, 238], ["magnesium phosphate", "SIMPLE_CHEMICAL", 239, 258], ["SYBR Green I", "GENE_OR_GENE_PRODUCT", 266, 278], ["SYBR Green I", "PROTEIN", 86, 98], ["DNA33", "PROTEIN", 102, 107], ["the high amplification efficiency of LAMP31,32", "PROBLEM", 15, 61], ["LAMP detection", "TEST", 128, 142], ["calcein", "TREATMENT", 149, 156], ["calcein", "TREATMENT", 189, 196], ["the production of insoluble manganese/magnesium phosphate", "TREATMENT", 201, 258], ["SYBR Green I", "TEST", 266, 278]]], ["The visual inspection result with calcein and SYBR Green I dyes was found to match with gel electrophoresis.", [["calcein", "CHEMICAL", 34, 41], ["calcein", "CHEMICAL", 34, 41], ["calcein", "SIMPLE_CHEMICAL", 34, 41], ["SYBR Green I", "GENE_OR_GENE_PRODUCT", 46, 58], ["The visual inspection", "TEST", 0, 21], ["calcein", "TREATMENT", 34, 41], ["SYBR Green I dyes", "PROBLEM", 46, 63], ["gel electrophoresis", "TEST", 88, 107]]], ["Thereby, the visual inspection of LAMP amplified products by employing calcein and SYBR Green I dyes instead of gel electrophoresis made the RT-LAMP assay more rapid and simple.DiscussionThis one-step RT-LAMP established in this study will provide an effective assay for the rapid diagnosis, surveillance and the examination of molecular epidemiology of NDRV for both developed and underdeveloped countries.", [["calcein", "CHEMICAL", 71, 78], ["NDRV", "CHEMICAL", 354, 358], ["calcein", "CHEMICAL", 71, 78], ["calcein", "SIMPLE_CHEMICAL", 71, 78], ["SYBR Green I", "GENE_OR_GENE_PRODUCT", 83, 95], ["LAMP amplified products", "PROTEIN", 34, 57], ["NDRV", "SPECIES", 354, 358], ["LAMP amplified products", "TREATMENT", 34, 57], ["calcein", "TREATMENT", 71, 78], ["gel electrophoresis", "TEST", 112, 131], ["the RT", "TEST", 137, 143], ["LAMP assay", "TEST", 144, 154], ["this study", "TEST", 224, 234], ["surveillance", "TEST", 292, 304], ["the examination", "TEST", 309, 324]]]], "27a507058bdcecbeba7a6466ed261d55a1b5d4cc": [["global recognition and revolutionized the way infectious diseases were treated, and in 1901, Emil von Behring was awarded the Nobel Prize for Medicine for his work, which served as a basis for treatment of multiple diseases in the 1900s as well as the development of vaccines [15] .", [["infectious diseases", "DISEASE", 46, 65], ["global recognition", "PROBLEM", 0, 18], ["revolutionized the way infectious diseases", "PROBLEM", 23, 65], ["treatment", "TREATMENT", 193, 202], ["multiple diseases", "PROBLEM", 206, 223], ["vaccines", "TREATMENT", 267, 275], ["multiple", "OBSERVATION_MODIFIER", 206, 214], ["diseases", "OBSERVATION", 215, 223]]], ["In fact, there are numerous examples throughout history in which convalescent serum was used with some degree of success to treat an array of diseases, including rheumatic fever [16] , scarlet fever [17] , mumps [18] , measles [18, 19] , chickenpox [18] , and pneumococcal and meningococcal infections [20] (Fig 1) .", [["serum", "ANATOMY", 78, 83], ["rheumatic fever", "DISEASE", 162, 177], ["scarlet fever", "DISEASE", 185, 198], ["mumps", "DISEASE", 206, 211], ["measles", "DISEASE", 219, 226], ["chickenpox", "DISEASE", 238, 248], ["pneumococcal and meningococcal infections", "DISEASE", 260, 301], ["convalescent", "ORGANISM", 65, 77], ["serum", "ORGANISM_SUBSTANCE", 78, 83], ["pneumococcal", "SPECIES", 260, 272], ["pneumococcal", "SPECIES", 260, 272], ["convalescent serum", "TEST", 65, 83], ["diseases", "PROBLEM", 142, 150], ["rheumatic fever", "PROBLEM", 162, 177], ["scarlet fever", "PROBLEM", 185, 198], ["mumps", "PROBLEM", 206, 211], ["measles", "PROBLEM", 219, 226], ["chickenpox", "PROBLEM", 238, 248], ["pneumococcal", "PROBLEM", 260, 272], ["meningococcal infections", "PROBLEM", 277, 301], ["numerous", "OBSERVATION_MODIFIER", 19, 27], ["diseases", "OBSERVATION", 142, 150], ["meningococcal", "OBSERVATION_MODIFIER", 277, 290], ["infections", "OBSERVATION", 291, 301]]], ["Most notable use was during the Spanish Flu pandemic (1918 to 1920) , where meta-analysis studies showed a significantly reduced mortality risk in patients treated with convalescent serum [8, 12] .", [["serum", "ANATOMY", 182, 187], ["patients", "ORGANISM", 147, 155], ["serum", "ORGANISM_SUBSTANCE", 182, 187], ["patients", "SPECIES", 147, 155], ["meta-analysis studies", "TEST", 76, 97], ["a significantly reduced mortality risk", "PROBLEM", 105, 143], ["convalescent serum", "TEST", 169, 187]]], ["However, with the advent of antimicrobials, by the middle of the 20th century, the use of serum therapy had declined.", [["serum", "ANATOMY", 90, 95], ["serum", "ORGANISM_SUBSTANCE", 90, 95], ["antimicrobials", "TREATMENT", 28, 42], ["serum therapy", "TREATMENT", 90, 103]]], ["Nevertheless, the interest in passive antibody therapy has been renewed periodically when new epidemics or pandemics have emerged.", [["passive antibody therapy", "TREATMENT", 30, 54], ["new epidemics", "PROBLEM", 90, 103], ["pandemics", "PROBLEM", 107, 116]]], ["One example is during the Ebola virus (EBOV) outbreak in 1976 in the Democratic Republic of Congo, where an infected laboratory worker recovered after transfusion with convalescent plasma containing anti-EBOV antibodies.", [["plasma", "ANATOMY", 181, 187], ["Ebola virus (EBOV) outbreak", "DISEASE", 26, 53], ["Ebola virus", "ORGANISM", 26, 37], ["EBOV", "ORGANISM", 39, 43], ["plasma", "ORGANISM_SUBSTANCE", 181, 187], ["anti-EBOV antibodies", "PROTEIN", 199, 219], ["Ebola virus", "SPECIES", 26, 37], ["Ebola virus", "SPECIES", 26, 37], ["EBOV", "SPECIES", 39, 43], ["the Ebola virus", "PROBLEM", 22, 37], ["transfusion", "TREATMENT", 151, 162], ["convalescent plasma containing anti-EBOV antibodies", "TREATMENT", 168, 219], ["infected", "OBSERVATION", 108, 116]]], ["Similarly, in 1979, patients with Argentine hemorrhagic fever virus treated with convalescent plasma had a lower mortality rate compared with subjects treated with normal plasma, and similar results were reported for subsequent epidemics of the disease [21] .", [["plasma", "ANATOMY", 94, 100], ["plasma", "ANATOMY", 171, 177], ["Argentine hemorrhagic fever", "DISEASE", 34, 61], ["patients", "ORGANISM", 20, 28], ["Argentine hemorrhagic fever virus", "ORGANISM", 34, 67], ["plasma", "ORGANISM_SUBSTANCE", 94, 100], ["plasma", "ORGANISM_SUBSTANCE", 171, 177], ["patients", "SPECIES", 20, 28], ["Argentine hemorrhagic fever virus", "SPECIES", 34, 67], ["Argentine hemorrhagic fever virus", "SPECIES", 34, 67], ["Argentine hemorrhagic fever virus", "PROBLEM", 34, 67], ["convalescent plasma", "TREATMENT", 81, 100], ["a lower mortality rate", "PROBLEM", 105, 127], ["the disease", "PROBLEM", 241, 252], ["hemorrhagic", "OBSERVATION_MODIFIER", 44, 55], ["fever", "OBSERVATION", 56, 61]]], ["Over the following decades, convalescent plasma therapy was successfully employed during the H1N1 swine influenza pandemic (2009), the H5N1 avian flu epidemic (2003), as well as during the EBOV outbreak in West Africa in 2013.PLOS PATHOGENSMost relevant and encouraging is the use of convalescent plasma during 2 previous coronavirus epidemics: severe acute respiratory syndrome (SARS) in 2003, and Middle East respiratory syndrome (MERS) in 2012 [21] .", [["plasma", "ANATOMY", 41, 47], ["plasma", "ANATOMY", 297, 303], ["influenza pandemic", "DISEASE", 104, 122], ["avian flu", "DISEASE", 140, 149], ["EBOV", "DISEASE", 189, 193], ["coronavirus epidemics", "DISEASE", 322, 343], ["acute respiratory syndrome", "DISEASE", 352, 378], ["SARS", "DISEASE", 380, 384], ["Middle East respiratory syndrome", "DISEASE", 399, 431], ["convalescent", "ORGANISM", 28, 40], ["plasma", "ORGANISM_SUBSTANCE", 41, 47], ["convalescent", "ORGANISM", 284, 296], ["plasma", "ORGANISM_SUBSTANCE", 297, 303], ["H1N1 swine influenza", "SPECIES", 93, 113], ["H5N1 avian flu", "SPECIES", 135, 149], ["H1N1 swine influenza pandemic", "SPECIES", 93, 122], ["EBOV", "SPECIES", 189, 193], ["Middle East respiratory syndrome (MERS)", "SPECIES", 399, 438], ["convalescent plasma therapy", "TREATMENT", 28, 55], ["the H1N1 swine influenza pandemic", "PROBLEM", 89, 122], ["convalescent plasma", "TREATMENT", 284, 303], ["severe acute respiratory syndrome", "PROBLEM", 345, 378], ["SARS", "PROBLEM", 380, 384], ["Middle East respiratory syndrome", "PROBLEM", 399, 431], ["severe", "OBSERVATION_MODIFIER", 345, 351], ["acute", "OBSERVATION_MODIFIER", 352, 357], ["respiratory syndrome", "OBSERVATION", 358, 378], ["Middle", "ANATOMY_MODIFIER", 399, 405], ["respiratory syndrome", "OBSERVATION", 411, 431]]], ["The high degree of success in achieving favorable clinical outcomes during these coronaviruses outbreaks establishes a strong precedent and supports the notion that convalescent plasma could be a viable option for treatment of COVID-19 patients, particularly upon early administration [6, 9, 12, [21] [22] [23] .Buying time with the help of the convalescentThe convalescent plasma therapeutic approach is based on the principle of passive antibody therapy, a short-term strategy whereby antibodies from the blood of someone who recovered from an infection can be administered to protect or treat another person [6, 21] .", [["plasma", "ANATOMY", 178, 184], ["plasma", "ANATOMY", 374, 380], ["blood", "ANATOMY", 507, 512], ["coronaviruses", "DISEASE", 81, 94], ["infection", "DISEASE", 546, 555], ["coronaviruses", "ORGANISM", 81, 94], ["convalescent", "ORGANISM", 165, 177], ["plasma", "ORGANISM_SUBSTANCE", 178, 184], ["patients", "ORGANISM", 236, 244], ["[21] [22] [23]", "SIMPLE_CHEMICAL", 296, 310], ["plasma", "ORGANISM_SUBSTANCE", 374, 380], ["blood", "ORGANISM_SUBSTANCE", 507, 512], ["someone", "ORGANISM", 516, 523], ["antibodies", "PROTEIN", 487, 497], ["patients", "SPECIES", 236, 244], ["person", "SPECIES", 604, 610], ["these coronaviruses outbreaks", "PROBLEM", 75, 104], ["COVID", "TEST", 227, 232], ["The convalescent plasma therapeutic approach", "TREATMENT", 357, 401], ["passive antibody therapy", "TREATMENT", 431, 455], ["an infection", "PROBLEM", 543, 555], ["high degree", "OBSERVATION_MODIFIER", 4, 15], ["antibody therapy", "OBSERVATION", 439, 455], ["infection", "OBSERVATION", 546, 555]]], ["Effectively, the end goal is the same as vaccines, making antibodies against a specific infectious agent readily available.", [["antibodies", "PROTEIN", 58, 68], ["vaccines", "TREATMENT", 41, 49], ["antibodies", "TREATMENT", 58, 68], ["a specific infectious agent", "PROBLEM", 77, 104]]], ["For instance, a vaccine relies on the host immune cells (B lymphocytes specifically) to produce antibodies after antigen recognition and signal amplification by the immune system, a process that may take weeks [24] ; on the other hand, in the case of passive antibody therapy, the process is expedited by providing a patient with immediate immunity when the premade antibodies are given.", [["immune cells", "ANATOMY", 43, 55], ["B lymphocytes", "ANATOMY", 57, 70], ["immune system", "ANATOMY", 165, 178], ["host immune cells", "CELL", 38, 55], ["B lymphocytes", "CELL", 57, 70], ["patient", "ORGANISM", 317, 324], ["host immune cells", "CELL_TYPE", 38, 55], ["B lymphocytes", "CELL_TYPE", 57, 70], ["antibodies", "PROTEIN", 96, 106], ["premade antibodies", "PROTEIN", 358, 376], ["patient", "SPECIES", 317, 324], ["a vaccine", "TREATMENT", 14, 23], ["antigen recognition", "TEST", 113, 132], ["signal amplification", "TEST", 137, 157], ["passive antibody therapy", "TREATMENT", 251, 275], ["the premade antibodies", "TREATMENT", 354, 376]]], ["Therefore, for COVID-19 patients, the expedited approach could prove lifesaving.", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["the expedited approach", "TREATMENT", 34, 56]]], ["Nevertheless, this advantage does not come without caveats, as immunization with passive antibody therapy is typically of shorter-term protection, in part because of the half-life of antibodies in circulation [25] and lack of new production by B lymphocytes.", [["B lymphocytes", "ANATOMY", 244, 257], ["B lymphocytes", "CELL", 244, 257], ["antibodies", "PROTEIN", 183, 193], ["B lymphocytes", "CELL_TYPE", 244, 257], ["immunization", "TREATMENT", 63, 75], ["passive antibody therapy", "TREATMENT", 81, 105], ["shorter-term protection", "TREATMENT", 122, 145], ["antibodies in circulation", "PROBLEM", 183, 208]]], ["Today, passive antibody therapy relies primarily on pooled immunoglobulin preparations that contain high concentrations of antibodies.", [["immunoglobulin", "GENE_OR_GENE_PRODUCT", 59, 73], ["immunoglobulin", "PROTEIN", 59, 73], ["antibodies", "PROTEIN", 123, 133], ["passive antibody therapy", "TREATMENT", 7, 31], ["pooled immunoglobulin preparations", "TREATMENT", 52, 86], ["high concentrations of antibodies", "PROBLEM", 100, 133], ["antibody therapy", "OBSERVATION", 15, 31], ["high concentrations", "OBSERVATION_MODIFIER", 100, 119]]], ["In contrast, plasma has been used emergently in epidemics in which there is insufficient time or resources to generate immunoglobulin preparations [21] .Buying time with the help of the convalescentDespite the high rate of SARS-CoV-2 infection, the relatively low mortality rate provides a rich pool of donors [26] .", [["plasma", "ANATOMY", 13, 19], ["SARS-CoV-2 infection", "DISEASE", 223, 243], ["plasma", "ORGANISM_SUBSTANCE", 13, 19], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 119, 133], ["SARS-CoV-2", "ORGANISM", 223, 233], ["donors", "ORGANISM", 303, 309], ["immunoglobulin", "PROTEIN", 119, 133], ["SARS-CoV-2", "SPECIES", 223, 233], ["immunoglobulin preparations", "TREATMENT", 119, 146], ["SARS", "PROBLEM", 223, 227], ["CoV-2 infection", "PROBLEM", 228, 243], ["the relatively low mortality rate", "PROBLEM", 245, 278]]], ["However, potential COVID-19 donors must meet several eligibility criteria that ensure the donor has antibodies against SARS-CoV-2 and lacks the presence of other types of infections [21, 27] .", [["SARS", "DISEASE", 119, 123], ["infections", "DISEASE", 171, 181], ["donors", "ORGANISM", 28, 34], ["SARS-CoV-2", "ORGANISM", 119, 129], ["antibodies", "PROTEIN", 100, 110], ["SARS-CoV", "SPECIES", 119, 127], ["COVID-19 donors", "TREATMENT", 19, 34], ["antibodies", "TEST", 100, 110], ["SARS", "PROBLEM", 119, 123], ["CoV", "TEST", 124, 127], ["infections", "PROBLEM", 171, 181], ["infections", "OBSERVATION", 171, 181]]], ["Additionally, only plasma with high anti-SARS-CoV-2 titers of immunoglobulins G and M (IgG and IgM) are used.", [["plasma", "ANATOMY", 19, 25], ["plasma", "ORGANISM_SUBSTANCE", 19, 25], ["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 36, 51], ["immunoglobulins G", "GENE_OR_GENE_PRODUCT", 62, 79], ["IgG", "GENE_OR_GENE_PRODUCT", 87, 90], ["IgM", "GENE_OR_GENE_PRODUCT", 95, 98], ["anti-SARS", "PROTEIN", 36, 45], ["immunoglobulins G", "PROTEIN", 62, 79], ["IgG", "PROTEIN", 87, 90], ["IgM", "PROTEIN", 95, 98], ["plasma", "TEST", 19, 25], ["anti-SARS", "TEST", 36, 45], ["CoV", "TEST", 46, 49], ["immunoglobulins G", "TEST", 62, 79], ["IgG", "TEST", 87, 90], ["IgM", "TEST", 95, 98]]], ["Once collected, plasma can be tested and administered within hours, following conventional donor-patient blood compatibility typing [27] .", [["plasma", "ANATOMY", 16, 22], ["blood", "ANATOMY", 105, 110], ["plasma", "ORGANISM_SUBSTANCE", 16, 22], ["blood", "ORGANISM_SUBSTANCE", 105, 110], ["conventional donor-patient blood compatibility typing", "TEST", 78, 131]]], ["In addition to rapid mobilization, this therapeutic approach is also versatile in applicability as it can be used for prophylaxis or treatment, as illustrated in Fig 2.", [["rapid mobilization", "TREATMENT", 15, 33], ["this therapeutic approach", "TREATMENT", 35, 60], ["prophylaxis", "TREATMENT", 118, 129], ["treatment", "TREATMENT", 133, 142], ["rapid", "OBSERVATION_MODIFIER", 15, 20], ["mobilization", "OBSERVATION", 21, 33]]], ["In the case of prophylaxis, a subject considered at high risk for infection (because of age or underlying medical conditions or who is likely to be in contact with people with COVID-19) could be administered convalescent plasma or neutralizing antibodies for protection against infection.", [["plasma", "ANATOMY", 221, 227], ["infection", "DISEASE", 66, 75], ["infection", "DISEASE", 278, 287], ["people", "ORGANISM", 164, 170], ["convalescent", "ORGANISM", 208, 220], ["plasma", "ORGANISM_SUBSTANCE", 221, 227], ["neutralizing antibodies", "PROTEIN", 231, 254], ["people", "SPECIES", 164, 170], ["prophylaxis", "TREATMENT", 15, 26], ["infection", "PROBLEM", 66, 75], ["underlying medical conditions", "PROBLEM", 95, 124], ["COVID", "TEST", 176, 181], ["convalescent plasma", "TREATMENT", 208, 227], ["neutralizing antibodies", "TREATMENT", 231, 254], ["infection", "PROBLEM", 278, 287], ["prophylaxis", "OBSERVATION", 15, 26], ["infection", "OBSERVATION", 66, 75], ["infection", "OBSERVATION", 278, 287]]], ["Alternatively, plasma can be administered to treat subjects who have contracted the infection but have not made sufficient antibodies against the virus yet in order to augment their immune response, improve disease course, and enhance recovery [21] .", [["plasma", "ANATOMY", 15, 21], ["infection", "DISEASE", 84, 93], ["plasma", "ORGANISM_SUBSTANCE", 15, 21], ["antibodies", "PROTEIN", 123, 133], ["the infection", "PROBLEM", 80, 93], ["sufficient antibodies", "PROBLEM", 112, 133], ["the virus", "PROBLEM", 142, 151], ["infection", "OBSERVATION", 84, 93]]], ["However, it is important to note that passive antibody therapy is most effective when administered prophylactically or implemented early after the onset of symptoms [21] .Buying time with the help of the convalescentConvalescent plasma with neutralizing antibodies is currently being used for investigational purposes in the COVID-19 pandemic, and preliminary results from 2 small studies performed in China are encouraging.", [["plasma", "ANATOMY", 229, 235], ["plasma", "ORGANISM_SUBSTANCE", 229, 235], ["neutralizing antibodies", "PROTEIN", 241, 264], ["passive antibody therapy", "TREATMENT", 38, 62], ["symptoms", "PROBLEM", 156, 164], ["the convalescentConvalescent plasma", "TREATMENT", 200, 235], ["neutralizing antibodies", "TREATMENT", 241, 264], ["investigational purposes", "TEST", 293, 317], ["the COVID", "TEST", 321, 330], ["2 small studies", "TEST", 373, 388]]], ["A pilot study exploring the feasibility of convalescent plasma transfusion to rescue a group of 10 patients with severe disease showed that 1 dose (200 mL) of convalescent plasma with high neutralizing antibody titers was well tolerated, resulted in disappearance of viremia, and improved clinical symptoms in all patients within days of administration [8] .", [["plasma", "ANATOMY", 56, 62], ["plasma", "ANATOMY", 172, 178], ["viremia", "DISEASE", 267, 274], ["convalescent", "ORGANISM", 43, 55], ["plasma", "ORGANISM_SUBSTANCE", 56, 62], ["patients", "ORGANISM", 99, 107], ["convalescent", "ORGANISM", 159, 171], ["plasma", "ORGANISM_SUBSTANCE", 172, 178], ["patients", "ORGANISM", 314, 322], ["patients", "SPECIES", 99, 107], ["patients", "SPECIES", 314, 322], ["A pilot study", "TEST", 0, 13], ["convalescent plasma transfusion", "TREATMENT", 43, 74], ["severe disease", "PROBLEM", 113, 127], ["convalescent plasma", "TEST", 159, 178], ["high neutralizing antibody titers", "TREATMENT", 184, 217], ["viremia", "PROBLEM", 267, 274], ["improved clinical symptoms", "PROBLEM", 280, 306], ["severe", "OBSERVATION_MODIFIER", 113, 119], ["disease", "OBSERVATION", 120, 127], ["viremia", "OBSERVATION", 267, 274], ["improved", "OBSERVATION_MODIFIER", 280, 288]]], ["Similar results were reported from another study with 5 critically ill patients on mechanical ventilation [7] .", [["critically ill", "DISEASE", 56, 70], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["another study", "TEST", 35, 48], ["mechanical ventilation", "TREATMENT", 83, 105]]], ["Although these small, nonrandomized studies had limitations, these findings indicate that convalescent plasma could be a promising rescue option for severe COVID-19 [21] .Limitations and potential risksAlthough convalescent plasma therapy is considered a relatively safe therapeutic modality, there are some potential risks [12] .", [["plasma", "ANATOMY", 103, 109], ["plasma", "ANATOMY", 224, 230], ["COVID-19", "CHEMICAL", 156, 164], ["plasma", "ORGANISM_SUBSTANCE", 103, 109], ["plasma", "ORGANISM_SUBSTANCE", 224, 230], ["nonrandomized studies", "TEST", 22, 43], ["convalescent plasma", "PROBLEM", 90, 109], ["severe COVID", "PROBLEM", 149, 161], ["convalescent plasma therapy", "TREATMENT", 211, 238], ["small", "OBSERVATION_MODIFIER", 15, 20]]], ["One theoretical complication that may arise is an antibodymediated proinflammatory disease enhancement known as antibody-dependent enhancement (ADE), whereby antibodies that developed during a prior infection exacerbate severity of the disease [12, 28] .", [["infection", "DISEASE", 199, 208], ["antibodies", "PROTEIN", 158, 168], ["One theoretical complication", "PROBLEM", 0, 28], ["an antibodymediated proinflammatory disease enhancement", "PROBLEM", 47, 102], ["antibody-dependent enhancement", "PROBLEM", 112, 142], ["a prior infection", "PROBLEM", 191, 208], ["the disease", "PROBLEM", 232, 243], ["complication", "OBSERVATION", 16, 28], ["may arise", "UNCERTAINTY", 34, 43], ["proinflammatory disease", "OBSERVATION", 67, 90], ["dependent", "OBSERVATION_MODIFIER", 121, 130], ["enhancement", "OBSERVATION_MODIFIER", 131, 142], ["disease", "OBSERVATION", 236, 243]]], ["The transfer of these antibodies may aberrantly activate fragment crystallizable (Fc) or complement receptors, increasing recruitment of proinflammatory cytokines and chemokines to the site of infection and causing severe tissue damage [29] [30] [31] .", [["tissue", "ANATOMY", 222, 228], ["infection", "DISEASE", 193, 202], ["complement receptors", "GENE_OR_GENE_PRODUCT", 89, 109], ["tissue", "TISSUE", 222, 228], ["antibodies", "PROTEIN", 22, 32], ["fragment crystallizable (Fc) or complement receptors", "PROTEIN", 57, 109], ["proinflammatory cytokines", "PROTEIN", 137, 162], ["chemokines", "PROTEIN", 167, 177], ["these antibodies", "TREATMENT", 16, 32], ["complement receptors", "TREATMENT", 89, 109], ["proinflammatory cytokines", "TREATMENT", 137, 162], ["chemokines", "TREATMENT", 167, 177], ["infection", "PROBLEM", 193, 202], ["severe tissue damage", "PROBLEM", 215, 235], ["increasing", "OBSERVATION_MODIFIER", 111, 121], ["recruitment", "OBSERVATION_MODIFIER", 122, 133], ["proinflammatory cytokines", "OBSERVATION", 137, 162], ["infection", "OBSERVATION", 193, 202], ["severe", "OBSERVATION_MODIFIER", 215, 221]]], ["Additionally, the presence of non-neutralizing antibodies may exacerbate viral endocytosis or phagocytosis into host cells via Fc receptors, potentializing viral replication [29, 32] .", [["cells", "ANATOMY", 117, 122], ["host cells", "CELL", 112, 122], ["Fc receptors", "GENE_OR_GENE_PRODUCT", 127, 139], ["non-neutralizing antibodies", "PROTEIN", 30, 57], ["host cells", "CELL_TYPE", 112, 122], ["Fc receptors", "PROTEIN", 127, 139], ["non-neutralizing antibodies", "PROBLEM", 30, 57], ["viral endocytosis", "PROBLEM", 73, 90], ["phagocytosis", "PROBLEM", 94, 106], ["Fc receptors", "TEST", 127, 139], ["viral replication", "PROBLEM", 156, 173], ["non-neutralizing antibodies", "OBSERVATION", 30, 57], ["viral replication", "OBSERVATION", 156, 173]]], ["However, although this phenomenon is well known with Dengue and other viral diseases, there have not been any reported ADE cases with the use of convalescent plasma for SARS, MERS, or COVID-19 [12, 29, [32] [33] [34] [35] .", [["plasma", "ANATOMY", 158, 164], ["Dengue", "DISEASE", 53, 59], ["viral diseases", "DISEASE", 70, 84], ["SARS", "DISEASE", 169, 173], ["COVID-19", "CHEMICAL", 184, 192], ["convalescent", "ORGANISM", 145, 157], ["plasma", "ORGANISM_SUBSTANCE", 158, 164], ["[32] [33] [34] [35]", "SIMPLE_CHEMICAL", 202, 221], ["Dengue", "PROBLEM", 53, 59], ["other viral diseases", "PROBLEM", 64, 84], ["SARS", "PROBLEM", 169, 173], ["COVID", "TEST", 184, 189]]], ["Transmission of the virus through transfusion is another concern; however, the risk is relatively low because of strict transfusion protocols, and when used for treatment purposes, the recipient is already infected [12, 36] .PLOS PATHOGENSThe success of convalescent plasma therapy hinges on the availability of plasma with high concentrations of antibodies, which may not be a major limitation for COVID-19 because SARS-CoV-2 has been shown to elicit high neutralizing antibody titers in recently convalesced individuals [7] [8] [9] .", [["plasma", "ANATOMY", 267, 273], ["plasma", "ANATOMY", 312, 318], ["convalescent", "ORGANISM", 254, 266], ["plasma", "ORGANISM_SUBSTANCE", 267, 273], ["plasma", "ORGANISM_SUBSTANCE", 312, 318], ["SARS-CoV-2", "ORGANISM", 416, 426], ["antibodies", "PROTEIN", 347, 357], ["SARS-CoV", "SPECIES", 416, 424], ["the virus", "PROBLEM", 16, 25], ["transfusion", "TREATMENT", 34, 45], ["strict transfusion protocols", "TREATMENT", 113, 141], ["treatment purposes", "TREATMENT", 161, 179], ["convalescent plasma therapy", "TREATMENT", 254, 281], ["high concentrations of antibodies", "PROBLEM", 324, 357], ["COVID", "TEST", 399, 404], ["SARS", "PROBLEM", 416, 420], ["CoV", "TEST", 421, 424], ["high neutralizing antibody titers", "PROBLEM", 452, 485], ["virus", "OBSERVATION", 20, 25]]], ["Apheresis is an automated technology that allows for selective collection of a blood fraction while other components can be transfused back to the donor.", [["blood", "ANATOMY", 79, 84], ["blood", "ORGANISM_SUBSTANCE", 79, 84], ["Apheresis", "TREATMENT", 0, 9], ["a blood fraction", "TREATMENT", 77, 93], ["the donor", "TREATMENT", 143, 152]]], ["Therefore, for donation of convalescent plasma, plasmapheresis is recommended because it is highly efficient and approximately 400-800 mL of plasma can be collected in a single donation, providing 2-4 units of convalescent plasma for transfusion [21] .", [["plasma", "ANATOMY", 40, 46], ["plasma", "ANATOMY", 141, 147], ["plasma", "ANATOMY", 223, 229], ["convalescent", "ORGANISM", 27, 39], ["plasma", "ORGANISM_SUBSTANCE", 40, 46], ["plasma", "ORGANISM_SUBSTANCE", 141, 147], ["convalescent", "ORGANISM", 210, 222], ["plasma", "ORGANISM_SUBSTANCE", 223, 229], ["convalescent plasma", "TREATMENT", 27, 46], ["plasmapheresis", "TREATMENT", 48, 62], ["convalescent plasma", "TREATMENT", 210, 229], ["transfusion", "TREATMENT", 234, 245]]], ["There are some practical and logistical limitations for the implementation of a large-scale convalescent plasma transfusion program such as training of study personnel, recruitment of donors, and transport of plasma to hospitals, as well considerations for plasma shelf-life and half-life of antibodies in the plasma [21, 36] .PLOS PATHOGENSAlthough large-scale randomized clinical trials will ultimately confirm the safety and efficacy of convalescent plasma therapy for COVID-19, a recent safety study by Joyner and colleagues [12] provided encouraging data.", [["plasma", "ANATOMY", 105, 111], ["plasma", "ANATOMY", 209, 215], ["plasma", "ANATOMY", 257, 263], ["plasma", "ANATOMY", 310, 316], ["plasma", "ANATOMY", 453, 459], ["plasma", "ORGANISM_SUBSTANCE", 105, 111], ["donors", "ORGANISM", 184, 190], ["plasma", "ORGANISM_SUBSTANCE", 209, 215], ["plasma", "ORGANISM_SUBSTANCE", 257, 263], ["plasma", "ORGANISM_SUBSTANCE", 310, 316], ["convalescent", "ORGANISM", 440, 452], ["plasma", "ORGANISM_SUBSTANCE", 453, 459], ["antibodies", "PROTEIN", 292, 302], ["a large-scale convalescent plasma transfusion program", "TREATMENT", 78, 131], ["donors", "TREATMENT", 184, 190], ["plasma shelf-life", "TREATMENT", 257, 274], ["convalescent plasma therapy", "TREATMENT", 440, 467], ["COVID", "TEST", 472, 477], ["a recent safety study", "TEST", 482, 503], ["large", "OBSERVATION_MODIFIER", 80, 85], ["large", "OBSERVATION_MODIFIER", 350, 355]]], ["By analyzing key safety metrics following transfusion of convalescent plasma in 5,000 hospitalized adults with severe or life-threatening COVID-19, the incidence of serious adverse events was found to be <1%, and the 7-day mortality incidence was 14.9%.", [["plasma", "ANATOMY", 70, 76], ["COVID", "DISEASE", 138, 143], ["convalescent", "ORGANISM", 57, 69], ["plasma", "ORGANISM_SUBSTANCE", 70, 76], ["convalescent plasma", "TREATMENT", 57, 76], ["serious adverse events", "PROBLEM", 165, 187]]], ["These early indicators are encouraging and highly supportive of the use of convalescent plasma as a rescue therapy in hospitalized patients, given that the reported fatality rate of COVID-19 among patients admitted to the intensive care units (ICUs) is 57% [37] .", [["plasma", "ANATOMY", 88, 94], ["COVID-19", "CHEMICAL", 182, 190], ["convalescent", "ORGANISM", 75, 87], ["plasma", "ORGANISM_SUBSTANCE", 88, 94], ["patients", "ORGANISM", 131, 139], ["patients", "ORGANISM", 197, 205], ["patients", "SPECIES", 131, 139], ["patients", "SPECIES", 197, 205], ["convalescent plasma", "TREATMENT", 75, 94], ["a rescue therapy", "TREATMENT", 98, 114], ["COVID", "TEST", 182, 187]]], ["In fact, the low risk indicated by the study support expanding the use of convalescent plasma therapy in less ill individuals [6] .Future perspectivesThe global reach of the COVID-19 pandemic and the desperate need for effective treatments have provided an impetus to develop convalescent plasma therapy into a viable (albeit shortterm) treatment option particularly for the critically ill.", [["plasma", "ANATOMY", 87, 93], ["plasma", "ANATOMY", 289, 295], ["critically ill", "DISEASE", 375, 389], ["convalescent", "ORGANISM", 74, 86], ["plasma", "ORGANISM_SUBSTANCE", 87, 93], ["convalescent", "ORGANISM", 276, 288], ["plasma", "ORGANISM_SUBSTANCE", 289, 295], ["convalescent plasma therapy", "TREATMENT", 74, 101], ["the COVID", "TEST", 170, 179], ["pandemic", "PROBLEM", 183, 191], ["effective treatments", "TREATMENT", 219, 239], ["convalescent plasma therapy", "TREATMENT", 276, 303], ["a viable (albeit shortterm) treatment option", "TREATMENT", 309, 353], ["global", "OBSERVATION_MODIFIER", 154, 160]]], ["Although its efficacy and safety have not yet been fully proven, convalescent plasma therapy for COVID-19 patients is projected to be a safe and potentially effective therapy for prophylaxis and treatment.", [["plasma", "ANATOMY", 78, 84], ["convalescent", "ORGANISM", 65, 77], ["plasma", "ORGANISM_SUBSTANCE", 78, 84], ["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["convalescent plasma therapy", "TREATMENT", 65, 92], ["COVID", "TEST", 97, 102], ["prophylaxis", "TREATMENT", 179, 190], ["treatment", "TREATMENT", 195, 204]]], ["However, it is critically important to perform rigorous randomized controlled trials to confirm efficacy and safety and to provide evidence for improved meaningful clinical outcomes.", [["rigorous randomized controlled trials", "TREATMENT", 47, 84]]], ["Nevertheless, despite the nuanced challenges, the substantial evidence of benefit with use for prior viral infections offers strong precedent for convalescent plasma as a therapeutic approach.", [["plasma", "ANATOMY", 159, 165], ["viral infections", "DISEASE", 101, 117], ["convalescent", "ORGANISM", 146, 158], ["plasma", "ORGANISM_SUBSTANCE", 159, 165], ["prior viral infections", "PROBLEM", 95, 117], ["convalescent plasma", "TREATMENT", 146, 165], ["a therapeutic approach", "TREATMENT", 169, 191]]], ["Importantly, efforts should be focused not only on evaluation of the feasibility of plasma treatment for infectious diseases but also ensure that use of convalescent plasma therapy takes place according to ethical and controlled conditions.", [["plasma", "ANATOMY", 84, 90], ["plasma", "ANATOMY", 166, 172], ["infectious diseases", "DISEASE", 105, 124], ["plasma", "ORGANISM_SUBSTANCE", 84, 90], ["convalescent", "ORGANISM", 153, 165], ["plasma", "ORGANISM_SUBSTANCE", 166, 172], ["evaluation", "TEST", 51, 61], ["plasma treatment", "TREATMENT", 84, 100], ["infectious diseases", "PROBLEM", 105, 124], ["convalescent plasma therapy", "TREATMENT", 153, 180]]]], "fc4bb9e664fb2c1d99d2060359372eff58a4e13a": [["www.nature.com/scientificreports/ in the NBU on day 18, after Patient 3 had been admitted to the unit for four days.", [["Patient", "SPECIES", 62, 69]]], ["We obtained surface samples, high-volume [50 L/min (Lpm)] air samples, and low-volume (4 Lpm) personal air samples.", [["surface samples", "ANATOMY", 12, 27], ["surface samples", "TEST", 12, 27], ["air samples", "TEST", 58, 69], ["personal air samples", "TEST", 94, 114]]], ["The surface samples came from common room surfaces, personal items, and toilets.", [["surface samples", "ANATOMY", 4, 19], ["The surface samples", "TEST", 0, 19], ["surface", "OBSERVATION_MODIFIER", 4, 11]]], ["Personal air sampling devices were worn by study personnel on two days during sampling of NBU and NQU rooms.", [["Personal air sampling devices", "TREATMENT", 0, 29]]], ["During the sampling, individuals in isolation were recording symptoms and oral temperatures twice a day.", [["oral", "ANATOMY", 74, 78], ["oral", "ORGANISM_SUBDIVISION", 74, 78], ["the sampling", "TEST", 7, 19], ["individuals in isolation", "PROBLEM", 21, 45], ["recording symptoms", "PROBLEM", 51, 69], ["oral temperatures", "TEST", 74, 91]]], ["The maximum temperature, during the three days preceding sampling, was recorded, as was the presence of any symptoms.", [["The maximum temperature", "TEST", 0, 23], ["any symptoms", "PROBLEM", 104, 116], ["maximum", "OBSERVATION_MODIFIER", 4, 11], ["temperature", "OBSERVATION_MODIFIER", 12, 23]]], ["During this time, 57.9% of patients recorded a temperature greater than 37.2 \u00b0C (99.0 \u00b0F), and 15.8% had a temperature greater than 37.8 C (100 \u00b0F).", [["patients", "ORGANISM", 27, 35], ["patients", "SPECIES", 27, 35], ["a temperature", "TEST", 45, 58], ["a temperature", "TEST", 105, 118]]], ["Independent of temperature, 57.9% of patients reported other symptoms, primarily cough.", [["cough", "DISEASE", 81, 86], ["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["temperature", "TEST", 15, 26], ["other symptoms", "PROBLEM", 55, 69], ["primarily cough", "PROBLEM", 71, 86], ["cough", "OBSERVATION", 81, 86]]]], "bdb515e3260ec338047616be3e48f1331c708c74": [["T he N95 or higher-level respirator is an essential element of personal protective equipment to be worn when in contact with patients with known or suspected coronavirus disease 2019 (COVID-19) infection.", [["coronavirus disease", "DISEASE", 158, 177], ["COVID-19", "CHEMICAL", 184, 192], ["infection", "DISEASE", 194, 203], ["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 125, 133], ["T he N95", "TREATMENT", 0, 8], ["higher-level respirator", "TREATMENT", 12, 35], ["personal protective equipment", "TREATMENT", 63, 92], ["suspected coronavirus disease", "PROBLEM", 148, 177], ["COVID", "TEST", 184, 189], ["infection", "PROBLEM", 194, 203], ["infection", "OBSERVATION", 194, 203]]], ["Three varieties are commonly available: preformed/cup, flat fold/ duck bill, and elastomeric.", [["cup", "ANATOMY", 50, 53], ["cup", "TISSUE", 50, 53], ["duck", "ORGANISM", 66, 70], ["duck", "ANATOMY", 66, 70]]], ["1 Wearing an N95 mask invokes a number of physiologic implications, particularly with prolonged use (greater than 1 h), higher workloads, or an overlying surgical mask (table 1).", [["an N95 mask", "TREATMENT", 10, 21], ["an overlying surgical mask", "TREATMENT", 141, 167], ["surgical mask", "OBSERVATION", 154, 167]]], ["2,3 Concomitant surgical mask use augments the impact of a cup mask due to further resistance to airflow, but diminishes the impact of a flat fold mask due to a reduction in deadspace.", [["cup", "ANATOMY", 59, 62], ["cup", "ORGANISM_SUBDIVISION", 59, 62], ["Concomitant surgical mask", "TREATMENT", 4, 29], ["a cup mask", "TREATMENT", 57, 67], ["further resistance to airflow", "PROBLEM", 75, 104], ["a flat fold mask", "TREATMENT", 135, 151], ["a reduction in deadspace", "TREATMENT", 159, 183], ["Concomitant", "OBSERVATION_MODIFIER", 4, 15], ["surgical mask", "OBSERVATION", 16, 29], ["airflow", "OBSERVATION", 97, 104], ["reduction", "OBSERVATION_MODIFIER", 161, 170], ["deadspace", "OBSERVATION", 174, 183]]], ["2 At 2 metabolic equivalents (e.g., walking slowly during rounds), N95 mask use noticeably increases inhaled carbon dioxide, reduces inspired oxygen, and increases the work of breathing.", [["carbon dioxide", "CHEMICAL", 109, 123], ["oxygen", "CHEMICAL", 142, 148], ["carbon dioxide", "CHEMICAL", 109, 123], ["oxygen", "CHEMICAL", 142, 148], ["inhaled carbon dioxide", "SIMPLE_CHEMICAL", 101, 123], ["oxygen", "SIMPLE_CHEMICAL", 142, 148], ["N95 mask", "TREATMENT", 67, 75], ["inhaled carbon dioxide", "TREATMENT", 101, 123], ["inspired oxygen", "TREATMENT", 133, 148], ["carbon dioxide", "OBSERVATION", 109, 123], ["inspired oxygen", "OBSERVATION", 133, 148]]], ["The resulting inhaled carbon dioxide of 2 to 3% (normal, 0.04%) produces transient acidosis and compensatory increases in minute ventilation, work of breathing, and cardiac output.", [["cardiac", "ANATOMY", 165, 172], ["carbon dioxide", "CHEMICAL", 22, 36], ["acidosis", "DISEASE", 83, 91], ["carbon dioxide", "CHEMICAL", 22, 36], ["cardiac", "ORGAN", 165, 172], ["The resulting inhaled carbon dioxide", "TREATMENT", 0, 36], ["transient acidosis", "PROBLEM", 73, 91], ["compensatory increases", "PROBLEM", 96, 118], ["minute ventilation", "TREATMENT", 122, 140], ["work of breathing", "PROBLEM", 142, 159], ["cardiac output", "TEST", 165, 179], ["acidosis", "OBSERVATION", 83, 91], ["compensatory", "OBSERVATION_MODIFIER", 96, 108], ["increases", "OBSERVATION_MODIFIER", 109, 118], ["minute ventilation", "OBSERVATION", 122, 140], ["cardiac", "ANATOMY", 165, 172], ["output", "OBSERVATION", 173, 179]]], ["2 Symptoms include sweating, visual changes, headache, dyspnea, increased irritability, and decreased reasoning, alertness, and exercise endurance.", [["headache", "DISEASE", 45, 53], ["dyspnea", "DISEASE", 55, 62], ["irritability", "DISEASE", 74, 86], ["Symptoms", "PROBLEM", 2, 10], ["sweating", "PROBLEM", 19, 27], ["visual changes", "PROBLEM", 29, 43], ["headache", "PROBLEM", 45, 53], ["dyspnea", "PROBLEM", 55, 62], ["increased irritability", "PROBLEM", 64, 86], ["decreased reasoning", "PROBLEM", 92, 111], ["alertness", "PROBLEM", 113, 122], ["dyspnea", "OBSERVATION", 55, 62], ["increased", "OBSERVATION_MODIFIER", 64, 73], ["irritability", "OBSERVATION", 74, 86], ["decreased", "OBSERVATION_MODIFIER", 92, 101]]], ["3 Independently, the inspired oxygen of 17% (normal, 21%), yields headache, lightheadedness, drowsiness, muscular weakness, dyspnea on exertion, nausea, and vomiting.", [["muscular", "ANATOMY", 105, 113], ["oxygen", "CHEMICAL", 30, 36], ["headache", "DISEASE", 66, 74], ["lightheadedness", "DISEASE", 76, 91], ["muscular weakness", "DISEASE", 105, 122], ["dyspnea", "DISEASE", 124, 131], ["nausea", "DISEASE", 145, 151], ["vomiting", "DISEASE", 157, 165], ["oxygen", "CHEMICAL", 30, 36], ["oxygen", "SIMPLE_CHEMICAL", 30, 36], ["the inspired oxygen", "TEST", 17, 36], ["headache", "PROBLEM", 66, 74], ["lightheadedness", "PROBLEM", 76, 91], ["drowsiness", "PROBLEM", 93, 103], ["muscular weakness", "PROBLEM", 105, 122], ["dyspnea", "PROBLEM", 124, 131], ["nausea", "PROBLEM", 145, 151], ["vomiting", "PROBLEM", 157, 165], ["muscular", "ANATOMY", 105, 113], ["weakness", "OBSERVATION", 114, 122], ["dyspnea", "OBSERVATION", 124, 131], ["nausea", "OBSERVATION", 145, 151]]], ["4 Simultaneously, the augmented resistance to inspiratory (15% of maximum) and expiratory flow, when experienced for greater than 10 min, results in respiratory alkalosis, increased lactate levels, fatigue, and impaired physical work capacity.", [["respiratory", "ANATOMY", 149, 160], ["respiratory alkalosis", "DISEASE", 149, 170], ["lactate", "CHEMICAL", 182, 189], ["fatigue", "DISEASE", 198, 205], ["impaired physical work capacity", "DISEASE", 211, 242], ["lactate", "CHEMICAL", 182, 189], ["lactate", "SIMPLE_CHEMICAL", 182, 189], ["inspiratory", "TEST", 46, 57], ["expiratory flow", "TEST", 79, 94], ["respiratory alkalosis", "PROBLEM", 149, 170], ["increased lactate levels", "PROBLEM", 172, 196], ["fatigue", "PROBLEM", 198, 205], ["impaired physical work capacity", "PROBLEM", 211, 242], ["augmented resistance", "OBSERVATION", 22, 42], ["expiratory flow", "OBSERVATION", 79, 94], ["respiratory alkalosis", "OBSERVATION", 149, 170], ["increased", "OBSERVATION_MODIFIER", 172, 181], ["lactate levels", "OBSERVATION", 182, 196]]], ["5 However, a number of exercise benefits can be achieved with surprisingly low effort while wearing an N95 mask.", [["an N95 mask", "TREATMENT", 100, 111]]], ["At 2 metabolic equivalents, the inspiratory resistance load of 6 to 7 cm H 2 O (4.5 to 5 mmHg; normal, 1.3 mmHg [men] to 1.6 mmHg [women]) of an N95 mask creates a \"respiratory pump\" that decreases intrathoracic, central venous, and intracranial pressures, 6 and increases preload, cardiac output, and mean arterial pressure, particularly during hypotensive states.", [["respiratory", "ANATOMY", 165, 176], ["intrathoracic", "ANATOMY", 198, 211], ["central venous", "ANATOMY", 213, 227], ["intracranial", "ANATOMY", 233, 245], ["cardiac", "ANATOMY", 282, 289], ["arterial", "ANATOMY", 307, 315], ["hypotensive", "DISEASE", 346, 357], ["women", "ORGANISM", 131, 136], ["venous", "MULTI-TISSUE_STRUCTURE", 221, 227], ["cardiac", "ORGAN", 282, 289], ["arterial", "MULTI-TISSUE_STRUCTURE", 307, 315], ["men", "SPECIES", 113, 116], ["women", "SPECIES", 131, 136], ["the inspiratory resistance load", "TEST", 28, 59], ["an N95 mask", "TREATMENT", 142, 153], ["a \"respiratory pump", "PROBLEM", 162, 181], ["intracranial pressures", "TEST", 233, 255], ["preload", "TEST", 273, 280], ["cardiac output", "TEST", 282, 296], ["mean arterial pressure", "TEST", 302, 324], ["hypotensive states", "PROBLEM", 346, 364], ["inspiratory resistance", "OBSERVATION", 32, 54], ["N95 mask", "OBSERVATION", 145, 153], ["respiratory pump", "OBSERVATION", 165, 181], ["central", "ANATOMY_MODIFIER", 213, 220], ["venous", "ANATOMY", 221, 227], ["intracranial", "ANATOMY_MODIFIER", 233, 245], ["pressures", "OBSERVATION_MODIFIER", 246, 255], ["output", "OBSERVATION_MODIFIER", 290, 296], ["mean arterial pressure", "OBSERVATION", 302, 324]]], ["7 At 4 metabolic equivalents, consciously taking 30 dynamic (fast in) inspiratory efforts twice daily for 4 weeks increases respiratory muscle strength.", [["respiratory muscle", "ANATOMY", 124, 142], ["muscle", "ORGAN", 136, 142], ["respiratory muscle strength", "PROBLEM", 124, 151], ["respiratory muscle", "ANATOMY", 124, 142]]], ["Maintaining 4 metabolic equivalents of activity for 10 to 30 min, 3 to 5 days/ week for 4 weeks improves respiratory muscle endurance.", [["respiratory muscle", "ANATOMY", 105, 123], ["muscle", "ORGAN", 117, 123], ["respiratory muscle endurance", "PROBLEM", 105, 133], ["4", "OBSERVATION_MODIFIER", 12, 13], ["metabolic equivalents", "OBSERVATION", 14, 35], ["respiratory muscle", "ANATOMY", 105, 123]]], ["Such conditioning of respiratory muscle strength and respiratory muscle endurance improves ventilatory efficiency (e.g., ventilation-perfusion and alveolar capillary exchange), oxygen delivery/lactate removal at locomotor muscles, and overall exercise performance.", [["respiratory muscle", "ANATOMY", 21, 39], ["respiratory muscle", "ANATOMY", 53, 71], ["alveolar capillary", "ANATOMY", 147, 165], ["locomotor muscles", "ANATOMY", 212, 229], ["oxygen", "CHEMICAL", 177, 183], ["lactate", "CHEMICAL", 193, 200], ["oxygen", "CHEMICAL", 177, 183], ["lactate", "CHEMICAL", 193, 200], ["muscle", "ORGAN", 33, 39], ["muscle", "ORGAN", 65, 71], ["alveolar capillary", "TISSUE", 147, 165], ["oxygen", "SIMPLE_CHEMICAL", 177, 183], ["lactate", "SIMPLE_CHEMICAL", 193, 200], ["muscles", "ORGANISM_SUBDIVISION", 222, 229], ["respiratory muscle strength", "PROBLEM", 21, 48], ["respiratory muscle endurance", "PROBLEM", 53, 81], ["ventilatory efficiency", "PROBLEM", 91, 113], ["ventilation", "TEST", 121, 132], ["alveolar capillary exchange", "TREATMENT", 147, 174], ["oxygen delivery", "TREATMENT", 177, 192], ["lactate removal", "TREATMENT", 193, 208], ["respiratory muscle", "ANATOMY", 21, 39], ["respiratory muscle", "ANATOMY", 53, 71], ["ventilatory efficiency", "OBSERVATION", 91, 113], ["alveolar capillary", "ANATOMY", 147, 165], ["muscles", "ANATOMY", 222, 229]]]], "9dc7ed399b155b98925b970b95f4af237de0aa06": [["IntroductionHyponatremia is defined as a low sodium concentration in blood serum.", [["blood serum", "ANATOMY", 69, 80], ["Hyponatremia", "DISEASE", 12, 24], ["sodium", "CHEMICAL", 45, 51], ["sodium", "CHEMICAL", 45, 51], ["sodium", "SIMPLE_CHEMICAL", 45, 51], ["blood", "ORGANISM_SUBSTANCE", 69, 74], ["serum", "ORGANISM_SUBSTANCE", 75, 80], ["Hyponatremia", "PROBLEM", 12, 24], ["a low sodium concentration", "PROBLEM", 39, 65], ["blood serum", "TEST", 69, 80], ["Hyponatremia", "OBSERVATION", 12, 24]]], ["The sodium concentration below the lower reference limit of 135 mmol/L is diagnostic for this disorder.", [["sodium", "CHEMICAL", 4, 10], ["sodium", "CHEMICAL", 4, 10], ["sodium", "SIMPLE_CHEMICAL", 4, 10], ["The sodium concentration", "TEST", 0, 24], ["this disorder", "PROBLEM", 89, 102]]], ["Hyponatremia is one of the most commonly known water-electrolyte imbalances in the human organism.", [["Hyponatremia", "DISEASE", 0, 12], ["human", "ORGANISM", 83, 88], ["human", "SPECIES", 83, 88], ["human", "SPECIES", 83, 88], ["Hyponatremia", "PROBLEM", 0, 12], ["electrolyte imbalances in the human organism", "PROBLEM", 53, 97], ["one of the most commonly", "OBSERVATION_MODIFIER", 16, 40], ["electrolyte imbalances", "OBSERVATION", 53, 75]]], ["Its prevalence reaches 15-30% among hospitalized patients, which is even higher in the intensive care units (ICU), where it reaches up to 40% [1, 2] .", [["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["higher", "OBSERVATION_MODIFIER", 73, 79]]], ["The incidence of hyponatremia in the general population is estimated at about 1.74%, according to National Health and Nutrition Examination Survey [3] .", [["hyponatremia", "DISEASE", 17, 29], ["hyponatremia", "PROBLEM", 17, 29], ["Nutrition Examination", "TEST", 118, 139], ["hyponatremia", "OBSERVATION", 17, 29]]], ["It is worth mentioning that in both in-patient and out-patient settings, hyponatremia is an acknowledged mortality predictor, although its causes are different in these populations [4] .", [["hyponatremia", "DISEASE", 73, 85], ["patient", "ORGANISM", 39, 46], ["patient", "ORGANISM", 55, 62], ["patient", "SPECIES", 39, 46], ["patient", "SPECIES", 55, 62], ["hyponatremia", "PROBLEM", 73, 85], ["hyponatremia", "OBSERVATION", 73, 85]]], ["Furthermore, hyponatremia prevalence was shown to be positively associated with comorbidity, expressed as Charlston Comorbidity Index, and was more profound among the most moribund patients [5] .", [["hyponatremia", "DISEASE", 13, 25], ["patients", "ORGANISM", 181, 189], ["patients", "SPECIES", 181, 189], ["hyponatremia prevalence", "PROBLEM", 13, 36], ["comorbidity", "PROBLEM", 80, 91], ["hyponatremia", "OBSERVATION", 13, 25]]], ["Winzler et al. also emphasize that 1-year mortality among patients admitted to hospital due to severe hyponatremia (<125 mmol/L) reached 20% in their study, which underlines the gravity of this pathology and the need for adequate causal treatment.", [["hyponatremia", "DISEASE", 102, 114], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["severe hyponatremia", "PROBLEM", 95, 114], ["their study", "TEST", 144, 155], ["this pathology", "TEST", 189, 203], ["adequate causal treatment", "TREATMENT", 221, 246], ["severe", "OBSERVATION_MODIFIER", 95, 101], ["hyponatremia", "OBSERVATION", 102, 114]]], ["A recently performed meta-analysis has confirmed that the improvement of hyponatremia is independently associated with the reduction of all-cause-mortality risk [4] .IntroductionHyponatremia may occur as a result of numerous disorders [6] .", [["hyponatremia", "DISEASE", 73, 85], ["Hyponatremia", "DISEASE", 178, 190], ["hyponatremia", "PROBLEM", 73, 85], ["Hyponatremia", "PROBLEM", 178, 190], ["numerous disorders", "PROBLEM", 216, 234], ["hyponatremia", "OBSERVATION", 73, 85]]], ["These include common infectious diseases as well as endocrine, nutritional, metabolic, cardiovascular, renal or hepatic pathologies.", [["endocrine", "ANATOMY", 52, 61], ["cardiovascular", "ANATOMY", 87, 101], ["renal", "ANATOMY", 103, 108], ["hepatic", "ANATOMY", 112, 119], ["infectious diseases", "DISEASE", 21, 40], ["endocrine, nutritional, metabolic, cardiovascular, renal or hepatic pathologies", "DISEASE", 52, 131], ["renal", "MULTI-TISSUE_STRUCTURE", 103, 108], ["hepatic", "ORGAN", 112, 119], ["common infectious diseases", "PROBLEM", 14, 40], ["nutritional, metabolic, cardiovascular, renal or hepatic pathologies", "PROBLEM", 63, 131], ["common", "OBSERVATION_MODIFIER", 14, 20], ["infectious", "OBSERVATION", 21, 31], ["cardiovascular", "ANATOMY", 87, 101], ["renal", "ANATOMY", 103, 108], ["hepatic", "ANATOMY", 112, 119], ["pathologies", "OBSERVATION", 120, 131]]], ["It is worth mentioning that hospital-associated hyponatremia includes admission hyponatremia and hospital-acquired hyponatremia, which may be associated with different outcomes [7] .IntroductionPatients presenting with hyponatremia may often be asymptomatic, which applies especially to elderly patients or patients with mild hyponatremia.", [["hyponatremia", "DISEASE", 48, 60], ["hyponatremia", "DISEASE", 80, 92], ["hyponatremia", "DISEASE", 115, 127], ["hyponatremia", "DISEASE", 219, 231], ["hyponatremia", "DISEASE", 326, 338], ["Patients", "ORGANISM", 194, 202], ["patients", "ORGANISM", 295, 303], ["patients", "ORGANISM", 307, 315], ["Patients", "SPECIES", 194, 202], ["patients", "SPECIES", 295, 303], ["patients", "SPECIES", 307, 315], ["hyponatremia", "PROBLEM", 48, 60], ["admission hyponatremia", "PROBLEM", 70, 92], ["acquired hyponatremia", "PROBLEM", 106, 127], ["hyponatremia", "PROBLEM", 219, 231], ["asymptomatic", "PROBLEM", 245, 257], ["mild hyponatremia", "PROBLEM", 321, 338], ["hyponatremia", "OBSERVATION", 48, 60], ["hyponatremia", "OBSERVATION", 80, 92], ["hyponatremia", "OBSERVATION", 115, 127], ["mild", "OBSERVATION_MODIFIER", 321, 325], ["hyponatremia", "OBSERVATION", 326, 338]]], ["On the contrary, most moderate to severe, as well as acute cases of hyponatremia present a broad spectrum of symptoms as nausea, confusion, headache, vomiting, which in severe cases may progress to delirium, impaired consciousness, and seizures [8] .", [["hyponatremia", "DISEASE", 68, 80], ["nausea", "DISEASE", 121, 127], ["confusion", "DISEASE", 129, 138], ["headache", "DISEASE", 140, 148], ["vomiting", "DISEASE", 150, 158], ["delirium", "DISEASE", 198, 206], ["impaired consciousness", "DISEASE", 208, 230], ["seizures", "DISEASE", 236, 244], ["hyponatremia", "PROBLEM", 68, 80], ["symptoms", "PROBLEM", 109, 117], ["nausea", "PROBLEM", 121, 127], ["confusion", "PROBLEM", 129, 138], ["headache", "PROBLEM", 140, 148], ["vomiting", "PROBLEM", 150, 158], ["delirium", "PROBLEM", 198, 206], ["impaired consciousness", "PROBLEM", 208, 230], ["seizures", "PROBLEM", 236, 244], ["most moderate", "OBSERVATION_MODIFIER", 17, 30], ["severe", "OBSERVATION_MODIFIER", 34, 40], ["acute", "OBSERVATION_MODIFIER", 53, 58], ["hyponatremia", "OBSERVATION", 68, 80]]], ["Due to its non-specific presentation, many healthcare professionals are not aware of the association of hyponatremia and ongoing inflammation [9] .IntroductionThe primary purpose of this review was to perform a meta-analysis, which would elucidate the impact of hyponatremia on the prognosis, mortality, and outcomes among in-patients with an acute infective process.", [["hyponatremia", "DISEASE", 104, 116], ["inflammation", "DISEASE", 129, 141], ["hyponatremia", "DISEASE", 262, 274], ["patients", "ORGANISM", 326, 334], ["patients", "SPECIES", 326, 334], ["hyponatremia", "PROBLEM", 104, 116], ["ongoing inflammation", "PROBLEM", 121, 141], ["a meta-analysis", "TEST", 209, 224], ["hyponatremia", "PROBLEM", 262, 274], ["an acute infective process", "PROBLEM", 340, 366], ["non-specific", "OBSERVATION_MODIFIER", 11, 23], ["hyponatremia", "OBSERVATION", 104, 116], ["inflammation", "OBSERVATION", 129, 141], ["hyponatremia", "OBSERVATION", 262, 274], ["acute", "OBSERVATION_MODIFIER", 343, 348], ["infective", "OBSERVATION", 349, 358]]], ["Although the paper does not strictly meet the definition of a systemic review, we have decided to still adhere to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) model as to ensure the highest quality of the selected material and scientific content.Pathogenesis of HyponatremiaSodium and potassium are the main osmotically active inorganic substances and their plasma concentrations are maintained within a narrow range [6, 10] .", [["plasma", "ANATOMY", 393, 399], ["HyponatremiaSodium", "CHEMICAL", 297, 315], ["potassium", "CHEMICAL", 320, 329], ["HyponatremiaSodium", "CHEMICAL", 297, 315], ["potassium", "CHEMICAL", 320, 329], ["HyponatremiaSodium", "SIMPLE_CHEMICAL", 297, 315], ["potassium", "SIMPLE_CHEMICAL", 320, 329], ["inorganic substances", "SIMPLE_CHEMICAL", 362, 382], ["plasma", "ORGANISM_SUBSTANCE", 393, 399], ["Systematic Reviews", "TEST", 156, 174], ["Meta-Analyses", "TEST", 179, 192], ["HyponatremiaSodium", "PROBLEM", 297, 315], ["potassium", "TREATMENT", 320, 329], ["their plasma concentrations", "TEST", 387, 414], ["main", "OBSERVATION_MODIFIER", 338, 342], ["osmotically", "OBSERVATION_MODIFIER", 343, 354], ["active", "OBSERVATION_MODIFIER", 355, 361], ["inorganic substances", "OBSERVATION", 362, 382]]], ["The water transfers between intra and extracellular compartments are driven by an osmotic pressure gradient exerted by osmotically active solutes, including sodium.", [["extracellular compartments", "ANATOMY", 38, 64], ["sodium", "CHEMICAL", 157, 163], ["sodium", "CHEMICAL", 157, 163], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 38, 51], ["sodium", "SIMPLE_CHEMICAL", 157, 163], ["The water transfers between intra and extracellular compartments", "TREATMENT", 0, 64], ["an osmotic pressure gradient", "TREATMENT", 79, 107], ["osmotically active solutes", "PROBLEM", 119, 145], ["sodium", "TEST", 157, 163], ["osmotic pressure", "OBSERVATION", 82, 98], ["active solutes", "OBSERVATION", 131, 145]]], ["The amount of active osmolytes in serum is expressed by tonicity, which is a substantial parameter utilized for distinguishing between hyponatremia causes.", [["serum", "ANATOMY", 34, 39], ["hyponatremia", "DISEASE", 135, 147], ["osmolytes", "SIMPLE_CHEMICAL", 21, 30], ["serum", "ORGANISM_SUBSTANCE", 34, 39], ["active osmolytes in serum", "PROBLEM", 14, 39], ["hyponatremia", "PROBLEM", 135, 147], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["active", "OBSERVATION_MODIFIER", 14, 20], ["osmolytes", "OBSERVATION", 21, 30], ["hyponatremia", "OBSERVATION", 135, 147]]], ["Thus, for diagnostic purposes hyponatremia can be divided into hypotonic and non-hypotonic hyponatremia, as presented on Figure 1 [1, 6] .Pathogenesis of Hyponatremiaanalysis has confirmed that the improvement of hyponatremia is independently associated with the reduction of all-cause-mortality risk [4] .Pathogenesis of HyponatremiaHyponatremia may occur as a result of numerous disorders [6] .", [["hyponatremia", "DISEASE", 30, 42], ["hyponatremia", "DISEASE", 91, 103], ["Hyponatremiaanalysis", "CHEMICAL", 154, 174], ["hyponatremia", "DISEASE", 213, 225], ["HyponatremiaHyponatremia", "DISEASE", 322, 346], ["hyponatremia", "PROBLEM", 30, 42], ["hypotonic and non-hypotonic hyponatremia", "PROBLEM", 63, 103], ["hyponatremia", "PROBLEM", 213, 225], ["HyponatremiaHyponatremia", "PROBLEM", 322, 346], ["numerous disorders", "PROBLEM", 372, 390], ["hyponatremia", "OBSERVATION", 91, 103], ["improvement", "OBSERVATION_MODIFIER", 198, 209], ["hyponatremia", "OBSERVATION", 213, 225], ["HyponatremiaHyponatremia", "OBSERVATION", 322, 346]]], ["These include common infectious diseases as well as endocrine, nutritional, metabolic, cardiovascular, renal or hepatic pathologies.", [["endocrine", "ANATOMY", 52, 61], ["cardiovascular", "ANATOMY", 87, 101], ["renal", "ANATOMY", 103, 108], ["hepatic", "ANATOMY", 112, 119], ["infectious diseases", "DISEASE", 21, 40], ["endocrine, nutritional, metabolic, cardiovascular, renal or hepatic pathologies", "DISEASE", 52, 131], ["renal", "MULTI-TISSUE_STRUCTURE", 103, 108], ["hepatic", "ORGAN", 112, 119], ["common infectious diseases", "PROBLEM", 14, 40], ["nutritional, metabolic, cardiovascular, renal or hepatic pathologies", "PROBLEM", 63, 131], ["common", "OBSERVATION_MODIFIER", 14, 20], ["infectious", "OBSERVATION", 21, 31], ["cardiovascular", "ANATOMY", 87, 101], ["renal", "ANATOMY", 103, 108], ["hepatic", "ANATOMY", 112, 119], ["pathologies", "OBSERVATION", 120, 131]]], ["It is worth mentioning that hospital-associated hyponatremia includes admission hyponatremia and hospital-acquired hyponatremia, which may be associated with different outcomes [7] .Pathogenesis of HyponatremiaPatients presenting with hyponatremia may often be asymptomatic, which applies especially to elderly patients or patients with mild hyponatremia.", [["hyponatremia", "DISEASE", 48, 60], ["hyponatremia", "DISEASE", 80, 92], ["hyponatremia", "DISEASE", 115, 127], ["HyponatremiaPatients", "DISEASE", 198, 218], ["hyponatremia", "DISEASE", 235, 247], ["hyponatremia", "DISEASE", 342, 354], ["patients", "ORGANISM", 311, 319], ["patients", "ORGANISM", 323, 331], ["patients", "SPECIES", 311, 319], ["patients", "SPECIES", 323, 331], ["hyponatremia", "PROBLEM", 48, 60], ["admission hyponatremia", "PROBLEM", 70, 92], ["acquired hyponatremia", "PROBLEM", 106, 127], ["HyponatremiaPatients", "PROBLEM", 198, 218], ["hyponatremia", "PROBLEM", 235, 247], ["asymptomatic", "PROBLEM", 261, 273], ["mild hyponatremia", "PROBLEM", 337, 354], ["hyponatremia", "OBSERVATION", 48, 60], ["hyponatremia", "OBSERVATION", 80, 92], ["hyponatremia", "OBSERVATION", 115, 127], ["mild", "OBSERVATION_MODIFIER", 337, 341], ["hyponatremia", "OBSERVATION", 342, 354]]], ["On the contrary, most moderate to severe, as well as acute cases of hyponatremia present a broad spectrum of symptoms as nausea, confusion, headache, vomiting, which in severe cases may progress to delirium, impaired consciousness, and seizures [8] .", [["hyponatremia", "DISEASE", 68, 80], ["nausea", "DISEASE", 121, 127], ["confusion", "DISEASE", 129, 138], ["headache", "DISEASE", 140, 148], ["vomiting", "DISEASE", 150, 158], ["delirium", "DISEASE", 198, 206], ["impaired consciousness", "DISEASE", 208, 230], ["seizures", "DISEASE", 236, 244], ["hyponatremia", "PROBLEM", 68, 80], ["symptoms", "PROBLEM", 109, 117], ["nausea", "PROBLEM", 121, 127], ["confusion", "PROBLEM", 129, 138], ["headache", "PROBLEM", 140, 148], ["vomiting", "PROBLEM", 150, 158], ["delirium", "PROBLEM", 198, 206], ["impaired consciousness", "PROBLEM", 208, 230], ["seizures", "PROBLEM", 236, 244], ["most moderate", "OBSERVATION_MODIFIER", 17, 30], ["severe", "OBSERVATION_MODIFIER", 34, 40], ["acute", "OBSERVATION_MODIFIER", 53, 58], ["hyponatremia", "OBSERVATION", 68, 80]]], ["Due to its non-specific presentation, many healthcare professionals are not aware of the association of hyponatremia and ongoing inflammation [9] .Pathogenesis of HyponatremiaThe primary purpose of this review was to perform a meta-analysis, which would elucidate the impact of hyponatremia on the prognosis, mortality, and outcomes among in-patients with an acute infective process.", [["hyponatremia", "DISEASE", 104, 116], ["inflammation", "DISEASE", 129, 141], ["Hyponatremia", "DISEASE", 163, 175], ["hyponatremia", "DISEASE", 278, 290], ["patients", "ORGANISM", 342, 350], ["patients", "SPECIES", 342, 350], ["hyponatremia", "PROBLEM", 104, 116], ["ongoing inflammation", "PROBLEM", 121, 141], ["Hyponatremia", "PROBLEM", 163, 175], ["a meta-analysis", "TEST", 225, 240], ["hyponatremia", "PROBLEM", 278, 290], ["an acute infective process", "PROBLEM", 356, 382], ["non-specific", "OBSERVATION_MODIFIER", 11, 23], ["hyponatremia", "OBSERVATION", 104, 116], ["inflammation", "OBSERVATION", 129, 141], ["Hyponatremia", "OBSERVATION", 163, 175], ["hyponatremia", "OBSERVATION", 278, 290], ["acute", "OBSERVATION_MODIFIER", 359, 364], ["infective", "OBSERVATION", 365, 374]]], ["Although the paper does not strictly meet the definition of a systemic review, we have decided to still adhere to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) model as to ensure the highest quality of the selected material and scientific content.Pathogenesis of HyponatremiaSodium and potassium are the main osmotically active inorganic substances and their plasma concentrations are maintained within a narrow range [6, 10] .", [["plasma", "ANATOMY", 393, 399], ["HyponatremiaSodium", "CHEMICAL", 297, 315], ["potassium", "CHEMICAL", 320, 329], ["HyponatremiaSodium", "CHEMICAL", 297, 315], ["potassium", "CHEMICAL", 320, 329], ["HyponatremiaSodium", "SIMPLE_CHEMICAL", 297, 315], ["potassium", "SIMPLE_CHEMICAL", 320, 329], ["inorganic substances", "SIMPLE_CHEMICAL", 362, 382], ["plasma", "ORGANISM_SUBSTANCE", 393, 399], ["Systematic Reviews", "TEST", 156, 174], ["Meta-Analyses", "TEST", 179, 192], ["HyponatremiaSodium", "PROBLEM", 297, 315], ["potassium", "TREATMENT", 320, 329], ["their plasma concentrations", "TEST", 387, 414], ["main", "OBSERVATION_MODIFIER", 338, 342], ["osmotically", "OBSERVATION_MODIFIER", 343, 354], ["active", "OBSERVATION_MODIFIER", 355, 361], ["inorganic substances", "OBSERVATION", 362, 382]]], ["The water transfers between intra and extracellular compartments are driven by an osmotic pressure gradient exerted by osmotically active solutes, including sodium.", [["extracellular compartments", "ANATOMY", 38, 64], ["sodium", "CHEMICAL", 157, 163], ["sodium", "CHEMICAL", 157, 163], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 38, 51], ["sodium", "SIMPLE_CHEMICAL", 157, 163], ["The water transfers between intra and extracellular compartments", "TREATMENT", 0, 64], ["an osmotic pressure gradient", "TREATMENT", 79, 107], ["osmotically active solutes", "PROBLEM", 119, 145], ["sodium", "TEST", 157, 163], ["osmotic pressure", "OBSERVATION", 82, 98], ["active solutes", "OBSERVATION", 131, 145]]], ["The amount of active osmolytes in serum is expressed by tonicity, which is a substantial parameter utilized for distinguishing between hyponatremia causes.", [["serum", "ANATOMY", 34, 39], ["hyponatremia", "DISEASE", 135, 147], ["osmolytes", "SIMPLE_CHEMICAL", 21, 30], ["serum", "ORGANISM_SUBSTANCE", 34, 39], ["active osmolytes in serum", "PROBLEM", 14, 39], ["hyponatremia", "PROBLEM", 135, 147], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["active", "OBSERVATION_MODIFIER", 14, 20], ["osmolytes", "OBSERVATION", 21, 30], ["hyponatremia", "OBSERVATION", 135, 147]]], ["Thus, for diagnostic purposes hyponatremia can be divided into hypotonic and non-hypotonic hyponatremia, as presented on Figure 1 [1, 6] .Hypotonic HyponatremiaHypotonic hyponatremia is associated with serum osmolality values of less than 275 mOsm/kg [1] .", [["serum", "ANATOMY", 202, 207], ["hyponatremia", "DISEASE", 30, 42], ["hyponatremia", "DISEASE", 91, 103], ["hyponatremia", "DISEASE", 170, 182], ["serum", "ORGANISM_SUBSTANCE", 202, 207], ["hyponatremia", "PROBLEM", 30, 42], ["hypotonic and non-hypotonic hyponatremia", "PROBLEM", 63, 103], ["Hypotonic HyponatremiaHypotonic hyponatremia", "PROBLEM", 138, 182], ["serum osmolality values", "TEST", 202, 225], ["hyponatremia", "OBSERVATION", 91, 103], ["hyponatremia", "OBSERVATION", 170, 182]]], ["It can be classified into the following three groups: hypovolemic, euvolemic, or hypervolemic hypotonic hyponatremia.", [["hypovolemic", "DISEASE", 54, 65], ["euvolemic", "DISEASE", 67, 76], ["hyponatremia", "DISEASE", 104, 116], ["hypovolemic", "PROBLEM", 54, 65], ["euvolemic", "PROBLEM", 67, 76], ["hypervolemic hypotonic hyponatremia", "PROBLEM", 81, 116], ["hypovolemic", "OBSERVATION", 54, 65], ["euvolemic", "OBSERVATION", 67, 76], ["hypervolemic", "OBSERVATION_MODIFIER", 81, 93], ["hypotonic hyponatremia", "OBSERVATION", 94, 116]]], ["The diagnosis is made depending on extracellular volume status.", [["extracellular", "ANATOMY", 35, 48], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 35, 48]]], ["The most commonly utilized tools for volemic estimation are clinical assessment, inferior vena cava or central venous pressure measurement, as well as a lung ultrasound [11] .", [["inferior vena cava", "ANATOMY", 81, 99], ["venous", "ANATOMY", 111, 117], ["lung", "ANATOMY", 153, 157], ["vena cava", "MULTI-TISSUE_STRUCTURE", 90, 99], ["central venous", "MULTI-TISSUE_STRUCTURE", 103, 117], ["lung", "ORGAN", 153, 157], ["volemic estimation", "TEST", 37, 55], ["clinical assessment", "TEST", 60, 79], ["inferior vena cava", "TREATMENT", 81, 99], ["central venous pressure measurement", "TEST", 103, 138], ["a lung ultrasound", "TEST", 151, 168], ["inferior vena cava", "ANATOMY", 81, 99], ["central", "ANATOMY_MODIFIER", 103, 110], ["venous", "ANATOMY", 111, 117], ["pressure", "OBSERVATION", 118, 126], ["lung", "ANATOMY", 153, 157]]], ["Each of these methods has certain limitations and should be used supplementary to each other to ensure proper volemia assessment [6] .Hypotonic Hypovolemic HyponatremiaThis type of hyponatremia is characterized by extracellular fluid volume depletion secondary to a deficit of both total body sodium and water.", [["extracellular fluid", "ANATOMY", 214, 233], ["body", "ANATOMY", 288, 292], ["hyponatremia", "DISEASE", 181, 193], ["sodium", "CHEMICAL", 293, 299], ["sodium", "CHEMICAL", 293, 299], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 214, 227], ["fluid", "ORGANISM_SUBSTANCE", 228, 233], ["body", "ORGANISM_SUBDIVISION", 288, 292], ["sodium", "SIMPLE_CHEMICAL", 293, 299], ["water", "SIMPLE_CHEMICAL", 304, 309], ["proper volemia assessment", "TEST", 103, 128], ["Hypotonic Hypovolemic", "PROBLEM", 134, 155], ["hyponatremia", "PROBLEM", 181, 193], ["extracellular fluid volume depletion", "PROBLEM", 214, 250], ["a deficit", "PROBLEM", 264, 273], ["total body sodium", "TREATMENT", 282, 299], ["Hypovolemic HyponatremiaThis", "OBSERVATION", 144, 172], ["hyponatremia", "OBSERVATION", 181, 193], ["extracellular", "OBSERVATION_MODIFIER", 214, 227], ["fluid volume depletion", "OBSERVATION", 228, 250], ["deficit", "OBSERVATION", 266, 273]]], ["Baroregulated secretion of vasopressin in response to hypovolemia and inappropriate oral or parenteral hypotonic fluid intake leads to water retention, causing hyponatremia [12] .", [["oral", "ANATOMY", 84, 88], ["parenteral", "ANATOMY", 92, 102], ["vasopressin", "CHEMICAL", 27, 38], ["hypovolemia", "DISEASE", 54, 65], ["hyponatremia", "DISEASE", 160, 172], ["vasopressin", "CHEMICAL", 27, 38], ["vasopressin", "GENE_OR_GENE_PRODUCT", 27, 38], ["oral", "ORGANISM_SUBDIVISION", 84, 88], ["water", "SIMPLE_CHEMICAL", 135, 140], ["vasopressin", "TREATMENT", 27, 38], ["hypovolemia", "PROBLEM", 54, 65], ["inappropriate oral or parenteral hypotonic fluid intake", "TREATMENT", 70, 125], ["water retention", "PROBLEM", 135, 150], ["hyponatremia", "PROBLEM", 160, 172], ["hypovolemia", "OBSERVATION", 54, 65], ["hyponatremia", "OBSERVATION", 160, 172]]], ["Solute loss can be classified as renal, due to salt-wasting nephropathy or mineralocorticoid deficiency, and non-renal causes.", [["renal", "ANATOMY", 33, 38], ["non-renal", "ANATOMY", 109, 118], ["Solute loss", "DISEASE", 0, 11], ["nephropathy", "DISEASE", 60, 71], ["mineralocorticoid deficiency", "DISEASE", 75, 103], ["renal", "ORGAN", 33, 38], ["mineralocorticoid", "SIMPLE_CHEMICAL", 75, 92], ["Solute loss", "PROBLEM", 0, 11], ["salt-wasting nephropathy", "PROBLEM", 47, 71], ["mineralocorticoid deficiency", "PROBLEM", 75, 103], ["non-renal causes", "PROBLEM", 109, 125], ["renal", "ANATOMY", 33, 38], ["wasting", "OBSERVATION_MODIFIER", 52, 59], ["nephropathy", "OBSERVATION", 60, 71], ["mineralocorticoid deficiency", "OBSERVATION", 75, 103], ["non-renal", "ANATOMY", 109, 118]]], ["Exemplary causes of non-renal hypovolemic hyponatremia include skin losses as a consequence of burns or perspiration and gastrointestinal losses such as diarrhea or vomiting, which are often associated with infections [1, 6] .", [["non-renal", "ANATOMY", 20, 29], ["skin", "ANATOMY", 63, 67], ["gastrointestinal", "ANATOMY", 121, 137], ["hyponatremia", "DISEASE", 42, 54], ["skin losses", "DISEASE", 63, 74], ["burns", "DISEASE", 95, 100], ["perspiration", "DISEASE", 104, 116], ["gastrointestinal losses", "DISEASE", 121, 144], ["diarrhea", "DISEASE", 153, 161], ["vomiting", "DISEASE", 165, 173], ["infections", "DISEASE", 207, 217], ["skin", "ORGAN", 63, 67], ["gastrointestinal", "ORGANISM_SUBDIVISION", 121, 137], ["non-renal hypovolemic hyponatremia", "PROBLEM", 20, 54], ["skin losses", "PROBLEM", 63, 74], ["burns", "PROBLEM", 95, 100], ["perspiration", "PROBLEM", 104, 116], ["gastrointestinal losses", "PROBLEM", 121, 144], ["diarrhea", "PROBLEM", 153, 161], ["vomiting", "PROBLEM", 165, 173], ["infections", "PROBLEM", 207, 217], ["non-renal", "OBSERVATION_MODIFIER", 20, 29], ["hypovolemic", "OBSERVATION_MODIFIER", 30, 41], ["hyponatremia", "OBSERVATION", 42, 54], ["skin", "ANATOMY", 63, 67], ["losses", "OBSERVATION", 68, 74], ["burns", "OBSERVATION", 95, 100], ["perspiration", "OBSERVATION", 104, 116], ["gastrointestinal", "ANATOMY", 121, 137], ["losses", "OBSERVATION", 138, 144]]], ["Cerebral salt wasting syndrome (CSWS) is also a cause of hypovolemic hyponatremia.", [["Cerebral", "ANATOMY", 0, 8], ["Cerebral salt wasting syndrome", "DISEASE", 0, 30], ["CSWS", "DISEASE", 32, 36], ["hypovolemic hyponatremia", "DISEASE", 57, 81], ["Cerebral salt wasting syndrome", "PROBLEM", 0, 30], ["hypovolemic hyponatremia", "PROBLEM", 57, 81], ["salt", "OBSERVATION", 9, 13], ["wasting syndrome", "OBSERVATION", 14, 30], ["hypovolemic", "OBSERVATION_MODIFIER", 57, 68], ["hyponatremia", "OBSERVATION", 69, 81]]], ["CSWS is sporadically observed in patients with intracranial pathologies.", [["intracranial", "ANATOMY", 47, 59], ["CSWS", "DISEASE", 0, 4], ["intracranial pathologies", "DISEASE", 47, 71], ["patients", "ORGANISM", 33, 41], ["intracranial pathologies", "PATHOLOGICAL_FORMATION", 47, 71], ["patients", "SPECIES", 33, 41], ["intracranial pathologies", "PROBLEM", 47, 71], ["intracranial", "ANATOMY", 47, 59], ["pathologies", "OBSERVATION", 60, 71]]], ["A variety of infections of the central nervous system (CNS) such as tuberculous meningitis, poliomyelitis, and toxoplasmosis have also been linked to CSWS [13] .", [["central nervous system", "ANATOMY", 31, 53], ["CNS", "ANATOMY", 55, 58], ["infections of the central nervous system", "DISEASE", 13, 53], ["tuberculous meningitis", "DISEASE", 68, 90], ["poliomyelitis", "DISEASE", 92, 105], ["toxoplasmosis", "DISEASE", 111, 124], ["CSWS", "DISEASE", 150, 154], ["central nervous system", "ANATOMICAL_SYSTEM", 31, 53], ["CNS", "ANATOMICAL_SYSTEM", 55, 58], ["infections of the central nervous system", "PROBLEM", 13, 53], ["tuberculous meningitis", "PROBLEM", 68, 90], ["poliomyelitis", "PROBLEM", 92, 105], ["toxoplasmosis", "PROBLEM", 111, 124], ["CSWS", "TEST", 150, 154], ["variety", "OBSERVATION_MODIFIER", 2, 9], ["infections", "OBSERVATION", 13, 23], ["central", "ANATOMY_MODIFIER", 31, 38], ["nervous system", "ANATOMY", 39, 53], ["CNS", "ANATOMY", 55, 58], ["tuberculous", "OBSERVATION_MODIFIER", 68, 79], ["meningitis", "OBSERVATION", 80, 90], ["poliomyelitis", "OBSERVATION", 92, 105]]], ["The clinical signs of this type of hyponatremia include dry mucous membranes, decreased skin turgor, tachycardia, hypotension, raised urea, and creatinine levels in serum [12] .Hypotonic Euvolemic HyponatremiaEuvolemic hyponatremia is the most common cause of hyponatremia among hospitalized patients [12] .", [["mucous membranes", "ANATOMY", 60, 76], ["skin", "ANATOMY", 88, 92], ["serum", "ANATOMY", 165, 170], ["hyponatremia", "DISEASE", 35, 47], ["tachycardia", "DISEASE", 101, 112], ["hypotension", "DISEASE", 114, 125], ["urea", "CHEMICAL", 134, 138], ["creatinine", "CHEMICAL", 144, 154], ["hyponatremia", "DISEASE", 219, 231], ["hyponatremia", "DISEASE", 260, 272], ["urea", "CHEMICAL", 134, 138], ["creatinine", "CHEMICAL", 144, 154], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 60, 76], ["skin", "ORGAN", 88, 92], ["urea", "SIMPLE_CHEMICAL", 134, 138], ["creatinine", "SIMPLE_CHEMICAL", 144, 154], ["serum", "ORGANISM_SUBSTANCE", 165, 170], ["patients", "ORGANISM", 292, 300], ["patients", "SPECIES", 292, 300], ["hyponatremia", "PROBLEM", 35, 47], ["dry mucous membranes", "PROBLEM", 56, 76], ["decreased skin turgor", "PROBLEM", 78, 99], ["tachycardia", "PROBLEM", 101, 112], ["hypotension", "PROBLEM", 114, 125], ["raised urea", "PROBLEM", 127, 138], ["creatinine levels", "TEST", 144, 161], ["serum", "TEST", 165, 170], ["Hypotonic Euvolemic", "PROBLEM", 177, 196], ["hyponatremia", "PROBLEM", 219, 231], ["hyponatremia", "PROBLEM", 260, 272], ["hyponatremia", "OBSERVATION", 35, 47], ["mucous membranes", "OBSERVATION", 60, 76], ["decreased", "OBSERVATION_MODIFIER", 78, 87], ["skin turgor", "OBSERVATION", 88, 99], ["hypotension", "OBSERVATION", 114, 125], ["Euvolemic", "OBSERVATION", 187, 196], ["HyponatremiaEuvolemic", "OBSERVATION_MODIFIER", 197, 218], ["hyponatremia", "OBSERVATION", 219, 231], ["hyponatremia", "OBSERVATION", 260, 272]]], ["The most frequent underlying disorder is Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH).", [["SIADH", "DISEASE", 99, 104], ["The most frequent underlying disorder", "PROBLEM", 0, 37], ["Syndrome", "PROBLEM", 41, 49], ["Inappropriate Antidiuretic Hormone Secretion (SIADH", "PROBLEM", 53, 104], ["most frequent", "OBSERVATION_MODIFIER", 4, 17], ["disorder", "OBSERVATION", 29, 37], ["Antidiuretic Hormone Secretion", "OBSERVATION", 67, 97]]], ["SIADH is defined as the presence of hypoosmolality when urine osmolality is inappropriately high and there is no evidence of renal salt wasting or hypovolemia in an individual with normal organ functions.", [["urine", "ANATOMY", 56, 61], ["renal", "ANATOMY", 125, 130], ["organ", "ANATOMY", 188, 193], ["SIADH", "DISEASE", 0, 5], ["hypoosmolality", "DISEASE", 36, 50], ["renal salt wasting", "DISEASE", 125, 143], ["hypovolemia", "DISEASE", 147, 158], ["urine", "ORGANISM_SUBSTANCE", 56, 61], ["renal", "ORGAN", 125, 130], ["organ", "ORGAN", 188, 193], ["SIADH", "PROBLEM", 0, 5], ["hypoosmolality", "PROBLEM", 36, 50], ["urine osmolality", "TEST", 56, 72], ["inappropriately high", "PROBLEM", 76, 96], ["renal salt wasting", "PROBLEM", 125, 143], ["hypovolemia", "PROBLEM", 147, 158], ["no evidence of", "UNCERTAINTY", 110, 124], ["renal", "ANATOMY", 125, 130], ["salt wasting", "OBSERVATION", 131, 143], ["hypovolemia", "OBSERVATION", 147, 158], ["normal", "OBSERVATION", 181, 187], ["organ functions", "OBSERVATION", 188, 203]]], ["In SIADH, high antidiuretic hormone (ADH) activity is considered to be inappropriate, since there is no identifiable osmotic or hemodynamic stimulus for its secretion [6] .", [["SIADH", "DISEASE", 3, 8], ["antidiuretic hormone", "GENE_OR_GENE_PRODUCT", 15, 35], ["ADH", "GENE_OR_GENE_PRODUCT", 37, 40], ["SIADH", "PROBLEM", 3, 8], ["high antidiuretic hormone", "PROBLEM", 10, 35], ["hemodynamic stimulus", "TEST", 128, 148], ["its secretion", "PROBLEM", 153, 166], ["SIADH", "OBSERVATION", 3, 8], ["no identifiable", "UNCERTAINTY", 101, 116], ["hemodynamic stimulus", "OBSERVATION", 128, 148]]], ["The most common causes of SIADH are malignancies, pulmonary disorders such as community-acquired pneumonia, central nervous system disorders, and drugs [6, 13, 14] .", [["malignancies", "ANATOMY", 36, 48], ["pulmonary", "ANATOMY", 50, 59], ["central nervous system", "ANATOMY", 108, 130], ["SIADH", "DISEASE", 26, 31], ["malignancies", "DISEASE", 36, 48], ["pulmonary disorders", "DISEASE", 50, 69], ["pneumonia", "DISEASE", 97, 106], ["central nervous system disorders", "DISEASE", 108, 140], ["malignancies", "CANCER", 36, 48], ["pulmonary", "ORGAN", 50, 59], ["nervous system", "ANATOMICAL_SYSTEM", 116, 130], ["SIADH", "PROBLEM", 26, 31], ["malignancies", "PROBLEM", 36, 48], ["pulmonary disorders", "PROBLEM", 50, 69], ["community-acquired pneumonia", "PROBLEM", 78, 106], ["central nervous system disorders", "PROBLEM", 108, 140], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["SIADH", "OBSERVATION", 26, 31], ["malignancies", "OBSERVATION", 36, 48], ["pulmonary", "ANATOMY", 50, 59], ["pneumonia", "OBSERVATION", 97, 106], ["central", "ANATOMY_MODIFIER", 108, 115], ["nervous system", "ANATOMY", 116, 130]]], ["In HIV/AIDS patients, opportunistic infections of the pulmonary tract or CNS can also induce the release of excessive ADH [15] .Hypotonic Euvolemic HyponatremiaIn rare cases, patients may develop hyponatremia due to true volume depletion, glucocorticoid deficiency, polydipsia, malnutrition, or severe hypothyroidism [6, 16, 17] .", [["pulmonary tract", "ANATOMY", 54, 69], ["CNS", "ANATOMY", 73, 76], ["HIV/AIDS", "DISEASE", 3, 11], ["opportunistic infections of the pulmonary tract", "DISEASE", 22, 69], ["hyponatremia", "DISEASE", 196, 208], ["glucocorticoid deficiency", "DISEASE", 239, 264], ["polydipsia", "DISEASE", 266, 276], ["malnutrition", "DISEASE", 278, 290], ["hypothyroidism", "DISEASE", 302, 316], ["HIV/AIDS", "ORGANISM", 3, 11], ["patients", "ORGANISM", 12, 20], ["pulmonary tract", "ORGAN", 54, 69], ["CNS", "ANATOMICAL_SYSTEM", 73, 76], ["ADH", "GENE_OR_GENE_PRODUCT", 118, 121], ["patients", "ORGANISM", 175, 183], ["HIV", "SPECIES", 3, 6], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 175, 183], ["HIV", "SPECIES", 3, 6], ["opportunistic infections of the pulmonary tract", "PROBLEM", 22, 69], ["excessive ADH", "PROBLEM", 108, 121], ["Hypotonic Euvolemic", "PROBLEM", 128, 147], ["hyponatremia", "PROBLEM", 196, 208], ["true volume depletion", "PROBLEM", 216, 237], ["glucocorticoid deficiency", "PROBLEM", 239, 264], ["polydipsia", "PROBLEM", 266, 276], ["malnutrition", "PROBLEM", 278, 290], ["severe hypothyroidism", "PROBLEM", 295, 316], ["pulmonary tract", "ANATOMY", 54, 69], ["Euvolemic", "OBSERVATION", 138, 147], ["hyponatremia", "OBSERVATION", 196, 208], ["volume depletion", "OBSERVATION", 221, 237], ["glucocorticoid deficiency", "OBSERVATION", 239, 264], ["malnutrition", "OBSERVATION", 278, 290], ["severe", "OBSERVATION_MODIFIER", 295, 301], ["hypothyroidism", "OBSERVATION", 302, 316]]], ["Sometimes, long-lasting physical activity and diet poor in sodium may also be a reason of hypovolemic or euvolemic hyponatremia.Hypotonic Hypervolemic HyponatremiaHypervolemic hyponatremia occurs in states such as decompensated heart failure, advanced liver disease or renal disease, where excessive water causes plasma dilution [8] .", [["heart", "ANATOMY", 228, 233], ["liver", "ANATOMY", 252, 257], ["renal", "ANATOMY", 269, 274], ["plasma", "ANATOMY", 313, 319], ["sodium", "CHEMICAL", 59, 65], ["hypovolemic", "DISEASE", 90, 101], ["hyponatremia", "DISEASE", 115, 127], ["hyponatremia", "DISEASE", 176, 188], ["decompensated heart failure", "DISEASE", 214, 241], ["liver disease", "DISEASE", 252, 265], ["renal disease", "DISEASE", 269, 282], ["sodium", "CHEMICAL", 59, 65], ["sodium", "SIMPLE_CHEMICAL", 59, 65], ["heart", "ORGAN", 228, 233], ["liver", "ORGAN", 252, 257], ["renal", "ORGAN", 269, 274], ["plasma", "ORGANISM_SUBSTANCE", 313, 319], ["hypovolemic", "PROBLEM", 90, 101], ["euvolemic hyponatremia", "PROBLEM", 105, 127], ["Hypotonic Hypervolemic HyponatremiaHypervolemic hyponatremia", "PROBLEM", 128, 188], ["decompensated heart failure", "PROBLEM", 214, 241], ["advanced liver disease", "PROBLEM", 243, 265], ["renal disease", "PROBLEM", 269, 282], ["excessive water causes plasma dilution", "PROBLEM", 290, 328], ["euvolemic", "OBSERVATION_MODIFIER", 105, 114], ["hyponatremia", "OBSERVATION", 115, 127], ["Hypervolemic", "OBSERVATION_MODIFIER", 138, 150], ["HyponatremiaHypervolemic hyponatremia", "OBSERVATION", 151, 188], ["decompensated", "OBSERVATION_MODIFIER", 214, 227], ["heart", "ANATOMY", 228, 233], ["failure", "OBSERVATION", 234, 241], ["advanced", "OBSERVATION_MODIFIER", 243, 251], ["liver", "ANATOMY", 252, 257], ["disease", "OBSERVATION", 258, 265], ["renal", "ANATOMY", 269, 274], ["disease", "OBSERVATION", 275, 282]]], ["In liver diseases with cirrhosis at their end-stage, lacking mineralocorticoid elimination leads to excessive water and salt retention, while low blood albumin levels induce a water shift from vessel lumen into the tissue compartment [18] .", [["liver", "ANATOMY", 3, 8], ["blood", "ANATOMY", 146, 151], ["vessel lumen", "ANATOMY", 193, 205], ["tissue compartment", "ANATOMY", 215, 233], ["liver diseases", "DISEASE", 3, 17], ["cirrhosis", "DISEASE", 23, 32], ["liver", "ORGAN", 3, 8], ["mineralocorticoid", "SIMPLE_CHEMICAL", 61, 78], ["water", "SIMPLE_CHEMICAL", 110, 115], ["salt", "SIMPLE_CHEMICAL", 120, 124], ["blood", "ORGANISM_SUBSTANCE", 146, 151], ["albumin", "GENE_OR_GENE_PRODUCT", 152, 159], ["vessel lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 193, 205], ["tissue", "TISSUE", 215, 221], ["liver diseases", "PROBLEM", 3, 17], ["cirrhosis", "PROBLEM", 23, 32], ["lacking mineralocorticoid elimination", "PROBLEM", 53, 90], ["excessive water and salt retention", "PROBLEM", 100, 134], ["low blood albumin levels", "PROBLEM", 142, 166], ["a water shift", "PROBLEM", 174, 187], ["liver", "ANATOMY", 3, 8], ["diseases", "OBSERVATION", 9, 17], ["cirrhosis", "OBSERVATION", 23, 32], ["mineralocorticoid elimination", "OBSERVATION", 61, 90], ["excessive", "OBSERVATION_MODIFIER", 100, 109], ["water", "OBSERVATION_MODIFIER", 110, 115], ["salt retention", "OBSERVATION", 120, 134], ["water shift", "OBSERVATION", 176, 187], ["vessel", "ANATOMY", 193, 199], ["lumen", "ANATOMY_MODIFIER", 200, 205], ["tissue", "ANATOMY", 215, 221], ["compartment", "ANATOMY_MODIFIER", 222, 233]]], ["Such a constellation leads to hypervolemia, edemas, and finally hypervolemic hyponatremia.", [["hypervolemia", "DISEASE", 30, 42], ["edemas", "DISEASE", 44, 50], ["hyponatremia", "DISEASE", 77, 89], ["hypervolemia", "PROBLEM", 30, 42], ["edemas", "PROBLEM", 44, 50], ["finally hypervolemic hyponatremia", "PROBLEM", 56, 89], ["hypervolemia", "OBSERVATION", 30, 42], ["edemas", "OBSERVATION", 44, 50], ["hypervolemic", "OBSERVATION_MODIFIER", 64, 76], ["hyponatremia", "OBSERVATION", 77, 89]]], ["On the contrary, in heart failure, decreased cardiac output and venous congestion are the primary underlying pathologies, leading to impaired water elimination in the kidneys, volume overload, and secondary sodium dilution [19] .", [["heart", "ANATOMY", 20, 25], ["cardiac", "ANATOMY", 45, 52], ["venous", "ANATOMY", 64, 70], ["kidneys", "ANATOMY", 167, 174], ["heart failure", "DISEASE", 20, 33], ["decreased cardiac output", "DISEASE", 35, 59], ["venous congestion", "DISEASE", 64, 81], ["volume overload", "DISEASE", 176, 191], ["sodium", "CHEMICAL", 207, 213], ["sodium", "CHEMICAL", 207, 213], ["heart", "ORGAN", 20, 25], ["cardiac", "ORGAN", 45, 52], ["venous congestion", "PATHOLOGICAL_FORMATION", 64, 81], ["water", "SIMPLE_CHEMICAL", 142, 147], ["kidneys", "ORGAN", 167, 174], ["sodium", "SIMPLE_CHEMICAL", 207, 213], ["heart failure", "PROBLEM", 20, 33], ["decreased cardiac output", "PROBLEM", 35, 59], ["venous congestion", "PROBLEM", 64, 81], ["the primary underlying pathologies", "PROBLEM", 86, 120], ["impaired water elimination in the kidneys", "PROBLEM", 133, 174], ["volume overload", "PROBLEM", 176, 191], ["secondary sodium dilution", "PROBLEM", 197, 222], ["heart", "ANATOMY", 20, 25], ["failure", "OBSERVATION", 26, 33], ["decreased", "OBSERVATION_MODIFIER", 35, 44], ["cardiac", "ANATOMY", 45, 52], ["output", "OBSERVATION_MODIFIER", 53, 59], ["venous", "ANATOMY", 64, 70], ["congestion", "OBSERVATION", 71, 81], ["pathologies", "OBSERVATION", 109, 120], ["impaired", "OBSERVATION_MODIFIER", 133, 141], ["water elimination", "OBSERVATION", 142, 159], ["kidneys", "ANATOMY", 167, 174], ["volume overload", "OBSERVATION", 176, 191]]], ["Thus, the treatment of this hyponatremia type relies mainly on diuretics use and proper management of the underlying disorder.Non-Hypotonic HyponatremiaThere are two types of nonhypotonic hyponatremia: pseudohyponatremia and hypertonic hyponatremia.", [["hyponatremia", "DISEASE", 28, 40], ["HyponatremiaThere", "DISEASE", 140, 157], ["hyponatremia", "DISEASE", 188, 200], ["pseudohyponatremia", "DISEASE", 202, 220], ["hyponatremia", "DISEASE", 236, 248], ["this hyponatremia", "PROBLEM", 23, 40], ["diuretics", "TREATMENT", 63, 72], ["proper management", "TREATMENT", 81, 98], ["the underlying disorder", "PROBLEM", 102, 125], ["nonhypotonic hyponatremia", "PROBLEM", 175, 200], ["pseudohyponatremia", "PROBLEM", 202, 220], ["hypertonic hyponatremia", "PROBLEM", 225, 248], ["hyponatremia", "OBSERVATION", 28, 40], ["two types", "OBSERVATION_MODIFIER", 162, 171], ["hyponatremia", "OBSERVATION", 188, 200], ["hypertonic", "OBSERVATION_MODIFIER", 225, 235], ["hyponatremia", "OBSERVATION", 236, 248]]], ["Hypertonic hyponatremia occurs due to an increased concentration of osmotic active agents as mannitol or excess glucose.", [["hyponatremia", "DISEASE", 11, 23], ["mannitol", "CHEMICAL", 93, 101], ["glucose", "CHEMICAL", 112, 119], ["mannitol", "CHEMICAL", 93, 101], ["glucose", "CHEMICAL", 112, 119], ["mannitol", "SIMPLE_CHEMICAL", 93, 101], ["glucose", "SIMPLE_CHEMICAL", 112, 119], ["Hypertonic hyponatremia", "PROBLEM", 0, 23], ["osmotic active agents", "TREATMENT", 68, 89], ["mannitol", "TREATMENT", 93, 101], ["excess glucose", "PROBLEM", 105, 119], ["hyponatremia", "OBSERVATION", 11, 23], ["osmotic active agents", "OBSERVATION", 68, 89]]], ["The mentioned sugars earlier are osmotically active substances and they do not cross freely into the cell, causing water movement [20] .", [["cell", "ANATOMY", 101, 105], ["sugars", "CHEMICAL", 14, 20], ["cell", "CELL", 101, 105], ["The mentioned sugars", "TEST", 0, 20], ["osmotically active substances", "PROBLEM", 33, 62], ["active", "OBSERVATION_MODIFIER", 45, 51], ["substances", "OBSERVATION", 52, 62], ["cell", "ANATOMY", 101, 105], ["water movement", "OBSERVATION", 115, 129]]], ["As a consequence, water transfers from the intracellular compartment to the extracellular compartment.Non-Hypotonic HyponatremiaPseudohyponatremia is hyponatremia occurring along with isotonic osmolality.", [["intracellular compartment", "ANATOMY", 43, 68], ["extracellular compartment", "ANATOMY", 76, 101], ["HyponatremiaPseudohyponatremia", "DISEASE", 116, 146], ["hyponatremia", "DISEASE", 150, 162], ["water", "SIMPLE_CHEMICAL", 18, 23], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 43, 56], ["compartment", "IMMATERIAL_ANATOMICAL_ENTITY", 57, 68], ["extracellular compartment", "CELLULAR_COMPONENT", 76, 101], ["Hypotonic HyponatremiaPseudohyponatremia", "PROBLEM", 106, 146], ["hyponatremia", "PROBLEM", 150, 162], ["isotonic osmolality", "PROBLEM", 184, 203], ["extracellular", "ANATOMY_MODIFIER", 76, 89], ["compartment", "ANATOMY_MODIFIER", 90, 101], ["Hypotonic", "OBSERVATION_MODIFIER", 106, 115], ["HyponatremiaPseudohyponatremia", "OBSERVATION", 116, 146], ["hyponatremia", "OBSERVATION", 150, 162]]], ["It is mainly caused by the displacement of serum water because of elevated concentrations of serum lipids or proteins.", [["serum", "ANATOMY", 43, 48], ["serum", "ANATOMY", 93, 98], ["serum", "ORGANISM_SUBSTANCE", 43, 48], ["serum", "ORGANISM_SUBSTANCE", 93, 98], ["lipids", "SIMPLE_CHEMICAL", 99, 105], ["the displacement of serum water", "PROBLEM", 23, 54], ["elevated concentrations of serum lipids", "PROBLEM", 66, 105], ["displacement", "OBSERVATION_MODIFIER", 27, 39], ["elevated", "OBSERVATION", 66, 74]]], ["Expansion of the lipid or protein portion decreases the water portion resulting in artificially lowered serum sodium compared with serum measured directly in the water portion of plasma volume [6, 20] .Materials and MethodsWe performed a systematic search of the literature in June 2020.", [["serum", "ANATOMY", 104, 109], ["serum", "ANATOMY", 131, 136], ["plasma", "ANATOMY", 179, 185], ["sodium", "CHEMICAL", 110, 116], ["sodium", "CHEMICAL", 110, 116], ["lipid", "SIMPLE_CHEMICAL", 17, 22], ["serum", "ORGANISM_SUBSTANCE", 104, 109], ["sodium", "SIMPLE_CHEMICAL", 110, 116], ["serum", "ORGANISM_SUBSTANCE", 131, 136], ["plasma", "ORGANISM_SUBSTANCE", 179, 185], ["the lipid or protein portion", "PROBLEM", 13, 41], ["artificially lowered serum sodium", "PROBLEM", 83, 116], ["serum", "TEST", 131, 136], ["plasma volume", "TEST", 179, 192], ["lipid", "OBSERVATION_MODIFIER", 17, 22], ["portion", "OBSERVATION_MODIFIER", 34, 41], ["decreases", "OBSERVATION_MODIFIER", 42, 51], ["water portion", "OBSERVATION_MODIFIER", 56, 69]]], ["Research terms comprised a combination of words: \"hyponatremia\", \"adults\", \"infection\", and \"SIADH\".", [["hyponatremia", "DISEASE", 50, 62], ["infection", "DISEASE", 76, 85], ["SIADH", "DISEASE", 93, 98], ["hyponatremia", "PROBLEM", 50, 62], ["infection", "PROBLEM", 76, 85], ["SIADH", "PROBLEM", 93, 98], ["hyponatremia", "OBSERVATION", 50, 62], ["infection", "OBSERVATION", 76, 85]]], ["The articles were evaluated according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) protocol ( Figure 2 ) and were included after fulfilling following inclusion criteria.Hyponatremia Due to InfectionsDuring the literature search, we identified the following infection-related causes of hyponatremia: viral infections, bacterial infections, fungal infections, and protozoal infections.", [["Hyponatremia", "DISEASE", 207, 219], ["Infections", "DISEASE", 227, 237], ["infection", "DISEASE", 295, 304], ["hyponatremia", "DISEASE", 323, 335], ["viral infections", "DISEASE", 337, 353], ["bacterial infections", "DISEASE", 355, 375], ["fungal infections", "DISEASE", 377, 394], ["protozoal infections", "DISEASE", 400, 420], ["Systematic Reviews", "TEST", 75, 93], ["Meta-Analyses", "TEST", 98, 111], ["Hyponatremia", "PROBLEM", 207, 219], ["Infections", "PROBLEM", 227, 237], ["infection", "PROBLEM", 295, 304], ["hyponatremia", "PROBLEM", 323, 335], ["viral infections", "PROBLEM", 337, 353], ["bacterial infections", "PROBLEM", 355, 375], ["fungal infections", "PROBLEM", 377, 394], ["protozoal infections", "PROBLEM", 400, 420], ["Infections", "OBSERVATION", 227, 237], ["hyponatremia", "OBSERVATION", 323, 335], ["viral infections", "OBSERVATION", 337, 353], ["bacterial", "OBSERVATION_MODIFIER", 355, 364], ["infections", "OBSERVATION", 365, 375], ["fungal infections", "OBSERVATION", 377, 394], ["protozoal", "OBSERVATION_MODIFIER", 400, 409], ["infections", "OBSERVATION", 410, 420]]], ["The most prevalent microorganisms within each group are presented in Table 1 .", [["most prevalent", "OBSERVATION_MODIFIER", 4, 18], ["microorganisms", "OBSERVATION", 19, 33]]], ["In several papers, hyponatremia has been reported as a concomitant finding in patients with mixed infections.", [["hyponatremia", "DISEASE", 19, 31], ["infections", "DISEASE", 98, 108], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["hyponatremia", "PROBLEM", 19, 31], ["mixed infections", "PROBLEM", 92, 108], ["hyponatremia", "OBSERVATION", 19, 31], ["mixed", "OBSERVATION_MODIFIER", 92, 97], ["infections", "OBSERVATION", 98, 108]]], ["Exclusion criteria:Hyponatremia Due to Infections\u2022 Case reports, \u2022 Cases series.Hyponatremia Due to InfectionsFinally, 62 articles were found eligible as presented on the flowchart below and representative information was investigated.Hyponatremia Due to InfectionsDuring the literature search, we identified the following infection-related causes of hyponatremia: viral infections, bacterial infections, fungal infections, and protozoal infections.", [["Hyponatremia", "DISEASE", 19, 31], ["Infections", "DISEASE", 39, 49], ["Hyponatremia", "DISEASE", 80, 92], ["Infections", "DISEASE", 100, 110], ["Hyponatremia", "DISEASE", 235, 247], ["Infections", "DISEASE", 255, 265], ["infection", "DISEASE", 323, 332], ["hyponatremia", "DISEASE", 351, 363], ["viral infections", "DISEASE", 365, 381], ["bacterial infections", "DISEASE", 383, 403], ["fungal infections", "DISEASE", 405, 422], ["protozoal infections", "DISEASE", 428, 448], ["Hyponatremia", "PROBLEM", 19, 31], ["Hyponatremia", "PROBLEM", 80, 92], ["Infections", "PROBLEM", 100, 110], ["Hyponatremia", "PROBLEM", 235, 247], ["Infections", "PROBLEM", 255, 265], ["infection", "PROBLEM", 323, 332], ["hyponatremia", "PROBLEM", 351, 363], ["viral infections", "PROBLEM", 365, 381], ["bacterial infections", "PROBLEM", 383, 403], ["fungal infections", "PROBLEM", 405, 422], ["protozoal infections", "PROBLEM", 428, 448], ["Hyponatremia", "OBSERVATION", 19, 31], ["Infections", "OBSERVATION", 100, 110], ["Infections", "OBSERVATION", 255, 265], ["hyponatremia", "OBSERVATION", 351, 363], ["viral infections", "OBSERVATION", 365, 381], ["bacterial", "OBSERVATION_MODIFIER", 383, 392], ["infections", "OBSERVATION", 393, 403], ["fungal infections", "OBSERVATION", 405, 422], ["protozoal", "OBSERVATION_MODIFIER", 428, 437], ["infections", "OBSERVATION", 438, 448]]], ["The most prevalent microorganisms within each group are presented in Table 1 .", [["most prevalent", "OBSERVATION_MODIFIER", 4, 18], ["microorganisms", "OBSERVATION", 19, 33]]], ["In several papers, hyponatremia has been reported as a concomitant finding in patients with mixed infections.", [["hyponatremia", "DISEASE", 19, 31], ["infections", "DISEASE", 98, 108], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["hyponatremia", "PROBLEM", 19, 31], ["mixed infections", "PROBLEM", 92, 108], ["hyponatremia", "OBSERVATION", 19, 31], ["mixed", "OBSERVATION_MODIFIER", 92, 97], ["infections", "OBSERVATION", 98, 108]]], ["Abbreviations: CAP-community acquired pneumonia; SBP-spontaneous bacterial peritonitis; HIV-human immunodeficiency virus; AIDS-acquired immune deficiency syndrome; HHV-6-human herpesvirus 6; SFTSV-severe fever with thrombocytopenia syndrome virus; CNS-central nervous system.Influenza Virus and other Respiratory VirusesIn general population community-acquired pneumonia (CAP) is one of the most common viral infections associated with hyponatremia.", [["CNS", "ANATOMY", 248, 251], ["central nervous system", "ANATOMY", 252, 274], ["pneumonia", "DISEASE", 38, 47], ["bacterial peritonitis", "DISEASE", 65, 86], ["HIV-human immunodeficiency virus", "DISEASE", 88, 120], ["AIDS", "DISEASE", 122, 126], ["acquired immune deficiency syndrome", "DISEASE", 127, 162], ["fever", "DISEASE", 204, 209], ["thrombocytopenia syndrome", "DISEASE", 215, 240], ["Influenza Virus", "DISEASE", 275, 290], ["pneumonia", "DISEASE", 361, 370], ["CAP", "DISEASE", 372, 375], ["viral infections", "DISEASE", 403, 419], ["hyponatremia", "DISEASE", 436, 448], ["HIV-", "ORGANISM", 88, 92], ["human immunodeficiency virus", "ORGANISM", 92, 120], ["HHV-6-human herpesvirus 6", "ORGANISM", 164, 189], ["SFTSV", "ORGANISM", 191, 196], ["central nervous system", "ANATOMICAL_SYSTEM", 252, 274], ["Influenza Virus", "ORGANISM", 275, 290], ["HIV-", "SPECIES", 88, 92], ["human immunodeficiency virus", "SPECIES", 92, 120], ["HHV-6-", "SPECIES", 164, 170], ["human", "SPECIES", 170, 175], ["herpesvirus", "SPECIES", 176, 187], ["Influenza Virus", "SPECIES", 275, 290], ["HIV-human immunodeficiency virus", "SPECIES", 88, 120], ["HHV-6-human herpesvirus 6; SFTSV-severe fever with thrombocytopenia syndrome virus", "SPECIES", 164, 246], ["Influenza Virus", "SPECIES", 275, 290], ["community acquired pneumonia", "PROBLEM", 19, 47], ["SBP", "TEST", 49, 52], ["spontaneous bacterial peritonitis", "PROBLEM", 53, 86], ["HIV", "PROBLEM", 88, 91], ["human immunodeficiency virus", "PROBLEM", 92, 120], ["AIDS", "PROBLEM", 122, 126], ["acquired immune deficiency syndrome", "PROBLEM", 127, 162], ["HHV", "TEST", 164, 167], ["human herpesvirus", "TEST", 170, 187], ["SFTSV", "PROBLEM", 191, 196], ["severe fever", "PROBLEM", 197, 209], ["thrombocytopenia syndrome virus", "PROBLEM", 215, 246], ["central nervous system", "PROBLEM", 252, 274], ["Influenza Virus", "PROBLEM", 275, 290], ["other Respiratory VirusesIn", "PROBLEM", 295, 322], ["acquired pneumonia (CAP)", "PROBLEM", 352, 376], ["viral infections", "PROBLEM", 403, 419], ["hyponatremia", "PROBLEM", 436, 448], ["CAP", "OBSERVATION_MODIFIER", 15, 18], ["pneumonia", "OBSERVATION", 38, 47], ["bacterial peritonitis", "OBSERVATION", 65, 86], ["immune deficiency", "OBSERVATION", 136, 153], ["severe", "OBSERVATION_MODIFIER", 197, 203], ["fever", "OBSERVATION", 204, 209], ["thrombocytopenia syndrome", "OBSERVATION", 215, 240], ["central", "ANATOMY_MODIFIER", 252, 259], ["nervous system", "ANATOMY", 260, 274], ["Virus", "OBSERVATION", 285, 290], ["pneumonia", "OBSERVATION", 361, 370], ["most common", "OBSERVATION_MODIFIER", 391, 402], ["viral", "OBSERVATION_MODIFIER", 403, 408], ["infections", "OBSERVATION", 409, 419], ["hyponatremia", "OBSERVATION", 436, 448]]], ["Although CAP is mainly caused by bacteria such as Streptococcus pneumoniae or Legionella pneumophila, viruses still remain a relevant etiologic factor for CAP and secondary bacterial pneumonias.", [["CAP", "DISEASE", 9, 12], ["Streptococcus pneumoniae", "DISEASE", 50, 74], ["Legionella pneumophila", "DISEASE", 78, 100], ["CAP", "DISEASE", 155, 158], ["bacterial pneumonias", "DISEASE", 173, 193], ["Streptococcus pneumoniae", "ORGANISM", 50, 74], ["Legionella pneumophila", "ORGANISM", 78, 100], ["Streptococcus pneumoniae", "SPECIES", 50, 74], ["Legionella pneumophila", "SPECIES", 78, 100], ["Streptococcus pneumoniae", "SPECIES", 50, 74], ["Legionella pneumophila", "SPECIES", 78, 100], ["CAP", "PROBLEM", 9, 12], ["bacteria", "PROBLEM", 33, 41], ["Streptococcus pneumoniae", "PROBLEM", 50, 74], ["Legionella pneumophila", "PROBLEM", 78, 100], ["viruses", "PROBLEM", 102, 109], ["CAP", "PROBLEM", 155, 158], ["secondary bacterial pneumonias", "PROBLEM", 163, 193], ["CAP", "OBSERVATION_MODIFIER", 9, 12], ["bacteria", "OBSERVATION", 33, 41], ["secondary", "OBSERVATION_MODIFIER", 163, 172], ["bacterial", "OBSERVATION_MODIFIER", 173, 182], ["pneumonias", "OBSERVATION", 183, 193]]], ["The main viral pathogens causing CAP are rhinovirus, respiratory syncytial virus, influenza viruses, parainfluenza viruses, and adenovirus [21] .", [["CAP", "DISEASE", 33, 36], ["respiratory syncytial virus", "DISEASE", 53, 80], ["influenza viruses", "DISEASE", 82, 99], ["parainfluenza viruses", "DISEASE", 101, 122], ["rhinovirus", "ORGANISM", 41, 51], ["respiratory syncytial virus", "ORGANISM", 53, 80], ["influenza viruses", "ORGANISM", 82, 99], ["parainfluenza viruses", "ORGANISM", 101, 122], ["adenovirus", "ORGANISM", 128, 138], ["respiratory syncytial virus", "SPECIES", 53, 80], ["influenza viruses", "SPECIES", 82, 99], ["parainfluenza", "SPECIES", 101, 114], ["respiratory syncytial virus", "SPECIES", 53, 80], ["The main viral pathogens", "PROBLEM", 0, 24], ["CAP", "PROBLEM", 33, 36], ["rhinovirus", "PROBLEM", 41, 51], ["respiratory syncytial virus", "PROBLEM", 53, 80], ["influenza viruses", "PROBLEM", 82, 99], ["parainfluenza viruses", "PROBLEM", 101, 122], ["adenovirus", "PROBLEM", 128, 138], ["main", "OBSERVATION_MODIFIER", 4, 8], ["viral pathogens", "OBSERVATION", 9, 24], ["syncytial virus", "OBSERVATION", 65, 80], ["influenza viruses", "OBSERVATION", 82, 99], ["parainfluenza viruses", "OBSERVATION", 101, 122]]], ["Yet, in many cases the cause of CAP remains unidentified.", [["CAP", "DISEASE", 32, 35], ["CAP", "PROBLEM", 32, 35], ["CAP", "OBSERVATION", 32, 35]]], ["CAP was one of the complications of influenza A(H1N1) infection in 2009 during the pandemic and it was associated with high morbidity, mortality, and frequent admission to ICU [22] .", [["CAP", "DISEASE", 0, 3], ["influenza A(H1N1) infection", "DISEASE", 36, 63], ["influenza A(H1N1)", "ORGANISM", 36, 53], ["influenza A(H1N1", "SPECIES", 36, 52], ["influenza A(H1N1) infection", "PROBLEM", 36, 63], ["high morbidity", "PROBLEM", 119, 133], ["complications", "OBSERVATION", 19, 32], ["influenza", "OBSERVATION", 36, 45]]], ["According to data, most of the incidences of influenza cases during the post-pandemic season period occurred in the first weeks of 2011 with dominant viral CAP etiology [22] .", [["influenza", "DISEASE", 45, 54], ["influenza cases", "PROBLEM", 45, 60], ["dominant viral CAP etiology", "PROBLEM", 141, 168], ["influenza", "OBSERVATION", 45, 54], ["dominant", "OBSERVATION_MODIFIER", 141, 149], ["viral CAP", "OBSERVATION", 150, 159]]], ["Previous studies revealed that among patients diagnosed with CAP, an etiological diagnosis could be established only in 42.2% of them, with 21.9% of them being infected by bacteria, 16.7% by viruses, and 4.8% of patients had mixed infection (bacterial and viral).", [["CAP", "DISEASE", 61, 64], ["infection", "DISEASE", 231, 240], ["patients", "ORGANISM", 37, 45], ["patients", "ORGANISM", 212, 220], ["patients", "SPECIES", 37, 45], ["patients", "SPECIES", 212, 220], ["Previous studies", "TEST", 0, 16], ["CAP", "PROBLEM", 61, 64], ["bacteria", "TEST", 172, 180], ["viruses", "TEST", 191, 198], ["mixed infection (bacterial and viral)", "PROBLEM", 225, 262], ["bacteria", "OBSERVATION_MODIFIER", 172, 180], ["mixed", "OBSERVATION_MODIFIER", 225, 230], ["infection", "OBSERVATION", 231, 240]]], ["Patients that required ICU admission were mainly affected by influenza A (H1N1) virus and influenza B virus infection.", [["influenza A (H1N1) virus", "DISEASE", 61, 85], ["influenza B virus infection", "DISEASE", 90, 117], ["Patients", "ORGANISM", 0, 8], ["influenza A (H1N1) virus", "ORGANISM", 61, 85], ["influenza B virus", "ORGANISM", 90, 107], ["Patients", "SPECIES", 0, 8], ["H1N1) virus", "SPECIES", 74, 85], ["influenza B virus", "SPECIES", 90, 107], ["influenza A (H1N1) virus", "SPECIES", 61, 85], ["influenza B virus", "SPECIES", 90, 107], ["influenza A (H1N1) virus", "PROBLEM", 61, 85], ["influenza B virus infection", "PROBLEM", 90, 117]]], ["What is more, the patient cohort with viral pneumonia was younger and was less moribund than the group with non-viral pneumonia.", [["viral pneumonia", "DISEASE", 38, 53], ["pneumonia", "DISEASE", 118, 127], ["patient", "ORGANISM", 18, 25], ["patient", "SPECIES", 18, 25], ["viral pneumonia", "PROBLEM", 38, 53], ["non-viral pneumonia", "PROBLEM", 108, 127], ["pneumonia", "OBSERVATION", 44, 53], ["pneumonia", "OBSERVATION", 118, 127]]], ["Those with viral and mixed pneumonia, not only required ICU admission more often but also had a higher in-hospital mortality.", [["pneumonia", "DISEASE", 27, 36], ["viral and mixed pneumonia", "PROBLEM", 11, 36], ["viral", "OBSERVATION", 11, 16], ["mixed", "OBSERVATION_MODIFIER", 21, 26], ["pneumonia", "OBSERVATION", 27, 36]]], ["Severe disease occurred in 16.6% of patients.", [["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["Severe disease", "PROBLEM", 0, 14], ["disease", "OBSERVATION", 7, 14]]], ["Hyponatremia was independently associated with disease severity and was found in 17.6% of patients with viral pneumonia, 13.8% of patients with bacterial pneumonia, 11.1% of patients with mixed pneumonia, and 5.4% of patients with pneumonia of undetermined etiology.", [["Hyponatremia", "DISEASE", 0, 12], ["viral pneumonia", "DISEASE", 104, 119], ["bacterial pneumonia", "DISEASE", 144, 163], ["pneumonia", "DISEASE", 194, 203], ["pneumonia", "DISEASE", 231, 240], ["patients", "ORGANISM", 90, 98], ["patients", "ORGANISM", 130, 138], ["patients", "ORGANISM", 174, 182], ["patients", "ORGANISM", 217, 225], ["patients", "SPECIES", 90, 98], ["patients", "SPECIES", 130, 138], ["patients", "SPECIES", 174, 182], ["patients", "SPECIES", 217, 225], ["Hyponatremia", "PROBLEM", 0, 12], ["disease severity", "PROBLEM", 47, 63], ["viral pneumonia", "PROBLEM", 104, 119], ["bacterial pneumonia", "PROBLEM", 144, 163], ["mixed pneumonia", "PROBLEM", 188, 203], ["pneumonia", "PROBLEM", 231, 240], ["viral", "OBSERVATION_MODIFIER", 104, 109], ["pneumonia", "OBSERVATION", 110, 119], ["bacterial", "OBSERVATION_MODIFIER", 144, 153], ["pneumonia", "OBSERVATION", 154, 163], ["mixed", "OBSERVATION_MODIFIER", 188, 193], ["pneumonia", "OBSERVATION", 194, 203], ["5.4%", "OBSERVATION_MODIFIER", 209, 213], ["pneumonia", "OBSERVATION", 231, 240], ["undetermined etiology", "OBSERVATION_MODIFIER", 244, 265]]], ["Hyponatremia at admission was also associated with a longer hospital stay [23] .", [["Hyponatremia", "DISEASE", 0, 12], ["Hyponatremia", "PROBLEM", 0, 12]]], ["According to these findings, hyponatremia occurs most frequently when patients suffer from viral and bacterial pneumonia and is less frequent in patients with unknown etiology of CAP [22] .Influenza Virus and other Respiratory VirusesLow serum sodium concentrations along with other dyselectrolytemias were also identified in patients with avian-origin influenza A(H7N9).", [["serum", "ANATOMY", 238, 243], ["hyponatremia", "DISEASE", 29, 41], ["viral and bacterial pneumonia", "DISEASE", 91, 120], ["CAP", "DISEASE", 179, 182], ["Influenza Virus", "DISEASE", 189, 204], ["sodium", "CHEMICAL", 244, 250], ["avian-origin influenza A", "DISEASE", 340, 364], ["sodium", "CHEMICAL", 244, 250], ["patients", "ORGANISM", 70, 78], ["patients", "ORGANISM", 145, 153], ["Influenza Virus", "ORGANISM", 189, 204], ["Respiratory Viruses", "ORGANISM", 215, 234], ["serum", "ORGANISM_SUBSTANCE", 238, 243], ["sodium", "SIMPLE_CHEMICAL", 244, 250], ["patients", "ORGANISM", 326, 334], ["avian-origin influenza A", "ORGANISM", 340, 364], ["patients", "SPECIES", 70, 78], ["patients", "SPECIES", 145, 153], ["Influenza Virus", "SPECIES", 189, 204], ["patients", "SPECIES", 326, 334], ["Influenza Virus", "SPECIES", 189, 204], ["H7N9", "SPECIES", 365, 369], ["hyponatremia", "PROBLEM", 29, 41], ["viral and bacterial pneumonia", "PROBLEM", 91, 120], ["Influenza Virus", "PROBLEM", 189, 204], ["other Respiratory Viruses", "PROBLEM", 209, 234], ["Low serum sodium concentrations", "PROBLEM", 234, 265], ["other dyselectrolytemias", "PROBLEM", 277, 301], ["influenza A", "PROBLEM", 353, 364], ["hyponatremia", "OBSERVATION", 29, 41], ["viral", "OBSERVATION", 91, 96], ["bacterial", "OBSERVATION_MODIFIER", 101, 110], ["pneumonia", "OBSERVATION", 111, 120], ["less frequent", "OBSERVATION_MODIFIER", 128, 141], ["Virus", "OBSERVATION", 199, 204]]], ["On initial presentation, hypokalemia, hyponatremia, and hypocalcemia were common.", [["hypokalemia", "DISEASE", 25, 36], ["hyponatremia", "DISEASE", 38, 50], ["hypocalcemia", "DISEASE", 56, 68], ["hypokalemia", "PROBLEM", 25, 36], ["hyponatremia", "PROBLEM", 38, 50], ["hypocalcemia", "PROBLEM", 56, 68], ["hypokalemia", "OBSERVATION", 25, 36], ["hyponatremia", "OBSERVATION", 38, 50], ["hypocalcemia", "OBSERVATION", 56, 68]]], ["Almost half of the patients with confirmed H7N9 infection (43.6%) were hyponatremic [24] .HIV InfectionsHyponatremia is a very common electrolyte abnormality among patients with AIDS [15] .", [["H7N9 infection", "DISEASE", 43, 57], ["hyponatremic", "DISEASE", 71, 83], ["HIV Infections", "DISEASE", 90, 104], ["Hyponatremia", "DISEASE", 104, 116], ["electrolyte abnormality", "DISEASE", 134, 157], ["AIDS", "DISEASE", 178, 182], ["patients", "ORGANISM", 19, 27], ["patients", "ORGANISM", 164, 172], ["patients", "SPECIES", 19, 27], ["HIV", "SPECIES", 90, 93], ["patients", "SPECIES", 164, 172], ["H7N9", "SPECIES", 43, 47], ["HIV", "SPECIES", 90, 93], ["H7N9 infection", "PROBLEM", 43, 57], ["hyponatremic", "PROBLEM", 71, 83], ["HIV Infections", "PROBLEM", 90, 104], ["Hyponatremia", "PROBLEM", 104, 116], ["a very common electrolyte abnormality", "PROBLEM", 120, 157], ["AIDS", "PROBLEM", 178, 182], ["Infections", "OBSERVATION", 94, 104]]], ["According to literature, hyponatremia may occur in 20-80% of hospitalized patients with HIV disease or AIDS [15] .", [["hyponatremia", "DISEASE", 25, 37], ["HIV disease", "DISEASE", 88, 99], ["AIDS", "DISEASE", 103, 107], ["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["HIV", "SPECIES", 88, 91], ["HIV", "SPECIES", 88, 91], ["hyponatremia", "PROBLEM", 25, 37], ["HIV disease", "PROBLEM", 88, 99], ["AIDS", "PROBLEM", 103, 107], ["hyponatremia", "OBSERVATION", 25, 37]]], ["A common comorbidity in HIV-infected patients are pulmonary or CNS infections, which may result in SIADH.", [["pulmonary", "ANATOMY", 50, 59], ["CNS", "ANATOMY", 63, 66], ["HIV-infected", "DISEASE", 24, 36], ["pulmonary or CNS infections", "DISEASE", 50, 77], ["SIADH", "DISEASE", 99, 104], ["HIV", "ORGANISM", 24, 27], ["patients", "ORGANISM", 37, 45], ["pulmonary", "ORGAN", 50, 59], ["CNS", "ANATOMICAL_SYSTEM", 63, 66], ["HIV", "SPECIES", 24, 27], ["patients", "SPECIES", 37, 45], ["HIV", "SPECIES", 24, 27], ["A common comorbidity", "PROBLEM", 0, 20], ["HIV", "PROBLEM", 24, 27], ["pulmonary or CNS infections", "PROBLEM", 50, 77], ["SIADH", "PROBLEM", 99, 104], ["common", "OBSERVATION_MODIFIER", 2, 8], ["comorbidity", "OBSERVATION", 9, 20], ["HIV", "OBSERVATION", 24, 27], ["infected", "OBSERVATION_MODIFIER", 28, 36], ["pulmonary", "ANATOMY", 50, 59], ["CNS", "ANATOMY", 63, 66], ["infections", "OBSERVATION", 67, 77], ["SIADH", "OBSERVATION", 99, 104]]], ["It may explain why hyponatremia is inherent in this disease.HIV InfectionsHyponatremia also occurs as a result of adrenal insufficiency, renal disorders, and gastrointestinal sodium loss due to diarrhea and vomiting, which are observed frequently in AIDS patients [25] [26] [27] .", [["adrenal", "ANATOMY", 114, 121], ["renal", "ANATOMY", 137, 142], ["gastrointestinal", "ANATOMY", 158, 174], ["hyponatremia", "DISEASE", 19, 31], ["HIV Infections", "DISEASE", 60, 74], ["Hyponatremia", "DISEASE", 74, 86], ["adrenal insufficiency", "DISEASE", 114, 135], ["renal disorders", "DISEASE", 137, 152], ["gastrointestinal sodium loss", "DISEASE", 158, 186], ["diarrhea", "DISEASE", 194, 202], ["vomiting", "DISEASE", 207, 215], ["AIDS", "DISEASE", 250, 254], ["sodium", "CHEMICAL", 175, 181], ["adrenal", "ORGAN", 114, 121], ["renal", "ORGAN", 137, 142], ["gastrointestinal", "ORGANISM_SUBDIVISION", 158, 174], ["sodium", "SIMPLE_CHEMICAL", 175, 181], ["patients", "ORGANISM", 255, 263], ["HIV", "SPECIES", 60, 63], ["patients", "SPECIES", 255, 263], ["HIV", "SPECIES", 60, 63], ["hyponatremia", "PROBLEM", 19, 31], ["this disease", "PROBLEM", 47, 59], ["HIV Infections", "PROBLEM", 60, 74], ["Hyponatremia", "PROBLEM", 74, 86], ["adrenal insufficiency", "PROBLEM", 114, 135], ["renal disorders", "PROBLEM", 137, 152], ["gastrointestinal sodium loss", "PROBLEM", 158, 186], ["diarrhea", "PROBLEM", 194, 202], ["vomiting", "PROBLEM", 207, 215], ["may explain", "UNCERTAINTY", 3, 14], ["hyponatremia", "OBSERVATION", 19, 31], ["disease", "OBSERVATION", 52, 59], ["Infections", "OBSERVATION", 64, 74], ["adrenal", "ANATOMY", 114, 121], ["insufficiency", "OBSERVATION", 122, 135], ["renal", "ANATOMY", 137, 142], ["disorders", "OBSERVATION", 143, 152], ["gastrointestinal", "ANATOMY", 158, 174], ["sodium loss", "OBSERVATION", 175, 186], ["diarrhea", "OBSERVATION", 194, 202]]], ["According to studies, there is a positive correlation between serum sodium concentrations and the number of CD4+ cells, as hyponatremic patients presented with lower CD4+ cell count and showed a negative correlation with the WHO clinical stage [27, 28] .", [["serum", "ANATOMY", 62, 67], ["CD4+ cells", "ANATOMY", 108, 118], ["CD4+ cell", "ANATOMY", 166, 175], ["sodium", "CHEMICAL", 68, 74], ["hyponatremic", "DISEASE", 123, 135], ["sodium", "CHEMICAL", 68, 74], ["serum", "ORGANISM_SUBSTANCE", 62, 67], ["sodium", "SIMPLE_CHEMICAL", 68, 74], ["CD4", "GENE_OR_GENE_PRODUCT", 108, 111], ["patients", "ORGANISM", 136, 144], ["CD4", "GENE_OR_GENE_PRODUCT", 166, 169], ["CD4", "PROTEIN", 108, 111], ["CD4", "PROTEIN", 166, 169], ["patients", "SPECIES", 136, 144], ["serum sodium concentrations", "TEST", 62, 89], ["CD4+ cells", "PROBLEM", 108, 118], ["hyponatremic", "PROBLEM", 123, 135], ["lower CD4+ cell count", "PROBLEM", 160, 181], ["CD4+ cells", "OBSERVATION", 108, 118]]], ["This may suggest that serum sodium concentrations can be used as an indicator of the progression of HIV-infection or AIDS, although it is not a specific marker.", [["serum", "ANATOMY", 22, 27], ["sodium", "CHEMICAL", 28, 34], ["HIV-infection", "DISEASE", 100, 113], ["AIDS", "DISEASE", 117, 121], ["sodium", "CHEMICAL", 28, 34], ["serum", "ORGANISM_SUBSTANCE", 22, 27], ["sodium", "SIMPLE_CHEMICAL", 28, 34], ["HIV", "ORGANISM", 100, 103], ["HIV", "SPECIES", 100, 103], ["serum sodium concentrations", "PROBLEM", 22, 49], ["HIV", "PROBLEM", 100, 103], ["infection", "PROBLEM", 104, 113], ["AIDS", "PROBLEM", 117, 121], ["progression", "OBSERVATION_MODIFIER", 85, 96], ["infection", "OBSERVATION", 104, 113]]], ["What is more, a significantly higher proportion of patients with hyponatremia are hospitalized at first contact, the time between the diagnosis and their first hospitalization is shorter, and they have a higher incident hospitalization rate compared to normonatremic patients [28] .HIV InfectionsDespite numerous observations that link hyponatremia development with HIV-disease progression, it still remains a topic of controversy whether hyponatremia does directly increase the mortality among HIV infected patients.", [["hyponatremia", "DISEASE", 65, 77], ["HIV Infections", "DISEASE", 282, 296], ["hyponatremia", "DISEASE", 336, 348], ["HIV-disease", "DISEASE", 366, 377], ["hyponatremia", "DISEASE", 439, 451], ["HIV infected", "DISEASE", 495, 507], ["patients", "ORGANISM", 51, 59], ["patients", "ORGANISM", 267, 275], ["HIV", "ORGANISM", 495, 498], ["patients", "ORGANISM", 508, 516], ["patients", "SPECIES", 51, 59], ["patients", "SPECIES", 267, 275], ["HIV", "SPECIES", 282, 285], ["HIV", "SPECIES", 366, 369], ["HIV", "SPECIES", 495, 498], ["patients", "SPECIES", 508, 516], ["HIV", "SPECIES", 282, 285], ["HIV", "SPECIES", 366, 369], ["HIV", "SPECIES", 495, 498], ["hyponatremia", "PROBLEM", 65, 77], ["HIV Infections", "PROBLEM", 282, 296], ["hyponatremia", "PROBLEM", 336, 348], ["HIV-disease progression", "PROBLEM", 366, 389], ["hyponatremia", "PROBLEM", 439, 451], ["hyponatremia", "OBSERVATION", 65, 77], ["Infections", "OBSERVATION", 286, 296], ["hyponatremia", "OBSERVATION", 336, 348], ["hyponatremia", "OBSERVATION", 439, 451]]], ["Currently, there is no strong data that would confidently support such a thesis.", [["no", "UNCERTAINTY", 20, 22]]], ["Braconnier et al. reported a similar amount of HIV-related deaths in hypo-and normonatremic patients at baseline [28] .", [["deaths", "DISEASE", 59, 65], ["HIV", "ORGANISM", 47, 50], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["HIV", "SPECIES", 47, 50], ["HIV", "PROBLEM", 47, 50], ["similar", "OBSERVATION_MODIFIER", 29, 36], ["amount", "OBSERVATION_MODIFIER", 37, 43], ["HIV", "OBSERVATION", 47, 50]]], ["In the same study it has also been reported that hyponatremic patients presented a higher all-cause mortality, which has been linked to lower CD4 count and higher prevalence of hepatitis C. On the other hand, moderate to severe hyponatremia was shown to be associated with higher long-term mortality [27] .", [["hyponatremic", "DISEASE", 49, 61], ["hepatitis", "DISEASE", 177, 186], ["hyponatremia", "DISEASE", 228, 240], ["patients", "ORGANISM", 62, 70], ["CD4", "GENE_OR_GENE_PRODUCT", 142, 145], ["CD4", "PROTEIN", 142, 145], ["patients", "SPECIES", 62, 70], ["the same study", "TEST", 3, 17], ["hyponatremic", "PROBLEM", 49, 61], ["CD4 count", "TEST", 142, 151], ["hepatitis C.", "PROBLEM", 177, 189], ["moderate to severe hyponatremia", "PROBLEM", 209, 240], ["higher long-term mortality", "PROBLEM", 273, 299], ["hepatitis", "OBSERVATION", 177, 186], ["moderate", "OBSERVATION_MODIFIER", 209, 217], ["severe", "OBSERVATION_MODIFIER", 221, 227], ["hyponatremia", "OBSERVATION", 228, 240]]], ["What is more, the majority of HIV-infected deaths occurred within the first 3 months of anti-retroviral therapy initiation, and hyponatremia was independently associated with mortality.", [["HIV-infected", "DISEASE", 30, 42], ["deaths", "DISEASE", 43, 49], ["hyponatremia", "DISEASE", 128, 140], ["HIV", "ORGANISM", 30, 33], ["HIV", "SPECIES", 30, 33], ["HIV-infected deaths", "PROBLEM", 30, 49], ["anti-retroviral therapy initiation", "TREATMENT", 88, 122], ["hyponatremia", "PROBLEM", 128, 140], ["infected", "OBSERVATION_MODIFIER", 34, 42], ["deaths", "OBSERVATION", 43, 49], ["anti-retroviral therapy", "OBSERVATION", 88, 111]]], ["It has also been observed that serum chloride and serum sodium levels are regulated together, and hyponatremia is frequently associated with hypochloremia, which leads to higher mortality, compared to patients with only one electrolyte abnormality.", [["serum", "ANATOMY", 31, 36], ["serum", "ANATOMY", 50, 55], ["chloride", "CHEMICAL", 37, 45], ["sodium", "CHEMICAL", 56, 62], ["hyponatremia", "DISEASE", 98, 110], ["hypochloremia", "DISEASE", 141, 154], ["chloride", "CHEMICAL", 37, 45], ["sodium", "CHEMICAL", 56, 62], ["serum", "ORGANISM_SUBSTANCE", 31, 36], ["chloride", "SIMPLE_CHEMICAL", 37, 45], ["serum", "ORGANISM_SUBSTANCE", 50, 55], ["sodium", "SIMPLE_CHEMICAL", 56, 62], ["patients", "ORGANISM", 201, 209], ["patients", "SPECIES", 201, 209], ["serum chloride", "TEST", 31, 45], ["serum sodium levels", "TEST", 50, 69], ["hyponatremia", "PROBLEM", 98, 110], ["hypochloremia", "PROBLEM", 141, 154], ["one electrolyte abnormality", "PROBLEM", 220, 247], ["hyponatremia", "OBSERVATION", 98, 110], ["abnormality", "OBSERVATION", 236, 247]]], ["Dao et al. have also suggested that subsequent mortality may also be caused by undiagnosed conditions primary to these electrolyte abnormalities and not by the electrolyte abnormality itself [29] .HIV InfectionsDespite the fact that SIADH is considered to be one of the factors leading to hyponatremia in HIV-infections or AIDS, no differences between the ADH, renin, or aldosterone levels of HIV patients and those of non-HIV-infected subjects were observed [30] .", [["HIV Infections", "DISEASE", 197, 211], ["SIADH", "DISEASE", 233, 238], ["hyponatremia", "DISEASE", 289, 301], ["HIV-infections", "DISEASE", 305, 319], ["AIDS", "DISEASE", 323, 327], ["aldosterone", "CHEMICAL", 371, 382], ["non-HIV-infected", "DISEASE", 419, 435], ["aldosterone", "CHEMICAL", 371, 382], ["HIV-infections", "ORGANISM", 305, 319], ["ADH", "GENE_OR_GENE_PRODUCT", 356, 359], ["renin", "GENE_OR_GENE_PRODUCT", 361, 366], ["aldosterone", "GENE_OR_GENE_PRODUCT", 371, 382], ["HIV", "ORGANISM", 393, 396], ["patients", "ORGANISM", 397, 405], ["renin", "PROTEIN", 361, 366], ["HIV", "SPECIES", 197, 200], ["HIV", "SPECIES", 305, 308], ["HIV", "SPECIES", 393, 396], ["patients", "SPECIES", 397, 405], ["HIV", "SPECIES", 197, 200], ["HIV", "SPECIES", 305, 308], ["HIV", "SPECIES", 393, 396], ["undiagnosed conditions", "PROBLEM", 79, 101], ["these electrolyte abnormalities", "PROBLEM", 113, 144], ["the electrolyte abnormality", "PROBLEM", 156, 183], ["HIV Infections", "PROBLEM", 197, 211], ["SIADH", "PROBLEM", 233, 238], ["hyponatremia", "PROBLEM", 289, 301], ["HIV-infections", "PROBLEM", 305, 319], ["AIDS", "PROBLEM", 323, 327], ["the ADH", "TEST", 352, 359], ["renin", "TEST", 361, 366], ["aldosterone levels", "PROBLEM", 371, 389], ["HIV patients", "PROBLEM", 393, 405], ["non-HIV-infected subjects", "PROBLEM", 419, 444], ["Infections", "OBSERVATION", 201, 211], ["SIADH", "OBSERVATION", 233, 238], ["hyponatremia", "OBSERVATION", 289, 301]]], ["Currently, there is no strong data that would support the thesis that hyponatremia may contribute directly to increased mortality among HIV-infected patients.", [["hyponatremia", "DISEASE", 70, 82], ["HIV-infected", "DISEASE", 136, 148], ["HIV", "ORGANISM", 136, 139], ["patients", "ORGANISM", 149, 157], ["HIV", "SPECIES", 136, 139], ["patients", "SPECIES", 149, 157], ["HIV", "SPECIES", 136, 139], ["hyponatremia", "PROBLEM", 70, 82], ["increased mortality", "PROBLEM", 110, 129], ["no", "UNCERTAINTY", 20, 22]]], ["That is why it should only be treated as a surrogate marker of the severity of the underlying disease.Coronaviruses InfectionsEarly reports analyzing COVID-19 (Coronavirus Disease 2019) show that hyponatremia may be a common laboratory finding among infected patients [31] .", [["hyponatremia", "DISEASE", 196, 208], ["patients", "ORGANISM", 259, 267], ["patients", "SPECIES", 259, 267], ["the underlying disease", "PROBLEM", 79, 101], ["Coronaviruses Infections", "PROBLEM", 102, 126], ["analyzing COVID", "TEST", 140, 155], ["Coronavirus Disease", "PROBLEM", 160, 179], ["hyponatremia", "PROBLEM", 196, 208], ["disease", "OBSERVATION", 94, 101], ["hyponatremia", "OBSERVATION", 196, 208]]], ["However, different reports show that hyponatremia in this patient cohort may not only be associated with COVID-related pneumonia, but may also be attributed to inadequate dietary intake by COVID-19 patients or the gastrointestinal presentation of the disease.", [["gastrointestinal", "ANATOMY", 214, 230], ["hyponatremia", "DISEASE", 37, 49], ["pneumonia", "DISEASE", 119, 128], ["patient", "ORGANISM", 58, 65], ["patients", "ORGANISM", 198, 206], ["gastrointestinal", "ORGAN", 214, 230], ["patient", "SPECIES", 58, 65], ["patients", "SPECIES", 198, 206], ["hyponatremia", "PROBLEM", 37, 49], ["COVID-related pneumonia", "PROBLEM", 105, 128], ["the disease", "PROBLEM", 247, 258], ["hyponatremia", "OBSERVATION", 37, 49], ["pneumonia", "OBSERVATION", 119, 128], ["gastrointestinal", "ANATOMY", 214, 230], ["disease", "OBSERVATION", 251, 258]]], ["In patients described by Yiqun Wu et al., 17.6% of the study group presented with hyponatremia.", [["hyponatremia", "DISEASE", 82, 94], ["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["the study", "TEST", 51, 60], ["hyponatremia", "PROBLEM", 82, 94], ["hyponatremia", "OBSERVATION", 82, 94]]], ["Irrespectively from the hyponatremia etiology, it appeared more frequently in patients with a hospital stay longer than 14 days.", [["hyponatremia", "DISEASE", 24, 36], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["the hyponatremia", "PROBLEM", 20, 36], ["hyponatremia", "OBSERVATION", 24, 36]]], ["Nonetheless, in a multivariate analysis, it was not recognized as an independent risk factor associated with long-term hospitalization in patients with COVID-19.", [["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 138, 146], ["a multivariate analysis", "TEST", 16, 39], ["an independent risk factor", "PROBLEM", 66, 92], ["COVID", "TEST", 152, 157]]], ["Berni et al. reported that among non-ICU, COVID-patients, hyponatremia correlated positively with oxygenation index (PaO2/FiO2 ratio) and inversely with IL-6 levels.", [["hyponatremia", "DISEASE", 58, 70], ["patients", "ORGANISM", 48, 56], ["IL-6", "GENE_OR_GENE_PRODUCT", 153, 157], ["IL", "PROTEIN", 153, 155], ["patients", "SPECIES", 48, 56], ["hyponatremia", "PROBLEM", 58, 70], ["oxygenation index", "TEST", 98, 115], ["PaO2", "TEST", 117, 121], ["FiO2 ratio", "TEST", 122, 132], ["IL", "TEST", 153, 155], ["hyponatremia", "OBSERVATION", 58, 70]]], ["The investigated patient cohort in this study was partially qualified for tocilizumab (anti-IL6 antibody) treatment, based on IL-6 levels.", [["patient", "ORGANISM", 17, 24], ["tocilizumab", "SIMPLE_CHEMICAL", 74, 85], ["anti-IL6", "GENE_OR_GENE_PRODUCT", 87, 95], ["IL-6", "GENE_OR_GENE_PRODUCT", 126, 130], ["IL6 antibody", "PROTEIN", 92, 104], ["IL", "PROTEIN", 126, 128], ["patient", "SPECIES", 17, 24], ["this study", "TEST", 35, 45], ["tocilizumab (anti-IL6 antibody) treatment", "TREATMENT", 74, 115]]], ["Interestingly, the initiation of such treatment was associated with significant improvement of hyponatremia at 48 h, as compared to control group [33] .", [["hyponatremia", "DISEASE", 95, 107], ["such treatment", "TREATMENT", 33, 47], ["hyponatremia", "PROBLEM", 95, 107], ["hyponatremia", "OBSERVATION", 95, 107]]], ["The authors of this study also emphasize that hyponatremic patients have presented worse outcome (more ICU-transfers and more non-invasive ventilation initiations) than their normonatremic counterparts.", [["hyponatremic", "DISEASE", 46, 58], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["this study", "TEST", 15, 25], ["hyponatremic", "PROBLEM", 46, 58], ["non-invasive ventilation initiations", "TREATMENT", 126, 162]]], ["No information about long-term outcomes in patients treated with tocilizumab have been presented in this study.Coronaviruses InfectionsTherefore, further research has to be carried out to state the role of hyponatremia in this new disease and to explore its possible association with response to treatment, morbidity, time of hospitalization, and mortality.Other Viral InfectionsOther viral infections associated with hyponatremia include human herpesvirus-6 (HHV-6), SFTS virus (SFTSV), hantavirus, herpes simplex virus (HSV), and Ebola virus infections [34] [35] [36] [37] [38] [39] [40] .Other Viral InfectionsSevere fever with thrombocytopenia syndrome (SFTS) is an infectious disease caused by the SFTSV.", [["tocilizumab", "CHEMICAL", 65, 76], ["Infections", "DISEASE", 125, 135], ["hyponatremia", "DISEASE", 206, 218], ["viral infections", "DISEASE", 385, 401], ["hyponatremia", "DISEASE", 418, 430], ["hantavirus, herpes simplex virus (HSV)", "DISEASE", 488, 526], ["Ebola virus infections", "DISEASE", 532, 554], ["Viral Infections", "DISEASE", 597, 613], ["fever", "DISEASE", 620, 625], ["thrombocytopenia syndrome", "DISEASE", 631, 656], ["SFTS", "DISEASE", 658, 662], ["patients", "ORGANISM", 43, 51], ["tocilizumab", "SIMPLE_CHEMICAL", 65, 76], ["Viral InfectionsOther viral", "ORGANISM", 363, 390], ["human herpesvirus-6", "ORGANISM", 439, 458], ["HHV-6)", "ORGANISM", 460, 466], ["SFTS virus", "ORGANISM", 468, 478], ["SFTSV", "ORGANISM", 480, 485], ["hantavirus,", "ORGANISM", 488, 499], ["herpes simplex virus", "ORGANISM", 500, 520], ["HSV", "ORGANISM", 522, 525], ["Ebola virus", "ORGANISM", 532, 543], ["[34] [35] [36] [37] [38] [39] [40]", "SIMPLE_CHEMICAL", 555, 589], ["patients", "SPECIES", 43, 51], ["human", "SPECIES", 439, 444], ["herpesvirus-6", "SPECIES", 445, 458], ["HHV-6", "SPECIES", 460, 465], ["SFTS virus", "SPECIES", 468, 478], ["herpes simplex virus", "SPECIES", 500, 520], ["Ebola virus", "SPECIES", 532, 543], ["human herpesvirus-6 (HHV-6", "SPECIES", 439, 465], ["SFTS virus", "SPECIES", 468, 478], ["SFTSV", "SPECIES", 480, 485], ["herpes simplex virus", "SPECIES", 500, 520], ["HSV", "SPECIES", 522, 525], ["Ebola virus", "SPECIES", 532, 543], ["SFTSV", "SPECIES", 703, 708], ["tocilizumab", "TREATMENT", 65, 76], ["this study", "TEST", 100, 110], ["Coronaviruses Infections", "PROBLEM", 111, 135], ["hyponatremia", "PROBLEM", 206, 218], ["this new disease", "PROBLEM", 222, 238], ["treatment", "TREATMENT", 296, 305], ["morbidity", "PROBLEM", 307, 316], ["Other Viral InfectionsOther viral infections", "PROBLEM", 357, 401], ["hyponatremia", "PROBLEM", 418, 430], ["human herpesvirus", "TEST", 439, 456], ["HHV", "TEST", 460, 463], ["SFTS virus (SFTSV)", "PROBLEM", 468, 486], ["hantavirus", "PROBLEM", 488, 498], ["herpes simplex virus (HSV)", "PROBLEM", 500, 526], ["Ebola virus infections", "PROBLEM", 532, 554], ["Other Viral Infections", "PROBLEM", 591, 613], ["Severe fever", "PROBLEM", 613, 625], ["thrombocytopenia syndrome", "PROBLEM", 631, 656], ["SFTS", "PROBLEM", 658, 662], ["an infectious disease", "PROBLEM", 667, 688], ["the SFTSV", "PROBLEM", 699, 708], ["Infections", "OBSERVATION", 125, 135], ["hyponatremia", "OBSERVATION", 206, 218], ["Viral InfectionsOther", "OBSERVATION", 363, 384], ["viral infections", "OBSERVATION", 385, 401], ["Viral", "OBSERVATION_MODIFIER", 597, 602], ["Infections", "OBSERVATION", 603, 613], ["thrombocytopenia", "OBSERVATION", 631, 647], ["infectious", "OBSERVATION_MODIFIER", 670, 680], ["SFTSV", "OBSERVATION", 703, 708]]], ["Retrospectively, SFTSV infections are uncommon but are associated with high mortality, reported at the level of 33% [34] .", [["infections", "DISEASE", 23, 33], ["SFTSV", "SPECIES", 17, 22], ["SFTSV infections", "PROBLEM", 17, 33], ["high mortality", "PROBLEM", 71, 85], ["SFTSV", "OBSERVATION_MODIFIER", 17, 22], ["infections", "OBSERVATION", 23, 33]]], ["Hyponatremia was found to be an independent risk factor of death in SFTS patients.", [["Hyponatremia", "DISEASE", 0, 12], ["death", "DISEASE", 59, 64], ["SFTS", "DISEASE", 68, 72], ["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["Hyponatremia", "PROBLEM", 0, 12], ["death in SFTS patients", "PROBLEM", 59, 81]]], ["In the non-survivor group, hyponatremia occurred in 12 cases (60%), and in the survivor group in eight cases (20%).", [["hyponatremia", "DISEASE", 27, 39], ["non-survivor", "CANCER", 7, 19], ["hyponatremia", "PROBLEM", 27, 39], ["hyponatremia", "OBSERVATION", 27, 39]]], ["Generally, electrolyte imbalances including hyponatremia are common in SFTS and are related to higher disease severity and worse outcome.Other Viral InfectionsMany papers also discuss acute CNS infections, with the main focus on encephalitis.", [["CNS", "ANATOMY", 190, 193], ["hyponatremia", "DISEASE", 44, 56], ["SFTS", "DISEASE", 71, 75], ["Viral Infections", "DISEASE", 143, 159], ["infections", "DISEASE", 194, 204], ["encephalitis", "DISEASE", 229, 241], ["SFTS", "CANCER", 71, 75], ["CNS", "ANATOMICAL_SYSTEM", 190, 193], ["electrolyte imbalances", "PROBLEM", 11, 33], ["hyponatremia", "PROBLEM", 44, 56], ["SFTS", "PROBLEM", 71, 75], ["higher disease severity", "PROBLEM", 95, 118], ["Other Viral Infections", "PROBLEM", 137, 159], ["acute CNS infections", "PROBLEM", 184, 204], ["encephalitis", "PROBLEM", 229, 241], ["electrolyte imbalances", "OBSERVATION", 11, 33], ["hyponatremia", "OBSERVATION", 44, 56], ["SFTS", "OBSERVATION", 71, 75], ["higher", "OBSERVATION_MODIFIER", 95, 101], ["disease", "OBSERVATION", 102, 109], ["Viral", "OBSERVATION_MODIFIER", 143, 148], ["Infections", "OBSERVATION", 149, 159], ["acute", "OBSERVATION_MODIFIER", 184, 189], ["CNS", "ANATOMY", 190, 193], ["infections", "OBSERVATION", 194, 204], ["encephalitis", "OBSERVATION", 229, 241]]], ["The most common viral pathogens responsible for CNS infections are HSV, Enterovirus, and Varicella zoster virus (VZV) [35] .", [["CNS", "ANATOMY", 48, 51], ["CNS infections", "DISEASE", 48, 62], ["Enterovirus", "DISEASE", 72, 83], ["Varicella zoster", "DISEASE", 89, 105], ["CNS", "ANATOMICAL_SYSTEM", 48, 51], ["HSV", "ORGANISM", 67, 70], ["Varicella zoster virus", "ORGANISM", 89, 111], ["VZV", "ORGANISM", 113, 116], ["Varicella zoster virus", "SPECIES", 89, 111], ["HSV", "SPECIES", 67, 70], ["Varicella zoster virus", "SPECIES", 89, 111], ["VZV", "SPECIES", 113, 116], ["The most common viral pathogens", "PROBLEM", 0, 31], ["CNS infections", "PROBLEM", 48, 62], ["HSV", "PROBLEM", 67, 70], ["Enterovirus", "PROBLEM", 72, 83], ["Varicella zoster virus", "PROBLEM", 89, 111], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["responsible for", "UNCERTAINTY", 32, 47]]], ["Hyponatremia, both hypovolemic and euvolemic is associated with all viral CNS infections due to vomiting, SIADH, or fever.", [["CNS", "ANATOMY", 74, 77], ["Hyponatremia", "DISEASE", 0, 12], ["hypovolemic", "DISEASE", 19, 30], ["euvolemic", "DISEASE", 35, 44], ["infections", "DISEASE", 78, 88], ["vomiting", "DISEASE", 96, 104], ["SIADH", "DISEASE", 106, 111], ["fever", "DISEASE", 116, 121], ["Hyponatremia", "PROBLEM", 0, 12], ["hypovolemic", "PROBLEM", 19, 30], ["euvolemic", "PROBLEM", 35, 44], ["all viral CNS infections", "PROBLEM", 64, 88], ["vomiting", "PROBLEM", 96, 104], ["SIADH", "PROBLEM", 106, 111], ["fever", "PROBLEM", 116, 121], ["hypovolemic", "OBSERVATION", 19, 30], ["euvolemic", "OBSERVATION", 35, 44], ["viral", "OBSERVATION_MODIFIER", 68, 73], ["CNS", "ANATOMY", 74, 77], ["infections", "OBSERVATION", 78, 88], ["SIADH", "OBSERVATION", 106, 111]]], ["That is why CNS infections are related with high incidence of hyponatremia that reaches 30-66% [36] .", [["CNS", "ANATOMY", 12, 15], ["infections", "DISEASE", 16, 26], ["hyponatremia", "DISEASE", 62, 74], ["CNS", "ANATOMICAL_SYSTEM", 12, 15], ["CNS infections", "PROBLEM", 12, 26], ["hyponatremia", "PROBLEM", 62, 74], ["CNS", "ANATOMY", 12, 15], ["infections", "OBSERVATION", 16, 26], ["hyponatremia", "OBSERVATION", 62, 74]]], ["In general, hyponatremia is associated with CNS infections in about 30-66% of cases [36] .", [["CNS", "ANATOMY", 44, 47], ["hyponatremia", "DISEASE", 12, 24], ["infections", "DISEASE", 48, 58], ["CNS", "ANATOMICAL_SYSTEM", 44, 47], ["hyponatremia", "PROBLEM", 12, 24], ["CNS infections", "PROBLEM", 44, 58], ["hyponatremia", "OBSERVATION", 12, 24], ["CNS", "ANATOMY", 44, 47], ["infections", "OBSERVATION", 48, 58]]], ["It has been observed that low serum sodium levels appear more frequently in CNS HSV infections.", [["serum", "ANATOMY", 30, 35], ["CNS", "ANATOMY", 76, 79], ["sodium", "CHEMICAL", 36, 42], ["HSV infections", "DISEASE", 80, 94], ["sodium", "CHEMICAL", 36, 42], ["serum", "ORGANISM_SUBSTANCE", 30, 35], ["sodium", "SIMPLE_CHEMICAL", 36, 42], ["CNS HSV", "ORGANISM", 76, 83], ["HSV", "SPECIES", 80, 83], ["low serum sodium levels", "PROBLEM", 26, 49], ["CNS HSV infections", "PROBLEM", 76, 94], ["more frequently", "OBSERVATION_MODIFIER", 57, 72], ["CNS", "ANATOMY", 76, 79], ["HSV infections", "OBSERVATION", 80, 94]]], ["Thus, it has been suggested that serum sodium could be used to differentiate the HSV vs. non-HSV encephalitis etiology [36, 37] .Other Viral InfectionsThe reactivation of human herpesvirus-6 latent infection has been reported after allogeneic hematopoietic stem cell transplantation, leading to CNS disorders such as myelitis and encephalitis [38] .", [["serum", "ANATOMY", 33, 38], ["hematopoietic stem cell", "ANATOMY", 243, 266], ["CNS", "ANATOMY", 295, 298], ["sodium", "CHEMICAL", 39, 45], ["encephalitis", "DISEASE", 97, 109], ["Viral Infections", "DISEASE", 135, 151], ["infection", "DISEASE", 198, 207], ["CNS disorders", "DISEASE", 295, 308], ["myelitis", "DISEASE", 317, 325], ["encephalitis", "DISEASE", 330, 342], ["sodium", "CHEMICAL", 39, 45], ["serum", "ORGANISM_SUBSTANCE", 33, 38], ["sodium", "SIMPLE_CHEMICAL", 39, 45], ["HSV", "ORGANISM", 81, 84], ["non-HSV encephalitis", "ORGANISM", 89, 109], ["human herpesvirus-6", "ORGANISM", 171, 190], ["hematopoietic stem cell", "CELL", 243, 266], ["CNS", "ANATOMICAL_SYSTEM", 295, 298], ["human", "SPECIES", 171, 176], ["herpesvirus-6", "SPECIES", 177, 190], ["human herpesvirus-6", "SPECIES", 171, 190], ["serum sodium", "TEST", 33, 45], ["the HSV", "PROBLEM", 77, 84], ["non-HSV encephalitis", "PROBLEM", 89, 109], ["Other Viral Infections", "PROBLEM", 129, 151], ["The reactivation of human herpesvirus", "PROBLEM", 151, 188], ["latent infection", "PROBLEM", 191, 207], ["allogeneic hematopoietic stem cell transplantation", "TREATMENT", 232, 282], ["CNS disorders", "PROBLEM", 295, 308], ["myelitis", "PROBLEM", 317, 325], ["encephalitis", "PROBLEM", 330, 342], ["Viral", "OBSERVATION_MODIFIER", 135, 140], ["Infections", "OBSERVATION", 141, 151], ["latent", "OBSERVATION_MODIFIER", 191, 197], ["infection", "OBSERVATION", 198, 207], ["allogeneic hematopoietic stem cell transplantation", "OBSERVATION", 232, 282], ["CNS", "ANATOMY", 295, 298], ["myelitis", "OBSERVATION", 317, 325]]], ["At the onset of HHV-6 encephalitis, serum sodium level decreased in all patients with encephalitis (median of 129.1 mEq/L) and it was lower than in patients with myelitis.", [["serum", "ANATOMY", 36, 41], ["encephalitis", "DISEASE", 22, 34], ["sodium", "CHEMICAL", 42, 48], ["encephalitis", "DISEASE", 86, 98], ["myelitis", "DISEASE", 162, 170], ["sodium", "CHEMICAL", 42, 48], ["HHV-6 encephalitis", "ORGANISM", 16, 34], ["serum", "ORGANISM_SUBSTANCE", 36, 41], ["sodium", "SIMPLE_CHEMICAL", 42, 48], ["patients", "ORGANISM", 72, 80], ["patients", "ORGANISM", 148, 156], ["patients", "SPECIES", 72, 80], ["patients", "SPECIES", 148, 156], ["HHV-6 encephalitis", "SPECIES", 16, 34], ["HHV", "PROBLEM", 16, 19], ["encephalitis", "PROBLEM", 22, 34], ["serum sodium level", "TEST", 36, 54], ["encephalitis", "PROBLEM", 86, 98], ["myelitis", "PROBLEM", 162, 170], ["encephalitis", "OBSERVATION", 22, 34], ["encephalitis", "OBSERVATION", 86, 98], ["lower", "OBSERVATION_MODIFIER", 134, 139], ["myelitis", "OBSERVATION", 162, 170]]], ["Some factors, for instance antineoplastic agents, glucocorticoids, calcineurin inhibitors, diuretics, and malnutrition can possibly contribute to hyponatremia.", [["glucocorticoids", "CHEMICAL", 50, 65], ["malnutrition", "DISEASE", 106, 118], ["hyponatremia", "DISEASE", 146, 158], ["glucocorticoids", "SIMPLE_CHEMICAL", 50, 65], ["calcineurin", "GENE_OR_GENE_PRODUCT", 67, 78], ["diuretics", "SIMPLE_CHEMICAL", 91, 100], ["Some factors", "PROBLEM", 0, 12], ["instance antineoplastic agents", "TREATMENT", 18, 48], ["glucocorticoids", "TREATMENT", 50, 65], ["calcineurin inhibitors", "TREATMENT", 67, 89], ["diuretics", "TREATMENT", 91, 100], ["malnutrition", "PROBLEM", 106, 118], ["hyponatremia", "PROBLEM", 146, 158], ["hyponatremia", "OBSERVATION", 146, 158]]], ["What is more, SIADH occurs in a variety of CNS disorders or infections and it may be involved in the development of hyponatremia associated with HHV-6 encephalitis [38] .", [["CNS", "ANATOMY", 43, 46], ["SIADH", "DISEASE", 14, 19], ["CNS disorders", "DISEASE", 43, 56], ["infections", "DISEASE", 60, 70], ["hyponatremia", "DISEASE", 116, 128], ["encephalitis", "DISEASE", 151, 163], ["CNS", "ANATOMICAL_SYSTEM", 43, 46], ["HHV-6 encephalitis", "ORGANISM", 145, 163], ["HHV-6 encephalitis", "SPECIES", 145, 163], ["SIADH", "PROBLEM", 14, 19], ["CNS disorders", "PROBLEM", 43, 56], ["infections", "PROBLEM", 60, 70], ["hyponatremia", "PROBLEM", 116, 128], ["HHV", "PROBLEM", 145, 148], ["encephalitis", "PROBLEM", 151, 163], ["infections", "OBSERVATION", 60, 70], ["hyponatremia", "OBSERVATION", 116, 128]]], ["Some scientists propose that hyponatremia could be a sign of HHV-6 encephalitis, but not of myelitis after allogeneic hematopoietic stem cell transplantation.Other Viral InfectionsHantavirus causes hemorrhagic fever with renal syndrome.", [["hematopoietic stem cell", "ANATOMY", 118, 141], ["renal", "ANATOMY", 221, 226], ["hyponatremia", "DISEASE", 29, 41], ["encephalitis", "DISEASE", 67, 79], ["myelitis", "DISEASE", 92, 100], ["Viral Infections", "DISEASE", 164, 180], ["Hantavirus", "DISEASE", 180, 190], ["hemorrhagic fever", "DISEASE", 198, 215], ["renal syndrome", "DISEASE", 221, 235], ["HHV-6 encephalitis", "ORGANISM", 61, 79], ["hematopoietic stem cell", "CELL", 118, 141], ["renal", "ORGAN", 221, 226], ["HHV-6 encephalitis", "SPECIES", 61, 79], ["hyponatremia", "PROBLEM", 29, 41], ["HHV", "PROBLEM", 61, 64], ["6 encephalitis", "PROBLEM", 65, 79], ["myelitis", "PROBLEM", 92, 100], ["allogeneic hematopoietic stem cell transplantation", "TREATMENT", 107, 157], ["Other Viral InfectionsHantavirus", "PROBLEM", 158, 190], ["hemorrhagic fever", "PROBLEM", 198, 215], ["renal syndrome", "PROBLEM", 221, 235], ["hyponatremia", "OBSERVATION", 29, 41], ["encephalitis", "OBSERVATION", 67, 79], ["not of", "UNCERTAINTY", 85, 91], ["myelitis", "OBSERVATION", 92, 100], ["allogeneic hematopoietic stem cell transplantation", "OBSERVATION", 107, 157], ["Viral", "OBSERVATION_MODIFIER", 164, 169], ["Infections", "OBSERVATION", 170, 180], ["hemorrhagic", "OBSERVATION_MODIFIER", 198, 209], ["fever", "OBSERVATION", 210, 215], ["renal", "ANATOMY", 221, 226], ["syndrome", "OBSERVATION", 227, 235]]], ["Severe hyponatremia has been reported to be associated with this disease, predicting the development of acute kidney injury (AKI) [39] .Other Viral InfectionsThe lowered concentration of sodium, which is a common laboratory abnormality in Ebola patients, is most probably associated with sodium and water loss due to severe vomiting and diarrhea [40] .", [["kidney", "ANATOMY", 110, 116], ["hyponatremia", "DISEASE", 7, 19], ["acute kidney injury", "DISEASE", 104, 123], ["AKI", "DISEASE", 125, 128], ["Viral Infections", "DISEASE", 142, 158], ["sodium", "CHEMICAL", 187, 193], ["Ebola", "DISEASE", 239, 244], ["sodium", "CHEMICAL", 288, 294], ["vomiting", "DISEASE", 324, 332], ["diarrhea", "DISEASE", 337, 345], ["sodium", "CHEMICAL", 187, 193], ["sodium", "CHEMICAL", 288, 294], ["kidney", "ORGAN", 110, 116], ["sodium", "SIMPLE_CHEMICAL", 187, 193], ["Ebola", "ORGANISM", 239, 244], ["patients", "ORGANISM", 245, 253], ["sodium", "SIMPLE_CHEMICAL", 288, 294], ["patients", "SPECIES", 245, 253], ["Severe hyponatremia", "PROBLEM", 0, 19], ["this disease", "PROBLEM", 60, 72], ["acute kidney injury", "PROBLEM", 104, 123], ["Other Viral Infections", "PROBLEM", 136, 158], ["The lowered concentration of sodium", "PROBLEM", 158, 193], ["a common laboratory abnormality", "PROBLEM", 204, 235], ["sodium and water loss", "PROBLEM", 288, 309], ["severe vomiting", "PROBLEM", 317, 332], ["diarrhea", "PROBLEM", 337, 345], ["hyponatremia", "OBSERVATION", 7, 19], ["disease", "OBSERVATION", 65, 72], ["acute", "OBSERVATION_MODIFIER", 104, 109], ["kidney", "ANATOMY", 110, 116], ["injury", "OBSERVATION", 117, 123], ["Viral", "OBSERVATION_MODIFIER", 142, 147], ["Infections", "OBSERVATION", 148, 158], ["lowered", "OBSERVATION_MODIFIER", 162, 169], ["concentration", "OBSERVATION_MODIFIER", 170, 183], ["Ebola", "OBSERVATION", 239, 244], ["most probably", "UNCERTAINTY", 258, 271], ["severe", "OBSERVATION_MODIFIER", 317, 323], ["vomiting", "OBSERVATION", 324, 332]]], ["Retrospective studies have shown that hyponatremia was present in about 44% of patients diagnosed with Ebola virus infection on admission.", [["hyponatremia", "DISEASE", 38, 50], ["Ebola virus infection", "DISEASE", 103, 124], ["patients", "ORGANISM", 79, 87], ["Ebola virus", "ORGANISM", 103, 114], ["patients", "SPECIES", 79, 87], ["Ebola virus", "SPECIES", 103, 114], ["Ebola virus", "SPECIES", 103, 114], ["Retrospective studies", "TEST", 0, 21], ["hyponatremia", "PROBLEM", 38, 50], ["Ebola virus infection", "PROBLEM", 103, 124], ["hyponatremia", "OBSERVATION", 38, 50], ["Ebola virus infection", "OBSERVATION", 103, 124]]], ["In the course of hospitalization its prevalence has increased up to 78% [40] [41] [42] .", [["increased", "OBSERVATION_MODIFIER", 52, 61]]], ["All of the patients received treatment during hospitalization.Fungal InfectionsOnly one article was found, which described hyponatremia in a fungal infection-cryptococcosis.", [["Fungal Infections", "DISEASE", 62, 79], ["hyponatremia", "DISEASE", 123, 135], ["fungal infection", "DISEASE", 141, 157], ["cryptococcosis", "DISEASE", 158, 172], ["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["treatment", "TREATMENT", 29, 38], ["Fungal Infections", "PROBLEM", 62, 79], ["hyponatremia", "PROBLEM", 123, 135], ["a fungal infection", "PROBLEM", 139, 157], ["cryptococcosis", "PROBLEM", 158, 172], ["Infections", "OBSERVATION", 69, 79], ["hyponatremia", "OBSERVATION", 123, 135], ["fungal", "OBSERVATION_MODIFIER", 141, 147], ["infection", "OBSERVATION", 148, 157], ["cryptococcosis", "OBSERVATION", 158, 172]]], ["Cryptococcal infection has two most common manifestations: cryptococcal meningitis or pulmonary cryptococcosis.", [["pulmonary", "ANATOMY", 86, 95], ["Cryptococcal infection", "DISEASE", 0, 22], ["cryptococcal meningitis", "DISEASE", 59, 82], ["pulmonary cryptococcosis", "DISEASE", 86, 110], ["pulmonary", "ORGAN", 86, 95], ["Cryptococcal infection", "PROBLEM", 0, 22], ["cryptococcal meningitis", "PROBLEM", 59, 82], ["pulmonary cryptococcosis", "PROBLEM", 86, 110], ["infection", "OBSERVATION", 13, 22], ["most common", "OBSERVATION_MODIFIER", 31, 42], ["cryptococcal", "OBSERVATION_MODIFIER", 59, 71], ["meningitis", "OBSERVATION", 72, 82], ["pulmonary", "ANATOMY", 86, 95], ["cryptococcosis", "OBSERVATION", 96, 110]]], ["As a result, many mechanisms leading to hyponatremia development in this patient group must be considered.", [["hyponatremia", "DISEASE", 40, 52], ["patient", "ORGANISM", 73, 80], ["patient", "SPECIES", 73, 80], ["hyponatremia development", "PROBLEM", 40, 64], ["hyponatremia", "OBSERVATION", 40, 52]]], ["As multivariable analysis showed, hyponatremia at presentation is statistically significantly associated with cryptococcal infection [43] .Overlapping InfectionHyponatremia has long been recognized as a complication of malaria [44] .", [["hyponatremia", "DISEASE", 34, 46], ["cryptococcal infection", "DISEASE", 110, 132], ["Hyponatremia", "DISEASE", 160, 172], ["malaria", "DISEASE", 219, 226], ["multivariable analysis", "TEST", 3, 25], ["hyponatremia", "PROBLEM", 34, 46], ["cryptococcal infection", "PROBLEM", 110, 132], ["Overlapping InfectionHyponatremia", "PROBLEM", 139, 172], ["malaria", "PROBLEM", 219, 226], ["hyponatremia", "OBSERVATION", 34, 46], ["cryptococcal", "OBSERVATION_MODIFIER", 110, 122], ["infection", "OBSERVATION", 123, 132], ["Infection", "OBSERVATION", 151, 160], ["malaria", "OBSERVATION", 219, 226]]], ["Both malaria and HIV infections independently affect the electrolyte profiles, but not much is known how these two infections together affect the serum sodium level.", [["serum", "ANATOMY", 146, 151], ["malaria", "DISEASE", 5, 12], ["HIV infections", "DISEASE", 17, 31], ["infections", "DISEASE", 115, 125], ["sodium", "CHEMICAL", 152, 158], ["sodium", "CHEMICAL", 152, 158], ["HIV", "ORGANISM", 17, 20], ["serum", "ORGANISM_SUBSTANCE", 146, 151], ["sodium", "SIMPLE_CHEMICAL", 152, 158], ["HIV", "SPECIES", 17, 20], ["HIV", "SPECIES", 17, 20], ["Both malaria", "PROBLEM", 0, 12], ["HIV infections", "PROBLEM", 17, 31], ["the electrolyte profiles", "TEST", 53, 77], ["these two infections", "PROBLEM", 105, 125], ["the serum sodium level", "TEST", 142, 164], ["malaria", "OBSERVATION", 5, 12], ["HIV", "OBSERVATION_MODIFIER", 17, 20], ["infections", "OBSERVATION", 21, 31], ["electrolyte profiles", "OBSERVATION_MODIFIER", 57, 77], ["infections", "OBSERVATION", 115, 125]]], ["According to studies, comparing four groups of patients, HIV-uninfected with uncomplicated malaria, HIV-uninfected with severe malaria, HIV-infected with uncomplicated malaria, and HIV-infected with severe malaria, there is no statistically valuable connection between HIV and malaria causing hyponatremia.", [["malaria", "DISEASE", 91, 98], ["HIV-uninfected", "DISEASE", 100, 114], ["malaria", "DISEASE", 127, 134], ["HIV-infected", "DISEASE", 136, 148], ["uncomplicated malaria", "DISEASE", 154, 175], ["HIV-infected", "DISEASE", 181, 193], ["malaria", "DISEASE", 206, 213], ["HIV and malaria", "DISEASE", 269, 284], ["hyponatremia", "DISEASE", 293, 305], ["patients", "ORGANISM", 47, 55], ["HIV", "ORGANISM", 57, 60], ["HIV", "ORGANISM", 269, 272], ["patients", "SPECIES", 47, 55], ["HIV", "SPECIES", 57, 60], ["HIV", "SPECIES", 100, 103], ["HIV", "SPECIES", 136, 139], ["HIV", "SPECIES", 181, 184], ["HIV", "SPECIES", 269, 272], ["HIV", "SPECIES", 57, 60], ["HIV", "SPECIES", 100, 103], ["HIV", "SPECIES", 136, 139], ["HIV", "SPECIES", 181, 184], ["HIV", "SPECIES", 269, 272], ["HIV", "PROBLEM", 57, 60], ["uncomplicated malaria", "PROBLEM", 77, 98], ["HIV", "PROBLEM", 100, 103], ["severe malaria", "PROBLEM", 120, 134], ["HIV", "PROBLEM", 136, 139], ["uncomplicated malaria", "PROBLEM", 154, 175], ["HIV", "PROBLEM", 181, 184], ["severe malaria", "PROBLEM", 199, 213], ["HIV", "PROBLEM", 269, 272], ["malaria", "PROBLEM", 277, 284], ["hyponatremia", "PROBLEM", 293, 305], ["uncomplicated", "OBSERVATION_MODIFIER", 77, 90], ["malaria", "OBSERVATION", 91, 98], ["severe", "OBSERVATION_MODIFIER", 120, 126], ["malaria", "OBSERVATION", 127, 134], ["uncomplicated", "OBSERVATION_MODIFIER", 154, 167], ["malaria", "OBSERVATION", 168, 175], ["infected", "OBSERVATION_MODIFIER", 185, 193], ["severe", "OBSERVATION_MODIFIER", 199, 205], ["malaria", "OBSERVATION", 206, 213], ["no", "UNCERTAINTY", 224, 226], ["HIV", "OBSERVATION", 269, 272], ["malaria", "OBSERVATION", 277, 284], ["hyponatremia", "OBSERVATION", 293, 305]]], ["Separately and together, serum sodium level is similar in these four groups [45] .Overlapping InfectionToxoplasmic encephalitis (TE) is the most frequent neurologic disorder in patients with advanced HIV infection [46] .", [["serum", "ANATOMY", 25, 30], ["neurologic", "ANATOMY", 154, 164], ["sodium", "CHEMICAL", 31, 37], ["InfectionToxoplasmic encephalitis", "DISEASE", 94, 127], ["TE", "DISEASE", 129, 131], ["neurologic disorder", "DISEASE", 154, 173], ["HIV infection", "DISEASE", 200, 213], ["sodium", "CHEMICAL", 31, 37], ["serum", "ORGANISM_SUBSTANCE", 25, 30], ["sodium", "SIMPLE_CHEMICAL", 31, 37], ["InfectionToxoplasmic encephalitis", "ORGANISM", 94, 127], ["patients", "ORGANISM", 177, 185], ["patients", "SPECIES", 177, 185], ["HIV", "SPECIES", 200, 203], ["HIV", "SPECIES", 200, 203], ["serum sodium level", "TEST", 25, 43], ["Overlapping InfectionToxoplasmic encephalitis", "PROBLEM", 82, 127], ["frequent neurologic disorder", "PROBLEM", 145, 173], ["advanced HIV infection", "PROBLEM", 191, 213], ["InfectionToxoplasmic", "OBSERVATION_MODIFIER", 94, 114], ["encephalitis", "OBSERVATION", 115, 127], ["infection", "OBSERVATION", 204, 213]]], ["Alterations in serum sodium regulation are a common feature in neurologic disorders like TE.", [["serum", "ANATOMY", 15, 20], ["neurologic", "ANATOMY", 63, 73], ["sodium", "CHEMICAL", 21, 27], ["neurologic disorders", "DISEASE", 63, 83], ["sodium", "CHEMICAL", 21, 27], ["serum", "ORGANISM_SUBSTANCE", 15, 20], ["sodium", "SIMPLE_CHEMICAL", 21, 27], ["Alterations in serum sodium regulation", "PROBLEM", 0, 38], ["neurologic disorders", "PROBLEM", 63, 83]]], ["Neurologic-associated hyponatremia could be secondary to SIADH.", [["hyponatremia", "DISEASE", 22, 34], ["SIADH", "DISEASE", 57, 62], ["associated hyponatremia", "PROBLEM", 11, 34], ["SIADH", "PROBLEM", 57, 62], ["hyponatremia", "OBSERVATION", 22, 34], ["SIADH", "OBSERVATION", 57, 62]]], ["In one article, among the patients diagnosed with toxoplasmosis, hyponatremia on admission was verified in 46.7% and severe hyponatremia in 10.8% of the cases [47] .", [["toxoplasmosis", "DISEASE", 50, 63], ["hyponatremia", "DISEASE", 65, 77], ["hyponatremia", "DISEASE", 124, 136], ["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["toxoplasmosis", "PROBLEM", 50, 63], ["hyponatremia", "PROBLEM", 65, 77], ["severe hyponatremia", "PROBLEM", 117, 136], ["toxoplasmosis", "OBSERVATION", 50, 63], ["severe", "OBSERVATION_MODIFIER", 117, 123], ["hyponatremia", "OBSERVATION", 124, 136]]], ["What is more, HIV-infected and TE populations are at risk of developing acute kidney injury (AKI) mainly because of the treatment for TE, where the first line medicaments are the sulfonamides.", [["kidney", "ANATOMY", 78, 84], ["HIV-infected", "DISEASE", 14, 26], ["acute kidney injury", "DISEASE", 72, 91], ["AKI", "DISEASE", 93, 96], ["sulfonamides", "CHEMICAL", 179, 191], ["sulfonamides", "CHEMICAL", 179, 191], ["HIV", "ORGANISM", 14, 17], ["TE populations", "CELL", 31, 45], ["kidney", "ORGAN", 78, 84], ["sulfonamides", "SIMPLE_CHEMICAL", 179, 191], ["HIV", "SPECIES", 14, 17], ["HIV", "PROBLEM", 14, 17], ["acute kidney injury", "PROBLEM", 72, 91], ["AKI", "PROBLEM", 93, 96], ["the treatment", "TREATMENT", 116, 129], ["TE", "TREATMENT", 134, 136], ["the first line medicaments", "TREATMENT", 144, 170], ["the sulfonamides", "TREATMENT", 175, 191], ["infected", "OBSERVATION", 18, 26], ["acute", "OBSERVATION_MODIFIER", 72, 77], ["kidney", "ANATOMY", 78, 84], ["injury", "OBSERVATION", 85, 91], ["AKI", "OBSERVATION", 93, 96]]], ["Hyponatremia was proven to be an important risk factor for developing AKI.", [["Hyponatremia", "DISEASE", 0, 12], ["AKI", "DISEASE", 70, 73], ["Hyponatremia", "PROBLEM", 0, 12], ["developing AKI", "PROBLEM", 59, 73], ["AKI", "OBSERVATION", 70, 73]]], ["It triggers the release of ADH, leading to increased urine concentration, which in turn predisposes to sulfadiazine crystal deposition in kidneys.", [["urine", "ANATOMY", 53, 58], ["kidneys", "ANATOMY", 138, 145], ["sulfadiazine", "CHEMICAL", 103, 115], ["sulfadiazine", "CHEMICAL", 103, 115], ["ADH", "GENE_OR_GENE_PRODUCT", 27, 30], ["urine", "ORGANISM_SUBSTANCE", 53, 58], ["sulfadiazine crystal", "SIMPLE_CHEMICAL", 103, 123], ["kidneys", "ORGAN", 138, 145], ["ADH", "PROTEIN", 27, 30], ["ADH", "PROBLEM", 27, 30], ["increased urine concentration", "PROBLEM", 43, 72], ["sulfadiazine crystal deposition in kidneys", "PROBLEM", 103, 145], ["increased", "OBSERVATION_MODIFIER", 43, 52], ["urine concentration", "OBSERVATION", 53, 72], ["sulfadiazine crystal deposition", "OBSERVATION", 103, 134], ["kidneys", "ANATOMY", 138, 145]]], ["In this study survivors differed from non-survivors in serum sodium levels with a significantly higher prevalence of hyponatremia (35.4% vs. 92.3%; p < 0.0001).", [["serum", "ANATOMY", 55, 60], ["sodium", "CHEMICAL", 61, 67], ["hyponatremia", "DISEASE", 117, 129], ["sodium", "CHEMICAL", 61, 67], ["serum", "ORGANISM_SUBSTANCE", 55, 60], ["sodium", "SIMPLE_CHEMICAL", 61, 67], ["serum sodium levels", "TEST", 55, 74], ["hyponatremia", "PROBLEM", 117, 129], ["p", "TEST", 148, 149], ["hyponatremia", "OBSERVATION", 117, 129]]], ["A multivariable analysis showed that hyponatremia on admission was an independent risk factor for hospital mortality [47] .Overlapping InfectionTuberculosis is another common co-infection in HIV/AIDS patients, and it may be also associated with hyponatremia that occurred in 28.4% cases, which, together with active tuberculosis and WHO clinical stage 4 status, is thought to be an important risk factor for mortality within 6 months of admission.", [["hyponatremia", "DISEASE", 37, 49], ["InfectionTuberculosis", "DISEASE", 135, 156], ["HIV/AIDS", "DISEASE", 191, 199], ["hyponatremia", "DISEASE", 245, 257], ["tuberculosis", "DISEASE", 316, 328], ["HIV", "ORGANISM", 191, 194], ["patients", "ORGANISM", 200, 208], ["HIV", "SPECIES", 191, 194], ["patients", "SPECIES", 200, 208], ["HIV", "SPECIES", 191, 194], ["A multivariable analysis", "TEST", 0, 24], ["hyponatremia", "PROBLEM", 37, 49], ["Overlapping InfectionTuberculosis", "PROBLEM", 123, 156], ["HIV/AIDS", "PROBLEM", 191, 199], ["hyponatremia", "PROBLEM", 245, 257], ["active tuberculosis", "PROBLEM", 309, 328], ["hyponatremia", "OBSERVATION", 37, 49], ["InfectionTuberculosis", "OBSERVATION", 135, 156], ["common", "OBSERVATION_MODIFIER", 168, 174], ["co-infection", "OBSERVATION", 175, 187], ["hyponatremia", "OBSERVATION", 245, 257], ["active", "OBSERVATION_MODIFIER", 309, 315], ["tuberculosis", "OBSERVATION", 316, 328], ["thought to be", "UNCERTAINTY", 365, 378]]], ["Additionally, it is suggested that hyponatremia was not the direct cause of death but an indicator of the critical status of the patient, as deaths still occurred even after the patient's serum sodium levels had been corrected [48] .Bacterial InfectionsThe most common topic among articles concerning bacterial infections was CAP, where low serum sodium is one of the most frequent laboratory findings [49] .", [["serum", "ANATOMY", 188, 193], ["serum", "ANATOMY", 341, 346], ["hyponatremia", "DISEASE", 35, 47], ["death", "DISEASE", 76, 81], ["deaths", "DISEASE", 141, 147], ["sodium", "CHEMICAL", 194, 200], ["Infections", "DISEASE", 243, 253], ["bacterial infections", "DISEASE", 301, 321], ["CAP", "DISEASE", 326, 329], ["sodium", "CHEMICAL", 347, 353], ["sodium", "CHEMICAL", 194, 200], ["sodium", "CHEMICAL", 347, 353], ["patient", "ORGANISM", 129, 136], ["patient", "ORGANISM", 178, 185], ["serum", "ORGANISM_SUBSTANCE", 188, 193], ["sodium", "SIMPLE_CHEMICAL", 194, 200], ["serum", "ORGANISM_SUBSTANCE", 341, 346], ["sodium", "SIMPLE_CHEMICAL", 347, 353], ["patient", "SPECIES", 129, 136], ["patient", "SPECIES", 178, 185], ["hyponatremia", "PROBLEM", 35, 47], ["death", "PROBLEM", 76, 81], ["the patient's serum sodium levels", "TEST", 174, 207], ["Bacterial Infections", "PROBLEM", 233, 253], ["bacterial infections", "PROBLEM", 301, 321], ["CAP", "PROBLEM", 326, 329], ["low serum sodium", "TEST", 337, 353], ["hyponatremia", "OBSERVATION", 35, 47], ["Infections", "OBSERVATION", 243, 253], ["most common", "OBSERVATION_MODIFIER", 257, 268], ["bacterial", "OBSERVATION_MODIFIER", 301, 310], ["infections", "OBSERVATION", 311, 321]]], ["There are many theories about the association of hyponatremia with infections; however, the etiology remains unclear despite the many attempts to identify it.", [["hyponatremia", "DISEASE", 49, 61], ["infections", "DISEASE", 67, 77], ["hyponatremia", "PROBLEM", 49, 61], ["infections", "PROBLEM", 67, 77], ["hyponatremia", "OBSERVATION", 49, 61], ["infections", "OBSERVATION", 67, 77]]], ["There is a study that ruled out SIADH being the cause of hyponatremia in Legionnaires' disease by measuring and finding no connection between CT-ProVasopressin and sodium levels [50] .Bacterial InfectionsSome studies suggest that hyponatremia can be a useful marker in differentiating Legionella pneumophila from Streptococcus pneumoniae or other non-legionella pneumophila infections [51, 52] .", [["SIADH", "DISEASE", 32, 37], ["hyponatremia", "DISEASE", 57, 69], ["Legionnaires' disease", "DISEASE", 73, 94], ["sodium", "CHEMICAL", 164, 170], ["hyponatremia", "DISEASE", 230, 242], ["Legionella pneumophila", "DISEASE", 285, 307], ["Streptococcus pneumoniae", "DISEASE", 313, 337], ["non-legionella pneumophila infections", "DISEASE", 347, 384], ["ProVasopressin", "CHEMICAL", 145, 159], ["sodium", "CHEMICAL", 164, 170], ["CT-ProVasopressin", "SIMPLE_CHEMICAL", 142, 159], ["sodium", "SIMPLE_CHEMICAL", 164, 170], ["Legionella pneumophila", "ORGANISM", 285, 307], ["Streptococcus pneumoniae", "ORGANISM", 313, 337], ["non-legionella pneumophila", "ORGANISM", 347, 373], ["Legionella pneumophila", "SPECIES", 285, 307], ["Streptococcus pneumoniae", "SPECIES", 313, 337], ["non-legionella pneumophila", "SPECIES", 347, 373], ["Legionella pneumophila", "SPECIES", 285, 307], ["Streptococcus pneumoniae", "SPECIES", 313, 337], ["non-legionella pneumophila", "SPECIES", 347, 373], ["a study", "TEST", 9, 16], ["SIADH", "PROBLEM", 32, 37], ["hyponatremia", "PROBLEM", 57, 69], ["Legionnaires' disease", "PROBLEM", 73, 94], ["CT", "TEST", 142, 144], ["ProVasopressin", "TREATMENT", 145, 159], ["sodium levels", "TEST", 164, 177], ["Bacterial Infections", "PROBLEM", 184, 204], ["Some studies", "TEST", 204, 216], ["hyponatremia", "PROBLEM", 230, 242], ["Legionella pneumophila", "PROBLEM", 285, 307], ["Streptococcus pneumoniae", "PROBLEM", 313, 337], ["other non-legionella pneumophila infections", "PROBLEM", 341, 384], ["hyponatremia", "OBSERVATION", 57, 69], ["Legionnaires", "OBSERVATION", 73, 85], ["Infections", "OBSERVATION", 194, 204], ["hyponatremia", "OBSERVATION", 230, 242], ["Legionella pneumophila", "OBSERVATION", 285, 307], ["Streptococcus pneumoniae", "OBSERVATION", 313, 337], ["pneumophila infections", "OBSERVATION", 362, 384]]], ["The utility of pneumonia pathogen identification relies on the fact that L. pneumophila, unlike other pneumonia-typical pathogens, seems to be strongly associated with severe respiratory symptoms as well as sepsis with multiorgan dysfunction [53] .", [["respiratory", "ANATOMY", 175, 186], ["multiorgan", "ANATOMY", 219, 229], ["pneumonia", "DISEASE", 15, 24], ["pneumonia", "DISEASE", 102, 111], ["respiratory symptoms", "DISEASE", 175, 195], ["sepsis", "DISEASE", 207, 213], ["multiorgan dysfunction", "DISEASE", 219, 241], ["L. pneumophila", "ORGANISM", 73, 87], ["L. pneumophila", "SPECIES", 73, 87], ["L. pneumophila", "SPECIES", 73, 87], ["pneumonia pathogen", "PROBLEM", 15, 33], ["L. pneumophila", "PROBLEM", 73, 87], ["other pneumonia", "PROBLEM", 96, 111], ["typical pathogens", "PROBLEM", 112, 129], ["severe respiratory symptoms", "PROBLEM", 168, 195], ["sepsis", "PROBLEM", 207, 213], ["multiorgan dysfunction", "PROBLEM", 219, 241], ["pneumonia", "OBSERVATION", 15, 24], ["L.", "OBSERVATION_MODIFIER", 73, 75], ["pneumophila", "OBSERVATION", 76, 87], ["pneumonia", "OBSERVATION", 102, 111], ["typical", "OBSERVATION_MODIFIER", 112, 119], ["pathogens", "OBSERVATION", 120, 129], ["severe", "OBSERVATION_MODIFIER", 168, 174], ["respiratory symptoms", "OBSERVATION", 175, 195], ["sepsis", "OBSERVATION", 207, 213]]], ["First line antibiotics for pneumonia treatment, such as amoxicillin or other beta-lactams, do not possess antimicrobial activity against this pathogen.", [["pneumonia", "DISEASE", 27, 36], ["amoxicillin", "CHEMICAL", 56, 67], ["beta-lactams", "CHEMICAL", 77, 89], ["amoxicillin", "CHEMICAL", 56, 67], ["beta-lactams", "CHEMICAL", 77, 89], ["amoxicillin", "SIMPLE_CHEMICAL", 56, 67], ["First line antibiotics", "TREATMENT", 0, 22], ["pneumonia treatment", "TREATMENT", 27, 46], ["amoxicillin", "TREATMENT", 56, 67], ["other beta-lactams", "TREATMENT", 71, 89], ["antimicrobial activity", "TREATMENT", 106, 128], ["this pathogen", "PROBLEM", 137, 150], ["pneumonia", "OBSERVATION", 27, 36]]], ["Thus, easy and commonly available tests that could predict L. pneumophila infections with good sensitivity could prove useful, as different treatment is required by this pathogen.Bacterial InfectionsPatients with L. pneumophila tend to have lower serum sodium levels than patients with pneumonia caused by other pathogens [52] .", [["serum", "ANATOMY", 247, 252], ["L. pneumophila infections", "DISEASE", 59, 84], ["sodium", "CHEMICAL", 253, 259], ["pneumonia", "DISEASE", 286, 295], ["sodium", "CHEMICAL", 253, 259], ["L. pneumophila", "ORGANISM", 59, 73], ["L. pneumophila", "ORGANISM", 213, 227], ["serum", "ORGANISM_SUBSTANCE", 247, 252], ["sodium", "SIMPLE_CHEMICAL", 253, 259], ["patients", "ORGANISM", 272, 280], ["L. pneumophila", "SPECIES", 59, 73], ["L. pneumophila", "SPECIES", 213, 227], ["patients", "SPECIES", 272, 280], ["L. pneumophila", "SPECIES", 59, 73], ["L. pneumophila", "SPECIES", 213, 227], ["tests", "TEST", 34, 39], ["L. pneumophila infections", "PROBLEM", 59, 84], ["different treatment", "TREATMENT", 130, 149], ["this pathogen", "PROBLEM", 165, 178], ["Bacterial InfectionsPatients", "PROBLEM", 179, 207], ["L. pneumophila", "PROBLEM", 213, 227], ["lower serum sodium levels", "PROBLEM", 241, 266], ["pneumonia", "PROBLEM", 286, 295], ["other pathogens", "PROBLEM", 306, 321], ["pneumophila infections", "OBSERVATION", 62, 84], ["L.", "OBSERVATION_MODIFIER", 213, 215], ["pneumophila", "OBSERVATION", 216, 227], ["pneumonia", "OBSERVATION", 286, 295]]], ["It has also been shown that hyponatremia is positively associated with L. pneumophila Urinary Antigen Test positive result [54] .", [["hyponatremia", "DISEASE", 28, 40], ["Urinary Antigen", "GENE_OR_GENE_PRODUCT", 86, 101], ["L. pneumophila", "SPECIES", 71, 85], ["L. pneumophila", "SPECIES", 71, 85], ["hyponatremia", "PROBLEM", 28, 40], ["L. pneumophila Urinary Antigen Test", "TEST", 71, 106], ["hyponatremia", "OBSERVATION", 28, 40], ["pneumophila", "OBSERVATION_MODIFIER", 74, 85], ["Urinary", "ANATOMY", 86, 93]]], ["Still, there is no perfect scoring system that would differentiate these bacteria from others.", [["perfect scoring system", "PROBLEM", 19, 41], ["these bacteria", "PROBLEM", 67, 81], ["no", "UNCERTAINTY", 16, 18]]], ["In the six-point scoring system proposed in the cited article, the cut off value of serum sodium is 133 mmol/L, while the four-point scoring system defines it at 137 mmol/L. However, there are studies proving that the six-point scoring system is of no use and in many cases may lead to a misdiagnosis.", [["serum", "ANATOMY", 84, 89], ["sodium", "CHEMICAL", 90, 96], ["sodium", "CHEMICAL", 90, 96], ["serum", "ORGANISM_SUBSTANCE", 84, 89], ["sodium", "SIMPLE_CHEMICAL", 90, 96], ["serum sodium", "TEST", 84, 96], ["a misdiagnosis", "PROBLEM", 286, 300]]], ["That is why a microbiological investigation still remains the best way of confirming Legionella pneumonia infection [52, 55, 56] .Bacterial InfectionsNonetheless, hyponatremia in CAP is associated with higher mortality and longer in-hospital stay [57] .", [["Legionella pneumonia infection", "DISEASE", 85, 115], ["Infections", "DISEASE", 140, 150], ["hyponatremia", "DISEASE", 163, 175], ["CAP", "DISEASE", 179, 182], ["Legionella pneumonia", "ORGANISM", 85, 105], ["Legionella pneumonia", "SPECIES", 85, 105], ["a microbiological investigation", "TEST", 12, 43], ["Legionella pneumonia infection", "PROBLEM", 85, 115], ["Bacterial Infections", "PROBLEM", 130, 150], ["hyponatremia in CAP", "PROBLEM", 163, 182], ["Legionella", "OBSERVATION_MODIFIER", 85, 95], ["pneumonia", "OBSERVATION", 96, 105], ["Infections", "OBSERVATION", 140, 150], ["hyponatremia", "OBSERVATION", 163, 175]]], ["Although in most cases hyponatremia was only mild to moderate, it still resulted in relevant clinical symptoms [49] .Bacterial InfectionsOther articles about hyponatremia in bacterial infections included peritonitis, tuberculosis, murine typhus, sepsis, bacterial meningitis, skin, and soft tissue infection, Guillain Barre Syndrome, Mediterranean spotted fever (MSF), and scrub typhus [58] .Bacterial InfectionsLow serum of sodium is also common in Spontaneous Bacterial Peritonitis (SBP).", [["skin", "ANATOMY", 276, 280], ["soft tissue", "ANATOMY", 286, 297], ["serum", "ANATOMY", 416, 421], ["hyponatremia", "DISEASE", 23, 35], ["hyponatremia", "DISEASE", 158, 170], ["bacterial infections", "DISEASE", 174, 194], ["peritonitis", "DISEASE", 204, 215], ["tuberculosis", "DISEASE", 217, 229], ["murine typhus", "DISEASE", 231, 244], ["sepsis", "DISEASE", 246, 252], ["bacterial meningitis", "DISEASE", 254, 274], ["soft tissue infection", "DISEASE", 286, 307], ["Guillain Barre Syndrome", "DISEASE", 309, 332], ["Mediterranean spotted fever", "DISEASE", 334, 361], ["MSF", "DISEASE", 363, 366], ["scrub typhus", "DISEASE", 373, 385], ["sodium", "CHEMICAL", 425, 431], ["Spontaneous Bacterial Peritonitis", "DISEASE", 450, 483], ["sodium", "CHEMICAL", 425, 431], ["murine typhus", "ORGANISM", 231, 244], ["skin", "ORGAN", 276, 280], ["soft tissue", "TISSUE", 286, 297], ["serum", "ORGANISM_SUBSTANCE", 416, 421], ["sodium", "SIMPLE_CHEMICAL", 425, 431], ["murine", "SPECIES", 231, 237], ["Mediterranean spotted fever", "SPECIES", 334, 361], ["Guillain Barre Syndrome, Mediterranean spotted fever (MSF)", "SPECIES", 309, 367], ["hyponatremia", "PROBLEM", 23, 35], ["relevant clinical symptoms", "PROBLEM", 84, 110], ["Bacterial Infections", "PROBLEM", 117, 137], ["hyponatremia", "PROBLEM", 158, 170], ["bacterial infections", "PROBLEM", 174, 194], ["peritonitis", "PROBLEM", 204, 215], ["tuberculosis", "PROBLEM", 217, 229], ["murine typhus", "PROBLEM", 231, 244], ["sepsis", "PROBLEM", 246, 252], ["bacterial meningitis", "PROBLEM", 254, 274], ["soft tissue infection", "PROBLEM", 286, 307], ["Guillain Barre Syndrome", "PROBLEM", 309, 332], ["Mediterranean spotted fever", "PROBLEM", 334, 361], ["scrub typhus", "PROBLEM", 373, 385], ["Bacterial Infections", "PROBLEM", 392, 412], ["Low serum of sodium", "PROBLEM", 412, 431], ["Spontaneous Bacterial Peritonitis", "PROBLEM", 450, 483], ["SBP", "TEST", 485, 488], ["mild", "OBSERVATION_MODIFIER", 45, 49], ["to moderate", "OBSERVATION_MODIFIER", 50, 61], ["Infections", "OBSERVATION", 127, 137], ["bacterial", "OBSERVATION_MODIFIER", 174, 183], ["infections", "OBSERVATION", 184, 194], ["peritonitis", "OBSERVATION", 204, 215], ["tuberculosis", "OBSERVATION", 217, 229], ["murine", "OBSERVATION_MODIFIER", 231, 237], ["typhus", "OBSERVATION", 238, 244], ["sepsis", "OBSERVATION", 246, 252], ["bacterial", "OBSERVATION_MODIFIER", 254, 263], ["meningitis", "OBSERVATION", 264, 274], ["skin", "ANATOMY", 276, 280], ["soft tissue", "ANATOMY", 286, 297], ["infection", "OBSERVATION", 298, 307], ["Barre Syndrome", "OBSERVATION", 318, 332], ["Infections", "OBSERVATION", 402, 412], ["Spontaneous", "OBSERVATION_MODIFIER", 450, 461], ["Bacterial", "OBSERVATION_MODIFIER", 462, 471], ["Peritonitis", "OBSERVATION", 472, 483]]], ["A retrospective case-control study revealed that, among cirrhotic patients, those with SBP suffered more frequently from hyponatremia than non-SBP patients [59] .", [["cirrhotic", "DISEASE", 56, 65], ["hyponatremia", "DISEASE", 121, 133], ["non-SBP", "DISEASE", 139, 146], ["patients", "ORGANISM", 66, 74], ["patients", "ORGANISM", 147, 155], ["patients", "SPECIES", 66, 74], ["patients", "SPECIES", 147, 155], ["A retrospective case-control study", "TEST", 0, 34], ["SBP", "TEST", 87, 90], ["hyponatremia", "PROBLEM", 121, 133], ["cirrhotic", "OBSERVATION", 56, 65], ["hyponatremia", "OBSERVATION", 121, 133]]], ["Severe hyponatremia (<125 mmol/L) is also reported to be a risk factor of developing SBP, which may be related to higher volume overload with sodium dilution as well as intestine mucosa edema, allowing spontaneous bacterial migration through its wall [60] .", [["intestine mucosa", "ANATOMY", 169, 185], ["wall", "ANATOMY", 246, 250], ["hyponatremia", "DISEASE", 7, 19], ["volume overload", "DISEASE", 121, 136], ["sodium", "CHEMICAL", 142, 148], ["mucosa edema", "DISEASE", 179, 191], ["sodium", "CHEMICAL", 142, 148], ["sodium", "SIMPLE_CHEMICAL", 142, 148], ["intestine mucosa", "MULTI-TISSUE_STRUCTURE", 169, 185], ["Severe hyponatremia", "PROBLEM", 0, 19], ["developing SBP", "PROBLEM", 74, 88], ["higher volume overload", "PROBLEM", 114, 136], ["sodium dilution", "TREATMENT", 142, 157], ["intestine mucosa edema", "PROBLEM", 169, 191], ["spontaneous bacterial migration", "PROBLEM", 202, 233], ["hyponatremia", "OBSERVATION", 7, 19], ["SBP", "OBSERVATION", 85, 88], ["may be related to", "UNCERTAINTY", 96, 113], ["higher", "OBSERVATION_MODIFIER", 114, 120], ["volume overload", "OBSERVATION", 121, 136], ["sodium dilution", "OBSERVATION", 142, 157], ["intestine mucosa", "ANATOMY", 169, 185], ["edema", "OBSERVATION", 186, 191], ["spontaneous", "OBSERVATION_MODIFIER", 202, 213], ["bacterial migration", "OBSERVATION", 214, 233], ["wall", "OBSERVATION_MODIFIER", 246, 250]]], ["Moreover, hyponatremia is commonly observed in 27% of patients who suffer from peritoneal-dialysis-related peritonitis (PDRP).", [["peritoneal", "ANATOMY", 79, 89], ["hyponatremia", "DISEASE", 10, 22], ["peritonitis", "DISEASE", 107, 118], ["PDRP", "DISEASE", 120, 124], ["patients", "ORGANISM", 54, 62], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 79, 89], ["patients", "SPECIES", 54, 62], ["hyponatremia", "PROBLEM", 10, 22], ["peritoneal-dialysis", "TREATMENT", 79, 98], ["peritonitis", "PROBLEM", 107, 118], ["hyponatremia", "OBSERVATION", 10, 22], ["peritoneal", "ANATOMY", 79, 89], ["dialysis", "OBSERVATION", 90, 98], ["peritonitis", "OBSERVATION", 107, 118]]], ["In a retrospective analysis, serum sodium level was positively correlated with serum albumin and phosphate levels.", [["serum", "ANATOMY", 29, 34], ["serum", "ANATOMY", 79, 84], ["sodium", "CHEMICAL", 35, 41], ["phosphate", "CHEMICAL", 97, 106], ["sodium", "CHEMICAL", 35, 41], ["phosphate", "CHEMICAL", 97, 106], ["serum", "ORGANISM_SUBSTANCE", 29, 34], ["sodium", "SIMPLE_CHEMICAL", 35, 41], ["serum", "ORGANISM_SUBSTANCE", 79, 84], ["albumin", "GENE_OR_GENE_PRODUCT", 85, 92], ["phosphate", "SIMPLE_CHEMICAL", 97, 106], ["a retrospective analysis", "TEST", 3, 27], ["serum sodium level", "TEST", 29, 47], ["serum albumin", "TEST", 79, 92], ["phosphate levels", "TEST", 97, 113]]], ["In the hyponatremic group, the in-hospital stay was lengthened, and the mortality rate was higher [61, 62] .", [["hyponatremic", "DISEASE", 7, 19], ["the mortality rate", "TEST", 68, 86], ["hyponatremic", "OBSERVATION_MODIFIER", 7, 19]]], ["Another retrospective study shows that baseline hyponatremia (<130 mmol/L) is independently associated with refractory peritonitis [63] .Bacterial InfectionsIn miliary tuberculosis, hyponatremia is reported to be associated with an unfavorable clinical outcome and predicts the need for mechanical ventilation and critical care intervention [64] .", [["hyponatremia", "DISEASE", 48, 60], ["peritonitis", "DISEASE", 119, 130], ["Infections", "DISEASE", 147, 157], ["miliary tuberculosis", "DISEASE", 160, 180], ["hyponatremia", "DISEASE", 182, 194], ["Another retrospective study", "TEST", 0, 27], ["baseline hyponatremia", "PROBLEM", 39, 60], ["refractory peritonitis", "PROBLEM", 108, 130], ["Bacterial Infections", "PROBLEM", 137, 157], ["miliary tuberculosis", "PROBLEM", 160, 180], ["hyponatremia", "PROBLEM", 182, 194], ["mechanical ventilation", "TREATMENT", 287, 309], ["critical care intervention", "TREATMENT", 314, 340], ["hyponatremia", "OBSERVATION", 48, 60], ["refractory", "OBSERVATION_MODIFIER", 108, 118], ["peritonitis", "OBSERVATION", 119, 130], ["Infections", "OBSERVATION", 147, 157], ["miliary", "OBSERVATION_MODIFIER", 160, 167], ["tuberculosis", "OBSERVATION", 168, 180], ["hyponatremia", "OBSERVATION", 182, 194]]], ["While in miliary tuberculosis the reasons for hyponatremia remain unclear, there are studies which precisely define its etiology in tuberculous meningitis (TBM).", [["miliary tuberculosis", "DISEASE", 9, 29], ["hyponatremia", "DISEASE", 46, 58], ["tuberculous meningitis", "DISEASE", 132, 154], ["TBM", "DISEASE", 156, 159], ["miliary tuberculosis", "PROBLEM", 9, 29], ["hyponatremia", "PROBLEM", 46, 58], ["studies", "TEST", 85, 92], ["tuberculous meningitis", "PROBLEM", 132, 154], ["TBM", "PROBLEM", 156, 159], ["miliary", "OBSERVATION_MODIFIER", 9, 16], ["tuberculosis", "OBSERVATION", 17, 29], ["tuberculous", "OBSERVATION_MODIFIER", 132, 143], ["meningitis", "OBSERVATION", 144, 154]]], ["About 45% of TBM patients had hyponatremia, with CWS and SIADH being its two main causes.", [["TBM", "DISEASE", 13, 16], ["hyponatremia", "DISEASE", 30, 42], ["CWS", "DISEASE", 49, 52], ["SIADH", "DISEASE", 57, 62], ["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["TBM", "PROBLEM", 13, 16], ["hyponatremia", "PROBLEM", 30, 42], ["CWS", "PROBLEM", 49, 52], ["SIADH", "PROBLEM", 57, 62], ["TBM", "OBSERVATION", 13, 16], ["hyponatremia", "OBSERVATION", 30, 42], ["SIADH", "OBSERVATION", 57, 62], ["main", "OBSERVATION_MODIFIER", 77, 81]]], ["This study states the predictors of hyponatremia in TBM, which are lower Glasgow Coma Scale, higher frequency of infarction in both anterior and posterior circulation, and higher incidence of basal exudates [65] .Bacterial InfectionsAnother bacterial infection in which hyponatremia is observed is murine typhus.", [["anterior", "ANATOMY", 132, 140], ["posterior circulation", "ANATOMY", 145, 166], ["basal exudates", "ANATOMY", 192, 206], ["hyponatremia", "DISEASE", 36, 48], ["TBM", "DISEASE", 52, 55], ["Coma", "DISEASE", 81, 85], ["infarction", "DISEASE", 113, 123], ["bacterial infection", "DISEASE", 241, 260], ["hyponatremia", "DISEASE", 270, 282], ["murine typhus", "DISEASE", 298, 311], ["anterior", "MULTI-TISSUE_STRUCTURE", 132, 140], ["murine typhus", "ORGANISM", 298, 311], ["murine", "SPECIES", 298, 304], ["This study", "TEST", 0, 10], ["hyponatremia", "PROBLEM", 36, 48], ["TBM", "PROBLEM", 52, 55], ["infarction in both anterior and posterior circulation", "PROBLEM", 113, 166], ["basal exudates", "PROBLEM", 192, 206], ["Bacterial Infections", "PROBLEM", 213, 233], ["Another bacterial infection", "PROBLEM", 233, 260], ["hyponatremia", "PROBLEM", 270, 282], ["murine typhus", "PROBLEM", 298, 311], ["hyponatremia", "OBSERVATION", 36, 48], ["TBM", "OBSERVATION", 52, 55], ["infarction", "OBSERVATION", 113, 123], ["both", "ANATOMY_MODIFIER", 127, 131], ["anterior", "ANATOMY_MODIFIER", 132, 140], ["posterior", "ANATOMY_MODIFIER", 145, 154], ["circulation", "ANATOMY", 155, 166], ["higher", "OBSERVATION_MODIFIER", 172, 178], ["incidence", "OBSERVATION_MODIFIER", 179, 188], ["basal", "ANATOMY_MODIFIER", 192, 197], ["exudates", "OBSERVATION", 198, 206], ["Infections", "OBSERVATION", 223, 233], ["bacterial", "OBSERVATION_MODIFIER", 241, 250], ["infection", "OBSERVATION", 251, 260], ["hyponatremia", "OBSERVATION", 270, 282], ["murine", "OBSERVATION_MODIFIER", 298, 304], ["typhus", "OBSERVATION", 305, 311]]], ["Its prevalence reaches up to 44% of patients, occurring more often in children than in adults [66, 67] .Bacterial InfectionsAmong patients suffering from Guillain-Barre Syndrome, the elderly (more than 60 years old) were characterized by a higher rate of hyponatremia compared to the younger group (18-59 years old) with a ratio of 25% vs. 10.2%, (p < 0.01) [68] .Bacterial InfectionsAn analysis of the epidemiologic trend of adult bacterial meningitis reveals that the most common infections were monomicrobial, caused by Staphylococcal species.", [["Infections", "DISEASE", 114, 124], ["Guillain-Barre Syndrome", "DISEASE", 154, 177], ["hyponatremia", "DISEASE", 255, 267], ["bacterial meningitis", "DISEASE", 432, 452], ["infections", "DISEASE", 482, 492], ["patients", "ORGANISM", 36, 44], ["children", "ORGANISM", 70, 78], ["patients", "ORGANISM", 130, 138], ["Guillain-Barre", "ORGANISM", 154, 168], ["patients", "SPECIES", 36, 44], ["children", "SPECIES", 70, 78], ["patients", "SPECIES", 130, 138], ["Bacterial Infections", "PROBLEM", 104, 124], ["Guillain-Barre Syndrome", "PROBLEM", 154, 177], ["a higher rate of hyponatremia", "PROBLEM", 238, 267], ["a ratio", "TEST", 321, 328], ["Bacterial Infections", "PROBLEM", 364, 384], ["An analysis", "TEST", 384, 395], ["adult bacterial meningitis", "PROBLEM", 426, 452], ["the most common infections", "PROBLEM", 466, 492], ["monomicrobial", "PROBLEM", 498, 511], ["Staphylococcal species", "PROBLEM", 523, 545], ["Infections", "OBSERVATION", 114, 124], ["Barre Syndrome", "OBSERVATION", 163, 177], ["hyponatremia", "OBSERVATION", 255, 267], ["Infections", "OBSERVATION", 374, 384], ["bacterial", "OBSERVATION_MODIFIER", 432, 441], ["meningitis", "OBSERVATION", 442, 452], ["most common", "OBSERVATION_MODIFIER", 470, 481], ["infections", "OBSERVATION", 482, 492], ["monomicrobial", "OBSERVATION", 498, 511], ["Staphylococcal species", "OBSERVATION", 523, 545]]], ["Hyponatremia was also a common laboratory finding in this disease [69] .Bacterial InfectionsIt is well known that patients with liver cirrhosis have worse immunity and are prone to infections.", [["liver cirrhosis", "ANATOMY", 128, 143], ["Hyponatremia", "DISEASE", 0, 12], ["liver cirrhosis", "DISEASE", 128, 143], ["infections", "DISEASE", 181, 191], ["patients", "ORGANISM", 114, 122], ["liver", "ORGAN", 128, 133], ["patients", "SPECIES", 114, 122], ["Hyponatremia", "PROBLEM", 0, 12], ["Bacterial Infections", "PROBLEM", 72, 92], ["liver cirrhosis", "PROBLEM", 128, 143], ["infections", "PROBLEM", 181, 191], ["Infections", "OBSERVATION", 82, 92], ["liver", "ANATOMY", 128, 133], ["cirrhosis", "OBSERVATION", 134, 143]]], ["These include skin and soft tissue infection, which appear to be associated not only with hyponatremia, but also renal failure.", [["skin", "ANATOMY", 14, 18], ["soft tissue", "ANATOMY", 23, 34], ["renal", "ANATOMY", 113, 118], ["skin and soft tissue infection", "DISEASE", 14, 44], ["hyponatremia", "DISEASE", 90, 102], ["renal failure", "DISEASE", 113, 126], ["skin", "ORGAN", 14, 18], ["soft tissue", "TISSUE", 23, 34], ["renal", "ORGAN", 113, 118], ["skin and soft tissue infection", "PROBLEM", 14, 44], ["hyponatremia", "PROBLEM", 90, 102], ["renal failure", "PROBLEM", 113, 126], ["skin", "ANATOMY", 14, 18], ["soft tissue", "OBSERVATION_MODIFIER", 23, 34], ["infection", "OBSERVATION", 35, 44], ["hyponatremia", "OBSERVATION", 90, 102], ["renal", "ANATOMY", 113, 118], ["failure", "OBSERVATION", 119, 126]]], ["In most cases, the infection primary site is localized on the lower extremity.", [["primary site", "ANATOMY", 29, 41], ["lower extremity", "ANATOMY", 62, 77], ["infection", "DISEASE", 19, 28], ["lower extremity", "ORGANISM_SUBDIVISION", 62, 77], ["the infection primary site", "PROBLEM", 15, 41], ["infection", "OBSERVATION", 19, 28], ["lower extremity", "ANATOMY", 62, 77]]], ["In patients with skin and soft tissue infection, hyponatremia occurs significantly more often, and sodium concentration, precisely the Model of End-Stage Liver Disease sodium, is associated with mortality among infected patients [70] .Bacterial InfectionsOne article suggested that hyponatremia is of no prognostic value to predict the progression of sepsis to severe sepsis or septic shock [71] .Bacterial InfectionsElderly patients with MSF suffered more frequently from hyponatremia than non-elderly MSF patients with a prevalence of 20.0% vs. 8.1% (p = 0.014), respectively [72] .Protozoal InfectionsMalaria is a protozoal disease, in which hyponatremia is commonly observed in approximately 60% of the cases [73] .", [["skin", "ANATOMY", 17, 21], ["soft tissue", "ANATOMY", 26, 37], ["Liver", "ANATOMY", 154, 159], ["skin and soft tissue infection", "DISEASE", 17, 47], ["hyponatremia", "DISEASE", 49, 61], ["sodium", "CHEMICAL", 99, 105], ["sodium", "CHEMICAL", 168, 174], ["hyponatremia", "DISEASE", 282, 294], ["sepsis", "DISEASE", 351, 357], ["sepsis", "DISEASE", 368, 374], ["septic shock", "DISEASE", 378, 390], ["Infections", "DISEASE", 407, 417], ["hyponatremia", "DISEASE", 473, 485], ["MSF", "DISEASE", 503, 506], ["InfectionsMalaria", "DISEASE", 594, 611], ["protozoal disease", "DISEASE", 617, 634], ["hyponatremia", "DISEASE", 645, 657], ["sodium", "CHEMICAL", 99, 105], ["sodium", "CHEMICAL", 168, 174], ["patients", "ORGANISM", 3, 11], ["skin", "ORGAN", 17, 21], ["soft tissue", "TISSUE", 26, 37], ["sodium", "SIMPLE_CHEMICAL", 99, 105], ["Liver", "ORGAN", 154, 159], ["patients", "ORGANISM", 220, 228], ["patients", "ORGANISM", 425, 433], ["patients", "ORGANISM", 507, 515], ["patients", "SPECIES", 3, 11], ["patients", "SPECIES", 220, 228], ["patients", "SPECIES", 425, 433], ["patients", "SPECIES", 507, 515], ["skin and soft tissue infection", "PROBLEM", 17, 47], ["hyponatremia", "PROBLEM", 49, 61], ["sodium concentration", "TEST", 99, 119], ["End-Stage Liver Disease sodium", "PROBLEM", 144, 174], ["Bacterial Infections", "PROBLEM", 235, 255], ["hyponatremia", "PROBLEM", 282, 294], ["prognostic value", "PROBLEM", 304, 320], ["sepsis", "PROBLEM", 351, 357], ["severe sepsis", "PROBLEM", 361, 374], ["septic shock", "PROBLEM", 378, 390], ["Bacterial Infections", "PROBLEM", 397, 417], ["MSF", "PROBLEM", 439, 442], ["hyponatremia", "PROBLEM", 473, 485], ["a prevalence", "TEST", 521, 533], ["Protozoal InfectionsMalaria", "PROBLEM", 584, 611], ["a protozoal disease", "PROBLEM", 615, 634], ["hyponatremia", "PROBLEM", 645, 657], ["skin", "ANATOMY", 17, 21], ["soft tissue", "ANATOMY", 26, 37], ["infection", "OBSERVATION", 38, 47], ["hyponatremia", "OBSERVATION", 49, 61], ["Stage", "OBSERVATION_MODIFIER", 148, 153], ["Liver", "ANATOMY", 154, 159], ["Disease", "OBSERVATION", 160, 167], ["Infections", "OBSERVATION", 245, 255], ["hyponatremia", "OBSERVATION", 282, 294], ["sepsis", "OBSERVATION", 351, 357], ["severe", "OBSERVATION_MODIFIER", 361, 367], ["sepsis", "OBSERVATION", 368, 374], ["septic", "OBSERVATION_MODIFIER", 378, 384], ["Infections", "OBSERVATION", 407, 417], ["Infections", "OBSERVATION", 594, 604], ["protozoal disease", "OBSERVATION", 617, 634], ["hyponatremia", "OBSERVATION", 645, 657]]], ["A hypothesis has been proposed that it is caused by a dysregulation of vasopressin release.", [["vasopressin", "CHEMICAL", 71, 82], ["vasopressin", "CHEMICAL", 71, 82], ["vasopressin", "GENE_OR_GENE_PRODUCT", 71, 82], ["vasopressin release", "TREATMENT", 71, 90]]], ["It is also suggested that serum sodium of 131 mmol/L and lower characterizes severe falciparum malaria disease [74] .", [["serum", "ANATOMY", 26, 31], ["sodium", "CHEMICAL", 32, 38], ["falciparum malaria disease", "DISEASE", 84, 110], ["sodium", "CHEMICAL", 32, 38], ["serum", "ORGANISM_SUBSTANCE", 26, 31], ["sodium", "SIMPLE_CHEMICAL", 32, 38], ["serum sodium", "TEST", 26, 38], ["severe falciparum malaria disease", "PROBLEM", 77, 110], ["severe", "OBSERVATION_MODIFIER", 77, 83], ["falciparum malaria", "OBSERVATION", 84, 102]]], ["Yet, the WHO guidelines for diagnosing severe hyponatremia do not take into consideration sodium levels [75] .", [["hyponatremia", "DISEASE", 46, 58], ["sodium", "CHEMICAL", 90, 96], ["sodium", "CHEMICAL", 90, 96], ["sodium", "SIMPLE_CHEMICAL", 90, 96], ["diagnosing severe hyponatremia", "PROBLEM", 28, 58], ["sodium levels", "TEST", 90, 103]]], ["One of the studies identified hyponatremia as a mortality predictor, which predicted death at the cut off of 126 mEq/L with the specificity of 78.8% and sensitivity of 81.1% [73] .Protozoal InfectionsAnother study identified hyponatremia in 66% of malaria contracted patients during antineoplastic therapy [76] .Other Potentially Infection-Related Causes of HyponatremiaMany medical departments, as ICU or internal wards, deal with moribund patients who frequently develop both hyponatremia and infections in the course of hospitalization.", [["antineoplastic", "ANATOMY", 283, 297], ["hyponatremia", "DISEASE", 30, 42], ["death", "DISEASE", 85, 90], ["Protozoal Infections", "DISEASE", 180, 200], ["hyponatremia", "DISEASE", 225, 237], ["malaria", "DISEASE", 248, 255], ["hyponatremia", "DISEASE", 478, 490], ["infections", "DISEASE", 495, 505], ["patients", "ORGANISM", 267, 275], ["patients", "ORGANISM", 441, 449], ["patients", "SPECIES", 267, 275], ["patients", "SPECIES", 441, 449], ["the studies", "TEST", 7, 18], ["hyponatremia", "PROBLEM", 30, 42], ["the specificity", "TEST", 124, 139], ["sensitivity", "TEST", 153, 164], ["Protozoal Infections", "PROBLEM", 180, 200], ["Another study", "TEST", 200, 213], ["hyponatremia", "PROBLEM", 225, 237], ["malaria", "PROBLEM", 248, 255], ["antineoplastic therapy", "TREATMENT", 283, 305], ["both hyponatremia", "PROBLEM", 473, 490], ["infections", "PROBLEM", 495, 505], ["hyponatremia", "OBSERVATION", 30, 42], ["Infections", "OBSERVATION", 190, 200], ["hyponatremia", "OBSERVATION", 225, 237], ["Infection", "OBSERVATION", 330, 339], ["hyponatremia", "OBSERVATION", 478, 490], ["infections", "OBSERVATION", 495, 505]]], ["Due to high prevalence of neoplasms, AKI, pulmonary pathologies, and other comorbidities, the etiology of hyponatremia often remains unclear.", [["neoplasms", "ANATOMY", 26, 35], ["pulmonary", "ANATOMY", 42, 51], ["neoplasms", "DISEASE", 26, 35], ["AKI", "DISEASE", 37, 40], ["pulmonary pathologies", "DISEASE", 42, 63], ["hyponatremia", "DISEASE", 106, 118], ["neoplasms", "CANCER", 26, 35], ["pulmonary", "ORGAN", 42, 51], ["neoplasms", "PROBLEM", 26, 35], ["AKI", "PROBLEM", 37, 40], ["pulmonary pathologies", "PROBLEM", 42, 63], ["other comorbidities", "PROBLEM", 69, 88], ["hyponatremia", "PROBLEM", 106, 118], ["neoplasms", "OBSERVATION", 26, 35], ["AKI", "OBSERVATION", 37, 40], ["pulmonary", "ANATOMY", 42, 51], ["pathologies", "OBSERVATION", 52, 63], ["hyponatremia", "OBSERVATION", 106, 118]]], ["Thus, the knowledge about alternative hyponatremia causes and the distinction between them is crucial for proper decision making and patient management.SIADHOne retrospective study aimed to analyze the difference between hyponatremia in SIADH and hyponatremia in AKI.", [["hyponatremia", "DISEASE", 38, 50], ["hyponatremia", "DISEASE", 221, 233], ["SIADH", "DISEASE", 237, 242], ["hyponatremia", "DISEASE", 247, 259], ["AKI", "DISEASE", 263, 266], ["patient", "ORGANISM", 133, 140], ["patient", "SPECIES", 133, 140], ["alternative hyponatremia", "PROBLEM", 26, 50], ["patient management", "TREATMENT", 133, 151], ["retrospective study", "TEST", 161, 180], ["hyponatremia", "PROBLEM", 221, 233], ["SIADH", "PROBLEM", 237, 242], ["hyponatremia", "PROBLEM", 247, 259], ["AKI", "PROBLEM", 263, 266], ["hyponatremia", "OBSERVATION", 221, 233], ["SIADH", "OBSERVATION", 237, 242], ["hyponatremia", "OBSERVATION", 247, 259], ["AKI", "OBSERVATION", 263, 266]]], ["24.9% of patients with SIADH were diagnosed with an infection, either acute or chronic.", [["SIADH", "DISEASE", 23, 28], ["infection", "DISEASE", 52, 61], ["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["SIADH", "PROBLEM", 23, 28], ["an infection", "PROBLEM", 49, 61], ["infection", "OBSERVATION", 52, 61], ["acute", "OBSERVATION_MODIFIER", 70, 75], ["chronic", "OBSERVATION_MODIFIER", 79, 86]]], ["In general, patients with SIADH were characterized by a higher median survival time compared to those with AKI.", [["SIADH", "DISEASE", 26, 31], ["AKI", "DISEASE", 107, 110], ["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["SIADH", "PROBLEM", 26, 31], ["AKI", "PROBLEM", 107, 110], ["SIADH", "OBSERVATION", 26, 31], ["AKI", "OBSERVATION", 107, 110]]], ["Among patients who died within the first year, 23.8% had an infection.", [["infection", "DISEASE", 60, 69], ["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["an infection", "PROBLEM", 57, 69], ["infection", "OBSERVATION", 60, 69]]], ["Furthermore, mortality in the first 2.5 years after diagnosis was higher among AKI patients, but after 2.5 years it became similar in both groups [77] .SIADHAnother study strived to investigate the etiology of SIADH.", [["AKI", "DISEASE", 79, 82], ["SIADH", "DISEASE", 210, 215], ["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["SIADHAnother study", "TEST", 152, 170], ["SIADH", "PROBLEM", 210, 215], ["SIADH", "OBSERVATION", 210, 215]]], ["The main identified causes of this disorder were cancer (27.7%), drugs (26.5%), idiopathic (15.9%), pulmonary infections (12.3%), pain and nausea (10.4%), and CNS disorders (7.2%).", [["cancer", "ANATOMY", 49, 55], ["pulmonary", "ANATOMY", 100, 109], ["CNS", "ANATOMY", 159, 162], ["cancer", "DISEASE", 49, 55], ["idiopathic", "DISEASE", 80, 90], ["pulmonary infections", "DISEASE", 100, 120], ["pain", "DISEASE", 130, 134], ["nausea", "DISEASE", 139, 145], ["CNS disorders", "DISEASE", 159, 172], ["cancer", "CANCER", 49, 55], ["pulmonary", "ORGAN", 100, 109], ["this disorder", "PROBLEM", 30, 43], ["cancer", "PROBLEM", 49, 55], ["drugs", "TREATMENT", 65, 70], ["idiopathic", "PROBLEM", 80, 90], ["pulmonary infections", "PROBLEM", 100, 120], ["pain", "PROBLEM", 130, 134], ["nausea", "PROBLEM", 139, 145], ["CNS disorders", "PROBLEM", 159, 172], ["main", "OBSERVATION_MODIFIER", 4, 8], ["idiopathic", "OBSERVATION_MODIFIER", 80, 90], ["pulmonary", "ANATOMY", 100, 109], ["infections", "OBSERVATION", 110, 120], ["CNS", "ANATOMY", 159, 162]]], ["As far as pulmonary infections were concerned, these patients presented the highest median of serum sodium concentration, most of them (45.5%) suffered from moderate hyponatremia, and their long-term (30 months) survival-rate was extremely low with 36.8%.", [["pulmonary", "ANATOMY", 10, 19], ["serum", "ANATOMY", 94, 99], ["pulmonary infections", "DISEASE", 10, 30], ["sodium", "CHEMICAL", 100, 106], ["hyponatremia", "DISEASE", 166, 178], ["sodium", "CHEMICAL", 100, 106], ["pulmonary", "ORGAN", 10, 19], ["patients", "ORGANISM", 53, 61], ["serum", "ORGANISM_SUBSTANCE", 94, 99], ["sodium", "SIMPLE_CHEMICAL", 100, 106], ["patients", "SPECIES", 53, 61], ["pulmonary infections", "PROBLEM", 10, 30], ["serum sodium concentration", "TEST", 94, 120], ["moderate hyponatremia", "PROBLEM", 157, 178], ["survival", "TEST", 212, 220], ["rate", "TEST", 221, 225], ["pulmonary", "ANATOMY", 10, 19], ["infections", "OBSERVATION", 20, 30], ["moderate", "OBSERVATION_MODIFIER", 157, 165], ["hyponatremia", "OBSERVATION", 166, 178]]], ["According to this study, the etiology of SIADH is an important prognostic factor of survival [78] .SIADHThe mentioned SIADHs etiology is of great importance since it determines the patient's prognosis.", [["SIADH", "DISEASE", 41, 46], ["SIADHs", "CANCER", 118, 124], ["patient", "ORGANISM", 181, 188], ["patient", "SPECIES", 181, 188], ["this study", "TEST", 13, 23], ["SIADH", "PROBLEM", 41, 46], ["SIADH", "OBSERVATION", 41, 46]]], ["That is why one center retrospective study, focused on stating the characteristics of patients diagnosed with idiopathic SIADH was performed, in an attempt to re-diagnose those patients.", [["SIADH", "DISEASE", 121, 126], ["patients", "ORGANISM", 86, 94], ["patients", "ORGANISM", 177, 185], ["patients", "SPECIES", 86, 94], ["patients", "SPECIES", 177, 185], ["retrospective study", "TEST", 23, 42], ["idiopathic SIADH", "PROBLEM", 110, 126], ["idiopathic", "OBSERVATION_MODIFIER", 110, 120], ["SIADH", "OBSERVATION", 121, 126]]], ["The researchers managed to establish a new diagnosis only in 11 out of 99 patients, while in 88 out of 99 the etiology remained idiopathic.", [["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["idiopathic", "PROBLEM", 128, 138], ["idiopathic", "OBSERVATION", 128, 138]]], ["In the group of re-diagnosed patients, seven had a malignancy detected, two had chronic pulmonary infections, one had benign brain space-occupying lesion, and one had Kikuchi syndrome [79] .SIADHAlthough SIADH is known to be associated with certain infections and presents a well-known clinical range of symptoms, its precise mechanism still remains uncertain.", [["pulmonary", "ANATOMY", 88, 97], ["benign brain", "ANATOMY", 118, 130], ["lesion", "ANATOMY", 147, 153], ["malignancy", "DISEASE", 51, 61], ["chronic pulmonary infections", "DISEASE", 80, 108], ["Kikuchi syndrome", "DISEASE", 167, 183], ["SIADH", "DISEASE", 204, 209], ["infections", "DISEASE", 249, 259], ["patients", "ORGANISM", 29, 37], ["pulmonary", "ORGAN", 88, 97], ["brain", "ORGAN", 125, 130], ["space-occupying lesion", "CANCER", 131, 153], ["patients", "SPECIES", 29, 37], ["a malignancy", "PROBLEM", 49, 61], ["chronic pulmonary infections", "PROBLEM", 80, 108], ["benign brain space-occupying lesion", "PROBLEM", 118, 153], ["Kikuchi syndrome", "PROBLEM", 167, 183], ["SIADH", "PROBLEM", 204, 209], ["certain infections", "PROBLEM", 241, 259], ["symptoms", "PROBLEM", 304, 312], ["malignancy", "OBSERVATION", 51, 61], ["chronic", "OBSERVATION_MODIFIER", 80, 87], ["pulmonary", "ANATOMY", 88, 97], ["infections", "OBSERVATION", 98, 108], ["benign", "OBSERVATION_MODIFIER", 118, 124], ["brain", "ANATOMY", 125, 130], ["space", "OBSERVATION", 131, 136], ["occupying", "OBSERVATION_MODIFIER", 137, 146], ["lesion", "OBSERVATION", 147, 153], ["Kikuchi syndrome", "OBSERVATION", 167, 183], ["SIADH", "OBSERVATION", 204, 209], ["infections", "OBSERVATION", 249, 259]]], ["Studies designed to present a potential correlation between ADH-related peptides (as CT-ProVasopressin) and sodium serum levels have failed to do so.", [["serum", "ANATOMY", 115, 120], ["sodium", "CHEMICAL", 108, 114], ["sodium", "CHEMICAL", 108, 114], ["ADH", "GENE_OR_GENE_PRODUCT", 60, 63], ["CT-ProVasopressin", "SIMPLE_CHEMICAL", 85, 102], ["sodium", "SIMPLE_CHEMICAL", 108, 114], ["serum", "ORGANISM_SUBSTANCE", 115, 120], ["ADH", "PROTEIN", 60, 63], ["ADH", "TEST", 60, 63], ["related peptides", "PROBLEM", 64, 80], ["CT", "TEST", 85, 87], ["ProVasopressin", "TREATMENT", 88, 102], ["sodium serum levels", "TEST", 108, 127]]], ["Thus, the pathophysiology of SIADH in infectious diseases is complex and extends beyond simple inadequate ADH secretion [50] .Other-Dysnatremia in Critically Ill PatientsOne of the included articles analyzed dysnatremia among patients admitted to the ICU [80] .", [["SIADH", "DISEASE", 29, 34], ["infectious diseases", "DISEASE", 38, 57], ["Dysnatremia", "DISEASE", 132, 143], ["dysnatremia", "DISEASE", 208, 219], ["ADH", "GENE_OR_GENE_PRODUCT", 106, 109], ["Patients", "ORGANISM", 162, 170], ["patients", "ORGANISM", 226, 234], ["ADH", "PROTEIN", 106, 109], ["Patients", "SPECIES", 162, 170], ["patients", "SPECIES", 226, 234], ["SIADH in infectious diseases", "PROBLEM", 29, 57], ["simple inadequate ADH secretion", "PROBLEM", 88, 119], ["Dysnatremia", "PROBLEM", 132, 143], ["Critically Ill", "PROBLEM", 147, 161], ["SIADH", "OBSERVATION", 29, 34], ["infectious", "OBSERVATION", 38, 48], ["Dysnatremia", "OBSERVATION", 132, 143]]], ["This multi-center prospective study, which enrolled almost 14,000 patients (51% presented with infection on admission) has shown that 12.9% of patients presented low serum sodium concentration at the moment of inclusion.", [["serum", "ANATOMY", 166, 171], ["infection", "DISEASE", 95, 104], ["sodium", "CHEMICAL", 172, 178], ["sodium", "CHEMICAL", 172, 178], ["patients", "ORGANISM", 66, 74], ["patients", "ORGANISM", 143, 151], ["serum", "ORGANISM_SUBSTANCE", 166, 171], ["sodium", "SIMPLE_CHEMICAL", 172, 178], ["patients", "SPECIES", 66, 74], ["patients", "SPECIES", 143, 151], ["This multi-center prospective study", "TEST", 0, 35], ["infection", "PROBLEM", 95, 104], ["low serum sodium concentration", "PROBLEM", 162, 192]]], ["All kinds of hyponatremia, mild, moderate, and severe, were connected with higher mortality, irrespective of the presence or lack of infection.", [["hyponatremia", "DISEASE", 13, 25], ["infection", "DISEASE", 133, 142], ["hyponatremia", "PROBLEM", 13, 25], ["mild, moderate, and severe", "PROBLEM", 27, 53], ["infection", "PROBLEM", 133, 142], ["hyponatremia", "OBSERVATION", 13, 25], ["mild", "OBSERVATION_MODIFIER", 27, 31], ["moderate", "OBSERVATION_MODIFIER", 33, 41], ["severe", "OBSERVATION_MODIFIER", 47, 53], ["infection", "OBSERVATION", 133, 142]]], ["A positive relationship has been noticed between the severity of hyponatremia and in-hospital mortality.Drug-Induced HyponatremiaTrimethoprim-sulfamethoxazole (TMP-SMX) is an antibiotic used mainly for the treatment of urinary tract infections and in the prevention of pneumocystis pneumonia.", [["urinary tract", "ANATOMY", 219, 232], ["hyponatremia", "DISEASE", 65, 77], ["HyponatremiaTrimethoprim-sulfamethoxazole", "CHEMICAL", 117, 158], ["TMP-SMX", "CHEMICAL", 160, 167], ["urinary tract infections", "DISEASE", 219, 243], ["pneumocystis pneumonia", "DISEASE", 269, 291], ["HyponatremiaTrimethoprim-sulfamethoxazole", "CHEMICAL", 117, 158], ["TMP-SMX", "CHEMICAL", 160, 167], ["Drug", "SIMPLE_CHEMICAL", 104, 108], ["HyponatremiaTrimethoprim-sulfamethoxazole", "SIMPLE_CHEMICAL", 117, 158], ["TMP-SMX", "SIMPLE_CHEMICAL", 160, 167], ["urinary tract", "ORGANISM_SUBDIVISION", 219, 232], ["hyponatremia", "PROBLEM", 65, 77], ["Drug", "TREATMENT", 104, 108], ["HyponatremiaTrimethoprim", "TREATMENT", 117, 141], ["sulfamethoxazole (TMP-SMX)", "TREATMENT", 142, 168], ["an antibiotic", "TREATMENT", 172, 185], ["urinary tract infections", "PROBLEM", 219, 243], ["pneumocystis pneumonia", "PROBLEM", 269, 291], ["positive", "OBSERVATION", 2, 10], ["hyponatremia", "OBSERVATION", 65, 77], ["urinary tract", "ANATOMY", 219, 232], ["infections", "OBSERVATION", 233, 243], ["pneumocystis", "OBSERVATION_MODIFIER", 269, 281], ["pneumonia", "OBSERVATION", 282, 291]]], ["In a retrospective study, 72.3% of patients treated with this drug developed hyponatremia, 43.6% of which was moderate and severe [81] .", [["hyponatremia", "DISEASE", 77, 89], ["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["a retrospective study", "TEST", 3, 24], ["this drug", "TREATMENT", 57, 66], ["hyponatremia", "PROBLEM", 77, 89], ["hyponatremia", "OBSERVATION", 77, 89], ["moderate", "OBSERVATION_MODIFIER", 110, 118], ["severe", "OBSERVATION_MODIFIER", 123, 129]]], ["After the termination of the therapy, serum sodium normalized within about 4 weeks in 50% of patients who had severe to moderate hyponatremia and in 60% of patients who had mild hyponatremia.", [["serum", "ANATOMY", 38, 43], ["sodium", "CHEMICAL", 44, 50], ["hyponatremia", "DISEASE", 129, 141], ["hyponatremia", "DISEASE", 178, 190], ["sodium", "CHEMICAL", 44, 50], ["serum", "ORGANISM_SUBSTANCE", 38, 43], ["sodium", "SIMPLE_CHEMICAL", 44, 50], ["patients", "ORGANISM", 93, 101], ["patients", "ORGANISM", 156, 164], ["patients", "SPECIES", 93, 101], ["patients", "SPECIES", 156, 164], ["the therapy", "TREATMENT", 25, 36], ["serum sodium", "TEST", 38, 50], ["severe to moderate hyponatremia", "PROBLEM", 110, 141], ["mild hyponatremia", "PROBLEM", 173, 190], ["moderate", "OBSERVATION_MODIFIER", 120, 128], ["hyponatremia", "OBSERVATION", 129, 141], ["mild", "OBSERVATION_MODIFIER", 173, 177], ["hyponatremia", "OBSERVATION", 178, 190]]], ["Moreover, longer duration of therapy with TMP-SMX and its higher cumulative dose significantly lowered the serum sodium.", [["serum", "ANATOMY", 107, 112], ["TMP-SMX", "CHEMICAL", 42, 49], ["sodium", "CHEMICAL", 113, 119], ["TMP-SMX", "CHEMICAL", 42, 49], ["sodium", "CHEMICAL", 113, 119], ["TMP-SMX", "SIMPLE_CHEMICAL", 42, 49], ["serum", "ORGANISM_SUBSTANCE", 107, 112], ["sodium", "SIMPLE_CHEMICAL", 113, 119], ["therapy", "TREATMENT", 29, 36], ["TMP", "TREATMENT", 42, 45], ["SMX", "TREATMENT", 46, 49], ["the serum sodium", "TEST", 103, 119]]], ["Unfortunately, the pathomechanism of this state during TMP-SMX treatment remains unknown, though the authors suggest the main reason being renal salt wasting.", [["renal", "ANATOMY", 139, 144], ["TMP-SMX", "CHEMICAL", 55, 62], ["renal salt wasting", "DISEASE", 139, 157], ["TMP-SMX", "CHEMICAL", 55, 62], ["TMP-SMX", "SIMPLE_CHEMICAL", 55, 62], ["renal", "ORGAN", 139, 144], ["TMP-SMX treatment", "TREATMENT", 55, 72], ["renal salt wasting", "PROBLEM", 139, 157], ["renal", "ANATOMY", 139, 144], ["salt wasting", "OBSERVATION", 145, 157]]], ["An alternative mechanism has been suggested, that trimethoprim blocks sodium channels in the distal nephron, inducing excessive natriuresis [82] .ConclusionsThere is no doubt that hyponatremia in infections is a multidisciplinary problem, as it may be associated with the infection itself, but also with a variety of factors such as renal or intracranial pathologies, drugs intake, malnutrition, or critical state.", [["distal nephron", "ANATOMY", 93, 107], ["renal", "ANATOMY", 333, 338], ["intracranial", "ANATOMY", 342, 354], ["trimethoprim", "CHEMICAL", 50, 62], ["sodium", "CHEMICAL", 70, 76], ["hyponatremia", "DISEASE", 180, 192], ["infections", "DISEASE", 196, 206], ["infection", "DISEASE", 272, 281], ["renal or intracranial pathologies", "DISEASE", 333, 366], ["malnutrition", "DISEASE", 382, 394], ["trimethoprim", "CHEMICAL", 50, 62], ["sodium", "CHEMICAL", 70, 76], ["trimethoprim", "SIMPLE_CHEMICAL", 50, 62], ["sodium", "SIMPLE_CHEMICAL", 70, 76], ["nephron", "MULTI-TISSUE_STRUCTURE", 100, 107], ["renal", "ORGAN", 333, 338], ["sodium channels", "PROTEIN", 70, 85], ["trimethoprim blocks sodium channels", "TREATMENT", 50, 85], ["the distal nephron", "TREATMENT", 89, 107], ["excessive natriuresis", "PROBLEM", 118, 139], ["hyponatremia", "PROBLEM", 180, 192], ["infections", "PROBLEM", 196, 206], ["the infection itself", "PROBLEM", 268, 288], ["renal or intracranial pathologies", "PROBLEM", 333, 366], ["malnutrition", "PROBLEM", 382, 394], ["distal", "ANATOMY_MODIFIER", 93, 99], ["nephron", "ANATOMY", 100, 107], ["no doubt", "UNCERTAINTY", 166, 174], ["hyponatremia", "OBSERVATION", 180, 192], ["infections", "OBSERVATION", 196, 206], ["infection", "OBSERVATION", 272, 281], ["renal", "ANATOMY", 333, 338], ["intracranial", "ANATOMY", 342, 354], ["pathologies", "OBSERVATION", 355, 366]]], ["The knowledge about factors predisposing to hyponatremia remains essential for a proper diagnosis and treatment.ConclusionsMany publications show that hyponatremia is associated with prolonged hospital stay and severity, as well as mortality in a number of infectious diseases.", [["hyponatremia", "DISEASE", 44, 56], ["hyponatremia", "DISEASE", 151, 163], ["infectious diseases", "DISEASE", 257, 276], ["hyponatremia", "PROBLEM", 44, 56], ["treatment", "TREATMENT", 102, 111], ["hyponatremia", "PROBLEM", 151, 163], ["severity", "PROBLEM", 211, 219], ["infectious diseases", "PROBLEM", 257, 276], ["hyponatremia", "OBSERVATION", 44, 56], ["hyponatremia", "OBSERVATION", 151, 163], ["infectious", "OBSERVATION", 257, 267]]], ["Despite many attempts to state its etiology in infective settings, few studies, just one in our review, took into consideration measuring the level of CT-ProVassopressin.", [["CT-ProVassopressin", "SIMPLE_CHEMICAL", 151, 169], ["CT", "PROTEIN", 151, 153], ["ProVassopressin", "PROTEIN", 154, 169], ["few studies", "TEST", 67, 78], ["CT", "TEST", 151, 153], ["ProVassopressin", "TREATMENT", 154, 169]]], ["This seems to be an adequate method to differentiate at least whether the low level of sodium is caused by SIADH or not.", [["sodium", "CHEMICAL", 87, 93], ["SIADH", "DISEASE", 107, 112], ["sodium", "CHEMICAL", 87, 93], ["sodium", "SIMPLE_CHEMICAL", 87, 93], ["the low level of sodium", "PROBLEM", 70, 93], ["SIADH", "PROBLEM", 107, 112]]], ["Therefore, we suggest including this test in the future studies of the pathomechanism of hyponatremia.ConclusionsSeveral authors suggest that the correlation between hyponatremia during infection and mortality risk is causal, which might indeed be the case.", [["hyponatremia", "DISEASE", 89, 101], ["hyponatremia", "DISEASE", 166, 178], ["infection", "DISEASE", 186, 195], ["this test", "TEST", 32, 41], ["hyponatremia", "PROBLEM", 89, 101], ["hyponatremia", "PROBLEM", 166, 178], ["infection", "PROBLEM", 186, 195], ["hyponatremia", "OBSERVATION", 89, 101], ["infection", "OBSERVATION", 186, 195]]], ["However, it needs to be stressed that most of the infection-related deaths occur due to respiratory or circulatory failure, and not hyponatermia-associated neurologic damage.", [["respiratory", "ANATOMY", 88, 99], ["circulatory", "ANATOMY", 103, 114], ["neurologic", "ANATOMY", 156, 166], ["infection", "DISEASE", 50, 59], ["deaths", "DISEASE", 68, 74], ["respiratory or circulatory failure", "DISEASE", 88, 122], ["hyponatermia", "DISEASE", 132, 144], ["neurologic damage", "DISEASE", 156, 173], ["the infection", "PROBLEM", 46, 59], ["respiratory or circulatory failure", "PROBLEM", 88, 122], ["hyponatermia", "PROBLEM", 132, 144], ["associated neurologic damage", "PROBLEM", 145, 173], ["infection", "OBSERVATION", 50, 59], ["circulatory failure", "OBSERVATION", 103, 122], ["neurologic", "OBSERVATION_MODIFIER", 156, 166], ["damage", "OBSERVATION", 167, 173]]], ["Thus, to prove the causal relationship between hyponatremia and mortality in infective settings, large prospective trials will need to be conducted in the future.", [["hyponatremia", "DISEASE", 47, 59], ["hyponatremia", "PROBLEM", 47, 59], ["infective settings", "TREATMENT", 77, 95], ["large prospective trials", "TREATMENT", 97, 121], ["hyponatremia", "OBSERVATION", 47, 59]]], ["Until then, in patients with infections hyponatremia should be interpreted as an indirect marker of disease severity, a potential direct marker of other concomitant disease, or a predictor of poor prognosis in this setting.ConclusionsAs mentioned in the introduction, it has been recently proven that improvement of hyponatremia reduces the risk of death among patients admitted to hospital due to this disorder.", [["infections", "DISEASE", 29, 39], ["hyponatremia", "DISEASE", 40, 52], ["hyponatremia", "DISEASE", 316, 328], ["death", "DISEASE", 349, 354], ["patients", "ORGANISM", 15, 23], ["patients", "ORGANISM", 361, 369], ["patients", "SPECIES", 15, 23], ["patients", "SPECIES", 361, 369], ["infections hyponatremia", "PROBLEM", 29, 52], ["an indirect marker of disease severity", "PROBLEM", 78, 116], ["other concomitant disease", "PROBLEM", 147, 172], ["hyponatremia", "PROBLEM", 316, 328], ["death", "PROBLEM", 349, 354], ["this disorder", "PROBLEM", 398, 411], ["hyponatremia", "OBSERVATION", 316, 328]]], ["Therefore, there are no doubts that each case of hyponatremia should be treated causally in order to reinstate correct water-electrolyte balance in organism.", [["hyponatremia", "DISEASE", 49, 61], ["electrolyte", "SIMPLE_CHEMICAL", 125, 136], ["hyponatremia", "PROBLEM", 49, 61], ["no", "UNCERTAINTY", 21, 23], ["hyponatremia", "OBSERVATION", 49, 61]]], ["Mild-and moderate hyponatremia in certain settings may be well tolerated and treated ambulatory.", [["hyponatremia", "DISEASE", 18, 30], ["Mild-and moderate hyponatremia", "PROBLEM", 0, 30], ["moderate", "OBSERVATION_MODIFIER", 9, 17], ["hyponatremia", "OBSERVATION", 18, 30]]], ["However, most of the studies indicate that patients with serum sodium threshold of <125 mmol/L (irrespective of their symptoms) should be immediately admitted to hospital and treated intensively, due to high mortality reaching up to 20% in these patients.ConclusionsThe role of hyponatremia in HIV-infection remains uncertain.", [["serum", "ANATOMY", 57, 62], ["sodium", "CHEMICAL", 63, 69], ["hyponatremia", "DISEASE", 278, 290], ["HIV-infection", "DISEASE", 294, 307], ["sodium", "CHEMICAL", 63, 69], ["patients", "ORGANISM", 43, 51], ["serum", "ORGANISM_SUBSTANCE", 57, 62], ["sodium", "SIMPLE_CHEMICAL", 63, 69], ["patients", "ORGANISM", 246, 254], ["HIV", "ORGANISM", 294, 297], ["patients", "SPECIES", 43, 51], ["patients", "SPECIES", 246, 254], ["HIV", "SPECIES", 294, 297], ["HIV", "SPECIES", 294, 297], ["the studies", "TEST", 17, 28], ["serum sodium threshold", "TEST", 57, 79], ["their symptoms", "PROBLEM", 112, 126], ["high mortality", "PROBLEM", 203, 217], ["hyponatremia", "PROBLEM", 278, 290], ["HIV", "PROBLEM", 294, 297], ["infection", "PROBLEM", 298, 307], ["hyponatremia", "OBSERVATION", 278, 290], ["infection", "OBSERVATION", 298, 307]]], ["These patients were mostly excluded from studies focusing on the impact of hyponatremia on prognosis and mortality, and so the results of these cannot be extrapolated on the population of HIV positive patients.ConclusionsThe novelties in our paper, comparing to the similar review released in 2011, include description of hyponatremia in Ebola-infected patients, in COVID-19 patients, and in influenza-infected patients.", [["hyponatremia", "DISEASE", 75, 87], ["hyponatremia", "DISEASE", 322, 334], ["Ebola-infected", "DISEASE", 338, 352], ["influenza-infected", "DISEASE", 392, 410], ["patients", "ORGANISM", 6, 14], ["HIV", "ORGANISM", 188, 191], ["patients", "ORGANISM", 201, 209], ["Ebola", "ORGANISM", 338, 343], ["patients", "ORGANISM", 353, 361], ["patients", "ORGANISM", 375, 383], ["patients", "ORGANISM", 411, 419], ["patients", "SPECIES", 6, 14], ["HIV", "SPECIES", 188, 191], ["patients", "SPECIES", 201, 209], ["patients", "SPECIES", 353, 361], ["patients", "SPECIES", 375, 383], ["patients", "SPECIES", 411, 419], ["HIV", "SPECIES", 188, 191], ["studies", "TEST", 41, 48], ["hyponatremia", "PROBLEM", 75, 87], ["hyponatremia", "PROBLEM", 322, 334], ["Ebola", "PROBLEM", 338, 343], ["influenza", "PROBLEM", 392, 401], ["hyponatremia", "OBSERVATION", 75, 87], ["hyponatremia", "OBSERVATION", 322, 334], ["Ebola", "OBSERVATION", 338, 343], ["infected", "OBSERVATION_MODIFIER", 344, 352], ["infected", "OBSERVATION", 402, 410]]], ["Funding: The study is supported by the Wroclaw Medical University statutory funds (SUB.C160.19.055).", [["The study", "TEST", 9, 18]]], ["The funding body had no role in the study design, data collection, analyses, and interpretation, or in writing the manuscript.", [["body", "ANATOMY", 12, 16], ["body", "ORGANISM_SUBDIVISION", 12, 16], ["the study", "TEST", 32, 41], ["data collection", "TEST", 50, 65], ["analyses", "TEST", 67, 75], ["no", "UNCERTAINTY", 21, 23]]]]}